The multiple roles of interferon regulatory factor family in health and disease.

Introduction

Interferon regulatory factors (IRFs) constitute a comprehensive category of transcription factors initially identified as regulators of type I interferon (IFN-I) and IFN-responsive genes, and their mechanisms have been extensively researched for over the past 30 years. To date, notable progresses have been made in elucidating the multifaceted and pivotal role of IRFs within the homeostatic defense mechanisms of the host and in orchestrating immune responses to both internal and external stimuli; notably, they are instrumental in enhancing antiviral responses, provoking pro-inflammatory reactions, and cell development and differentiation. 1 – 3 Furthermore, IRF family members have been recognized to harbor dual roles in immunity, exhibiting both anticancer and cancer-promoting properties. 1 IRF family members are implicated across a spectrum of human pathologies, encompassing infectious diseases, autoimmune and inflammatory disorders, metabolic dysfunctions, and oncogenesis. 4 – 9

In mammals, nine IRF members have been reported, 10 designated as IRF1 (also known as MAR), IRF2, IRF3, IRF4 (known alternatively as LSIRF/ICSAT/ PIP), IRF5, IRF6, IRF7, IRF8 (also termed as ICSBP), and IRF9 (also named as ISGF3γ or P48), each characterized by conserved multi-domain structures. Furthermore, an additional pair of IRF members, IRF10 and IRF11, have been discovered in avian species (IRF10) and teleost fish (IRF10 and IRF11), but these are notably absent in human and murine genomes. 11 , 12 The inaugural member of the IRF family, IRF1, was unveiled by the Taniguchi laboratory in 1988, and it has been documented to facilitate virus-induced transcription by engaging with IFN-β enhancer elements. 13 , 14 Later, Taniguchi’s group isolated the cDNA of IRF2 in 1989 by cross-hybridization with IRF1 cDNA. 15 The IRF2 gene exhibits significant homology with the IRF1 gene within the 5’ portion of the protein-coding region. 15 Additionally, IRF2 acts as an antagonist to IRF1, competing for the same promoter elements of IFN-I and IFN-II-inducible genes, thus potentially suppressing IRF1 function in specific contexts. 15 In 1990, Driggers PH et al. characterized the IFN consensus sequence-binding protein (ICSBP), now identified as IRF8, initially cloned as a protein regulated by IFN-γ with a binding affinity for the IFN-inducible enhancer of major histocompatibility complex (MHC) class I genes. 16 Moreover, Driggers PH and colleagues elucidated that ICSBP serves as a negative regulator, repressing the transcription of target genes activated by IFN or IRF1. 17 Due to its derivation from a component of the IFNα-stimulated transcription factor 3 (ISGF3) complex, IRF9 was initially designated as ISGF3γ in 1990. 18 ISGF3 constitutes a multiprotein complex comprised of four discrete polypeptides with molecular weights of 113, 91, 84, and 48 kDa, respectively. 19 The 48 kD subunit is denoted as ISGF3γ, its expression level being upregulated by IFN-γ. 19 , 20 ISGF3γ can associate with ISGF3α subunits, which are activated from a latent cytosolic form by IFN-I, to mediate antiviral activities. In 1995, Pitha group identified a novel IRF family member, IRF3, by mining homologs of IRF1 and IRF2 within an EST database, which associates with the IFN-stimulated response element (ISRE) to activate the expression of IFN-induced genes 21 Furthermore, the Pitha group initially reported that IRF3 might potentiate transcription by forming complexes with other transcription factors, possibly members of the signal transducer and activator of transcription (STAT) family. 21 In the same year, Matsuyama T. and colleagues identified a novel member of the IRF family, initially called the lymphoid-specific member of the IRF (LSIRF) and subsequently renamed IRF4. 22 , 23 The cDNA for LSIRF was initially cloned from mouse spleen tissue, encoding a protein with 51 kDa molecular weight. 22 IRF4 has been characterized using various terms in different contexts: as PU.1 interacting partner (PIP), it is a lymphoid-specific protein that binds to the enhancer elements of immunoglobulin light-chain genes, contingent on the presence of PU.1; 24 as ICSAT, the human homolog of PIP and LSIRF, is isolated from adult T-cell leukemia cells or activated T cells. 25 Distinctly, IRF4 differs from other IRF members as it is the sole IRF factor that is not regulated by IFNs. 22 IRF4 induction can occur through a variety of antigen receptor-mediated stimuli, including plant lectins, CD3, and IgM cross-linking. Its function as a transcriptional activator or repressor is dictated by its interactions with an array of transcription factors or specific DNA-binding motifs 22 , 26 IRF5 and IRF6, sharing structural homology, were first identified as members of the IRF family through the GeneBank database (accession numbers: human IRF5, U51127 ; human IRF6, AF027292 ). 27 In 2001, Pitha group first demonstrated that IRF5 participated IFN-I gene induction. 28 Prior research has established that IRF6 is predominantly engaged in developmental processes rather than in IFN gene expression, with its mutations being implicated in genetic disorders such as van der Woude syndrome, characterized by orofacial clefts and skin abnormalities. 29 , 30 Likewise, IRF7 was initially identified as a novel constituent of the IRF family through the GeneBank database (accession numbers U73036 , U73037 ) and information on IRF7 can be traced back to 1997 10 , 31 The IRF7 cDNA was cloned by a yeast one-hybrid system, encoding proteins that interact with sequences in the Epstein-Barr virus (EBV) BamHI Q promoter. 31 Exhibiting the greatest amino acid homology with IRF3, IRF7 possesses the ability to bind to the ISRE sequence, thereby inhibiting transcriptional activation mediated by both IFN and IRF1. 10 , 31

In recent decades, substantial advancements have been made in elucidating the regulatory mechanisms of IRF family members and their diverse roles in various diseases. A majority of these members are crucial for cellular development, immunity, inflammation, and oncogenesis, serving as in human diseases. 32 – 34 However, IRFs may exhibit distinct regulatory effects depending on cell type and environmental context, rendering their roles complex and at times paradoxical and double-edged swords in human health. This review primarily synthesizes the structural characteristics, post-translational modification sites, biological roles, and associated signaling pathways of the IRF family, alongside an exploration of diseases linked to these genes and proteins, with a focus on infections, inflammatory conditions, and a spectrum of cancers, encompassing but not limited to cardiovascular, pulmonary, urinary, reproductive, and skin systems. This review provides a comprehensive insight into the IRF family, underscoring the significance of IRFs as emerging biomarkers and potential therapeutic targets in the realm of human diseases.

IRF protein family: genes, proteins and structures

The detailed genes and proteins of IRF family members are presented in Fig. 1 . The IRF family encompasses a cohort of transcription factors integral to the regulation of IFNs and the orchestration of immune response. IRF proteins regulate the expression of target genes through their interaction with ISREs or IFN regulatory elements within the DNA. All IRFs feature a highly conserved N-terminal DNA-binding domain (DBD), comprising around 120 amino acids that constitute a helix-turn-helix motif. This motif is essential for the identification of specific DNA sequence elements (A/GNGAAANNGAAACT), known as ISRE, present in the promoters of genes for IFN-I, IFN-III, and IFN-stimulated genes (ISGs). 27 The C-terminal regions of IRFs contain a conserved domain known as IFN association domain1 (IAD1)(IRF3, IRF4, IRF5, IRF6, IRF7, IRF8, and IRF9) or IAD2(IRF1 and IRF2) that have low sequence homology and serve as association domains by which IRFs interact with other IRF members or transcription factors and/or cofactors. 1 Many IRF family proteins also contain a regulatory region between the DBD and IAD, which includes multiple phosphorylation sites. Fig. 1 The genes and proteins structures of IRF family members. a The genomic structures. The boxes mark the exons, including non-coding exons (orange) and coding exons (green). blue lines mark the introns. Start and stop codons are indicated. The numbers below the genes indicate the sizes of the exons and introns. b The structures of IRF family proteins. DBD represents the DNA-binding domain, LK represents the linker region, IAD represents interferon association domain, and AR represents auto-inhibitory region. Active domains (AD) are also marked on the figure. The upper numbers refer to the starting amino acid sites of diferent domains, and the different post-translational modifications of the IRFs are presented, including Phosphorylation, Ubiquitylation, SUMOylation, Methylation, and Acetylation

IRF1 and IRF2

The human IRF1 gene maps to chromosome 5q31.1, spanning 9,165 base pairs (bp) and comprising 10 exons and 9 introns. Human IRF1 protein has an approximate molecular weight of 45 kDa and is composed of 325 amino acids. The IRF1 gene is constitutively expressed in human cells at low basal levels, but can be triggered by diverse stimuli, such as IFNs, tumor necrosis factor (TNF), and interleukin-1 (IL-1). 35 The human IRF2 gene is located on chromosome 4q35.1 with 86,822 bp, and contains 9 exons and 8 introns. Through alternative splicing, IRF2 produces two splice variants. Currently, the primary focus of research has been on isoform 1 of IRF2, the full-length variant, which encodes 349 amino acids. IRF2 is constitutively expressed in multiple cell types and its expression can be further induced by viruses and IFN. Despite sharing a similar DBD with IRF1, IRF2 frequently serves an antagonistic role in immune regulation by inhibiting the activation of genes such as IFN-β. This inhibition is achieved through competitive binding to shared sites, thereby functioning predominantly as a suppressor of IRF1-mediated gene activation.

IRF3 and IRF7

The human IRF3 gene is situated on chromosome 19q13.33, spans 6286 bp, and contains 8 exons and 7 introns. A variety of splicing variants of IRF3 exist, with a minimum of five distinct variants identified thus far. The most extensively investigated variant of IRF3 is isoform 1, which is approximately 50 kDa and encodes 427 amino acids. IRF3 is constitutively expressed in many tissues, and the relative steady-state levels of IRF3 mRNA do not increase by virus infection or IFN treatment in cells. 21 Situated on chromosome 11p15.5, the human IRF7 gene spans 1923 bp and contains 11 exons and 10 introns. The human IRF7 gene encodes four alternative splicing variants, named IRF7A, IRF7B, IRF7C, and IRF7H. 31 , 36 Among these, the variant that has been most thoroughly investigated is IRF7A, which is composed of 503 amino acids and has a molecular weight of 55kD. The C-terminal region of IRF7 contains multiple regulatory domains for its activation. 37 IRF7, sharing a close relationship with IRF3, operates as a transcription factor that requires activation. The virus-activated domain in human IRF7A is vital for the activation of IRF7. 38 IRF7 is inherently present in the cytoplasm, with its expression predominantly observed in B cells, plasmacytoid dendritic cells (pDCs), and monocytes in spleen, thymus, and peripheral blood leukocytes. 31 , 36 Various stimuli, including Lipopolysaccharide (LPS), IFN-α, EBV-latent membrane protein 1 (EBV-LMP1), viral infections, and certain chemical agents like phorbol myristate acetate (PMA) and sodium butyrate, can significantly induce the expression of IRF7 in specific cell lines. 36 , 39 , 40 Additionally, DNA damage agents, virus infection, and EBV-LMP1 can activate IRF7 phosphorylation and nuclear translocation. 38 , 41 , 42

IRF4 and IRF8

The human IRF4 gene maps to chromosome 6p25.3 with 19,692 bp, contains 9 exons and 8 introns, and gives rise to two splicing variants. The predominant isoform of IRF4, the full-length variant, encodes a protein of approximately 51 kDa, containing 451 amino acids. IRF4 is uniquely expressed within immune system cells and is responsive to various mitogenic stimuli, including PMA/Ionomycin and T-cell receptor (TCR) cross-linking. 22 , 24 , 25 , 43 IRF4’s role as a transcriptional activator or suppressor is determined by its interactions with various transcription factors or the DBD on distinct promoters. 44 , 45 The human IRF8 gene is situated on a 23 kb segment of chromosome 16q24.1, and contains 9 exons and 8 introns. IRF8 protein encodes 426 amino acids. IRF8 is predominantly constitutively expressed in lymphoid and myeloid cell lines and induced by IFN-γ, but also in epithelial cells of the intestine, skin, lung, liver, ocular lens, cornea, and heart. 46 – 48 IRF8 is highly expressed in both progenitor and mature cells within the B cell, conventional DC1 (cDC1), and pDC lineages, playing a crucial role in their development and functionality.

IRF5 and IRF6

Situated on chromosome 7q32.1, the human IRF5 gene spans 13,007 bp, and comprises 9 exons and 8 introns. Numerous splice variants of IRF5 have been identified, with at least six distinct variants documented thus far. The size of the encoded IRF5 protein varies depending on the splice variant. One of the most extensively studied isoforms of IRF5 is the V1, which encodes a protein approximately 57 kDa and consists of about 498 amino acids. Initially discovered as a key regulator of IFN-I gene expression. 28 IRF5 is primarily found in B cells, monocytes, macrophages, and pDCs. During viral-triggered activation of IFN-I genes, there are multiple spliced isoforms of IRF5, each characterized by different patterns of expression specific to cell types, cellular localization, differential regulatory mechanisms, and divergent functional roles. 49 The human IRF6 gene maps to chromosome 1q32.2 with 20,526 bp and contains 9 exons and 8 introns. Likewise, IRF6 can produce two primary splice variants (variant 1 and variant 2) via alternative splicing. The existence of these splice variants enables IRF6 to perform distinct roles across diverse cell types and under various physiological conditions. The encoded human IRF6 protein is typically around 56 kDa and consists of approximately 467 amino acids. IRF6 exhibits prominent cytoplasmic expression in various cell types and is crucial for embryonic development, particularly in the epidermal and oral mucosa formation.

IRF9

The human IRF9 gene is situated on chromosome 14q12 with 5301 bp, and contains 9 exons and 8 introns. Human IRF9 protein encodes 393 amino acids. IRF9 is ubiquitously expressed in various cell types and has been identified as playing an essential role in the antiviral defense mechanism mediated by IFN-α/β and IFN-γ. 50

Post-translational modifications (PTMs) of the IRFs

PTMs are covalent alterations that modify the properties of a protein through adding a modifying chemical group or peptide moieties to one or several of its amino acid residues. 51 A singular protein may undergo modifications by multiple PTM types or be recurrently modified by the same PTM at distinct residues. Key PTMs influencing IRFs encompass phosphorylation, ubiquitination, SUMOylation, methylation, and acetylation, each playing a pivotal role in dictating the functional dynamics, proteostasis, and conformational integrity of these transcription factors (Fig. 1b ).

Phosphorylation

IRFs undergo various PTMs, among which phosphorylation stands out as the most critical. Glycogen synthase kinase 3β mediates dual phosphorylation of IRF1 at Thr181 and Ser185, which is required for the regulation of IRF1 turnover by K48-linked polyubiquitination proteasomal degradation. 52 Moreover, IκB kinaseε (IKKε) mediates the phosphorylation of the C-terminal region of IRF1, significantly diminishing the stability of IRF1, accelerating it, and inhibiting the transcriptional activity of IRF1. 53 In addition, IRF1 undergoes phosphorylated at Tyr109 within the DBD. 54 , 55

Phosphorylation is a crucial PTM of IRF3, as it induces cytoplasm-to-nucleus translocation of phosphorylated IRF3, and stimulates DNA binding and transcriptional activity. 56 The two kinases, IKKε and TANK -binding kinase 1 (TBK1) are the major phosphorylation kinases of IRF3. 57 – 59 IRF3 features two significant phosphorylation sites: site 1 includes Ser385 and Ser386, whereas site 2 includes Ser396, Ser398, Ser402, Thr404, and Ser405 within the C-terminal region. 56 , 60 , 61 Moreover, c-Jun N-terminal kinase (JNK) can stimulate the phosphorylation of IRF3 at Ser173in the N-terminal. 62 In addition, IFN-I-induced long noncoding RNA-ISIR binds IRF3 at DBD promoting its phosphorylation, dimerization, and nuclear translocation upon infection, consequently facilitating IRF3 activation. 63 Recently, Wang et al. found that serine/threonine-protein kinase 38-like phosphorylates IRF3 at Ser303, which prevents IRF3 degradation mediated by the proteasome in the rest state. 64 However, mammalian sterile 20-like kinase 1-mediated IRF3 phosphorylation at Thr75 and Thr253 severely disrupted the ability of activated IRF3 to form homodimerization that impairs its transcriptional responses. 65

The phosphorylation sites of IRF4 include Tyr121 and Tyr124. LMP1 promotes IRF4 tyrosine phosphorylation and significantly stimulates its transcriptional activity. 66 Moreover, Rho-associated coiled-coil-containing protein kinase 2 can phosphorylate IRF4 to regulate the production of IL-17 and IL-21. 67 In microglia, IL-1 receptor associated kinase 4 (IRAK4) phosphorylates both IRF4 and IRF5 by forming a Myddosome with myeloid differentiation primary-response protein 88 (MyD88)/IRF5/IRF4. 68

The phosphorylation sits of IRF5 include Ser158, Ser309, Ser451, Ser466, and Ser462. 69 , 70 In myeloid cells, phosphorylation at Ser462, facilitated by IKKβ, activates IRF5, which triggers IRF5 dimerization of and subsequent nucleus translocation. 71 However, IKKα-induced phosphorylation of IRF5 has an inhibitory effect on the transcriptional activation of IFN-I and the promoters of inflammatory cytokines. 72

The phosphorylation of IRF6 at Ser413 and Ser424 primes IRF6 for activation. 73 In addition, receptor interacting protein kinase 4 (RIPK4) directly regulates the trans-activator activity and nuclear translocation of IRF6 via phosphorylating its C-terminal domain at Ser413 and Ser424. 74

The kinases implicated in the phosphorylation of IRF7 include IKKε, IKKα, IRAK1, and TBK1. 57 , 75 – 77 In response to viral infection, IRF7 is phosphorylated at Ser477 and Ser479 and activated by TBK1 and IKKε. 38 Additionally, phosphorylation at Ser471, Ser472, Ser483, Ser484, and Ser487 also contributes to the activation of IRF7. However, the exogenous expression of protein phosphatase 1(PP1) subunits, heat shock protein 70, vaccinia virus E3L protein, and the open reading frame 45 of Kaposi’s sarcoma-associated herpesvirus inhibit IKKε-stimulated IRF7 phosphorylation and significantly reduce IRF7 transcriptional activity. 78 – 81

Ubiquitylation

Ubiquitination is a universal reversible PTM that can either activate or deactivate protein, with IRFs being tightly regulated by ubiquitination in various respects. 82 Ubiquitination can either positively or negatively influence the stability, activation, and transcriptional activity of IRFs. The fundamental element of ubiquitination is ubiquitin, which is covalently attached to one or more lysine residues in cellular involving three classes of enzymes. 83 Ubiquitin itself contains seven lysine residues and one N-terminal methionine residue. Each of these can be further conjugated with another ubiquitin to form ubiquitin chains of different linkages.

IRF1 is characterized by a brief, undergoing rapid degradation through the ubiquitin-proteasome pathway. 84 K63-linked ubiquitination of IRF1 contributes to its activation, while K48-linked ubiquitination contributes to its degradation. 85 Notably, HIV-1 viruses have developed strategies to exploit this ubiquitin-proteasome pathway to inactivate IRF1 function and evade the host immune defense mediated by IRF1. 86 IRF1 K63-linked ubiquitination is mediated by TNFR-associated factor 6 (TRAF6) and cellular inhibitor of apoptosis 2 (clAP2). 87 In response to IL-1 stimulation, clAP2 mediates the K63-linked polyubiquitination of newly synthesized IRF1, leading to its activation. 88

MGF360-14L, a viral non-structural protein, facilitates the degradation of IRF3 via tripartite motif-containing protein (TRIM) 21-mediated K63-linked ubiquitination of IRF3. 89 Cellular E3 ligases c-Cbl, RTA-associated ubiquitin ligase (RAUL), RBCC protein interacting with PKC1 (RBCK1), and Midline-1 (MID1) target IRF3 for K48-linked polyubiquitination, leading to its proteasome-dependent degradation. Viral infection leads to the induction of RBCK1, which subsequently catalyzes the ubiquitination and degradation of IRF3. 90 During viral infection, MID1 inhibits IFN-I production by interacting with IRF3 and negatively regulating IRF3 protein levels. 91 MID1 induces the ubiquitination of IRF3 at Lys313 playing a role in the cellular antiviral response, which is governed by a negative feedback mechanism. Jumonji domain-containing protein 6 promotes activated IRF3 K48 ubiquitination and degradation by ring finger protein 5. 92 Sentrin/SUMO-specific protease 2 catalyzes K48-linked ubiquitination of IRF3 at Lys87 and competitively promotes IRF3 deSUMOylation at Lys70. 93

IRF3 ubiquitination not only leads to its degradation but also contributes to its activation. Specifically, the activation of IRF3 in the RLR-induced IRF-3-mediated pathway of apoptosis (RIPA) requires linear polyubiquitination of two specific lysine residues on IRF3 by the linear polyubiquitinating enzyme complex. 94 However, this pathway can be inhibited by Otulin, a deubiquitinase, which removes linear polyubiquitin chains, resulting in IRF3 deubiquitinating. 95

Moreover, E3 ligase ring finger protein 2 (RNF2) promotes the ubiquitination and degradation of IRF4 in colon cancer. 96 MiR-155-5p contributes to the development of childhood acute lymphoblastic leukemia (ALL) by the Casitas B-lineage lymphoma (CBL)-mediated degradation of IRF4 via ubiquitination. 97 In addition, CBLs exhibit elevated expression levels in germinal center light zone B cells, where they promote the ubiquitination and degradation of IRF4. 98 However, the ubiquitin specific peptidase 4 (USP4) interacts with and deubiquitinate IRF4 to stabilize IRF4 protein, thereby promoting IRF4 function to facilitate IL-4 expression in Th2. 99

K63-linked ubiquitination of IRF5 contributes to its activation and increases its nuclear translocation. 100 TARF6 and Pellino-1 have been identified as the ubiquitin E3 ligases for IRF5, which target and promote K63-linked ubiquitination of IRF5. In human and mouse M1 macrophages, the interaction between Pellino-1 and IRF5 in the cytoplasm activates IRF5 and increases its nuclear translocation via K63-linked ubiquitination. 101 , 102

The RTA immediate-early nuclear transcription factor, which is encoded by Kaposi’s sarcoma-associated herpesvirus, facilitates the ubiquitination and degradation of the IRF7 protein in a proteasome-dependent. 103 Additionally, RAUL regulates IFN-I via targeting both IRF7 and IRF3 for K48-linked polyubiquitination and proteolysis. 104 LMP1-induced antiapoptotic factor A20 possesses both deubiquitinase and ubiquitin E3 ligase activities, and negatively regulates LMP1-stimulated IRF7 K63-liked ubiquitination and activity during EBV latency. 105 N-Myc and STATs interactor is a Sendai virus-inducible protein, which promotes the IRF7 K48-linked ubiquitination and proteasome-dependent degradation. 106 Similarly, TRIM35 also promotes the K48-linked ubiquitination of IRF7 and induces its degradation via a proteasome-dependent pathway. The interaction of Fas-associated death domain (FADD) with TRIM21 can enhance TRIM21’s ubiquitin ligase activity, both of them can directly ubiquitinate IRF7, affect its phosphorylation status, and interfere with TRAF6 ubiquitin ligase activity. 107

Additionally, IRF7 can be activated by the EBV-LMP1 via receptor interacting protein (RIP)-dependent K63-linked ubiquitination. 108 Further studies found that both TRAF6 and its E3 ligase activity are required for LMP1-stimulated IRF7 ubiquitination. IRF7 is ubiquitinated by TRAF6 at multiple sites, but the K63-linked ubiquitination sites are independent of its C-terminal functional phosphorylation sites. 109 Nevertheless, TAR RNA binding protein 2, an inhibitor of IRF7, inhibits the K63-linked ubiquitination and phosphorylation of IRF7. 110

CBL also mediates IRF8 ubiquitination, leading to the degradation of IRF8. 111 Ro52 (also called TRIM21) can interact with and ubiquitinate IRF8 in a non-degradation pathway. This interaction in turn enhances IL-12p40 expression in an IRF8-dependent manner. 112 Similarly, USP4 also stabilizes IRF8 protein levels in regulatory T cells (Tregs) by interacting with IRF8 via a K48-linked deubiquitinase. 113 Likewise, IRF9 can be ubiquitinated and degraded by herpes simplex virus (HSV) type 2 ICP22 protein, which functions as a novel E3 ubiquitin protein ligase. 114

SUMOylation

SUMOylation, is a critical PTM that is catalyzed by a limited set of modifying enzymes yet dynamically regulates a vast array of target proteins. Small ubiquitin-like modifiers (SUMOs) are members of the ubiquitin-like family of proteins that predominantly target nuclear proteins. 115 Five SUMO family members have been identified in mammals. 116 SUMOylation is pivotal in the regulation of nuclear processes, including transcription, nuclear body formation, nucleocytoplasmic transport, RNA processing, cell cycle progression, DNA repair, chromosomal functions, and signal transduction. 117 , 118 Similar to ubiquitylation, SUMOylation is reversible, as SUMO proteases can remove SUMOs from their substrates. 118 , 119 IRFs are also regulated by SUMOylation

Lys275 is identified as the primary SUMOylation site of IRF1. The protein inhibitor of activated STAT3 serves as both a SUMO-1 ligase and an inhibitor of IRF1’s transcriptional functions. 120 Additionally, the SUMO-conjugating enzyme Ubc9 suppresses IRF1’s transcriptional activation by inducing IRF1 SUMOylation. 121 Moreover, some studies have demonstrated that SUMOylated IRF1 may act as an oncogenic protein in tumor cells. 122 SUMOylated IRF1 is elevated in tumors, which inactivates its tumor suppressor function by repression of its transcriptional activity that facilitates resistance to the immune response. 123 Furthermore, treatment with alpha-lipoic acid induced IRF1 SUMOylation by increased SUMO-1 in an IL-1β-stimulated chondrocyte model. 124 The level of SUMOylated IRF1 was significantly elevated in the myocardial infarction (MI) group treated with 5-azacytidine. 125

IRF2 SUMOylation sites include Lys137, Lys293, and Lys166. SUMOylation of IRF2, catalyzed by SUMO-E3 ligase PIASy, represses its transcriptional activity in an histone deacetylase (HDAC)-dependent manner. 126 SUMOylation of IRF2 has minimal effects on its nuclear localization and DNA-binding activity. However, it enhances the inhibition of IRF1’s transcriptional activity while reducing the capacity to activate ISRE and H4 promoters.

During vesicular stomatitis virus infection, both IRF3 and IRF7 undergo phosphorylation as well as modification by SUMO1, SUMO2, and SUMO3. 127 The SUMOylation of IRF3 at Lys152 and IRF7 at Lys 406 is independent of their phosphorylation, and vice versa. However, some studies have found that SUMOylation of IRF3 leads to a reduction in IRF3 phosphorylation and IFN synthesis. 128 SUMOylation of IRF3 and IRF7 negatively regulates IFN transcription. 127 The Ebola Zaire virus VP35 protein inhibited IFN transcription in DCs by increasing PIAS1-mediated SUMOylation of IRF7. 129 The SUMO conjugation sites of IRF7 include Lys406 and Lys452. 127 , 130 The EBV-LMP1 can limit the capacity of IRF7 to initiate innate immune responses via promoting IRF7 SUMOylation at Lys452. 130 The TRIM28 is a specific SUMO E3 ligase and a negative regulator of IRF7. 131

In addition, Ubc9-mediated IRF4 SUMOylation enhanced its nuclear localization and stability. 132 Similarly, IRF5 and IRF8 can undergo SUMOylated. 133 However, the SUMOylation of IRF8, catalyzed by SUMO3 at the Lys310, can be reversed by SUMO-specific protease (SENP) 1 and SENP3. 134 , 135

Methylation and acetylation

Protein methylation refers to the transfer of methyl to a protein residue. Acetylation modification is a reversible and evolutionarily conserved PTM. Some IRFs (IRF1, IRF2, IRF3, IRF7, and IRF9) also undergo methylation or acetylation.

In U937 cells treated with PMA, both IRF1 and IRF2 undergo acetylation facilitated by p300 and p300/ CREB-binding protein (CBP)-associated factor (PCAF). 136 The p300-mediated IRF1 acetylation sites include the N-terminal Lys39 and Lys78. 137 In addition, IRF1 can be specifically acetylated by KAT8 at Lys78. 138 The acetylation sites of IRF2 include N-terminal DBD Lys75 and Lys78. Furthermore, some studies have shown that the acetylation of IRF2 is dependent on cell growth. 139 , 140 The monomethylation of IRF3 at Lys366 by nuclear receptor-binding SET domain 3 (NSD3), enhances the transcriptional activity of IRF3 in antiviral innate immunity. 141 This is because NSD3-mediated IRF3 methylation obstructs IRF3 dephosphorylation by disrupting PP1’s association with IRF3, thereby maintaining IRF3 phosphorylation. 142 Furthermore, LPS induces the arginine methylation of IRF3 at Arg285, leading to its dimerization and promoting its translocation from the cytoplasm to the nucleus. 143

KAT8 mediates IRF3 acetylation at Lys359 through its MYST domain, which leads to the inhibition of IRF3 recruitment to IFN-I gene promoters and a decrease in its transcriptional activity. 144 In vivo, IRF7 undergoes acetylation at Lys92 located in the DBD by the histone acetyltransferases PCAF and GCN5, resulting in impaired DNA binding capability. 145 A subsequent study has shown that sirtuin1 (SIRT1) -mediated DBD deacetylation is a pivotal mechanism in the activation of IRF3 and IRF7. 146 Upon viral stimulation, viral interferon regulatory factor 3 engaged liquid-liquid phase separation with ISRE DNA and compartmentalized IRF7 in the nucleus, thus stimulating the expression of IFN-I. In addition, IRF5 and IRF9 also undergo lysine acetylation. 147 , 148

Biological functions of IRFs

Regulation of immune cell development

Diverse studies have shown that the IRF family can regulate immune cell differentiation. Herein, IRF family members with their functions and molecular mechanisms in immune cells are discussed in detail. The subtypes of myeloid cells and lymphoid cells are pesented in Fig. 2a . Fig. 2 The regulatory effects and molecular mechanisms of IRFs on immune cell development. a The subtypes of myeloid cells and lymphoid cells. b The induction effect of IRFs on DC maturation and cytokine production. c The role of IRFs in myeloid differentiation and MDSC aggregation. d Regulation of IRFs in Natural Killer Cells development. e Multistep regulation of B cells and plasma cells by IRFs. f IRFs regulate T cell development and differentiation

The induction effect of IRFs on DC maturation and cytokines production

DCs constitute a specialized subset of hematopoietic cells endowed with the capacity to secrete IFN-I and a plethora of other cytokines. As the quintessential antigen-presenting cells (APCs), DCs are instrumental in initiating both innate and adaptive immune responses. 149 Characterized by their high expression of MHC molecules, DCs, upon detecting invading pathogens via pattern recognition receptors (PRRs), secrete various cytokines and present antigen-MHC complexes to T cells, thereby eliciting helper T cell (Th) responses or inducing immunological tolerance. 150

DCs constitute a heterogeneous population, comprising subpopulations with distinct functionalities, which can be categorized into conventional DCs (cDCs) and pDCs based on unique surface markers. In mice, spleen DCs are further subdivided into at least four subgroups: CD4 + DCs, CD8α + DCs, CD4 - CD8α - (double negative, DN) DCs, and pDCs. 150 In humans, cDCs are bifurcated into two subgroups: CD141 + cDC1 and CD1c + DC2 cells, with their murine counterparts being CD11b - CD103 + (CD8α + ) cDC1 and CD11b + cDC2. These cell populations, characterized by different gene expression profiles, perform distinct functions. pDCs are prolific producers of IFN-I, whereas cDCs generate both pro-inflammatory and anti-inflammatory cytokines, such as IL-10 and IL-12. cDC1 cells are pivotal for eliciting CD8 + T cell responses under viral or tumoral challenges, while cDC2 cells exhibit a robust capacity to initiate CD4 + T cell responses. 151

The IRF family proteins governs the differentiation and functional activity of DCs (Fig. 2b ). IRF4 and IRF8 are selectively instrumental in the development of specific DC subgroups. 152 , 153 These two IRFs share overlapping roles in driving the general process of DC development, yet they also possess distinct activities that stimulate the expression of subgroup-specific genes, resulting in the emergence of functionally diverse DC subpopulations. During DC development, DN DCs appear to represent the prototypical DC subset, differentiating into various DC subtypes and functions under the differential regulation of IRFs. IRF4 is crucial for producing CD4 + DCs, while CD8α + DCs require IRF8. Both of the two IRFs are instrumental in the development of CD4-CD8α- DCs and pDCs. 154 These cells express both IRF4 and IRF8, with CD8α + DCs expressing high levels of IRF8 and CD4 + DCs predominantly expressing IRF4. 154 In Irf8 -/- mice, there is a notable absence of CD8α + DCs and pDCs, whereas in Irf4 -/- mice, the numbers of CD4 + DCs are significantly diminished. 152 , 155 , 156 Mice deficient in both IRF8 and IRF4 retain only a minor population of CD4 - CD8α - DCs, completely lacking other DC subtypes in the spleen. 154

Without IRF8, committed cDC1 cells acquire transcriptional, functional, and chromatin accessibility characteristics reminiscent of cDC2 cells. While IRF8 is not essential for the survival of committed cDC1 cells, it is critical for preventing their transdifferentiation into cDC2-like cells. 157 Furthermore, IRF1 and IRF2 also modulate the development of DC subgroups. 158 , 159 In Irf 1 -/- mice, pDCs predominate, while the cDC population, particularly the CD8α + subset, is selectively diminished. 158 The capacity of IRF1-deficient spleen DCs to produce pro-inflammatory cytokines such as IL-12 is significantly compromised. In Irf2 -/- mice, spleen CD4 + CD11b + DCs exhibit pronounced selective deficits. 159

IRF proteins also regulate the induction of IFN-I in DCs. 160 Among them, IRF3 and IRF7 are widely recognized as crucial transcription factors for IFN induction. 32 , 161 IRF7, activated under toll like receptor (TLR) signaling, promotes IFN induction in pDCs, cDCs, and non-DC cells. 160 , 162 – 164 IRF3 primarily facilitates IFN induction in fibroblasts and is not necessary for IFN induction in DCs. 151 IRF3 is the primary early regulatory factor that induces IFN-I during intracellular viral infection. 165 While IRF5 is not required for IFN induction, it can enhance the production of non-IFN pro-inflammatory cytokines through distinct mechanisms. 160 , 163 , 166 However, surprising findings from in vivo studies suggest the existence of an alternative IFN induction pathway that operates independently of IRF3, IRF5, and IRF7. It was expected that IRF3-5-7 triple knockout mice would exhibit impaired IFN-I production, yet IFN-I activity was still detected in their serum. 167 The most likely candidate responsible for this induction appears to be IRF1. IRF1 is expressed widely and can enhance early IFN production by modulating the phosphorylation and localization of IRF3. 168 It may also compensate for the role of IRF7 as a positive regulator of IFN, establishing a positive feedback mechanism to sustain IFN production. 32 The generation of IFN-I in DCs is heavily reliant on IRF8, particularly during the feedback phase of IFN gene induction. Exogenous expression of IRF8 can rescue the development of pDCs and CD8α + DCs in vitro, triggering IFN-I and IL-12p40 production, whereas IRF4 does not exert the same effect. 169 Conversely, the introduction of IRF4 can restore the expression of selectively expressed genes in CD4 + DCs. The activation of IFN-I in pDCs is mediated by a MyD88-dependent signaling pathway, reliant on TLR3 and retinoic acid inducible gene I (RIG-I)-like receptors(RLRs). 160 The cytokines produced by activated DCs, including IFN, subsequently promote DC maturation and alter DC phenotypes and functions, with IRF family proteins potentially involved in regulating these processes.

Beyond IFN-I, IRF family proteins are also pivotal in the induction of other pro-inflammatory cytokines. IL-12p70, produced by APCs and B cells, is a heterodimeric pro-inflammatory cytokine secreted into the extracellular milieu. 170 IL-12 can induce IFN-γ production. IL-12p70 comprises two subunits, p40 and p35. IL-12p40 is essential for inducing IFN in Natural Killer (NK) and T cells, with its production in DC cells being dependent on IRF8. 171 IRF8 ’ s role in inducing IL-12 extends beyond regulating DC cell development, it also directly participates as a transcriptional activator in the gene transcription regulation of these cytokines. 1 IRF1 is involved in the induction of IL-12p40 in DC cells and is necessary for macrophages to fully induce IL-12p40. 27 , 160 , 172 Additionally, IRF5 is involved in activities that include the induction of pro-inflammatory factors such as IL-12p40, TNF-α, and IL-6. This process is mediated by TLR signaling, which stimulates IRF5’s translocation to the nucleus, interaction with MyD88 and TRAF6, and initiation of IL-12p40 expression. 151

In conclusion, the IRF protein family is integral to the development of DCs, and the induction of IFN-I within these cells. The production of IFN in response to pathogen infection is crucial for activating effective innate immunity to combat infection before the establishment of adaptive immunity. IRFs endow DCs with the necessary versatility for the optimal regulation of immune responses.

The role of IRFs in myeloid differentiation and myeloid derived inhibitory cells (MDSCs) aggregation

The differentiation of macrophages and granulocytes is regulated by IRFs

The Fig. 2c reveals the role of IRFs in macrophages and granulocytes differentiation. IRF8 is predominantly localized within hematopoietic cells and is variably expressed throughout the differentiation, proliferation, and apoptotic processes during myeloid cell development, where it orchestrates their core functions. 169 The differentiation of myeloid progenitor cells yields granulocytes and macrophages, 173 with studies on Irf8 -/- myeloid progenitors revealing that IRF8 directs the trajectory of differentiation, favoring macrophage formation while suppressing granulocyte differentiation. Irf8 -/- mice manifest symptoms akin to human chronic myeloid leukemia (CML). 174 Irf8 gene deletion leads to an increased progenitor cell population that is hypersensitive to granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). These progenitors exhibit a diminished response to macrophage colony-stimulating factor (M-CSF) but retain the capacity to differentiate into granulocytes in the presence of M-CSF. 175 IRF8 expression is sustained in macrophages but reduced in granulocytes. It governs several pivotal genes implicated in myeloid cell proliferation and apoptosis, inhibiting cell growth and promoting apoptosis. 175 , 176 The absence of IRF8 disrupts the myeloid differentiation program, skewing differentiation towards granulocytes and culminating in a CML-like syndrome. Notably, a marked reduction in IRF8 transcription levels has also been noted in cells derived from human CML patients. 177

Mammalian rapamycin target (mTOR) affects M-CSF receptor CD115 expression by regulating the STAT5-IRF8 axis, controlling the development of monocytes/macrophages in the early stages. 178 Upon pathogenic stimulation of human blood monocytes, a transcription factor complex comprising IRF8 and PU.1 associate with IFN-β to initiate Ets-IRF complex element (EICE) binding in subregions, recruit IRF3, and swiftly induce IFN-β expression, quickly initiate innate immune response to pathogens. 179 IRF8 also upregulates multiple genes essential to macrophage function, including those linked to endosomes and lysosomal enzymes (e.g., cathepsin C, lysozyme, cystatin C), as well as genes that stimulate macrophage adhesion and migration (such as the Dab2 gene). 180 , 181 IRF8 can form heterogeneous complexes with other transcription factors, such as the ETS family member PU.1 and IRF1, as a co-activator of various IFN-induced genes in macrophages, indirectly modulating the transcription of IFN-γ-responsive genes at the gamma-activated site (GAS), including those encoding IL-12p40, IL-12p35, gp91phox, p67phox, TLR4, TLR9, inducible nitric oxide synthase (iNOS), Fcγ receptor I (FcγRI), IRF8 itself, IL-18, chemokine ligand 5 (CCL5)/RANTES, and the phagolysosomal natural resistance-associated macrophage protein 1 (NRAMP1), thereby bolstering host defenses against pathogens. 27 , 169 , 182 , 183 IRF8 regulates the nucleotide-binding domain, leucine-rich repeat-containing receptor (NLR) family of apoptosis inhibitory proteins, and nucleotide-binding oligomerization domain-containing (NOD)-like receptor family caspase activation and recruitment domains (CARD) containing 4 (NLRC4) inflammasome activation, eliciting cellular responses to bacterial proteins that lead to caspase-1 activation and subsequent secretion of pro-inflammatory cytokines IL-1β and IL-18, which promote pyroptosis and intracellular pathogen resistance within macrophages. 184 Additionally, IRF8 can bind to the promoters of autophagy-related genes, encompassing all stages of autophagy in macrophages under conditions such as IFN-γ/TLR stimulation or pathogen infection. 185 Macrophages possess intrinsic mechanisms to fine-tune IRF8 transcriptional activity, including the deSUMOylation of IRF8 by SUMOs, ubiquitination by ubiquitin ligase TRIM21, and nucleosome remodeling by IRF8, all of which influence the transcriptional output of IRF8 target genes. 135 , 186

IRF1 and IRF2 play critical roles in the regulation of myeloid cell differentiation. Myeloid cells deficient in IRF1 exhibit impaired maturation. In macrophages stimulated by IFN, the IFN-inducible transcriptional activator IRF1 targets and modulates the expression of a multitude of genes that contain ISREs. These genes include those encoding guanylate-binding proteins, iNOS, caspase-1, cyclooxygenase-2 (Cox-2), class II transactivator (CIITA), and gp91phox. 1 , 187 – 189 Under inflammatory conditions, IRF1 can also form complexes with IRF8, co-activating IFN-induced gene expression. Conversely, a deficiency in IRF2 results in the expansion of eosinophil populations, leading to elevated IL-4 expression and the promotion of Th2 cell polarization. Macrophages lacking IRF2 (Irf2 -/- ) show increased expression of caspase-1, suggesting that IRF1 and IRF2 have opposing regulatory effects on caspase-1 expression. Despite this, IRF1 and IRF2 demonstrate synergistic effects in the regulation of IL-12p40 and Cox-2 expression. 1

Regulatory functions of IRFs in microglia and osteoclasts

Macrophages are distributed across various tissues and organs, with their classification—including microglia, osteoclasts, and alveolar macrophages (AMs)-based on location and function. 190 , 191 Microglia, the resident macrophages of the central nervous system, are integral to the glial system, contributing to neural homeostasis and protection. 192 , 193 The Fig. 2c reveals the role of IRFs in microglia differentiation. Within microglia, IRF8 establishes a positive feedback loop with the transcription factor PU.1, sustaining IRF8 expression. 194 Following neural injury, IRF8 activates target genes that transition microglia to reactive phenotypes, which can have protective or neurotoxic effects on the nervous system. 195 , 196 In reactive microglia, IRF1 collaborates with IRF8 to initiate transcription of IL-1β. 197 The absence of Irf8 in microglia can lead to an increase in TNF-α, mediate an increase in hippocampal nerve excitability, and drive fatal epilepsy. 198

Studies have identified IRF7 as a factor that promotes glioblastoma multiforme progression. IRF7 regulates the expression of inflammatory cytokines, polarizes microglia towards an M2 phenotype, fosters an immunosuppressive tumor microenvironment, and facilitates tumor growth, invasion, and immune evasion. 164

Osteoclasts, specialized terminal differentiation cells within the monocyte-macrophage lineage, fuse with monocytes to form multinucleated giant cells involved in bone resorption. 199 The Fig. 2c presents the role of IRFs in osteoclast differentiation. IRF8 acts as a negative regulator in osteoclast differentiation and maturation. 200 The absence of IRF8 leads to an increase in osteoclasts, contributing to bone metabolic disorders and playing a pivotal role in osteoclast-related inflammatory diseases such as multiple root resorption. 201 – 204

The regulatory role of IRFs in MDSCs

MDSCs represent a heterogeneous set of myeloid progenitor cells, including precursors unable to differentiate into macrophages, granulocytes, and DCs. 205 These progenitor cells can become arrested at various stages of maturation due to influences such as tumors, inflammation, trauma, or certain autoimmune diseases, resulting in a population with potent immunosuppressive capabilities. 206 MDSCs are a hallmark of malignancy and a promising target for cancer treatment. 207

The regulatory role of IRFs in MDSCs is shown in the Fig. 2c . IRF8 is a critical factor in myeloid cell development and acts as a negative regulator of MDSCs. 208 Within the tumor microenvironment, tumor cells and infiltrating stromal cells release cytokines like G-CSF and GM-CSF, which activate the Janus kinase (JAK)/STAT signaling pathway and suppress IRF8 expression in MDSCs. This suppression of IRF8 hinders T cell activation and infiltration, thereby diminishing the anti-tumor immune response. 209 In murine models, overexpression of IRF8 has been shown to restrict MDSC accumulation, mitigate the immunosuppression exerted by MDSCs, counteract their tumor-promoting effects, and improve the effectiveness of immunotherapies. 208

IRF8 also interacts with the promoter of the Bax gene, influencing the Bax-mediated apoptotic pathway and promoting apoptosis of MDSCs. 210 Additionally, the expression of IRF4 within MDSCs is reduced, 211 and IRF4 deficiency contributes to MDSC proliferation in the tumor microenvironment, 212 Enhancing IRF4 expression can decrease MDSC numbers and attenuate their immunosuppressive function by inducing differentiation. 213 Besides, as a tumor suppressor, IRF7 is known to downregulate the expression of S100A9, a protein that inhibits the expansion and aggregation of granulocytic MDSCs, thereby curtailing tumor cell metastasis and dissemination. 214

Regulation of NK Cells development by IRFs

IRF1 exerts a selective impact on the stromal cells within the developmental niche of NK cells (Fig. 2d ). 215 IRF1 is implicated in regulating the expression of IL-15 in these stromal cells, a cytokine that is essential for NK cell development. 1 Consequently, in IRF1 knockout (Irf1 -/- ) mice, a significant reduction in NK cell populations is observed, accompanied by the abrogation of NK cell functions, including cytotoxicity and IFN-γ secretion, particularly following IL-12 stimulation.

Similarly, the absence of IRF2 also impairs the development and functionality of NK cells (Fig. 2d ). However, the underlying mechanism appears to differ from that of IRF1, as it may involve the promotion of accelerated apoptosis in NK cells. 216 This suggests that while both IRF1 and IRF2 are integral to NK cell biology, they contribute through distinct pathways, with IRF1 primarily influencing the cytokine milieu necessary for NK cell maturation, and IRF2 affecting NK cell survival. In a study on prostate cancer, researchers found that overexpression of IRF7 can increase IFN-β, significantly enhance NK cell activity, and limit bone metastasis of prostate cancer cells (Fig. 2d ). 164

Multistep regulation of B cells and plasma cells by IRFs

IRF4 is pivotal in B cell ontogeny, encompassing pre-B cell differentiation, receptor editing, germinal center reactions, and plasma cell formation. 217 IRF4 expression is characteristic of immature B cells and is subsequently downregulated as antigen-activated B cells transition into the germinal center. Within the germinal center, IRF4 protein is scarcely detectable in the majority of B cells, including both centripetal and most centroblasts. 218 The Fig. 2e shows the regulation of B cell differentiation by IRFs.

Both IRF4 and IRF8 are co-expressed in immature B cells, where they collaboratively modulate B cell differentiation. 1 Although their regulatory roles appear to be overlapping, compelling evidence indicates that a block in B cell development occurs exclusively in mice lacking both IRF4 and IRF8, manifesting as a pre-B cell stage arrest. 219 In mice deficient in either Irf4 or Irf8 alone, B cell maturation arrest can be compensated for by the normal expression of the other factor. The enhancer of the conventional immunoglobulin light chain gene contains an EICE, where IRF4 and IRF8 interact with ETS transcription factors such as PU.1 or SpiB. 217

Upon antigen stimulation, B cells migrate to the germinal center within lymphoid tissues, where IRF4 expression is suppressed and IRF8 expression is augmented in the germinal center’s dark zone. 220 , 221 In the light zone, centrocytes undergo affinity maturation and isotype switching to evade apoptosis and differentiate into plasma cells that secrete high-affinity antibodies. Here, IRF8 expression diminishes while IRF4 expression escalates. 222 , 223 In the dark zone germinal center response, IRF8 critically regulates genes such as activation-induced cytidine deaminase (AICDA or AID) and B cell leukemia/lymphoma 6 (BCL6). 224 The AICDA gene encodes AID protein, a crucial enzyme in the processes of DNA strand unwinding and recombination, governing somatic hypermutation and class-switch recombination, leading to diverse and highly specific antibody generation. BCL6 is a transcriptional repressor that orchestrates the germinal center response. IRF4 can regulate the Aicda and PR/SET domain 1 (Prdm1) genes, where low levels of IRF4 can stimulate Aicda, facilitating AID function, followed by an upsurge in IRF4 expression. Elevated levels of IRF4 induce Prdm1 expression, which in turn represses Bcl6 and Aicda through transcriptional inhibition, culminating in the maturation and differentiation of plasma cells. 222

Thymocyte development and Th1/Th2 differentiation regulated by IRFs

T cells orchestrate cellular immune responses within the body, possessing the ability to directly eliminate target cells or secrete cytokines to amplify immune responses. Additionally, they play a role in modulating B cell-mediated humoral immunity. T cells constitute a diverse and heterogeneous group, with various functional subsets at different stages of development. Based on their roles in immune responses, T cells can be categorized into Th, effector T cells (Te), cytotoxic T lymphocytes (CTLs), Tregs, memory T cells, and inhibitory T cells, among others. 225 Dysregulation of T cell subsets is commonly observed in immune pathologies. IRF family members have been implicated in the regulation of T cell development and differentiation (Fig. 2f ). Activated naive CD8 + T cells can differentiate into cytotoxic cells, secreting various cytokines and categorized into Tc1 (also known as CTL), Tc2, Tc17, Tc9, and Tc22 subsets. 226 Most CD8 + T cells differentiate into Tc1, which is stimulated by IL-12 and IL-2 to secrete cytokines such as IFN-γ and TNF-α, directly targeting and killing cells. Tc9 and Tc17 secrete IL-9 and IL-17, respectively.

IRF4 is significant for the differentiation identity of these CD8 + T cell subsets. Although not necessary for CTL activation and proliferation, IRF4 is crucial for maintaining and functioning their phenotype. Irf4 -/- mice display functional defects in effector CTLs, with IRF4 influencing the upstream effector functions of transcription factors T-bet, BLIMP-1 (also known as PRDM1), and the formation of memory CTLs. Tc9 cells, akin to Th9 cells, produce IL-9 and IL-10. The molecular mechanism by which IRF4 affects Tc9 development parallels that in Th9, regulating IL-9 expression via binding to its promoter. 227 Tc17 cells express IL-17, and Irf4 -/- mice also exhibit defects in Tc17 differentiation. 228 , 229

IRF1 is pivotal in CD8 + T cell development, regulating the expression of genes essential for lineage selection in developing thymic CD8 + T cells (Fig. 2f ). It also influences the activation of CTLs. 230 Moreover, the activation of CTLs is positively regulated by both IRF4 and IRF8. 212 While IRF2 also contributes to CTL activity, its absence does not significantly impair CTL function. Unique among its family, IRF2 is a negative regulator that modulates immune responses, maintaining balance in the IFN-I signaling pathway and preventing CD8 + T cells from overreacting to antigenic stimulation, which could otherwise lead to detrimental effects on the body. 231

IRF1 is not necessary for Th1 differentiation of CD4 + T cells; however, its absence can lead to developmental defects in various cell types, ultimately constraining Th1 differentiation. 232 Mice deficient in IRF1 are devoid of NK cells, which are critical for secreting IFN-γ that in turn stimulates macrophages to produce IL-12, a cytokine indispensable for Th1 differentiation. Additionally, CD4 + T cells with IRF1 deficiency exhibit a delayed response to IL-12. 232 Mice lacking IRF2 also present with differentiation impairments in both NK and Th1 cells, with IRF1 and IRF2 acting together to enhance the expression of IL-12p40. Furthermore, IRF2 serves to restrict the proliferation of eosinophils that secrete the Th2 cytokine IL-4, thereby attenuating Th2 cell polarization. 233

IRF4 expression in mature T cells does not influence thymocyte development; however, it does affect cytokine production and the cytotoxic capabilities of T cells, potentially impacting their apoptotic and proliferative capacities. 23 IRF4 is indispensable for the differentiation of CD4 + T cells into Th2 cells, while IRF8 exerts an antagonistic regulatory effect. 45 The absence of IRF8 leads to a deficiency of macrophages and, as well as a compromised Th1 response due to its essential role in IL-12 gene expression. Together, IRF4 and IRF8 orchestrate the Th1/Th2 balance, influencing the generation of plasma cells that secrete highly specific antibodies. 154 They are integral to the induction of both cellular and humoral immunity, underscoring their significance in the immune response.

Th1 cells are integral to the host defense mechanism against viruses, bacteria, and intracellular pathogens, producing cytokines such as GM-CSF, IL-2, TNF-β, and IFN-γ. 234 IRF5 is implicated in directing T cell differentiation towards the Th1 lineage, with a reduction in the Th1 subset observed in mice with systemic Irf5 knockout. 235 IFN-γ stimulation of CD4 + T cells activates STAT1, leading to its nuclear translocation and then production of the transcription factor T-bet. IRF5 enhances T-bet’s IFN-γ production at the encoding gene locus, mediates chromatin remodeling, and together with STAT4, induces IFN-γ expression, driving Th1 polarization. A deficiency in IRF5 results in decreased efficiency of Th1 polarization initiated by T-bet. 236

Th2 cells are involved in the immune response against parasitic infections, allergies, and chronic inflammation. 237 The differentiation mechanism of Th2 cells is not completely understood; however, IRF4 is a crucial factor in the development of the Th2 subset and acts as an inhibitor of IRF5 transcription. 238 , 239 IL-4 is a critical cytokine for Th2 polarization. Antigen stimulation leads to the upregulation of IRF4, while IL-4 induces the phosphorylation and nuclear translocation of STAT6. Phosphorylated STAT6, in conjunction with IRF4, activates the transcription factor GATA binding protein 3 (GATA3). Transcription factors IKAROS family zinc finger 1 (Ikaros or IKZF1) and GATA3 can promote the transcription of Th2 polarization cytokines IL-4, IL-5, and IL-13. 240 – 242 Within these regulatory mechanisms, IRF5 negatively regulates Ikaros transcription, whereas IRF4 antagonizes the MyD88-IRF5 interaction, inhibiting IRF5 activation. 243 A positive feedback loop exists between IRF4 and GATA3, and together with Ikaros, they can suppress the Th1 transcriptional network, ultimately reinforcing the Th2 phenotype.

Th9 cells, characterized by their secretion of IL-9 and IL-10, play a significant role in combating extracellular parasites. 244 IL-9 production by Th9 cells is highly dependent on IRF4, which activates the IL-9 gene promoter and regulates IL-9 expression. 245 , 246 IRF4-deficient T cells are hindered in their differentiation into Th9 cells. IRF4 collaborates with various interacting proteins, such as Basic Leucine Zipper ATF-Like Transcription Factor (BATF), EICEs, and SMAD2/3, to regulate Th9 cell differentiation. 244

The dysregulation of Th17 cells is closely associated with muptiple diseases, such as psoriasis, inflammatory bowel disease (IBD), and cancers, making them therapeutic targets for regulating immune dysfunctions. 247 Th17 and Treg cells both originate from CD4 + naive T cells. Transforming growth factor β (TGF-β) induces naive T cells to differentiate into immunosuppressive Treg cells, while in combination with pro-inflammatory factors like IL-6 and IL-21, it drives the differentiation into immune-promoting Th17 cells. 248 An imbalance between Th17 and Treg cells can lead to autoimmune and/or inflammatory diseases. The interplay between IRF4, Th17, and Treg cells is complex. IRF4 deficiency can confer resistance to Th17-related autoimmune diseases due to defects in Th17 cell differentiation. 247 , 249 , 250 While IRF4 is not essential for Treg production, it is associated with Treg effector functions. 244 Treg cells express high levels of IRF4, which can inhibit Th2 cell activity by regulating specific transcriptional programs within Treg cells. 251 IRF5 appears to act as a positive regulator in Th17 differentiation. IL-6 stimulates the phosphorylation and nuclear translocation of STAT3 in naive CD4 + T cells, inducing the key transcription factor RAR-related orphan receptor γt expression, which in turn induces IL-17A transcription and drives the Th17-mediated inflammatory response. 247 , 251 IRF5 upregulates IL-6 and STAT3, and inhibits Ikaros and IL-10, promoting the Th17 inflammatory response, while IRF4 negatively regulates this effect of IRF5. 236

Follicular helper T cells (Tfh) are a subset of CD4 + Th that are involved in the humoral response, present in secondary lymphoid tissues such as the tonsils, spleen, and lymph nodes. 252 Tfh cells are distinguished by their expression of C-X-C chemokine receptor 5 (CXCR5), and programmed cell death protein 1 (PD-1), and they facilitate germinal center B cells differentiation into antibody-secreting plasma cells and memory B cells. 253 A deficiency in IRF4 can result in diminished Tfh cell differentiation. IL-21 is a pivotal cytokine in Tfh development, with IRF4 regulating its production and synergizing with the transcription factor STAT3 to control IL-21 signaling. 254 IRF4 also cooperates with BATF and BCL6 to regulate Tfh development. 255 , 256

IRFs regulate cell cycle and apoptosis

IRFs are not only integral to the differentiation and development of immune cells but also exert a key role in modulating cell cycle progression and apoptosis. The majority of studies concerning the influence of IRFs on cell cycle and apoptosis have been centered on their role in modulating tumorigenesis. For instance, IRF1 is known to induce the expression of cell cycle inhibitors such as p21 and growth arrest and DNA damage-inducible 45 (GADD45), effectively halting cell cycle progression. In contrast, IRF2 has been shown to facilitate cell cycle processes, acting in opposition to the effects of IRF1. Additionally, IRF3 can directly bind to and activate genes associated with the cell cycle, often in concert with IRF4, thus contributing to the proliferation of myeloma cells. 257 IRF5 promotes apoptosis upon signaling via TNF-related apoptosis-inducing ligand (TRAIL) death receptors. This is due to TRAIL-induced IRF5 phosphorylation and nuclear localization, resulting in the transactivation of key death receptor signaling components. 258 Multiple studies have demonstrated that IRF5 negatively regulates cell growth and oncogenesis. However, in thyroid malignancies, IRF5 promotes cancer cell proliferation. 259 IRF6, as a tumor suppressor gene and transcription factor, functions to suppress tumorigenesis in nasopharyngeal carcinoma (NPC), squamous cell carcinomas (SCCs),and renal clear cell carcinoma. 260 – 262 In glioma, IRF6 impaired cell proliferation and induced apoptosis by inhibiting pyruvate kinase isozyme type M2 (PKM2) and glucose transporters 1 (GLUT1) transcription. 263 The regulation of tumor development by IRF family members will be extensively reviewed in later chapters.

Furthermore, certain members of the IRF family are crucial to the apoptosis of non-tumor cells. Research has demonstrated that IFN-γ induces apoptosis in primary cultured hepatocytes, and that the presence of IRF1 is necessary for Fas/CD95-mediated cellular apoptosis. Caspase-1/7/8 and TRAIL are potential target genes of IRF1 in the regulation of apoptosis.

Beyond directly impairing virus replication, another critical host defense strategy against viral propagation involves inducing apoptosis in virus-infected cells. IRF3 has dual functions in such cells: it not only activates antiviral genes but also initiates apoptotic cell death through the RIPA pathway. 264 , 265 The activation process of IRF3 in the RIPA pathway is different from its transcriptional activation mechanism, necessitating linear polyubiquitination at particular lysine residues on IRF3 (Fig. 3 ). In the RIPA signaling pathway, IRF3, upon activation, engages in a critical interaction with the pro-apoptotic protein Bax via the BH3 domain proximal to its C-terminal region. The ensuing IRF3-Bax complex undergoes translocation to the mitochondria, acting as a catalyst for the release of cytochrome C into the cytoplasm. 266 This event precipitates the subsequent activation of caspases, culminating in apoptosis. However, Otulin, a deubiquitinase that excises linear multiubiquitin chains, suppresses RIPA via deubiquitinating IRF3 in virus-infected cells. To counteract the inhibitory effect of Otulin RIPA facilitates the targeted degradation of Otulin through the continuous action of activated caspase-3 and proteasomes. 95 Caspase-3 cleaves Otulin at D31, and the fragment was totally degraded by proteasomes before K48-linked ubiquitination occurs. Fig. 3 Regulation of apoptosis by IRFs. IRF-1 is a tumor suppressor and a regulatory factor of the IFN-γ system, with IFN-γ promoting the expression of IRF-1. IFN-α also induces the rapid phosphorylation and DNA-binding activity of STAT-1, followed by the accumulation of IRF-1 and IRF7. These two transcription factors bind to the TRAIL promoter and induce TRAIL expression. TRAIL is a key participant in the apoptotic pathway and plays a significant role in IFN-induced cell killing. IRF-3 is also involved in the transcriptional induction of TRAIL, where it transactivates the TRAIL promoter upon viral infection, upregulating TRAIL transcription. Conversely, IRF4 actively inhibits the transactivation mediated by IRF1. IRF3 triggers apoptosis through the RIPA pathway, which depends on the linear ubiquitination of specific lysine residues of IRF3. Within the RIPA signaling pathway, IRF3 interacts with the pro-apoptotic protein Bax to form the IRF3-Bax complex and translocates to the mitochondria, catalyzing the release of cytochrome C into the cytoplasm, subsequently activating Caspase, and ultimately leading to apoptosis. Otulin, a deubiquitinase that removes linear ubiquitin chains, inhibits RIPA by deubiquitinating IRF3 in virus-infected cells

Moreover, in a mouse model of alcoholic hepatitis, the non-transcriptional activity of IRF3 regulates the live’s innate immune milieu via increasing immune cells’ apoptotic cell death, thereby promoting the resolution of injury. 267

IRF1 and IRF3 regulate PANoptosis

PANoptosis is a novel and unique inflammatory programmed cell death pathway, uniquely regulated by multifaceted PANoptosome complexes. 268 , 269 Previous studies have found that IRF1 is an upstream modulator of PANoptosis, helping to induce the activation of Z-DNA binding protein 1 (ZBP1), NOD-like receptor family, pyrin domain–containing 3 (NLRP3), absent in melanoma-2 (AIM2), RIPK1, NLRP12 associated PANoptosis (Fig. 4 ). 268 , 270 – 272 Fig. 4 Regulation of PANoptosis by IRFs. IRF1 has been identified as an upstream regulator of PANoptosis, facilitating the activation of PANoptosome and PANoptosis. To date, molecular characterizations have been conducted on four PANoptosome complexes: ZBP1-PANoptosome, AIM2-PANoptosome, RIPK1-PANoptosome, and NLRP12-PANoptosome. During SARS-CoV-2 infection, innate immune cells produce a variety of inflammatory cytokines, among which the combination of TNF-α and IFN-γ induces PANoptosis. Co-treatment with TNF-α and IFN-γ activates the JAK/STAT1/IRF1 axis, inducing the production of NO and driving caspase-8/FADD-mediated PANoptosis, thereby driving cytokine storms and inflammatory pathology. In the context of hemolytic diseases, heme and PAMPs bind to TLR2 and TLR4, inducing signal transduction through IRF1 and upregulating NLRP12 expression. NLRP12, an innate immune cytosolic sensor, is responsible for inflammasome and PANoptosome activation, inflammatory cell death, and the inflammatory response to heme plus PAMPs, driving inflammatory cell death and pathology under hemolytic conditions. The NLRP12-PANoptosome induces the maturation of IL-1β and IL-18 through caspase-8/RIPK3, driving PANoptosis

IRF1 is involved in the regulation of PANoptosis not only in inflammatory diseases but also in tumors, especially colorectal cancer. During influenza A virus (IAV) infection, ZBP1 protein expression, NLRP3 inflammasome, caspase-1, caspase-8, caspase-3, and mixed lineage kinase domain like pseudokinase (MLKL) activation were decreased in IRF1-defective cells. Further studies demonstrated that IRF1 is a transcriptional regulator of ZBP1. 271 Genes encoding IRF1, IRF5, and IRF7 are highly upregulated in patients with severe coronavirus disease-2019 (COVID-19), as well as in TNF-α and IFN-γ-treated bone-marrow-derived myeloid cells. Notably, IRF1-deficient cells exhibit resistance to cell death following TNF-α and IFN-γ exposure, a protective effect not observed in cells lacking IRF5 or IRF7. 273 Concurrent treatment with TNF-α and IFN-γ triggers the activation of the JAK/STAT1/IRF1 signaling pathway, which in turn stimulates nitric oxide synthesis and promotes caspase-8/FADD-mediated PANoptosis. 273 The recent study has uncovered that NLRP12 is a cytoplasmic sensor of heme plus pathogen-associated molecular patterns (PAMPs)-triggered PANoptosis, driving inflammasome and PANoptosome activation, cell death, and inflammation. 274 IRF1 is involved in the TLR2/4-mediating signaling pathway to induce Nlrp12 expression, leading to inflammasome assembly and the maturation of pro-inflammatory cytokines IL-1β and IL-18. 274 However, IRF1 does not influence inflammation and inflammasome activity but instead acts as an upstream regulator of PANoptosis, inducing cell death during colitis-related tumorigenesis. 275 Recently, Zhuang et al. reported that bile acid-induced phosphorylation of IRF3 mediates cell apoptosis through the regulation of ZBP1 gene expression in cholestasis-induced liver and kidney injury. 276

IRF6 regulates Keratinocyte development

IRF6 is essential for normal epidermal development and differentiation. Human mutations in the Irf6 gene underlie two genetic conditions: Van der Woude syndrome and popliteal pterygium syndrome. 277 Studies have found that mice with null or homozygous missense mutations in the Irf6 gene display a hyperproliferative epidermis incapable of terminal differentiation, leading to abnormal skin, limb, and craniofacial development. 278 , 279 Subsequent research has shown that IRF6 is a key target of Notch in keratinocytes and induces differentiation through a Notch-dependent mechanism. 280 Moreover, IRF6 deficiency results in impairing the expression of genes critical for lipids metabolism and formation of tight junctions. 73

Signaling pathways IRFs involved

IRFs regulate IFN-I via TLR signaling

TLRs are membrane-bound signal receptors identified in the innate system. 281 Structurally, TLRs consist of an extracellular region, a transmembrane region, and an intracellular region. 282 So far, 12 functional TLRs have been found in mice and 10 in human. 283 TLRs are situated on cell membranes or embedded within endosomes. Engagement with their respective homologous ligands prompts TLRs to recruit adaptors, including MyD88 and/or Toll/IL-1 receptor (TIR) domain-containing adaptor protein-including IFN-β (TRIF) to activate IRF proteins alongside other transcription factors (Fig. 5 ). 160 Fig. 5 IRFs Respond to TLR Signaling and Participate in the Expression and Function of IFNs. The basal expression of IRF1 maintains the expression of ISGs, thereby conferring antiviral activity. Following viral infection, higher expression of IRF1 is triggered, along with potential cytokines, inducing the expression of IFN and ISGs. Additionally, the secretion of IFN can activate the STAT1-STAT2-IRF9 complex, inducing IRF1 and IRF7 as part of a positive feedback loop. The binding of PAMPs with TLR activates the IRFs signaling pathway, promoting the expression of IFN, pro-inflammatory cytokines, and chemokines, thereby activating the host’s innate immune defense

Specifically, IRF1 is implicated in the TLR7/9-MyD88 signaling cascade, and both IRF3 and IRF7 are involved in the TLR3-MyD88/TLR4-TRIF/MyD88-TBK1 signaling pathways. Additionally, IRF7 is also recruited to the TLR7/9-MyD88 signaling pathway, but IRF3 is not. 284 , 285 IRF5 is involved in TLR7/8/9-MyD88 signaling pathways that lead to the induction of IFN-I genes.

IRF3 and IRF7 can be activated via TLR3/TLR4-TRIF/MyD88-TBK1 signaling pathways. Following ligand recognition, TRIF undergoes phosphorylation and subsequently recruits downstream signaling molecules, including TRAF3, Nucleosome Assembly Protein 1 (NAP1), and TBK1. This cascade facilitates the phosphorylation, dimerization, and nuclear translocation of IRF3 and IRF7 (Fig. 5 ). Finally induced IFN-I gene expression. Additionally, MyD88/TRAF6-dependent K63-linked ubiquitination of IRF7 is essential for the induction of the IFN-I gene in pDCs by TLR signaling. 285

IRF5 is also involved in TLR-dependent (TLR7/8/9) induction of IFNs-I. 286 , 287 The induction of the IFN-I gene via TLR7 and TLR9 is contingent upon the MyD88 adaptor protein. Activation downstream of the TLRs involves TRAF6-mediated K63-linked poly-ubiquitination as well as phosphorylation in the IAD, which is crucial for both IRF5 nuclear translocation and to dislocate a C-terminal autoinhibitory domain, thereby facilitating the interaction of activated IRF5 with transcriptional coactivators such as CBP/p300. 100 , 288 – 291 Recently studies showed that IRF5 was recruited to endolysosomes by “TLR adaptor interacting with solute carrier family 15 member 4 (SLC15A4) on the lysosome” (TASL) and then phosphorylated by IKKβ or TBK1/IKKε, ultimately inducing IFN-I gene expression(Fig. 5 ). 292 , 293 This mechanism is an analogy with the IRF3 adaptors stimulator of IFN genes (STING), mitochondrial antiviral signaling protein (MAVS) and TRIF.

IRF1 interaction with MyD88 to control the production of TLR9-dependent IFN-β in mouse DCs. 294 IRF1 also be efficiently activated by the TLR-MyD88 pathway, in turn inducing immunity-related GTPase B10 (IRGB10) expression. Moreover, IRF8 engages in the induction of IFN-I genes in TLR-stimulated pDCs but does not interact with MyD88. 295 IRF8 in conjunction with TRAF6, modulates TLR signaling, potentially facilitating the interaction between IFN-γ and TLR signal pathways. 296 In addition, IRF8 is essential for TLR7- and IFN-α-induced bone marrow differentiation into MDSCs in vitro. 297 IRF8 also directly regulates the expression of TLR9 in NK cells. IRF8 regulates hematopoietic stem cells, at least in part, by controlling TLR9 signaling in various innate immune cells. 298

IRFs induce IFNs on innate recognition of cytosolic RNA and DNA

RLRs are RNA sensors localized in the cytosol. 299 In innate antiviral immunity, except TLR7 and TLR9, the majority of cell types detect viral nucleic acids predominantly via RLRs, thereby initiating antiviral immune responses. 300 , 301 RIG-I and melanoma differentiation-associated gene 5 (MDA5) are two RNA helicase enzymes and essential members of the RLR family. RIG-I and MDA5 both contain two CARD at the N-terminus. 300 The MAVS, which contains one CARD domain, is the adaptor molecule linking the sensing of viral RNA by RIG-I or MDA5 to downstream signaling. 300 MAVS transmits downstream signaling via CARD-CARD interaction. 160

IRF3 and IRF7 are critical for the RIG-I/MDA5-mediated IFN-I gene-induction pathway (Fig. 6 ). Under basal conditions, IRF3 and IRF7 exist in inactive states within the cytoplasm of uninfected cells. After virus infection, TBK1, activated by RIG-I- or MDA5, phosphorylates IRF3 at multiple residues including Ser396, Ser398, Ser402, Ser404, and Ser405 within site 2, which alleviates autoinhibition and allows IRF3 nuclear translocation and interaction with the coactivator CBP. 302 – 304 Then, CBP promotes phosphorylation at Ser385 or Ser386 at site 1 within the regulatory region, permitting IRF3 dimerization. 303 Presumably, a similar mechanism occurs in IRF7, leading to a holocomplex containing dimerized IRF3 and IRF7, either as a homodimer or heterodimer, and coactivators such as CBP or p300 are formed in the nucleus. These holocomplexes bind to target ISRE DNA sequences within the promoters of IFN-I and IFN-III genes. Fig. 6 PRRs Detect Cytosolic DNA/RNA and Activation of IRFs.Cytosolic RNA or DNA triggers host responses through specific cellular PRRs. The binding of ssRNA or dsRNA to the helicase domain of RIG-I/MDA5 induces the activation of RIG-I/MDA5’s CARD and the interaction between the CARD-like domain of the adaptor MAVS located on the mitochondrial membrane. This receptor-adaptor interaction leads to the activation of TRAF, TBK1, and IKKε, inducing the phosphorylation of specific serine residues on IRF3 and IRF7. These IRFs then translocate into the nucleus and activate IFN-I genes. NF-κB is also activated and participates in the induction of IFN-I genes. dsDNA is recognized by cGAS, DAI, etc. The adaptor protein STING on the endoplasmic reticulum membrane signals downstream to these DNA receptors, recruiting TBK1 to phosphorylate IRF3, leading to the activation of IFN-I gene expression

Additionally, IRF5 participates in the RIG-I/MAVS signaling pathway. 167 Upon infection with vesicular stomatitis virus (VSV) or NDV, IRF5 undergoes translocation from the cytoplasm to the nucleus. However, detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by lung epithelial cells requires MDA5, laboratory of genetics and physiology 2 (LGP2), and NOD1, but not RIG-I (Fig. 6 ). 305 Subsequently, IRF3, IRF5, and nuclear factor kappaB (NF-κB) are phosphorylated and translocate into the nucleus to trigger IFN induction. During SARS-CoV-2 infection, IRF3, IRF5, and NF-κB/p65 are the key transcription factors regulating the IFN response. 305

IRF8 is also needed for IFN-I induction in virus-stimulated DCs, which helps to prolong the recruitment of basal transcription machinery to the IFN promoters, a role not shared by IRF7 or IRF3. This supports characteristically high IFN transcription in DCs. 295 Moreover, IRF8 and PU.1 collaborate to establish a scaffold complex at the IFN-β promoter, thereby enhancing the recruitment of IRF3 and enabling rapid IFN-β transcription in monocytes. 179

Although IRF1 is not critical for the induction of the IFN-I gene by viruses, its expression is usually typically upregulated swiftly after viral infection or poly(I: C) stimulation. 306 However, human IRF1 is vital for IFN-γ and STAT1-dependent immunity to mycobacteria. 307

Beyond mechanisms for sensing cytoplasmic RNA-, cytoplasmic DNA-sensing systems have also been mentioned (Fig. 6 ). Known DNA sensors include cyclic CMP-AMP synthase (cGAS), IFN inducible protein 16 (IFI16)/IFN-activated gene box polypeptide 41 (DDX41), IFI204, and (Asp-Glu-Ala-Asp) (DEAD). IRF3 is involved in an antiviral response triggered by double-stranded B-form DNA (B-DNA), and this signaling pathway requires the kinases TBK1 and IKKi. 308 ZBP1 is a candidate cytosolic DNA sensor. ZBP1 binds to double-stranded DNA (dsDNA) and, by doing so, enhances its association with IRF3 and TBK1. 309 A more recent study indicates that ZBP1 stabilizes Z-form mitochondrial DNA (mtDNA) and facilitates the formation of a cytosolic complex comprising cGAS, RIPK1, and RIPK3 to engage robust IFN-I signaling. 310

IRFs involved in the JAK/STAT signaling pathway

The JAK/STAT pathway is a critical cascade in cellular signaling that transmits information from chemical signals outside of a cell to the cell nucleus, resulting in DNA transcription and subsequent gene expression. The interaction between IRFs and the JAK/STAT pathway is not unidirectional. For instance, STAT1 can enhance the expression of IRF1, creating a positive feedback loop that amplifies the immune response. 307 Upon viral infection or recognition of PAMPs, IRF3, IRF5, and IRF7 are activated. These IRFs then promote the transcription of IFNs-I (IFN-α and IFN-β) and IFNs-III (Fig. 5 ). The secreted IFNs engage with their corresponding receptors on cell surfaces, leading to the activation of JAKs. Activated JAKs then phosphorylate the STAT1 and STAT2 leading to the formulation of ISGF3, or IFN-γ-activated factor (GAF). Subsequently, ISGF3 or GAF translocate into the nucleus, where they initiate the transcription of ISGs or GAS respectively and induce IRF1 expression in a positive feedback mechanism, orchestrating a robust antiviral response. 307 The IRF9, as part of the ISGF3 complex (together with STAT1 and STAT2), directly binds to the ISREs in the promoters of ISGs, enhancing their transcription.

IFN-II (IFN-γ) binds to cell-surface receptors composed of IFN-γ receptor 1 (IFNGR1) and IFNGR2 subunits, which bind to JAK1 and JAK2, respectively. Activation of these kinases leads to STAT1 homodimerization to formulate GAF, which translocates into nucleus to target GAS DNA sequences and induce IRF1 transcription (Fig. 5 ). 160 In humans, IRF1 is required for the IFN-γ-dependent immunity of macrophage against mycobacteria, whereas its role in IFN-α/β-dependent antiviral immunity is comparatively less critical. 307

IRFs involved in the NF-κB signaling pathway

The NF-κB pathway is a key signaling mechanism that controls the transcription of genes involved in immune and inflammatory responses, cell proliferation, and survival. Activation of NF-κB is tightly regulated and can be triggered by various stimuli, including pro-inflammatory cytokines, bacterial or viral infections, and other stress signals. Some IRF members have been shown to interact with the NF-κB pathway, influencing its activity in several ways.

IRF3, IRF5, and IRF7 can function cooperatively with NF-κB to enhance the transcription of certain genes implicated in the immune response. For example, upon viral infection, IRF3, IRF5, and NF-κB can be simultaneously activated and work together to promote the transcription of IFNs-I and other pro-inflammatory cytokines, amplifying the immune response (Fig. 5 ). 305 IRFs can also modulate the activation of NF-κB. For instance, IRF4 has been reported to interact with the NF-κB subunit RelA/p65, affecting its ability to bind DNA and activate transcription. This interaction can either enhance or suppress NF-κB target gene expression, depending on the cellular environment and the specific stimuli.

The role of IRF proteins family in health and diseases

IRFs and infections

Almost all IRFs have been reported to affect pathogenic processes (Fig. 7 ). Generally, IRF1, IRF3, IRF5, and IRF7 are the main members involved in various microbial infections and microbial-induced human diseases, playing strong roles in IFN-I gene regulation at the early phase of antiviral innate immunity and antibacterial pathogens in most cells. 32 , 63 , 311 , 312 Some studies indicate that activation of certain IRFs can also cause excessive inflammatory reactions and body damage, 313 – 315 and inhibition of IRFs may offer protection against microbial infections in some certain specific situations. 316 Fig. 7 The potential role of IRFs in infectious diseases. a The roles of IRFs in viral infections. IRF1 can regulate IFN and inflammasome to fight viral infections, while it also induces cell PANoptosis and virus immune evasion. IRF2, IRF3, IRF4,IRF5, IRF7, and IRF9 play protective roles to prevent viral infections. b The roles of IRFs in bacterial and parasitic infections. IRF1, IRF4, and IRF8 prevent host aginst bacterial infections. IRF3, IRF5, and IRF7 are double-edged swords in bacterial and parasitic infections

Viral infections

Following viral infection, IRFs like IRF1 and IRF3 are dramatically upregulated and activated, inducing endogenous IFN genes such as IFN-α and IFN-β1 production, and/or protein degradation in various cell types, which drive antiviral immunity to multiple clinically important viruses, including hepatitis C virus (HCV), West Nile virus,yellow fever virus, human immunodeficiency virus type 1(HIV1), gamma herpes virus, and human metapneumovirus, and VSV infection. 32 , 165 , 168 , 317 – 320 IRF1 basal expression provides cellular intrinsic antiviral protection against diverse pathogenic RNA viruses, such as HAV, HCV, dengue virus, and zika virus (ZIKV). 321 IRF1 can regulate ZBP1 and NLRP3 inflammasome, mediating inflammatory and cell death responses in IAV infection. 271 In addition, IRF1 is required for optimal early activation of IRF3, targeting and augmenting IRF3 phosphorylation, which enhances innate immunity to viral infection. 168 , 322 IRF2 is also identified to inhibit ZIKV and orthopoxvirus replication by enhancing FAM111 trypsin like peptidase A (FAM111A) expression to promote host restriction effect of replication factor C subunit 3 (RFC3). 323 , 324 Moreover, IRF2 is critical for the development and functional maturation of human NK cells to defend against virus-infected cells. 325 IRF3 has been reported to trigger apoptosis of virus-infected cells, restricting virus spread within the host, in a RIPA pathway, 95 , 264 , 326 and IRF3 inhibits NF-κB nuclear translocation to prevent viral inflammation. 327 IRF3 and IRF7 are vital for inflammatory responses control during HSV-induced encephalitis (HSE). 328 Studies presented that IRF3 and IRF7 deficiency might increase susceptibility to HSE and other respiratory viruses in humans, 329 , 330 and IRF7/9 variants might predispose humans to recurrent, severe HSV or IAV infection. 331 – 333 Besides, IRF3 agonist could alleviate Enterovirus A71-induced inflammatory response in mice, indicating a potential therapeutic target in Enterovirus A71-induced hand-foot-and-mouth disease. 334 IRF4 is able to promote CD8 + T cell function and exhaustion, limiting memory-like T cells development during lymphocytic choriomeningitis virus (LCMV)-induced infection. 335 , 336 IRF5 is critical for IFN-I and IL-6 induction followed by viral infections, 337 and it suppresses HCV replication and induces immune responses in the draining lymph node to defeat West Nile virus infection. 312 , 338 However, in some conditionsmany viruses, including human cytomegalovirus, influenza virus, rhinovirus, EBV, HCV, HIV, and SARS-CoV, can exploit host RNA-binding protein to inhibit expression and functions of IRF1/3/5, thereby preventing a cellular antiviral response. 326 , 339 – 341 Moreover, virus-induced damage and inflammation can activate TLR-IRF pathways, resulting in excessive inflammatory cytokines production and aggravating body damage. 313 , 314

COVID-19, caused by SARS-CoV-2, mainly infects human epithelial cells in the respiratory tract and intestine. Research indicates that patients with SARS-CoV-2 infection have high progesterone levels to facilitate IRF3 phosphorylation, which is associated with decreased severity of COVID-19. 342 Nonetheless, SARS-CoV-2 can suppress the IFN-mediated STAT1/2 signaling, diminishing NLRC5, IRF1 and IRF3 gene expression. 343 – 345 Furthermore, SARS-CoV-2 papain-like protease and nonstructural proteins (NSP) such as NSP5, NSP12, and NSP13 can cleave IRF3, suppress IRF3 phosphorylation and nuclear translocation to blunt IFN response, which further antagonizes host antiviral innate immunity. 346 – 351 On the other hand, a study presented that TNF-α and IFN-γ co-treatment caused the JAK/STAT1/IRF1 pathway activation, leading to caspase-8/FADD-mediated PANoptosis, which resulted in a lethal cytokine shock in mice that mirrored inflammation and tissue damage of COVID-19. 273 Shin et al. uncovered that pathological and/or genetic reasons-mediated higher basal IRF1 expression in multiple organs might contribute to the synergistic upregulation of IRF1 under SARS-CoV-2 infection, potentially making individuals more vulnerable to COVID-19. 352 Furthermore, Huang et al. illustrated that SARS-CoV-2 activated NF-κB/IRF1 axis to further promote programmed death-ligand 1 (PD-L1) expression and then might facilitate immune evasion, inducing sepsis and fatality. 353 Zhang et al. reported that inherent defects in the TLR3- and IRF7-dependent IFN-I immunity may encounter with life-threatening COVID-19 pneumonia in patients without a history of severe infection. 354 Besides, Lévy et al. reported an unvaccinated child with life-threatening COVID-19 risk because of an inherited IRF9 deficiency. 355 Moreover, it has been found that SARS-CoV-2 spike transfected cells release a large number of microRNAs-loaded exosomes, which are internalized by human microglia and inhibit USP33 expression and IRF9 levels, mediating central nervous system damage through the hyperactivation of human microglia. 356

Bacterial and parasitic infections

IRF1 is important for IFN-γ-dependent and TNF-α and IL-6 auto-paracrine signaling loop-mediated macrophagic immunity to mycobacteria . 307 , 357 and IRF1 inhibits mTOR/p70 S6K signaling in macrophages, which facilitates an anti-mycobacterial effect against tuberculosis (TB). 358 Furthermore, IRF1 is required for the AIM2 inflammasome activation in response to Francisella novicida ( F. novicida ) infection, 272 and for intestinal group 3 innate lymphoid cells (ILC3s) to produce lots of the protective effector cytokine IL-22 early in the course of Citrobacter rodentium -induced intestinal infection. 359 IRF1 also contributes to the innate defense of the cornea against Pseudomonas aeruginosa ( P. aeruginosa ) infection, 360 indicating it is crucial for anatomical containment and prevention of pathogen dissemination. Additionally, the STING/TBK1/IRF3 pathway activation is instrumental in stimulating IFN-I production and inducing apoptosis, thereby offering protection against TB during Mycobacterium bovis ( B. tuberculosis ) infection. 361 , 362 Furthermore, IRF3, IRF5, and IRF7 are key regulators in the IFN-I-mediated response to mycobacterium tuberculosis ( M. tuberculosis ). 363 , 364 Specifically, IRF7 facilitates the expression of miRNA-31, which significantly reduces lung pathology and bacilli burdens during M. tuberculosis infection. 365 Skjesol et al. found that the Rab11 family interacting protein 2 guided TLR4 sorting adapter translocating chain-associated membrane protein (TRAM) recruitment for orchestrates actin remodeling and IRF3 activation for macrophage phagocytosis of Gram-negative bacteria. 366 On the other hand, infections caused by bacteria like Helicobacter pylori ( H. pylori ) can downregulate IRF3 activation to interrupt STING and RIG-I signaling and then hamper their functions in eliminating bacteria and mobilizing adaptive immune responses. 367 A separate study revealed that airway acidification activated the IRF3/IFN-β signaling, subsequently compromising the host’s defensive mechanisms against pulmonary infection by Pseudomonas aeruginosa ( P. aeruginosa ). 315 Besides, mice with IRF3 deficiency were protected from the lethal malaria plasmodium yoelii infection. 368 Inflammasome-mediated IRF3 signaling upregulated SOCS1, further inhibiting MyD88-IRF7-mediated IFN-I response in pDCs, inducing parasite fast growth and host death. 368 , 369 Studies have shown that IRF4 expression in T cells is necessary for the effective control of M. tuberculosis and Listeria monocytogenes . 370 , 371 IRF5 has been reported to promote intracellular bacterial clearance and the induction of antimicrobial pathways. 372 , 373 However, IRF5 deficiency ameliorated immunopathology during Salmonella Typhimurium ( S. Typhimurium ) and Helicobacter hepaticus -induced colitis in vivo. 372 , 374 Moreover, Puthia et al. have illustrated that IRF7 inhibition can be used to prevent and treat bacterial infections other than acute pyelonephritis. 316 However, Mathy et al. showed that long non-coding RNA (lncRNA) Nostrill might function as a “guide” to promote recruitment of NF-κB p65 to the IRF7 gene promoter, thereby promoting IRF7 mRNA expression and contributing to intestinal epithelial defense against Cryptosporidium parvum ( C. parvum ). 375 IRF8 activated autophagy genes in macrophages and induced subsequent autophagic capturing and degradation of Listeria antigens to clear Listeria monocytogenes . 185 IRF8 also mediated IRF3 phosphorylation and promoted NLRP3 inflammasome activation during infection with Gram-negative bacteria. 376

Fungal infections

There are a small number of studies focused on the possible relationships between IRFs and fungal infections. Both A.fumigatus ( Aspergillus fumigatus ) and C.albicans ( Candida albicans ) are two major human fungal pathogens. IRF1 induces IRGB10 expression to target the fungal cell wall and cause hyphae damage, modify the A.fumigatus surface and inhibit fungal growth. 294 In addition, IRF1 is a fungal recognition pathway downstream and mice lacking IRF1 are hypersusceptible to systemic C.albicans infection. 377 Besides, C.albicans infection triggers the cGAS/STING pathway by promoting TBK1 recruitment and activation to phosphorylate IRF3 and mediate IFN-I responses, which further regulate antifungal innate immune responses. 378 , 379 IRF5 is required for Dectin-1-mediated IFN-β production in DCs to defense against C.albicans infection. 286 Moreover, IRF5 induces IL-12 production and subsequently generates IFN-γto resist C.albicans , and IRF5 activation blockade significantly increases the susceptibility of Clec2dknockout mice to bloodstream infection with C.albicans . 380 Conversely, IRF7 enhances C.albicans infection by regulating CD209 expression and p53-AMPK-mTOR-induced autophagy to inhibit macrophages phagocytosis and killing capacity. 381

There are also several researches on the relationships between IRFs and F. monophora ( Fonsecaea monophora ) infections. For example, F. monophora can triggers Dectin-1 and then activates IRF1 to mediate IL-12 production, which is crucial for antifungal defenses. 382 On the other hand, F. monophora has been reported to induce the loss of nuclear IRF1 activity, further blocking IL-12A transcription. 382 IRF4 is critical for Treg cell localization and IL-17 expression in Th17 cell to protect against the fungal opportunistic pathogens C.neoformans ( Cryptococcus neoformans ), 383 , 384 and prostaglandin E2 produced by C.neoformans can inhibit IRF4 function as well as IL-17 production to impede antifungal immunity in T cells. 384

IRFs and cancers

Numerous studies have illustrated that the IRF family is important for pathogenesis and therapy of various human cancers (Fig. 8 ). Traditionally, due to their role in inducing IFN-I to mediate tumors immunosurveillance, several IRFs, such as IRF1, IRF3, and IRF7 are regarded as anti-tumorigenic factors. Conversely, IRF2, which is ascribed as a negative regulator of IRF1, has been recognized as a pro-tumorigenic factor and it drives IFN-dependent CD8 + T cell exhaustion to suppress anti-tumor immunity. 8 , 385 IRF1 and IRF7 knockout mice were shown to have the higher metastasis score than wild-type. 386 Besides, activation of the IRF1-X-linked inhibitor of apoptosis-associated factor 1 (XAF1) loop significantly promotes stress-induced apoptosis and restricts the invasive capability of tumor cells. 387 However, both pro-tumor and anti-tumor functions have also been illustrated for different IRF members in human cancers. 388 It has been reported that IRF1 deficiency in tumor cell presented decreased tumor progression and IRF1 is necessary for PD-L1 upregulation in tumor cells and tumor progression in vivo. 389 Conversely, IRF2 is a repressor of PD-L1, and loss of IRF2 in cancers can lead to tumor immune evasion. 390 These diverse findings show a complex role for IRFs members in the inflammatory tumor microenvironment. Fig. 8 The potential role of IRFs in diverse common cancers. IRF family is involved in almost all human cancers, with protective roles or negative roles, and some IRF members are double-edged swords in cancers development

Oesophageal cancer

Oesophageal or esophageal cancer primarily comprises esophageal SCC (ESCC) and esophageal adenocarcinoma (EA/EAC). 391 Several IRF family members have been reported to be implicated in oesophageal cancers. IRF1 expression level was downregulated while IRF2 was upregulated in ESCC compared with normal esophageal tissues. 392 IRF1 suppresses ESCC cell proliferation, while IRF2 acts as an oncoprotein to block the function of IRF1 by preventing its translocation into the nucleus. 392 Additionally, IRF2 decreased endogenous IFNGR1 levels and the loss of IFNGR1 turned to increase the resistance of esophageal cancer cells to antitumor IFN-γ. 393 Huang et al. revealed that lncRNA IRF1 antisense RNA (lncRNA IRF1-AS) was downregulated in ESCC tissues, and it could repress ESCC proliferation and promote apoptosis. Furthermore, IRF1 directly binds to IRF1-AS promoter to activate IRF1-AS transcription. Therefore, IRF1-AS inhibits ESCC progression by facilitating IFN response via a positive regulatory loop with IRF1. 394 Similarly, Watson et al found that IRF1 overexpression inhibited tumor growth in an EA murine model. 395 However, a recent investigation described that high levels of forkhead box M1 (FOXM1c) and IRF1 were positively associated with low survival rate and indicated a poor prognosis of oesophageal cancer patients. 396 FOXM1c functions as a proliferation-associated transcription factor that is pivotal in driving tumorigenesis and progression of cancer, and is overexpressed in oesophageal cancer patients. 396 , 397 IRF1 is a transcriptional target of FOXM1c and can mediate FOXM1c-related ESCC cell invasion and migration to promote oesophageal cancer metastasis. 396 IRF3 single nucleotide polymorphisms (SNPs) may relate to esophageal cancer susceptibility among Chinese patients. 398 In addition, the whole-exome sequencing revealed metastatic ESCCs exhibit frequent mutations in multiple genes, including IRF5. 399 Additionally, genes like IRF7 may contribute to the susceptibility and/or development of esophageal cancer. 400 Sun et al. have identified a positive correlation between the IRF4 protein overexpression and improved outcomes within ESCC. 401

In conclusion, IRF1 serves a dual role in esophageal cancer. IRF1 acts as a tumor suppressor to inhibit esophageal cancer cell proliferation. On the other hand, it functions as a transcriptional target of FOXM1c to mediate FOXM1c-related ESCC cell invasion and migration. In addition, overexpression of IRF2 promotes esophageal cancer cell proliferation and mutations of SNPs in genes such as IRF3, IRF5, and IRF7 may facilitate the progress of esophageal cancers, while IRF4 may be regarded as a protective factor in ESCC.

Gastric cancer (GC)

Both IRF1 and IRF2 can restrict GC cell growth and act as protective factors in GC patients. Mutations of the IRF1 gene, inducing the production of functionally impaired IRF1, are critical for GC development. 402 In fact, IRF1 can induce apoptosis by upregulation of p53 upregulated modulator of apoptosis (PUMA) in GC cells. 403 In addition, IRF1 overexpression can enhance chemosensitivity to 5-fluorouracil in GC cells. 404 Recent studies illustrated that IRF1 could suppress DNA damage response (DDR) and reverse chemoresistance by downregulating P-glycoprotein and DNA repair protein RAD51 homolog 1 (RAD51) in GC. 405 , 406 Moreover, IRF1 can inhibit GC metastasis via downregulating microRNA-18a (miR-18a)/miR-19a and Wingless-related integration site (Wnt)/β-catenin signaling. 407 Similarly, IRF2 is also regarded as a tumor suppressor in GC, and its downregulation by miR-18a can enhance GC cell proliferation, migration, and invasion. 408 Additionally, IRF2 downregulates the expression level of matrix metalloproteinases 1 (MMP1), which promotes GC tumorigenesis, invasion, and metastasis. 409 Moreover, overexpressed IRF2 positively affects the prognoses of GC patients and inhibits cancer proliferation by directly promoting the tumor suppressor adenomatous polyposis coli membrane recruitment 1 (AMER1) transcription and inhibiting the Wnt/β-catenin signaling pathway. 410 On the other hand, a study showed that IRF3 was a risk factor for GC, and increased IRF3 level was negatively associated with survival in GC patients. 411 IRF3 facilitates H. pylori and gastric tumor formation through activating Yes-associated protein (YAP), an important downstream transcription coactivator of Hippo pathway to exacerbate tumor progression. 411 , 412 IRF3 inhibition by amlexanox impedes gastric tumor growth in a YAP-dependent manner. 411 Besides, miR-365 inhibited the TLR4/IRF3 axis to reduce IRF3 phosphorylation and YAP expression to restrict gastric precancerous lesions progression. 413

DNA methylation of IRF4, IRF5, IRF7, and/or IRF8 frequently occurs in GC cell lines and IRF4 methylation is often observed in GC specimens, which may be a useful biomarker for diagnosing the recurrence of GC. 414 , 415 Furthermore, treatment with demethylating agents restores the expression of IRF4, IRF5, and IRF8, which may result in antitumor activity. 414 IRF6 also acts as a tumor suppressor in GC, and its downregulation is clinically correlated with poor prognosis of GC. 416 Bioinformatics analysis indicates that IRF6 expression is negatively associated with its promoter methylation in GC cohorts from The Cancer Genome Atlas (TCGA). 416 Although Yamashita et al. illustrated IRF5 may exhibit antitumor activity in GC, 414 Du et al. indicated that IRF5 was cytoplasm-enriched in GC cells, which promoted GC cell migration by inhibiting expression and inducing degradation of Wnt5a and E-cadherin proteins. 417 IRF7 is an indirect target of circular RNA circ0007360 to exert tumor-suppressive role and attenuate GC progression. 418 A single-cell RNA sequencing revealed that IRF8 was decreased in CD8 + tumor-infiltrating lymphocytes in GC tissues, and patients with lower IRF8 levels in blood CD8 + T cells likely to be at a more advanced GC stage. 419

Overall, IRF1 expression is beneficial for inhibiting the growth of GC cells through inducing tumor cell apoptosis, enhancing sensitivity to chemotherapy drugs, and suppressing the miR-18a/19a and Wnt/β-catenin pathways. In addition, IRF2 can downregulate MMP1 and Wnt/β-catenin pathway, and promote AMER1 transcription to suppress GC proliferation, invasion, and metastasis. Methylation of IRF4, IRF5, IRF6, IRF7, and IRF8 may be associated with GC progression, and demethylation of these factors may increase antitumor activity. However, cytoplasmic IRF5 also can inhibit Wnt/E-catenin and then facilitate GC migration. Furthermore, IRF3 acts as a tumor promoter by activating YAP to exacerbate GC progression.

Liver cancer

Primary liver cancer can mainly be subdivided into hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, and other rare types. 391 IRF1 in HCC pathogenesis is bidirectional, serving as both a tumor promoter and suppressor. On the one hand, IRF1 upregulates PD-L1 expression, which is beneficial for HCC cells to escape from anti-tumor immunity. 420 IRF1 can activate mTOR/STAT3/ AKT serine/threonine kinase (AKT) signaling, upregulating Slug, Snail, and Twist to promote HCC cell invasion, migration, and epithelial-mesenchymal transition (EMT). 421 IRF1 also can activate human endogenous retrovirus-H long terminal repeat-associating 2 (HHLA2) by binding to the promoter region of HHLA2, which induces macrophages M2 polarization and chemotactic migration, leading to HCC immune escape and development. 422 Studies on the suppression of IRF1 activity may target HCC treatments. For example, the activity of IRF1 can be reversed by IL-33 SUMOylation, resulting in impaired antitumor immunity in HCC cells. 423 The overexpression of miR-130b and miR-345, which induces the suppression of IRF1, can markedly inhibit HCC cell migration and invasion. 421 , 424 However, IRF1 also can promote autophagy, cell death, and inhibit growth in HCC cells and mice. 425 , 426 It has been reported that the repression of IRF1 may facilitate the progression from chronic HCV to cirrhosis and HCC. 427 IRF1 has the tumor-suppressor effect and higher expression of IRF1 is associated with better outcomes in HCC patients. 428 , 429 In addition, Yan et al. revealed that IRF1 induces miR-195 to impede checkpoint kinase 1 (CHK1) protein expression, and subsequently upregulates HCC cellular apoptosis, while IRF1 expression or CHK1 inhibition facilitates PD-L1 expression by increased STAT3 phosphorylation. 430 Furthermore, a recent study discovered that IRF1 positively regulates C-X-C motif chemokine ligand 10 (CXCL10) and CXCR3 to induce CD8 + T cells, NK, and NK T cells enrichment and migration, and IFN-γ secretion, causing HCC cells apoptosis, thus overcoming proliferative effects from IRF1-induced PD-L1 expression. 431 Besides, Studies reported that miR-31, miR-23a, and miR-301a may induce HCC progression via the downregulation of IRF1. 432 – 434 Nuclear receptor subfamily 4 group A member 1 (NR4A1) mediates NK cells dysfunction in HCC by inhibiting the IFN-γ/p-STAT1/IRF1 signaling, and NR4A1 deficiency restores the cytotoxicity of NK cells and improves anti-PD-1 therapy efficacy. 435

Although Guichard et al. once identified that IRF2 might be a tumor suppressor gene in HCC and IRF2 inactivation impaired TP53 function, 436 other studies revealed that high expressed of IRF2 was relevant to increased recurrence probability in HCC patients and IRF2 downregulation resulted in significantly decreased invasion ability, combined with decreased STAT3, p-STAT3, and MMP9 in HCC cell lines. 428 IRF2 was found to promote proliferation and inhibit apoptosis of HCC, and increase lenvatinib resistance by upregulating β-catenin, indicating that inhibiting IRF2 is a potential strategy to enhance the therapeutic effect of lenvatinib on HCC. 437 Moreover, major vault protein induces human double minute 2 to liberate from IRF2, which causes P53 ubiquitination and then promotes HCC development. 438 In addition, as a competitive antagonist for IRF1, overexpressed IRF2 can downregulate CXCL10 expression via the inhibition of IRF1/CXCL10/CXCR3 axis and decrease PD-L1 expression via the inhibition of IFN-γ/IRF1 to partially inhibit anti-tumor activity of IRF1 in HCC. 420 , 431

The role of IRF3 in HCC has also been reported with varying outcomes. Yuan et al. showed that the survival rates in HCC patients improved significantly as a function of increased TLR3 and IRF3 expression levels. 439 Moreover, IRF3 was positively associated with TLR3 expression in HCC tissues, which may present a synergistic effect on apoptosis and restrain HCC cells proliferation, MMP2 expression, and angiogenesis. 439 On the other hand, other studies have illustrated that IRF3 has the potential to promote HCC progression. Overexpressed IRF3 was markedly correlated with clinical stages and pathological grades in HCC. 440 HBV-mediated N6 methyladenosine epitranscriptomic regulation of phosphatase and tensin homolog (PTEN), a well-known tumor suppressor, affects innate immunity by inhibiting IRF3 nuclear import and facilitates HCC development by activating the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. 441 Ionizing radiation, the main reason for the failure of radiotherapy, can activate the TBK1/IRF3 pathway, upregulating PD-L1 in HCC cells and restricting CTLs activity and protecting HCC cells from immune-mediated eradication. 442 Disruption of the BRCA1 DNA repair associated-partner and localizer of BRCA2 (PALB2) interaction causes persistent DNA damage in HCC cells, activating the cGAS/STING signaling, which induces PD-L1 expression via the STING/IRF3/STAT1 pathway and then suppresses immune to facilitate HCC tumorigenesis and progression. 443

Yuan et al. revealed that overexpressed IRF4 restricted HCC cell proliferation and migration capacity by inhibiting the JAK2/STAT3 signaling pathway and EMT. 444 Methylation arrays revealed that IRF5 and IRF7 were frequently hypermethylated in HCC tissues. 445 , 446 Furthermore, IRF5 was downregulated in livers of HCV-positive compared to HCV-negative HCC patients or healthy controls, and IRF5 suppressed HCV replication and HCC pathogenesis. 312 The expression of IRF8 was also decreased in HCC samples, and IRF8 overexpression in HCC cells significantly improved antitumor effects in immune-competent mice via regulating the recruitment of tumor-associated macrophages (TAMs), inhibiting CCL20 expression, and promoting anti-PD-1 therapy response. 447 Besides, it has been reported that IRF9 overexpression promoted IFN-induced activity of dsRNA-dependent protein kinase (PKR) in human hepatoma cells. 448 Reduction in IRF9 levels caused resistance to IFN-α2a treatment in HCC cells, 449 and another study showed that disease-free survival (DFS) and overall survival (OS) were better in IRF9-positive versus IRF9-negative patients with HBV-related HCC who received postoperative IFN-α treatment, indicating that IRF9 can act as a predictive marker of outcome after postoperative IFN-α therapy in HBV-related HCC patients. 450

In a word, the roles of IRF1, IRF2, and IRF3 in HCC are complex and bidirectional, exhibiting both tumor-promoting and anti-tumor effects. IRF1 upregulates PD-L1, and HHLA2, and activates the mTOR/STAT3/AKT pathway to facilitate HCC immune escape, invasion, and migration; meanwhile, IRF1 also enhances HCC autophagy and induces miR-195, CXCL10, and CXCR expression to cause HCC cell apoptosis and death. Although IRF2 positively regulates TP53 function to inhibit HCC growth, it also induces β-catenin expression and inhibits IFN-γ/IRF1 and IRF1/CXCL10/CXCR3 axis to suppress HCC apoptosis, enhance HCC proliferation and resistance to therapeutic drugs (Lenvatinib). IRF3 contributes to HCC apoptosis and inhibits HCC proliferation, yet it also causes HCC progression via upregulating PD-L1 expression. IRF4, IRF5, IRF8, and IRF9 act as protective factors to suppress HCC progress.

Pancreatic cancer (PC)

PC is mainly classified into exocrine and neuroendocrine neoplasms, of which pancreatic ductal adenocarcinoma (PDAC) accounts for >85% of pancreatic tumors. 451 IRF1 and IRF2 can regulate PC progression by functioning as an anti-oncoprotein and oncoprotein, respectively. 452 Additionally, IRF1 facilitates 2'3’-cGAMP/BV6/zVAD.fmk-induced necroptosis in PC. 453 Furthermore, the zinc finger protein ZBED2, essential for PDAC progression, can antagonize IRF1-induced transcriptional activation and suppress the pancreatic progenitor transcriptional program, promotemotility, and enhance invasion in PDAC cells. 454 These studies illustrate that IRF1 is a tumor suppressor in PC. Instead, IRF2 promotes PC tumorigenesis, and Cui et al. revealed that IRF2 was upregulated in primary PC tissues and was associated with tumor differentiation, size, tumor-node-metastasis stage, and survival of PC patients. 455 IRF2 inhibits apoptosis effectors to facilitate PC cell growth. 455 PC patients with high IRF2 and IRF6, and low IRF3 levels in tumors had significantly poorer OS. 456 Similarly, a study based on bioinformatics database and proteomics reported that PDAC patients with lower IRF3 expression had shorter OS. 457 However, another study described that IRF3 promoted circRNA ubiquitin-like with PHD and RING finger domain 1 (circUHRF1) expression, which can regulate ADP ribosylation factor like GTPase 4 C (ARL4C) expression and then induce PDAC progression by sponging miR-1306-5p. 458 The role of IRF6 in PC is currently unclear, Xie et al. revealed that IRF6 might be one of the risk genes in pyroptosis-related genes (PRG), and high PRG prognostic index had a lower probability of survival in PC patients based on the TCGA dataset. 459

A recent study showed that IRF4 played a critical role in shaping the immune cell composition within the tumor microenvironment (TME) of murine PC and deficiency of IRF4 accelerated tumor growth and reduced survival, combined with a dense tumor infiltration with polymorphonuclear myeloid-MDSC (PMN-MDSC) and reduced numbers of CD8 + T cells. 460 Similarly, the repression of IRF5 and IRF7 promotes MYC proto-oncogene, bHLH transcription factor (MYC)/ KRAS proto-oncogene, GTPase (KRAS)-dependent evasion of B cells and NK cells in PDAC, and the de-repression of IRF5 and IRF7 results in increased survival. 461 Furthermore, Meyer et al. revealed that reduced IRF8 level in circulating pre-DCs was correlated with decreased OS and relapse-free survival (RFS) in PC patients. 462

In conclusion, IRF1 can suppress mitochondrial respiration and fatty acid synthesis in PC cells and induce PC cell necroptosis. In addition, the inhibition of IRF4, IRF5, IRF7, and IRF8 decreases the survival of PC patients, indicating these IRFs probably act as anti-tumor factors in PC. On the other hand, IRF2 and IRF6 may function as oncogenic proteins due to they are negatively related to PC patients’ survival, and IRF2 can inhibit PC cell apoptosis. Although lower IRF3 is associated with shorter OS for PDAC patients, it upregulates circUHRF1 to induce PDAC progression.

Colorectal cancer (CRC)

IRF1 is a protective factor and functions as a tumor suppressor to prevent CRC progress. Hong et al. revealed that IRF1 expression was reduced in CRC and IRF1 level was inversely associated with CRC metastasis. 463 A study based on bioinformatics methods indicates that CRC patients with higher IRF1 expression presented better RFS time, and the DNA methylation in the IRF1 gene region is indicated to be negatively correlated with IRF1 expression and positively correlated with CRC recurrence. 464 Moreover, IRF1 can promote Ras association domain-containing protein 5 (RASSF5) expression, and then suppress CRC proliferation and metastasis, possibly through downregulating the RAS-Rac family small GTPase 1(RAC1) pathway. 463 IRF1 positively regulates PANoptosis to restrict tumorigenesis in CRC. 275 More recently, Yuan et al. found that IRF1 reduces autophagy related 13 (ATG13) expression to inhibit autophagy and induce apoptosis, which further prevents CRC progression. 465 Besides, upregulated IRF1 can promote the radiosensitivity of CRC both in vitro and in vivo. 91

Sun et al. reported that CRC patients with high exosomal IRF2 content had a poorer OS rate compared to patients with lower exosomal IRF2 content. 466 Exosomal IRF2 can induce vascular endothelial growth factor C (VEGFC) release by macrophages, and inhibition of IRF2 attenuates the lymphatic network remodeling in the sentinel lymph node (SLN) and suppresses the SLN metastasis in CRC. 466 However, Liao et al. revealed that CRC patients with low IRF2 expression may be non-responders to anti-PD-1, while patients with high IRF2 expressional most presented a complete response, partial response, or stable disease. 467 Furthermore, IRF2 suppresses the migration and infiltration of MDSCs by repressing the CXCL3/CXCR2 axis, and IRF2 overexpression in microsatellite instability-high (MSI-H) CRC overcomes the resistance of tumors, expressing KRAS to anti-PD-1 therapy. 467

IRF3 acts as both a tumor promoter and suppressor in different studies. A bioinformatic investigation reported that IRF3 was upregulated in CRC and suggested a shorter survival time in CRC patients. 468 Besides, another study revealed that drugs like wogonin exhibit anti-tumor activity against CRC by downregulating IRF3 expression. 469 However, Tian et al. identified IRF3 as a tumor suppressor and a prognosis marker for CRC patients. 470 IRF3-deficient mice are more susceptible to the development of intestinal tumors and IRF3 negatively regulates the Wnt/β-catenin pathway to prevent tumorigenesis in CRC. 470 In fact, β-catenin may exert oncogene activity in part through impeding the nuclear translocation of IRF3 and then inhibiting the IRF3-mediated immune signaling pathway in CRC cells. 471 , 472 Similar to IRF3, the role of IRF7 in CRC development is also controversial. Chen et al. reported that IRF7 was also upregulated in CRC and suggested a shorter survival time in CRC patients. 468 On the other hand, evidence showed that tumor-infiltrating pDCs with positive IRF7 expression were associated with prolonged survival of CRC patients, 473 and 5-aza-2-deoxycytidine exhibited anti-tumor efficacy via activating MDA5/MAVS/IRF7 pathway in CRC-initiating cells, 474 suggesting that IRF7 may have an anti-tumor effect in CRC.

There are a few researches focused on the role of IRF4, IRF5, IRF6, IRF8, and IRF9 in CRC. Wang et al. revealed that IRF4 was downregulated in colon cancer tissues and that overexpression of RNF2 could increase the ability of proliferation, migration, and invasion in colon cancer cells (SW480 cells) by promoting the ubiquitination and degradation of IRF4. 96 Moreover, Udden et al. showed that NOD2 plays a vital role in the suppression of inflammation and tumorigenesis in the colon via inducing IRF4 and then downregulating the TLR signaling pathways. 475 Integrated multi-omics analyses identified that patients who carried concurrent IRF5 and NEFH mutations had worse survival outcomes. 476 Hu et al. presented that IRF5 probably was a significant mediator of DNA damage signaling and the induction/activation of IRF5 signaling pathway might enhance CRC cell death with chemotherapeutic agents. 477 In addition, Arnold et al. revealed that GM-CSF induced IRF5 activation in eosinophils and then promoted antitumor immunity in CRC. 478 Tan et al. found that IRF6 expression was reduced in CRC and liver metastasis, and IRF6 enhanced CRC cell sensitivity to cisplatin to inhibit cell proliferation, migration, and invasion along with aggravating cell apoptosis. 479 Ibrahim et al. described that human colorectal carcinomas had significantly lower IRF8 expression and higher IRF8 promoter DNA methylation compared to normal colon, and mice with Irf8 deleted in colonic epithelial cells showed higher inflammation-induced tumor incidence. 480 IRF8 can repress osteopontin expression in colon epithelial cells, and IRF8 expression is silenced during the transformation of colon epithelial cells into colon tumor cells, indicating that tumor cells may inhibit IRF8 to upregulate osteopontin, which functions as an immune checkpoint to restrict CTL activation and promote host tumor immune tolerance and evasion. 481 On the other hand, IRF9 may promote CRC development by activating IL-6/STAT3 pathway in CRC models. 482

These evidences illustrate that IRF1, IRF4, IRF5, IRF6, and IRF8 may be candidate tumor-suppressors in CRC. IRF1 enhances RASSF5 expression and CRC cells PANoptosis as well as radiosensitivity to suppress CRC tumorigenesis and progression. IRF5 induces CRC cell DNA damage, and cell death, and enhances antitumor immunity. IRF6 contributes to CRC cell apoptosis and enhances sensitivity to cisplatin chemotherapy. However, the roles of IRF2, IRF3, and IRF7 in CRC are controversial. Although exosomal IRF2 induces VEGFC release and the inhibition of IRF2 suppresses SLN metastasis in CRC, IRF2 also inhibits the CXCL3/CXCR2 axis to prevent CRC, and its overexpression reverses CRC cells’ resistance to anti-PD-1 treatment. Similarly, high expression of IRF3 and IRF7 led to poor survival time in CRC patients. On the other hand, IRF3 suppresses Wnt/β-catenin to inhibit CRC tumorigenesis and IRF7 activation induces anti-tumor activity in CRC cells.

Lung cancer

Lung cancer is divided into two broad categories: the common non-small cell lung cancer (NSCLC) and the relatively rare SCLC. 483 NSCLC can be further divided into lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and large cell carcinoma (LCC). 484 Decreased IRF1 has been reported in NSCLC tissues, 485 , 486 and inhibition of the IRF1/IFN-γ pathway by phosphoserine aminotransferase 1 promotes LUAD metastasis. 487 Frequent genomic aberrations of IRF1 were also found in LUAD metastatic samples by regulator network analysis based on TCGA. 488 IRF1 acts as a prognostic factor for NSCLC and acts as a potential tumor suppressor by suppressing oncogenic protein Karyopherin alpha 2 (KPNA2) gene expression in LUAD cells. 485 Zhang et al. revealed that the first-line NSCLC chemotherapy drug cisplatin, could induce IRF1 activation in vitro, which further enhanced mitochondrial depolarization, oxidative stress, apoptotic cell death, and suppressed autophagy in NSCLC A549 cells, 486 indicating that IRF1 is a possible target for promoting the sensitivity to cisplatin therapy in NSCLC.

The possible function of IRF2 in lung cancer is unclear. A few studies demonstrated that both miR-18a-5p and miR-1290 promote NSCLC proliferation and invasion by suppressing IRF2. 489 , 490 Moreover, lncRNA GAS5 and CASC2 can inhibit the progression of NSCLC and repress cisplatin resistance of NSCLC in vitro and in vivo through inhibiting miR-221-3p and miR-18a, thus increasing IRF2 expression in NSCLC cells, respectively. 491 , 492 However, another study reported that miR-450 could inhibit lung cancer progress by downregulating IRF2 in vitro and in vivo. 493 These researches indirectly indicate that IRF2 acts as both a protective and risk factor in NSCLC.

Yi et al. revealed that overexpressed IRF3 induced the apoptosis of NSCLC cells and phosphorylated IRF3 (p-IRF3) was decreased in NSCLC samples. 494 Gong et al. presented that inhibiting mutant epidermal growth factor receptor (EGFR) activated the RIG‑I/TBK1/IRF3 pathway and then resulted in a tumor-suppressive role in NSCLC with EGFR-activating mutations. 495 Zhang et al. found that Niraparib and radiation synergistically inhibited tumor immunity in EGFR-mutated NSCLC both in vitro and in vivo, accompanied by increased CD8 + T lymphocytes and the STING/TBK1/IRF3 pathway activation. 496 Similarly, other studies described that inhibition of WEE1 G2 checkpoint kinase (WEE1) or use of carboplatin or other DDR inhibitors could activate the STING/TBK1/IRF3 pathway, promoting the antitumor immune response to PD-L1 blockade in lung cancer models. 497 – 499 In addition, Long et al. illustrated that G protein-coupled receptor 162 could act as a novel radiotherapy sensitizer by interacting with STING, which then promoted DDR and activated IRF3 to inhibit the occurrence and development of tumors in lung cell lines. 500

Some studies reported that IRF4 in peripheral mononuclear cells was a protective prognostic factor in NSCLC patients and LUAD patients with high IRF4 expression correlated with significantly longer OS. 501 , 502 Another study pointed out that IRF4 in tumor tissues was associated with poorer survival of NSCLC patients. 503 In fact, IRF4 facilitates macrophages M2 polarization, and the E74 like ETS transcription factor 4 (ELF4)/IRF4 pathway activation by exosomal circZNF451 in LUAD patients reshapes the immunosuppressive TME and impedes the effect of PD-1 blockade treatment. 504 IRF4 downregulation by liver X receptors (LXR) contributes to the anti-tumoral effects of LXR activation in lung carcinoma models. 505 Besides, thigh-dimensional single-cell profiling of T cells from chemotherapy-naive patients with NSCLC revealed that IRF4 + CD4 + effector Tregs suppress antitumor immunity through expressing molecules related to enhanced immunosuppression. 506

Feng et al. found reduced IRF5 expression in human NSCLC tissues, 507 while Guo et al. revealed that IRF5 level was significantly higher in the peripheral blood of NSCLC patients. 508 Yamashina et al. identified IRF5 as a specific factor for cancer stem-like cells from chemoresistant tumors and it was important for M-CSF and tumorigenic myeloid cellsgeneration. IRF5/M-CSF pathway activation in tumor cells was correlated with the number of tumor-associated CSF1 receptor + M2 macrophages in NSCLC patients. 509 IRF6 level was also reported to be upregulated in both LUAD and LUSC tissues, and inhibition of IRF6 revealed the antitumor effects in lung cancer cells. 510 Huang et al. demonstrated that higher IRF7 levels in LUAD tumors were associated with higher microvessel density in LUAD tissues, potentially responsible for the hemorrhage outcomes following bevacizumab treatment. 511 Besides, IRF7 can enhance constitutive PD-L1 expression though directly promoting transcription of PD-L1 and tumor cell immune evasion, and methylated IRF7 is negatively correlated to PD-L1 expression in NSCLC. 512

Suzuki et al. revealed that the IRF8 methylation level was significantly higher in NSCLC specimens compared to non-malignant lung tissues, and that IRF8 methylation may act as a prognostic marker for NSCLC recurrence. 513 In addition, Liang et al. showed that IRF8 expression was frequently diminished in lung tumoral tissues, and IRF8 induced lung cancer cell senescence through inhibiting AKT signaling and promoting P27 protein accumulation. 514 However, survival analyses based on the TCGA database reported that LUAD patients with higher expression levels of IRF8 were associated with poor survival. 515 IRF9 has been reported to be overexpressed in lung cancer and is associated with poor survival, promoting lung cancer progression via the upregulated expression of oncogene versican. 516

In conclusion, IRF1 and IRF3 present inhibitory functions in lung cancer. IRF1 activation induces lung cancer cell death and suppresses KPNA2 expression to inhibit LUAD growth. IRF1/IFN-γ inhibition facilitates LUAD metastasis. IRF3 contributes to NSCLC apoptosis and the activation of RIG-I/STING/TBK1/IRF3 pathway inhibits NSCLC growth and increases antitumor immunity. Conversely, IRF5, IRF6, IRF7, and IRF9 may induce lung cancer progression. IRF5/CSF activation facilitates tumor-associated M2 expression, and IRF7 induces PD-L1 production. IRF9 increases versican expression,which is associated with poor survival in lung cancer patients. Decreased IRF6 showed an antitumor effect. The detailed functions of IRF2, IRF4, and IRF8 in lung cancer are complex and controversial. On the one hand, IRF2 inhibition by miR-18a-5p and miR-129 induces NSCLC proliferation and invasion. However, IRF2 inhibition by miR-450 suppresses lung cancer cells’ progress. IRF4 overexpression causes poor survival in NSCLC patients, and ELF4/IRF4 axis activation causes M2 polarization to promote LUAD. Inhibition of IRF4 facilitates the LXR anti-tumor effect; while other studies have shown that IRF4 expression contributes to long OS in lung cancer patients. IRF8 has been reported to suppress ATK and induce P27 expression to cause lung cancer cell senescence, and IRF8 methylation leads to NSCLC recurrence. Another report showed that IRF8 upregulation was associated with poor survival of LUAD patients.

Ovarian cancer (OC)

Transcriptome analysis identified IRF1 was associated with platinum sensitivity, and its overexpression was correlated with increased OS and progression-free survival in high-grade serous OC (HGSOC). 517 However, another study revealed that IFN-γ induced IRF1 expression, which was followed by increased PD-L1 expression in OC cells, and IRF1 inhibition attenuated the IFN-γ-induced gene and PD-L1 protein levels. Moreover, IFN-γ-induced PD-L1 expression is modulated by the JAK1/STAT1/IRF1 pathway in OC. 518 Additionally, activation of the TLR4/IL-6/IRF1 signaling causes androgen receptor (AR) upregulation and taxol resistance genes transactivation in OC. 519 Furthermore, the chemotherapeutic drug cisplatin upregulates IRF1 expression, which in turn limits the cell response to cisplatin in OC cells, 520 indicating that IRF1 is a potential target in OC chemoresistance and progression.

Zhang et al. showed that deubiquitinase USP35 was significantly elevated in cisplatin-resistant OC cells, partially inhibiting the STING/TBK1/IRF3 pathway and then resisting the antitumor effect of IFN-I. 521 On the other hand, POL I inhibitor CX-5461 activates cGAS/STING/TBK1/IRF3 pathway, increasing immunotherapy efficacy in OC. 522 The immunostaining analysis showed that IRF4 was expressed in most HGSOC patients; 523 however, the possible function of IRF4 on OC remains unclear. Zhang et al. illustrated IRF5 overexpression in combination with its activating kinase IKKβ reprogramed TAMs to a phenotype that induced anti-tumor immunity and promote tumor regression in OC model. 524 In addition, IRF9 was reported to be the critical upstream regulator to mediate growth-inhibitory effects of IFN-α on OC cells, and the anti-tumoral effect of chemerin on OC cells in vitro was regulated by the activation of IFN-α response genes via IRF9. 525 , 526 Therefore, IRF3, IRF5, and IRF9 may be protective and function as anti-tumor factors in OC.

Prostate cancer (PCa)

Adenocarcinoma is the major type of PCa. 527 Bioinformatics analysis revealed that IRF1 was a tumor suppressor within this core transcriptional regulatory network in modulating PCa cell proliferation. 528 IRF1 was also associated with necroptosis in the prostate adenocarcinoma cell line PC-3 cells, 529 and oncogenic factor the Deltex-3-like E3 ubiquitin ligase (DTX3L) can induce proliferation and survival of metastatic PCa cells via the inhibition of IRF1. 530 Wu et al. identified that IRF8 expression was increased in primary PCa but reduced in castration-resistant prostate cancer compared with normal prostate tissue. 531 IRF8 promoted the degradation of the AR and decreased IRF8 facilitated AR-induced PCa progression and enzalutamide resistance, indicating that IRF8 may act as a tumor suppressor in PCa pathogenesis and represent a potential therapeutic option to defeat enzalutamide resistance. 531

Although the detailed function of IRF2, IRF3, and IRF7 in PCa remain unclear, studies demonstrated that miR-221 could inhibit cell growth and invasiveness, and induce cell apoptosis, in part by suppressing IRF2 and SOCS3 in PCa cells, and anti-cancer drug nobiletin inhibits PCa cell growth through suppressing TLR4/TRIF/IRF3 and TLR9/IRF7 pathways. 532 , 533 On the contrary, Zhao et al. illustrated that IRF7 overexpression in PCa cells had a marked effect on inhibiting bone metastases in xenograft nude mice. 534

Renal cancer

IL-4 was reported to increase IRF1 expression, which then inhibited the proliferation of human renal cell carcinoma (RCC) cell lines. 535 Tomita et al. demonstrated that IFN-γ induced STAT1/IRF1 activation, followed by caspase-7-mediated apoptosis in RCCs cell line ACHN cells. 536 However, with IFN-γ stimulation, activation of JAK2/STAT1/IRF1 signaling also induced PD-L1 expression in both WT- and Mut-VHL clear cell RCC (ccRCC) cells. 537 IRF3 was overexpressed in ccRCC and significantly associated with worse clinical outcomes and adverse OS in ccRCC patients based on databases. 538 The multi-omics analysis on ccRCC samples extracted from Gene set enrichment (GSE) and TCGA data sets identified IRF4 as a protective factor in ccRCC. 539 Moreover, Wang et al. illustrated that Zinc finger protein 692 induced tumorigenesis in ccRCC via the transcriptional repression of IRF4 and other genes. 540 IRF6 expression was reduced in ccRCC tissues and cell lines, and downregulated IRF6 was associated with worse clinicopathological features and poorer prognosis. 541 IRF6 inhibited ccRCC cell proliferation, invasion, and migration at both the cellular and animal levels which may be through the inhibition of kinesin family member 20 A (KIF20A). 262 Studies illustrated that IRF7 was one of upregulated differentially expressed genes in ccRCC samples and patients with high IRF7 expression presented a relatively worse survival rate. 542 , 543 CircEGLN3 sponged miR-1299 to enhance the IRF7 level, which is responsible for RCC cell proliferation and aggressiveness in vitro. 543 It was reported that ccRCC patients with high IRF8 expression within metastatic sites had longer OS than those with low IRF8 expression. 544 IRF8 was identified to inhibit RCC cell colony formation and migration through promoting cell cycle G2/M arrest and apoptosis, upregulating tumor suppressor genes like caspase-1, p21, and PTEN expression, and inhibiting oncogenes YAP1 and survivin expression. 545 However, Nixon et al. revealed that TAMs expressed IRF8 to promote T cell exhaustion in RCC and other cancers, and ccRCC patients with abundant CD8 + T cell infiltration might have worse survival if they expressed higher IRF8-TAM gene signature. 546

In conclusion, IRF1 and IRF8 have dual effects on renal cancers. IRF1 can inhibit RCC proliferation, and STAT1/IRF1 activates caspase-7-mediated apoptosis in RCC cells; meanwhile, the JAK2/ STAT1/IRF1 pathway also induces PD-L1 expression in ccRCC cells. Similarly, IRF8 induces G2/M arrest and cell apoptosis, upregulates tumor suppressors p21, and PTEN and inhibits oncogenic YAP1 and surviving, thus suppressing RCC cell colony formation and migration; but IRF8 + TAMs promote T cell exhaustion, which is associated with worse survival in ccRCC patients. IRF3 and IRF7 may be oncogenic factors due to they are associated with worse outcomes and survival in ccRCC patients, and IRF7 facilitates RCC cell proliferation and aggressiveness. On the other hand, IRF4 and IRF6 are tumor suppressors. ZNF692 represses IRF4 to induce ccRCC tumorigenesis and IRF6 inhibits cRCC cell proliferation, invasion, and migration.

Leukemia

The most common leukemias are acute myeloid leukemia (AML), acute lymphocytic leukemia/lymphoma (ALL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and CML. There are also some relatively rare leukemias, such as chronic myelomonocytic leukemia (CMML) and adult T-cell leukemia/lymphoma (ATL). IRF1 plays a vital role in myeloid differentiation by acting as a tumor suppressor gene in leukemia, and mutations in IRF1 are likely to influence IRF1 and its DNA binding affinity, leading to the inhibition of cancer suppression. 547 Semmes et al. identified IRF1 SNP as one risk locus in ALL. 548 . Massimino et al. showed that IRF5 exerted antiproliferative effects, inhibited B-cell receptor (BCR)-ABL signaling, and increased the cytotoxicity of imatinib mesylate in both immortalized and primary CML cells. 549 Mathew et al. presented that with sorafenib treatment, active IRF7 (p-IRF7/t-IRF7) levels were increased in both mouse and human leukemia cells, which then facilitated IL-15 production. This, in turn, promoted immune memory against tumor cells, inducing an immune-mediated cure of AML FLT3-ITD -relapse. 550 Moreover, IRF7 overexpression decreased AML cell proliferation and leukemia stem cell levels, while IRF7 knockout accelerated AML progression and induced vascular cell adhesion molecule 1 (VCAM1)- very late antigen 4 (VLA-4) mediated intracerebral invasion in AML mouse models. 551 In addition, IRF7/stress-activated protein kinase (SAPK)/JNK pathway activation resulted in more M1 characteristics and contributed to prolonged survival in leukemia mice. 552 Tian et al. revealed that both IRF9 mRNA and protein levels were decreased in human AML samples. 553 IRF9 is a negative regulator for AML, which binds with the SIRT1 promoter, represses SIRT1 expression, and promotes p53 expression to inhibit AML cells proliferation, colony formation, and survival. 553 These evidences suggest that IRF1, IRF5, IRF7, and IRF9 are tumor suppressors in leukemia.

However, studies revealed that IRF2 and IRF3 act as oncoproteins in leukemia. IRF2 promotes inositol polyphosphate-4-phosphatase, type-II (INPP4B) expression, which then facilitates AML cell growth and colony formation, and IRF2/INPP4B pathway activation represses apoptosis through induction of autophagy combined with the inhibition of Th1 cell differentiation and promotion of Th2 cell differentiation in AML cells. 554 – 556 In addition, the inhibition of IRF2 and the IRF2/INPP4B axis by miR-222-3p exposed to human bone marrow mesenchymal stem cells (hBM-MSCs-Exo) suppressed proliferation and promoted apoptosis of AML cells; while overexpressed either IRF2 or INPP4B resisted the proliferation-inhibitory and pro-apoptotic effects mediated by BM-MSCs-Exo. 557 Tian et al. showed that both IRF3 mRNA and protein levels were significantly increased in AML samples than in those from healthy controls. 558 The inhibition of IRF3 restricted AML cell proliferation and colony formation, and promoted AML cell apoptosis, whereas overexpression of IRF3 promoted AML cell survival, which was positively correlated with the oncogenic presence of miR-155 in AML. 558

A genome-wide association study (GWAS) study revealed that IRF4 was a major susceptibility gene for CLL and AML. 559 , 560 Higher IRF4 levels attenuated BCR signaling by negatively regulating the expression of the spleen tyrosine kinase (SYK) and IKAROS in CLL cells. 561 Additionally, murine CLL with low B cell-specific IRF4 expression showed a poorer prognosis due to enhanced tumor immune evasion. 562 Furthermore, IRF4 expression in CD3 + T cells from CML patients was significantly reduced. 563 CML patients who achieved an early molecular response had higher IRF4 values at both diagnoses and after 3 months of therapy compared to those who did not achieve early molecular response. 564 In addition, PU.1 can collaborate with IRF4 and IRF8 to repress pre-B-cell leukemia. 565 It was found that repression of IRF4 by miR-125b induced both myeloid and B-cell leukemia in vitro. 566 However, Sun et al. demonstrated that miR-155-5p inhibited IRF4 protein degradation, thereby promoting cyclin dependent kinase 6 (CDK6) expression and facilitating childhood ALL development. 97 IRF4 is also an oncogenic transcription factor in adult ATL. IRF4 gene was expressed higher in ATL cells than in normal T cells, and overexpression of IRF4 induced the upregulation of oncogenes such as MYC and baculoviral IAP repeat-containing protein 3 (BIRC3). 567 Moreover, the CDK9 inhibitor alvocidib could downregulate super-enhancers-mediated IRF4, thereby inhibiting ATL cell proliferation. 568

Watanabe et al. demonstrated that IRF8 expression was downregulated in CML patients, and Irf8 -/- mice developed a CML-like disease. 569 IRF8 partially suppressed CML development in vivo through a Fas-dependent apoptosis mechanism. 570 IRF8 acts as a roadblock for β-catenin-driven leukemia. The deletion of IRF8, combined with constitutive β-catenin activation, resulted in the progression of CML into a fatal blast crisis and imatinib resistance. 571 Additionally, the loss of IRF8 facilitates the initiation of acute promyelocytic leukemia (APL). 572 Furthermore, IRF8 has been shown to suppress T-cell ALL proliferation and invasion by suppressing the PI3K/AKT pathway. 573 However, some studies have found that high IRF8 expression was associated with poorer prognoses in AML patients, and IRF8 loss inhibited AML cell growth. 574 , 575 Pingul et al. uncovered that the transcriptional circuit of myocyte enhancer factor 2D (MEF2D)/IRF8 was required for AML maintenance. 576 , 577

The single-cell RNA sequencing study demonstrated that CMML-2 stem cells from CMML patients were characterized by highly expressed regulome associated with IRF1, IRF7, and IRF8, factors that are highly expressed in monocytic lineage differentiation. 578 However, the detailed functions of these IRF members in CMML require further exploration.

Multiple myeloma (MM)

The roles of IRF1 and IRF3 in MM are complex. Wang et al. demonstrated that all-trans retinoic acid activated the retinoic acid receptor γ and IFN-β response pathway, which induced IRF1 overexpression to initiate 2’-5’-oligoadenylate synthetase 1 (OAS1) transcription. This caused cellular RNA degradation and cell death, enhancing MM sensitivity to carfilzomib (Cfz)-induced cytotoxicity and resensitizing Cfz-resistant MM cells to Cfz in vitro. 579 Additionally, drug MEDI2228 activated the cGAS/STING/TBK1/IRF3 and STAT1/IRF1-induced IFN-I pathway to fight MM cell immune evasion. 580 Moreover, macrophage inflammatory protein 1α (MIP-1α) induced osteoclast formation through activating the MEK/ERK/c-Fos pathway and suppressing the p38 map kinase (p38MAPK)/IRF3 pathway and IFN-β expression in MM. 581 However, Liu et al. found that myeloma cell-secreted 2-deoxy-D-ribose induced the STAT1/IRF1 pathway activation and then upregulated CIITA expression in osteocytes to facilitate myeloma-induced bone lesions. 582 In myeloma plasma cells, the interaction of ZBP1 with TBK1 and IRF3 causes IRF3 phosphorylation, which allows IRF3 to directly bind to and activate cell cycle genes, in part through cooperation with IRF4, promoting myeloma cell proliferation in MM. 257

IRF4 is highly expressed in MM cells and is strictly required for MM cell survival, downregulating pro-apoptotic BCL2-modifying factor (BMF) and BCL2L11. 583 Moreover, the oncogenic MAF bZIP transcription factor (MAF) activated enhancers and super-enhancers in B cells and plasma cells and cooperated with the plasma cell IRF4 to endow myeloma plasma cells with migratory and proliferative transcriptional potential. 584 Overexpression of IRF4 and the oncogene c-Myc is a major mechanism of lenalidomide resistance in MM. Inhibition of SUMOylation enzymes suppressed IRF4 gene transcription and reduced IRF4 protein level by enhancing IRF4 degradation to enhance lenalidomide sensitivity. 585 In addition, lenalidomide selectively degraded IKZF1, leading to IRF4 repression and IRF5 increase, which then promotes macrophage polarization from an anti-inflammatory M2-like phenotype toward a tumoricidal M1 phenotype. 586 IRF4 down-regulation inhibited tumor formation and myeloma dissemination, eradicated myeloma progenitors, and improved survival and sensitivity to myeloma drugs. 587 , 588 The bioinformatics analysis revealed that IRF7 was an important immune-related gene in MM patients, and it could promote tumor progression in vitro. 589 An IRF8 mutation was reported in MM patients by the GWAS. 590 In Myeloma cells, heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1) upregulated miR-92a-2-5p and miR-373-3p expression, activating osteoclastogenesis and suppressing osteoblastogenesis through inhibiting IRF8 or RUNX family transcription factor 2 (RUNX2) to drive MM osteolytic bone disease. 591 These studies reveal that IRF4 and IRF7 are oncogenic, while IRF5 and IRF8 may act as tumoricidal factors in MM.

Myelodysplastic syndrome (MDS)

Although IRF1 is regarded as a tumor suppressor in pre-leukemia myelodysplasia, 547 it has been reported that myelodysplasia patients without IRF1 expression had a decreased incidence of autoimmune manifestations, indicating that IRF1 may increase the probability of autoimmune phenomena in MDS, companied by a decline in quality of life. 592 , 593 Compared to controls, MDS patients displayed upregulated expression of IRF2, IRF3, and IRF7. 594 TLR3 hyperactivation can induce IRF3, IRF7, and NF-κB translocating to the nucleus, which then activates IFN-α/β transcription to promote the IFN response and result in aggressive MDS. 595 The GWAS and bioinformatic analysis showed that IRF4 was a major susceptibility gene for MDS, and patients with IRF4 alterations presented worse OS than those without alterations. 560 , 596

Head and neck SCC (HNSCC)

Wang et al. demonstrated that the inhibition of CTLA4 activated CD8 + T cells and increased IFN-γ and TNF-α levels, which in turn induced the STAT1/IRF1 axis activation to trigger tumor cell pyroptosis with tumor cell death in HNSCC cell lines. 597 IRF2-induced claudin-7 upregulation to suppress oral SCC cell lines proliferation, invasion, and migration. 598 The m6A demethylase alkB homolog 5, RNA demethylase (ALKBH5) overexpression inhibited RIG-I protein, resulting in the downregulation of IFN-α secretion mediated by the IKKε/TBK1/IRF3 axis. This reduction leads to reduced immune-killing cell infiltration and facilitates HNSCC progression and immune evasion. 599 Yan et al. displayed that Irf6 loss triggered rapid HNSCC development in mouse models, while Notch/Ripk4/Irf6 axis activation suppressed tumor growth in vitro. 600 These findings illustrate that IRF1, IRF2, IRF3, and IRF6 play an inhibitory effect on HNSCC.

Nasopharyngeal carcinoma (NPC)

IRF1 has been identified as one of the motifs enriched in the NPC unique cluster; 601 however, the deeper function of IRF1 in NPC remains unclear. The IRF2 motif is also enriched in the NPC unique cluster, 601 and IRF2 promotes centromere protein N (CENP-N) expression in NPC cells, further facilitates NPC cell proliferation, cell cycling, and apoptosis resistance, alongside increased aerobic glycolysis. 602 Ge et al. demonstrated that circBART2.2 promoted PD-L1 expression via activating IRF3 and NF-κB in NPC, thereby inducing tumor immune escape. 603 These studies suggest that IRF2 and IRF3 likely act as tumor promoters in NPC. On the other hand, Xu et al. demonstrated that IRF6 was reduced in highly metastatic NPC cells, cancer stem-like NPC cells, and NPC animal models. 261 IRF6 directly restricts ATP-binding cassette sub-family G member 2 (ABCG2) expression in NPC cell lines and NPC tissues, resulting in the inhibition of NPC cancer cell proliferation, colony formation, and self-renewal. 261

Cholangiocarcinoma (CCA)

IRF1 was found to be low expressed in CCA, and IRF1 acted as a tumor suppressor in regulation of CCA cell proliferation, cell cycle, migration, and invasion. 604 Moreover, miR-383 could enhance proliferation, migration, and invasion of CCA cells via negatively regulating IRF1. 605 Instead, IRF4 could upregulate lncRNA SOX2-OT, which further upregulated SOX2 and activated PI3K/AKT pathway to promote CCA cell proliferation and metastasis. 606

Breast cancer (BC)

The potential roles of IRF1 and IRF9 in BC are controversial. IRF1 was found to be overexpressed in patients with highly aggressive BC subtypes, facilitating EMT, migration, dissemination, and metastasis formation. 607 Moreover, Wu et al. showed that ubiquitin ligase E3 component N-recognition protein 5 (UBR5) enhanced PD-L1 transactivation by upregulating PKR, STAT1 and IRF1 to induce tumorigenesis in triple-negative breast cancer (TNBC). 608 On the other hand, IRF1 can upregulate autophagy and apoptosis, and inhibit NF-κB activity to inhibit BC cell growth. 609 , 610 IKKε showed its oncogenic potential by accelerating IRF1 degradation and inhibiting IRF1 transcriptional activity in a BC cell line. 53 Luker et al. reported that IRF9 overexpression caused resistance to antimicrotubule agents in BC cells. 611 However, Brockwell et al. displayed that IRF9 was a marker of reduced risk of distant relapse, and IRF9 loss was a poor prognostic biomarker for pre-chemotherapy in TNBC. 612

Studies have revealed that IRF2, IRF3, IRF4, IRF5, IRF6, and IRF8 are protective factors in BC progression. Kriegsman et al. revealed that IRF2 negatively regulated PD-L1 expression to inhibit BC immune evasion. 390 IRF3 was shown to facilitate retinoic acid (RA)/polyinosinic-polycytidylic acid (poly(I: C))-induced apoptosis in BC cells, driving the death of BC cells. 613 Activated cGAS-STING-IRF3 pathway by cGAMP reversed the EMT and PI3K/AKT pathways and prevented TNBC metastasis. 614 STING/TBK1/IRF3 pathway activation to recruit CD8 + T cells is a critical determinant of the therapeutic efficacy of PARP inhibition in TNBC. 615 IRF4 was regarded as a tumor suppressor and higher IRF4 expression was associated with improved outcome in node-negative BC. 616 , 617 Overexpression of IRF5 in BC cells inhibited in vitro and in vivo cell growth, and migration, and sensitized them to DNA damage. Additionally, IRF5 downregulation was correlated with increased invasiveness in human ductal carcinoma. 618 , 619 IRF6 was downregulated in highly invasive BC cell lines, but increased in poorly aggressive ones, and drugs like bortezomib and lapatinib upregulated IRF6 expression to inhibit BC growth. 620 – 622 BC-produced GSF decreased IRF8 in cDC progenitors, which was followed by reduced cDC1 and subsequently impeded immune surveillance in BC, impairing anti-tumor CD8 + T-cell responses and causing poor outcomes in BC patients. 462 Additionally, IRF8 deficiency negatively impacted BC therapeutic efficacy. 623

Cervical cancer (CC)

The most common histological subtype of cervical cancer (CC) is SCC, followed by adenocarcinoma. 624 The human papillomavirus 16 (HPV16) E6 oncoprotein facilitates CC growth and angiogenesis, while IRF1 inhibits tumourigenesis and the angiogenic activity of HPV16 E6 in CC. 625 In addition, patients with overexpressed IRF1 in pretreatment CC biopsy cells had a significantly better response to neoadjuvant radio/chemotherapy, and STAT3/IRF1 pathway activation sensitizes CC cells to chemotherapeutic drugs. 626 IFN-γ/IRF1 signaling also upregulates P27, which inhibits the expression and telomerase activity of human telomerase reverse transcriptase (hTERT), thereby resulting in the inhibition of CC. 627 IRF4 low expression is associated with a significantly poorer OS in CC patients. 628 Similarly, it has been reported that IRF6 expression was significantly downregulated in CC specimens and cell lines, and miR-587 could repress IRF6 protein expression to abrogate the antineoplastic activity of IRF6 in CC cells and promote HeLa tumor growth. 629 These results indicate that the loss of IRF1, IRF4, and IRF6 expression facilitates CC development, and IRF1 pathway activation may be beneficial for enhancing the efficacy of CC chemotherapeutic drugs.

Endometrial cancer (EC)

Although Kuroboshi et al. reported that IRF1 expression was decreased in human endometrioid adenocarcinoma compared with normal endometrium and postmenopausal endometrium, 630 Gao et al. revealed that enhanced IRF1 protein stability may upregulate PD-L1 in ECs and promote tumor immune escape. 631 Zeng et al. presented that IL-6 enhanced reactive oxygen species (ROS) generation and induced mtDNA leakage in EC cells, which further activated the cGAS/STING/TBK1/IRF3 pathway, subsequently PD-L1 production, leading to tumor immune escape. 632 The adenosine deaminase family acting on RNA1 (ADAR1) knockdown induced the expression of IRF7 and other proteins, which in turn resulted in apoptosis in EC cells. 633 Therefore, IRF1 and IRF3 probably promote EC cell’s immune escape via PD-L1 production, while IRF7 may inhibit EC growth via inducing apoptosis, which is needed for further investigation.

Melanoma

NF-κB/IRF1 axis activation, in association with cDC1s, was linked to better clinical outcomes to improve cancer immunotherapy in melanoma patients. 634 A bioinformatic analysis revealed that IRF1 expression might act as a biomarker indicating CD8 + T cell infiltration in melanoma. 635 Compared to healthy controls, patients with metastatic melanoma had a significantly lower level of IRF1 signaling molecules in their peripheral blood lymphocytes. 636 On the other hand, Yokoyama et al. revealed that SOX10 repressed IRF1 transcription via directly inducing IRF4, which then impaired PD-L1 expression in melanoma cells. 637 Under ultraviolet radiation treatment, IRF3 formed a transcriptional complex with NF-κB/p65 to promote PD-L1 transcription and reduced CD8 + T-cell-mediated cytotoxicity, thereby facilitating immune evasion of oncogenic melanocytes and melanoma development. 638 However, Type 2 transglutaminase negatively regulated IRF3 activation, resulting in reduced IFN-β expression and inducing immune evasion of melanoma cells. 639 Moreover, Musick et al. found that IRF3 overexpression reduced tumor growth in a melanoma mouse model. 640 Humblin et al. identified that IRF8 was essential for IL-9-producing Th9 cells anti-tumor effects in mouse melanoma models. 641 Wang et al. illustrated that the IRF9/STAT2 signaling activation induced adaptive resistance to BRAF inhibitor therapy in melanoma by inhibiting gasdermin E (GSDME)-dependent pyroptosis in melanoma cells and in a xenograft tumor model. 642 Moreover, the loss of stromal antigen 2 activated IRF9, which in turn enhanced IFN-I signaling and PD-L1 expression in melanoma. 643

Osteosarcoma

Ectopic expression of IRF1 induced caspase-7 and Bcl-2 downregulation to activate apoptosis in cell lines of Ewing’s sarcoma. 644 IRF1 activated miR-134 to inhibit osteosarcoma cell proliferation, invasion, and migration both in vitro and in vivo. 645 Moreover, IRF1 positively regulated growth arrest specific 5 (GAS5) expression, causing upregulation of downstream tumor suppressors in osteosarcoma cell lines. 646 Suppression of IRF1 expression by miR-4295 overexpression promoted osteosarcoma cell proliferation, migration, and invasion. 647 Similarly, it was reported that the inhibition of IRF2 by miR-18a-5p promotes osteosarcoma cell invasion and migration. 648 STING/IRF3/ IFN-β pathway activation by a sodium-glucose cotransporter 2 (SGLT2) inhibitor significantly inhibited osteosarcoma growth in vivo. 649 Higher IRF7 expression tended to a better prognosis in osteosarcoma patients, and IRF7 inhibited PKM2 expression to interfere with the Warburg effect in osteosarcoma cells. 650 , 651

Gliomas

IRF1 enhanced LGALS-9 transcription to encode galectin 9 (Gal-9) protein and then drive macrophage M2 polarization. In turn, these macrophages secreted vascular endothelial growth factor A (VEGFA) to promote angiogenesis and glioma growth. 652 Overexpression of IRF2 protected glioma cells from ferroptosis and enhanced their invasive and migratory abilities in vitro. 653 On the other hand, IRF3 was reported to inhibit glioma proliferation, migration, and invasion. 654 – 656 Yang et al. presented that a therapeutic nanosystem (SPP-ARV-825), targeting the bromodomain and extraterminal-containing protein family 4 (BRD4)-degrading proteolytic chimera, could inhibit IRF4 promoter transcription and STAT6, STAT3, and AKT phosphorylation. This inhibition attenuated cell proliferation, induced cell apoptosis, and suppressed M2 macrophage polarization, leading to an antitumor effect in the glioma xenograft model. 657 Li et al. showed that the knockdown of Gal-9 activated the TLR7/IRF5 pathway, which facilitated macrophages M1 polarization and enhanced CD8 + T cells anti-tumor effect in glioblastoma. 658 IRF6 inhibited PKM2 and GLUT1 transcription to impair glycolysis and cell proliferation, and induce apoptosis in glioma cells. Furthermore, IRF6 overexpression reduced glioma xenograft tumor growth and prolonged nude mice survival. 263 In addition, activation of the TLR7/MyD88/IRF5/IRF7 pathway induced IFN-β secretion, which then stimulated NK cells to eradicate glioma cells. 659

IRFs and inflammatory and autoimmune diseases

Inflammatory bowel disease (IBD)

Tang et al. found that IRF1 was upregulated in human IBD and dextran sulfate sodium (DSS)-induced mice colitis. 660 They also identified that TNF-α-mediated IRF1 activation suppressed osteopontin expression to inhibit p-AKT, p-P38, and p-ERK activities, and aggravate apoptosis and intestinal epithelial cell injury. 660 IRF1 deficiency could restrict TNF-α-induced intestinal epithelial cells shedding to maintain intestinal barrier integrity. 661 Moreover, downregulation of IRF1 expression by miR-24-3p was found to promote M2 polarization and subsequently reduced hyperinflammation-induced damage in the murine colon. 662 Wang et al. showed that increased activation of IRF3 and IRF7 facilitated inflammatory chemokines expression and promoted excessive intestinal inflammation in LPS-responsive beige-like anchor-deficient mice. 663 However, Chiriac et al. reported that both Irf3 -/- and Irf3 -/- Irf7 -/- mice developed more severe colitis after DSS administration compared to control mice. 664 Buchele et al. illustrated that IRF4 drove intestinal inflammation via both T cell-intrinsic and T cell-extrinsic mechanisms, 665 while other studies reported that increased IRF4 expression and suppressed IRF5 phosphorylation ameliorated colitis through inducing M2 macrophage polarization. 666 , 667 Yan et al. demonstrated that IRF5 in CD4 + T cells accelerated experimental colitis with increased chemokine migration, Th1/Th17 cytokines, and decreased Th2-associated anti-inflammatory cytokines in vivo. 668 IRF5-NF-κB p65 complex formation disruption or impairment of endogenous IRF5 activation could prevent intestinal inflammation in DSS-mediated colitis. 669 , 670 Moreover, inhibition of IRF5 by thalidomide or miR-144/451 could block M1 macrophage polarization or DC activation, which further attenuated colitis in DSS-induced models. 671 , 672 Zhang et al. found that the adoptive transfer of CD4 + T cells with IRF8 deficiency into Rag1 -/- recipients enhanced colitis development, which was associated with increased gut Tfh-related gene expression, and IRF8 represses Tfh differentiation by suppressing IRF4 transcription and transactivation to prevent IBD development. 673 However, Veiga et al. reported that IRF8 silencing in leukocytes presented promising anti-inflammatory properties in a murine colitis model. 674

Asthma

Polymorphisms of IRF1 were reported to increase childhood allergic asthma risk, which was associated with increased pro-inflammatory gene regulation. 675 IRF2 was identified as one of the key candidate genes to regulate genetic susceptibility to asthma in the Indian population. 676 A study found that intracellular STING/TBK1/IRF3/7 signaling pathway activation by cGAMP exacerbated allergic inflammation and asthma. 677 Moreover, IRF3 was shown to be essential for house dust mite (HDM)-induced airway allergy, and in Irf3 -/- mice, HDM-mediated airway allergy were strongly attenuated when compared with those in wild-type mice. 678 He et al. demonstrated that IRF7 was overexpressed in ILC2s from asthma patients compared to those from healthy controls. Furthermore, IRF7 deficiency impaired the expansion and function of lung ILC2s in multiple models of allergic asthma, leading to the remission of allergic airway inflammation. 679 Studies uncovered that the activation and upregulation of IRF4 promoted Th2 cell response, M2 macrophage activation, and Th9 cell development, exacerbating allergen-induced lung allergic inflammation. Additionally, the inhibition of IRF4-IL-33 axis activation or IRF4 expression could attenuate allergic inflammation in asthma mouse models. 680 – 685 Orissa et al. reported that IRF5 was markedly overexpressed in bronchoalveolar lavage cells of severe asthmatics compared to milder asthmatics or controls. Additionally, IRF5 drove a Th1 cell response and airway hyperreactivity in severe asthma mice. 686

Psoriasis and atopic dermatitis

Based on the in silico analysis, IRF1 was reported to recognize psoriasis response elements and was a psoriasis-activated transcription factor. 687 Kuai et al. revealed that IRF1 was highly expressed in human psoriasis specimens and that IRF1 inhibition alleviated psoriasis-like inflammation in vitro. 688 Moreover, TNF-α inhibitors impeded STAT1- and IRF-1-independent pathways, interrupting M1 polarization and further preventing psoriasis progress. 689 Studies have identified IRF2 as one of the potential susceptibility genes for psoriasis. 690 , 691 Mice with IRF2 deficiency displayed psoriasis-like skin inflammation. 692 In addition, Kawaguchi et al. illustrated that Irf2 +/- mice showed more severe imiquimod (IMQ)-induced skin inflammation, with higher levels of TNF-α, IL-12/23p40, IL-17A, and IL-22, compared to normal mice. 693 Moreover, IRF2 haploinsufficiency created heightened biological responses to IFN-α, leading to enhanced angiogenesis and psoriasis-like inflammation within the skin. 693 Li et al. presented that the STING/IRF3 pathway was activated in palmitic acid and IMQ induced human immortalized keratinocytes (HaCaT) cells. 694 Furthermore, STING and p-IRF3 expression levels were significantly increased in patients skin with psoriasis and diabetes, as well as in diabetic mice skin with psoriasis, indicating that the STING/IRF3 pathway might regulate inflammatory response in psoriasis with diabetes mellitus. 694 Ni et al. illustrated that IRF4 was significantly increased in keratinocytes and inflammatory cells in psoriasis vulgaris lesions compared to normal controls. 695 Cai et al. reported that IRF4 activation promoted dermal γδT cell IL-17 production, 696 which indicates that IRF4 may facilitate skin inflammation in psoriasis. Additionally, Nakao et al. uncovered that IRF5 deficiency caused IRF4 upregulation in DCs, followed by IL-23 augment, inducing Th17 response amplification and exacerbating IMQ-induced psoriasis-like skin inflammation. 697 The RNA sequencing revealed overexpressed IRF7 in patients with psoriatic skin. 698 , 699 Zdhhc2 was required by pDCs to induce IRF7 phosphorylation and IFN-α production in psoriasis-like inflamed murine skin. 700 Besides, TBK1 activation and IRF7 nuclear migration facilitate IMQ-induced acute psoriasis-like inflammation. 701 Moreover, the bromodomain and extraterminal domain inhibitor NHWD-870 could inhibit IRF7 and p-IRF7 expression to ameliorate IMQ-induced psoriasis-like inflammation. 699 The microarray data analysis revealed that IRF8 was an important hub gene in psoriasis complicated with atherosclerosis, 702 and the RNA sequencing analysis also revealed that IRF9 was a core transcriptional regulator associated with inflammation in psoriasis. 703 In cases of atopic dermatitis, Gao et al. revealed that IRF2 variants were associated with atopic dermatitis and eczema herpeticum. 704 A comprehensive bioinformatics analysis reported that IRF7 was upregulated in atopic dermatitis patients and identified it as a hub gene for atopic dermatitis. 705

Systemic lupus erythematosus (SLE) and related complications

Studies have uncovered that overexpressed IRF1 could produce a pattern of hyperacetylation at H4 lysine residues and induce the expression of target genes in vitro, a finding also shown in SLE patients. 706 – 709 Moreover, IRF1 overexpression in monocytes from SLE patients enhanced inflammasome activation. 710 Chen et al. reported that HDAC1 inhibited miR-124 and then promoted IRF1 expression to potentiate CD4 + T cell activation in SLE. 711 In lupus nephritis (LN) patients, an inverse correlation between IRF1 and miR-130b levels was observed in renal samples. Overexpression of miR-130b in vivo suppressed IRF1 expression and consequently ameliorated IFN-α-accelerated LN. 712 A joint analysis of GWAS and replication data found the missense variant in IRF3 was associated with LN patients, and identified IRF3 as a novel locus for SLE. 713 Xu et al. presented that circELK4 sponged miR-27b-3p, which facilitated STING/IRF3/IFN-I signaling activation and promoted inflammation, cell apoptosis, and renal injury in LN. 714 Phosphorylation of IRF3/IRF7 by TonEBP in macrophages facilitated autoimmune responses in SLE/LN pathogenesis. 715 Zheng et al. found that serine/threonine kinase AKT2 interacted with IRF3 and attenuated IRF3 nuclear translocation to reduce IFN-I production, which consequently prevented SLE development. 716 Additionally, Faridi et al. revealed that CD11b activation with the agonist LA1 reduced the phosphorylation of AKT and its substrate FOXO3a to suppress IRF3/7-mediated gene expression, thereby suppressing TLR and IFN-I signaling-associated inflammation and autoimmunity in SLE. 717 Besides, studies showed that IRF7 was an important transcript factor in the LN process, and the lupus risk allele in IRF7 was associated with significant IRF7 hypomethylation. 718 – 720 IRF7 was required for autoantibody production in murine lupus development. 721 Chandrasekaran et al. illustrated that IRF4 was required for the expansion and function of effector Treg cells to limit murine lupus-like disease development. 722 However, Lech et al. also demonstrated that IRF4 promoted LN development in mice. 723 Genetic variants within and around IRF5 were robustly associated with SLE risk. 724 – 728 IRF5 was an early regulator of human B cell activation, and monoallelic IRF5 deficiency in B cells prevented murine lupus. 729 , 730 Moreover, recent studies revealed that both genetic loss of Irf5 and chemical inhibition ameliorated disease in murine lupus models. 731 , 732 The IRF8 locus was also associated with an increased SLE risk. 733 IRF8 was critical for the differentiation of MDSCs, which further impaired Treg differentiation and promoted Th17-cell polarization in SLE development. 297 , 734 Studies also showed that IRF9 mRNA levels were increased in SLE monocytes, which was positively associated with both SLE activity and ISGs activity. 735 , 736

Multiple sclerosis (MS)

Annibali et al. found IRF1 was downregulated in B cells from MS patients, and IRF1/CXCL10 axis downregulation might promote a pro-survival status of B cells in MS. 737 On the other hand, Kortam et al. revealed serum IRF3 levels were upregulated in MS patients. 738 Estrogen receptor alpha in DCs degraded TRAF3 via ubiquitination, reducing IRF3 nuclear translocation and transcription of membrane lymphotoxin and IFN-β components, which consequently alleviated disease severity in MS mice. 739 Studies illustrated that IRF4 facilitated Th17 cells differentiation in relapsing-remitting MS, 740 and miR-30a reduced IRF4 expression to inhibit Th17 differentiation and prevent the development of autoimmune encephalomyelitis (EAE) in mice, an animal model of MS. 741 In addition, studies reported an IRF5 variant was associated with primary progressive MS, and variation near IRF6 was associated with IFN-β-mediated liver injury in MS. 742 , 743 Studies also revealed that IRF8 was a risk gene for both EAE in mice and MS patients, and IRF8 SNP was associated with mitogen-activated protein kinase kinase 1 (MP2K1) phosphorylation levels, which were overactive in MS. 744 – 746 IRF8 enhanced αvβ8 integrin expression in APCs and activated TGF-β signaling, resulting in Th17 cell differentiation and exacerbated neuroinflammation. 747

Sjögren’s syndrome (SS) and rheumatoid arthritis (RA)

Wei et al. found that IRF4 was upregulated in murine PMN-MDSCs during experimental SS (ESS) progression in mice and IRF4 deficiency facilitated aryl hydrocarbon receptor (AhR)-induced PMN-MDSC responses to attenuate ESS. 748 Furthermore, Xiao et al. presented that artesunate suppressed IRF4-mediated glycolysis and increased proteasomal degradation of IRF4 to inhibit Th17 response and ameliorate ESS in mice. 749 IRF5 was a risk gene in SS. 750 , 751 In RA, IRF1 was reported to induce IFN-β expression, which further activated the JAK/STAT pathway. 752 IRF3 was reported to be strongly associated with ISG expression in RA. 753 IRF4, IRF5, and IRF8 were identified as genetic risk factors for RA. 754 – 758 Moreover, Duffau et al. revealed that IRF5 promoted inflammatory arthritis in an RA mouse model. 759 The Fig. 9 shows the potential role of IRFs in diverse inflammatory and autoimmune diseases. Fig. 9 The potential role of IRFs in inflammatory and autoimmune diseases. The reported IRF family members show protective roles, negative roles, or dual roles in inflammatory bowel disease, psoriasis, systemic lupus erythematosus, and multiple sclerosis. On the other hand, the reported IRF family members almost play negative functions on atopic dermatitis, asthma, Sjögren’s syndrome and rheumatoid arthritis

IRFs and metabolic diseases

Nonalcoholic fatty liver disease (NAFLD)

NAFLD includes all kinds of fatty liver disease, from isolated hepatic steatosis or NAFL to nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. 760 Patel et al. revealed that hepatic IRF3 directly targets protein phosphatase 2 scaffold subunit Abeta (Ppp2r1b) to inhibit glucose production, and it was activated in obese humans with NAFLD. 761 Qiao et al. revealed that STING and IRF3 levels were increased in the livers of high-fat diet fed NAFLD-like mice models. 762 The STING/IRF3 pathway activation promoted hepatocyte injury, dysfunction, and liver fibrosis through inducing inflammation and apoptosis, and impeding glucose and lipid metabolism. 762 , 763 Besides, disruption of IRF3 activation by hepatocyte nuclear factor 1 A ameliorated the innate immune response and NAFLD/NASH in vitro. 764 Tong et al. demonstrated that IRF6 acted as a protective factor against liver steatosis in hepatocytes, and that hepatic IRF6 suppressed peroxisome proliferator-activated receptor γ to alleviate liver steatosis and metabolic problems in NAFLD transgenic mice. 765

A lcoholic liver disease (ALD)

The IRF1-induced caspase-1 and NADPH oxidase 2 (NOX2)-mediated ROS pathway could induce a gastrin-releasing peptide receptor pro-inflammatory and oxidative stress response in alcohol-associated liver injury (ALI). 766 The degradation of IRF1 and the removal of damaged mitochondria by murine macrophage autophagy prevented ALD in mice. 767 Patients with alcoholic hepatitis showed elevated p-IRF3 and IRF3-mediated signals in livers, and IRF3 enhanced immune cells apoptotic death, which then resulted in hepatocellular injury in ALD mice. 267 Moreover, IRF3, activated by endoplasmic reticulum stress or ethanol, also contributed to hepatocyte apoptosis and inflammatory response in early ALD. 768 cGAS/IRF3 pathway expression was positively correlated with ALD severity, and hepatic gap junctions propagated cGAS-mediated IRF3 activation to enhance alcohol liver injury in ALD models. 769 , 770

Atherosclerosis (AS)

IRF1 was overexpressed in both human and mouse AS lesions, 771 and it increased CCL19 expression, facilitating vascular smooth muscle cells (VSMCs) proliferation and migration in AS. 772 In addition, IRF1 facilitated non-canonical NF-κB-NLRP3-mediated endothelial pyroptosis and AS progression. 773 Inhibition of IRF1 suppressed modified lipoprotein uptake, promoted cholesterol efflux, and altered gene expressionrelated to lipid metabolism to prevent AS. 771 Liu et al. demonstrated that Irf3 -/- Apoe -/- mice presented significantly decreased AS lesions due to suppressed VCAM-1 and intercellular adhesion molecule 1 (ICAM-1) expression, which attenuated macrophage infiltration. 774 IRF5 acted as a detrimental factor in AS through maintaining pro-inflammatory macrophages, restricting necrotic core expansion o by impairing efferocytosis, and inducing rupture-prone atherosclerotic plaques formation. 775 , 776 IRF5-deficient macrophages facilitated a stable plaque phenotype generation to combat AS in mice. 777 IRF7 activation enhanced AS progress, and repression of IRF7-dependent TLR9 responses in macrophage induced decreased proatherogenic CXCL10 production. 778 Interruption of the RAGE/IRF7 pathway also triggered a switch from a pro- to an anti-inflammatory environment and accelerated AS regression. 779 Deficiency of IRF8 in hematopoietic cells with a CML-like phenotype was presented to promote AS progress in mice. 780 However, antoher study demonstrated that DCs-specific IRF8 deletion significantly reduced aortic T-cell accumulation and adaptive immune responses, resulting in the inhibition of AS development, especially in the aortic sinus. 781

Acute coronary syndrome (ACS) and myocardial ischemia reperfusion (MIR)

Guo et al. suggested that IRF1 might induce Th1 cell differentiation and thus contribute to ACS pathogenesis in vitro. 782 Furthermore, in ACS patients, IRF1 was found to be overexpressed in macrophages, facilitating macrophage pyroptosis and the downstream inflammatory response in AS and ACS. 783 , 784 The knockdown of cardiac-specific IRF1 significantly reduced infarct size, improved cardiac function, and inhibited myocardial apoptosis after MIR injury, while the overexpression of cardiac-specific IRF1 obviously enhanced MIR injury in mice. 785 IRF2-driven GSDMD-dependent pyroptosis and then contributed to MI in both in vivo and vitro models. 786 Activated IRF3/IFN axis in MI cardiac macrophages improved survival. 787 IRF3-dependent signaling interruption led to decreased inflammatory cell infiltration, cytokines, chemokines in the heart, and recovered cardiac function. 787 , 788 It was reported that the TLR7/MyD88/IRF5 signaling pathway activation aggravated MIR injury in mice. 789 The inhibition of the Dectin1/-Syk-IRF5 pathway interrupted M1 macrophage polarization and inflammation in both in vivo and in vitro coronary microvascular dysfunction models. 790 In addition, reduced IRF5 expression accelerated both cutaneous and infarct healing and alleviated post-MI heart failure development after coronary ligation. 791 The sequencing indicated that IRF5 gene polymorphisms might be associated with ACS susceptibility in the Chinese population. 792 IRF9 was upregulated in ischemic heart tissue after MIR injury, and IRF9 ablation prevented MIR-mediated cardiomyocyte inflammation, death, and heart dysfunction. 793

Obesity and diabetes

Friesen et al. demonstrated that IRF1 expression in adipocytes contributed to the upregulating of obesity-related inflammatory processes and metabolic dysregulation both in vitro and in vivo. 794 IRF3 expression was increased in the adipocytes of obese mice and humans. TLR3/4-IRF3 activation induced insulin resistance in murine adipocytes, while IRF3 knockdown prevented insulin resistance. This indicates that IRF3 facilitates adipose inflammation and insulin resistance and supresses browning. 795 In addition, IRF3 is a strong repressor of adipose thermogenesis via ISG15-mediated reprogramming of glycolysis. 796 IRF3 directly transcriptional regulates glucose homeostasis through induction of Ppp2r1b, and subsequent suppression of glucose production. 761 Moreover, STING/IRF3 axis triggered endothelial inflammation in response to free fatty acid-mediated mitochondrial damage in diet-induced obesity. 797 , 798 Furthermore, STING/IRF3 pathway activation triggered pancreatic β cells inflammation and apoptosis, causing β-cell damage and dysfunction, while STING or IRF3 silencing ameliorated inflammation and apoptosis, and reversed impaired insulin synthesis in type 2 diabetes. 799 Eguchi et al. reported that mice with a myeloid cell-specific IRF4 knockout developed serious insulin resistance on a high-fat diet. Furthermore, Irf4 -/- adipose tissue macrophages enhanced M1 polarization, 800 indicating that IRF4 negatively regulates inflammation in diet-induced obesity. Cavallari et al. also showed IRF4 was responsible for NOD2-induced insulin sensitizing and anti-inflammatory effects during obesity and endotoxemia. 801 Studies have identified that IRF5 gene expression is positively associated with adipose inflammatory signatures in both obesity and diabetic obese patients. 802 , 803 IRF5 facilitated M1 macrophage polarization and regulated mitochondrial architecture remodeling in obesity. 101 , 804 Moreover, Irf5 deficiency in macrophages promoted beneficial adipose tissue expansion and insulin sensitivity during obesity in vivo. 805 Studies demonstrated that suppressing IRF7 expression restored mtRNA-induced mitobiogenesis and thermogenesis, improved glucose and lipid homeostasis and insulin sensitivity, and finally mitigated obesity. 806 , 807 Additionally, GSDMD interacted with IRF7 and subsequently formed a complex to promote adipocyte pyroptosis. 808 IRF7-STAT2 cascade activation facilitated IFN-α signaling expression in islets and amplified the process of type 1 diabetes. 809 Wang et al. reported that IRF9 was more downregulated in the livers of obese mice than in controls. Hepatic IRF9 overexpression in obese mice significantly attenuated hepatic steatosis and inflammation, and improved hepatic insulin sensitivity. 810 The Fig. 10 presents the potential role of IRFs in diverse metabolic diseases. Fig. 10 The potential role of IRFs in metabolic and other diseases. a The roles of IRFs in metabolic diseases. b The roles of IRFs in other diseases. In brief, IRF1, IRF2, IRF5, and IRF7 present negative roles in these diseases. IRF3, IRF4, and IRF8 play protective roles, negative roles, or dual roles in these diseases. IRF6 is protective in non-alcoholic fatty liver disease, while a negative factor in kidney injury. IRF9 plays negative role in acute coronary syndrome and myocardial ischemia reperfusion, and kidney injury, while IRF9 plays protective role in obesity and diabetes

IRFs and other diseases

There are several studies uncovered the possible relationships between IRFs and other kinds of human diseases involved in the heart, lungs, kidneys, and mental and nervous systems (Fig. 10 ).

Cardiomyopathy

IRF1 elicited cardiac prohypertrophic effects by directly activating iNOS. 811 Studies illustrated that the activated cGAS-STING pathway and downstream targets like IRF3 overexpression induced cardiomyocyte inflammation, apoptosis, and pyroptosis in diabetic cardiomyopathy (DCM) mouse model. 812 , 813 Xie et al. showed that IRF3 suppression by ZNF593-AS ameliorated cardiac cell death and inflammation in DCM. 814 Additionally, STING/IRF3 axis activation could activate NLRP3 and exert apoptosis, pyroptosis, and inflammation in sepsis and sepsis-induced cardiomyopathy (SIC) models. 815 Gonzalez et al. identified IRF7 as the main mediator of autoinflammatory responses caused by ADAR1 absence in cardiomyocytes, resulting in late-onset autoinflammatory myocarditis progressing into DCM. 816 IRF8 was found to inhibit calcineurin signaling and thus inhibit the hypertrophic response. 48

Acute Lung Injury (ALI) and Acute respiratory distress syndrome (ARDS)

Wu et al. uncovered that IRF1 facilitated caspase1-mediated pyroptosis in AMs and induced downstream inflammatory cytokine release. IRF1 knockout mice significantly abrogated pyroptosis in AMs and attenuated LPS-induced lung injury and systemic inflammation. 817 Moreover, IRF1 deficiency strongly alleviated neutrophil extracellular traps (NETs) generation and ROS production in neutrophils from bronchoalveolar lavage fluid. 818 Chen et al. showed that endothelial-specific Irf1 knockout in ALI mice presented lung endothelium regeneration. Irf1 transactivation by LPS-induced Stat1Ser727 phosphorylation upregulated leukemia inhibitory factor (Lif), indicating that p-Stat1/Ser727/Irf1/Lif axis inhibited lung endothelial cell regeneration post-LPS injury, and IRF1 or LIF inhibition might be a promising option for improving endothelial cell regeneration and clinical outcomes in ARDS patients. 819 Wang et al. presented that the STING/IRF3 pathway activation contributed to paraquat-induced ALI. 820 In addition, the TBK1/IRF3 and other related pathways activation by the STING agonist diABZI amplified the inflammatory loop in ARDS. 821 Zhang et al. found that IFIH1 was strongly connected with ARDS, and IFIH1 could activate IRF3 to promote M1 polarization in vitro. 822 Anisodamine was shown to inhibit G9a-mediated methylation and IRF4 expression, promoting macrophage M2 polarization and inhibiting M1 polarization, which then attenuated LPS-induced ALI and pulmonary edema. 823 IRF5 inhibition induced M2 polarization to improve ALI/ARDS in vitro. 824 A bioinformatics analysis identified that IRF7 might regulate critical processes in ALI pathogenesis. 825 Furthermore, reduced IRF7 levels or activity in the lungs of mice led to decreased IFNα mRNA levels, reduced neutrophil infiltration in the lungs, and prolonged survival of IAV-induced ALI mice. 826

Kidney injury and kidney-related diseases

IRF1 was found to cause ROS-mediated IFN-α production in murine ischemic acute kidney injury (AKI) and was an important early pro-inflammatory signal during ischemic AKI in vitro and in vivo. 827 , 828 Yan et al. illustrated that lncRNA NEAT1 inhibited miR-130a-3p to upregulate IRF1 signaling and activate TLR4/NF-κB pathways, facilitating oxidative damage during calcium oxalate (CaOx) crystal deposition. 829 Moreover, studies uncovered that inhibition of IRF1 with HIF-1α or TLR4 expression by AhR or sulforaphane resulted in M1 polarization inhibition and M2 polarization progress, and finally alleviated renal CaOx crystal deposition and nephrocalcinosis-induced kidney inflammation and injury in vitro and in vivo. 830 – 832 IRF1 was also found to be overexpressed in fibrotic kidney of chronic kidney disease (CKD) patients and was identified as a driver for fibrosis, which repressed Klotho expression to promote renal fibrosis in vitro and in vivo. 833 , 834 A GWAS identified SNPs near IRF2 were associated with AKI, 835 while Renken et al. reported that there was no association between genetic loci near IRF2 and AKI in the critically Ill. 836 Zhang et al. demonstrated that IRF2 was increased in the serum of sepsis-mediated AKI patients and LPS-induced HK-2 cells. IRF2 downregulation induced cell proliferation and inhibited cell death, and IRF2 knockdown inhibited LPS-treated HK-2 cell pyroptosis by upregulating the expression of caspase-4, caspase-11, and GSDMD. In the caecal ligation and puncture (CLP)-induced Irf2 -/- animal models, the survival rate was increased, and pathological features and scores were alleviated. 837 Similarly, He et al. showed that IRF2 knockdown played anti-inflammatory and antioxidant stress functions to further decrease LPS-induced renal tissue injury in vivo and in vitro. 838 IRF3 activation triggered the Hippo pathway and then impeded proliferation and repair in surviving renal tubular epithelial cells, and exacerbated LPS-induced AKI progress in vitro cell model. 839 Overexpressed TRIM3 inhibited the IRF3 pathway and NLRP3 inflammasome activation to prevent LPS-induced AKI in rat models. 840 Moreover, STING/TBK1/IRF3/NF-κB signaling activation in dsDNA-induced Aim2-deficient macrophages aggravated inflammatory phenotypes in a rhabdomyolysis-induced AKI mouse model. 841 A genome-wide meta-analyses showed that IRF4 risk loci participated in membranous nephropathy and IgA nephropathy (IgAN) pathogenesis. 842 , 843 IRF4 was overexpressed and was a hub gene in drug-induced AKI cell and mouse models, as well as in human specimens based on integrated transcriptomic analysis. 844 Irf4 deletion in myeloid cells inhibited AKT-related monocyte recruitment to the injured kidney, and decreased activation and subsequent profibrotic M2 polarization to protect against tubulointerstitial fibrosis development after severe ischemia-reperfusion injury (IRI) in mice. 845 Similarly, other studies also found that inhibition of IRF4 disrupted macrophage to myofibroblast differentiation in the kidneys under a folic acid (FA)-induced AKI-CKD transition mouse model, and protected mice against kidney inflammation and fibrosis in deoxycorticosterone acetate/salt hypertension. 846 , 847 However, Lorenz et al. showed that IRF4 prevented CKD and kidney fibrosis following IRI, and Irf4 –/– mice presented chronic intrarenal inflammation, tubular epithelial cell loss, and renal fibrosis after IRI. 847 , 848 Liu et al. reported that ENSMUST_147219 sponged miR-221-5p to upregulate IRF6 expression to drive apoptosis and promote ischemic AKI development. 849 IRF8 was a risk locus that caused abnormal IgA levels and a high polygenic score for IgAN was associated with an earlier onset of kidney failure. 850 IRF8 upregulated renal tubular cell apoptosis in cisplatin-induced AKI, and that hypermethylation in the Irf8 promoter region, which repressed Irf8, could protect against cisplatin-induced AKI mice. 851 However, Li et al. identified that IRF8 was indispensable for kidney cDC1s development, and that IRF8-mediated cDC1s mildly protect mice against post-ischemic AKI/AKD. 852 The study by Liu et al. showed that IRF9 downregulated SIRT1 expression and increased acetylated p53 to promote rat renal cell apoptosis in hyperlipidemia acute pancreatitis associated with KI. 853

Mental and nervous system diseases

IRF1 was associated with an increased risk of the development of depression. 854 IRF3 was reported to be critical in maintaining the balance between neuronal excitation and inhibition, and a lack of IRF3-induced anxiety/depression-like behaviors in mice. 855 IRF3 and IRF7 were identified as risk candidate genes for schizophrenia. 856 , 857 Xu et al. uncovered that cGAMP/STING/IRF3 pathway stimulation induced triggering receptor expressed on myeloid cells 2 (TREM2) expression, which further decreased amyloid-β (Aβ) deposition and neuron loss to improve Alzheimer’s disease (AD) pathomorphology and cognitive impairment. 858 However, Guo et al. showed that IRF3 expression and phosphorylation were significantly elevated during the development of AD, and the silencing of ZBP1 could suppress IRF3 to inhibit cell injury and pyroptosis of neurons, thereby improving cognitive function in rats with AD. 859 Additionally, silencing IRF3 alleviated chronic neuropathic pain after chronic constriction injury by inhibiting NF-κB signaling activation in rats. 860 Studies showed that IRF8 drove the expression of microglial markers linked to AD, and IRF8 overexpression exacerbated microglial activation and neuroinflammation in AD. 861 , 862

Concluding remarks and future perspectives

This review provides a thorough examination of the structure, post-transcriptional modification sites, functional roles, and signaling pathways involving nine IRF family members across diverse cells, tissues, and human diseases. IRF family members exhibit multifaceted functions with certain activities being mutually synergistic or antagonistic. Additionally, IRF family members influence various signaling pathways differently across distinct cell types. Moreover, IRFs play complex and varied roles in immune cells, stem cells, tumor cells, and in the context of inflammatory and autoimmune diseases by engaging in numerous signaling pathways, with their regulation varying based on cell type, cellular environment, and interactions between IRF members. In immune cells, IRF family members are pivotal in the regulation of immune responses, primarily through their participation in the IFN signaling pathway. During viral infections, virus recognition receptors activate IRF3 and IRF7, which initiates IFN-I expression and the antiviral immune response. IRF4 is particularly critical for Th cell differentiation, while IRF8 plays a critical role in the maturation of bone marrow cells. In some cases, IRF1 can induce apoptosis and inhibit tumor cell growth by promoting the expression of apoptosis-associated genes, while IRF2 can promote cell survival and tumor proliferation by inhibiting the activity of IRF1. IRF5 is important in orchestrating the inflammatory response and in triggering autoimmune diseases via the activation of pro-inflammatory cytokines like IL-6 and TNF-α. In concert with STAT1 and STAT2, IRF9 forms the ISGF3 complex, which is involved in the IFN signaling pathway, regulating gene expression essential for antiviral defense and the control of autoimmune diseases.

In summary, IRF proteins serve critical functions in both human health and disease, attributed to their extensive engagement in a variety of physiological and pathological mechanisms. Research indicates that IRF family members are expressed aberrantly in an array of diseases, notably infections, inflammatory conditions, and a spectrum of cancers, affecting numerous systems including but not limited to the cardiovascular, pulmonary, urinary, reproductive, and integumentary systems. Depending on the cell types and the surrounding environment, IRF proteins can exert markedly different regulatory effects, rendering their roles intricate, and they may as double-edged swords in human health. For example, in infectious diseases, nearly all IRF members display protective functions that combat pathogens. However, in certain scenarios, activation of IRFs can trigger an inflammatory response, leading to damage within the body. Similarly, in the context of cancer, certain IRF members function as tumor suppressors, while others may behave as oncoproteins. Besides, there are IRF members that not only enhance antitumor responses but also aid in cancer immune evasion. The reasons for these discrepancies remain elusive and need further in-depth research.

Moreover, IRF proteins may function as biomarkers and therapeutic targets for diverse human diseases. Mouse models with knockout of IRF family genes exhibit a diverse array of phenotypes affecting immune system development and function, antiviral and anti-tumor immune responses, as well as cell differentiation and development (Table 1 ). Investigating these phenotypes provides valuable insights for identifying potential therapeutic targets for various diseases. Although therapeutic strategies on IRFs are mainly limited to indirect modulation, several direct inhibition and activated strategies have been reported in recent years (Table 2 ), which hold immunotherapeutic potential in the treatment of infections, inflammatory conditions, and tumors. More clinical researches are needed to explore their therapeutic potential. Therapies that augment IRF activity may be advantageous in combating a wide spectrum of pathogens; however, they could also pose significant risks to the host if uncontrolled immune activation leads to autoimmune-like disease. Considering the diverse roles played by IRF family members, unraveling the intricate mechanisms that underpin both their protective and deleterious effects is anticipated to yield valuable insights into the biology of microbial infections and host defense, autoimmune and inflammatory diseases, as well as cancers. Table 1 Phenotype of Mouse genetic models IRFs Mouse genetic models Phenotype Reference IRF1 IRF1 −/− Significantly attenuates high phosphate-induced alterations; less resistant than normal mice to EMCV infection, and knockout of IRF1 markedly alleviated cecal ligation and puncture -induced lung injury and M1-polarized infiltration 189 , 863 , 864 IRF1 silencing Alleviated bevacizumab -induced cardiomyocyte injury by regulating the VEGFA/14-3-3γ axis 865 IRF-1 –/– Can be transformed by expression of an activated c-Ha-ras oncogene 866 IRF1 –/– Bone marrow cells exhibit an increased number of immature granulocytic precursors 867 IRF1 deficiency TCRαβ + CD4 - CD8 + T cells were significantly reduced, and thymus cell development was defective. Th1 cell differentiation deficiency 230 , 232 , 868 , 869 IRF2 IRF-2-deficient mice Fail to control virus replication and recruit immune infiltrates into the brain. Mice spontaneously develop inflammatory skin disease as they age, and die within weeks from LCMV infection 230 , 870 , 871 IRF2 –/– Severely compromised development of natural killer and Th1 cells; exhibited a marked and selective defect in splenic CD4 + CD11b + DCs 159 , 872 IRF3 IRF3 knockout Develop obesity, insulin resistance, glucose intolerance, and eventually type 2 diabetes with aging 873 Mutant IRF3 A mutant IRF3 defective in both the transcriptional and the apoptotic activities was active in RIKA and inhibited virus replication 327 IRF3 –/– Sendai virus infection caused enhanced inflammation in the lungs 327 IRF3 deficiency Exhibited lethal defects in the inflammatory and recovery phases of the colitis, accompanied by marked defects in the gene induction for thymic stromal lymphopoietin; TMEV-specific memory T cells expressing granzyme B (GrB) were significantly lacking 874 , 875 IRF4 Loss of IRF4 Not conducive to the expansion and differentiation of virus-specific NK cells 876 IRF4 deficiency Could not clear L. monocytogenes infection and generated decreased numbers of L. monocytogenes-specific CD8 + T cells with impaired effector phenotype and function; display increased tubular cell loss and defective clearance of infiltrating macrophages, and showed defective development of alternatively activated macrophages 848 , 877 IRF5 Conditional KO IRF5 Suppresses SLE progression 731 IRF5 –/– Show higher susceptibility to viral infection, develop an age-related splenomegaly, and Splenic B cells also exhibited a decreased level of plasma cells 878 IRF6 IRF6 deficiency Abnormal skin, limb and craniofacial development 278 Simultaneously carrying a heterozygous deletion of p63 and the Irf6 knockin mutation R84C Displayed ectodermal abnormalities that led to cleft palate 879 Homozygous missense mutation in irf6 Hyperproliferative epidermis that fails to undergo terminal differentiation, resulting in soft tissue fusions 279 IRF7 IRF7 knockout Demonstrated attenuated dermal fibrosis and inflammation compared with wild-type mice in response to bleomycin 880 IRF7 –/– AML-IRF7 –/– mice exhibited accelerated disease progression with intracerebral invasion of AML cells 551 IRF7 deficiency Caused significant elevation of granulocytic myeloid-derived suppressor cells, thus enhanced tumor growth and metastasis in mice 214 IRF8 Null mutation in IRF8/ Irf8 -/- Deficiency in the ability of myeloid progenitor cells to mature into macrophage lineage, and eventually to the leukemic phenotype; develop a CML-like disease 174 , 881 Heterozygous and homozygous Irf8 knock-in Mice demonstrated significantly increased osteoclast formation and resorption activity in vivo and in vitro 203 , 882 IRF9 Whole-body IRF9 knockout More obese and had aggravated insulin resistance, hepatic steatosis, and inflammation after chronic high-fat diet feeding 810 IRF9 overexpressing Were subjected to warm I/R of the liver 883 IRF9 deficiency Markedly reduced the necrotic area, serum alanine amino transferase/aspartate amino transferase, immune cell infiltration, inflammatory cytokine levels, and hepatocyte apoptosis after liver I/R 883 Table 2 Direct target for IRF family Name Structure Function Mechanism Clinical stage Conditions Trial registration Geldanamycin (GA) 884 IRF3 inhibitor Inhibits heat-shock protein 90 (Hsp90) of the IRF3 phosphorylation chaperone NA NA NA KIN1148 885 , 886 IRF3 agonist Induces dose-dependent IRF3 nuclear translocation and specific activation of IRF3-responsive promoters and functions as an influenza vaccine adjuvant NA influenza A virus (IAV) H1N1 infection NA ION251 587 NA selective IRF4 inhibitor IRF4 antisense oligonucleotides Phase I malignant myeloma (MM) ClinicalTrials.gov NCT04398485 Compound C5 887 NA selective IRF5 inhibitor Reduces IRF5 nuclear translocation NA systemic lupus erythematosus(SLE) NA YE6144 731 selective IRF5 inhibitor Inhibits the phosphorylation of IRF5 NA SLE NA porcine fusion protein IRF7/3(5D) 888 NA a chimeric construct of porcine IRF7 and IRF3 A biotherapeutic and enhancer of IFN activity against foot-and-mouth disease virus (FMDV) NA foot-and-mouth disease virus NA

Acknowledgements

The study was supported by the Fundamental Research Funds for the National Natural Science Foundation of China (Nos. 82103757, 82273559, 82104373 and 82304063), and Sichuan Natural Science Foundation Project (2023NSFSC1554 and 24NSFSC5087). The authors acknowledge BioRender ( https://biorender.com ) for the production of some materials in the figures.

Author contributions

X.J.: Project administration, Supervision, Funding acquisition; X.W.: Conceptualization, Methodology, Supervision; L.W. and Y.Z.: Data curation, Writing-Original Draft, Visualization; N.Z.: Writing-Review & Editing, Visualization; Y.X., Y.T. and J.Y.: Data Curation; G.H.: Visualization; F.R.: Supervision. All authors have read and approved the article.

Competing interests

The authors declare no competing interests.

References

1. Tamura T Yanai H Savitsky D Taniguchi T The IRF family transcription factors in immunity and oncogenesis Annu. Rev. Immunol. 2008 26 535 584 10.1146/annurev.immunol.26.021607.090400 18303999 Tamura, T., Yanai, H., Savitsky, D. & Taniguchi, T. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26 , 535–584 (2008). 18303999 10.1146/annurev.immunol.26.021607.090400

2. Santana-de Anda K Gómez-Martín D Díaz-Zamudio M Alcocer-Varela J Interferon regulatory factors: beyond the antiviral response and their link to the development of autoimmune pathology Autoimmun. Rev. 2011 11 98 103 10.1016/j.autrev.2011.08.006 21872684 Santana-de Anda, K., Gómez-Martín, D., Díaz-Zamudio, M. & Alcocer-Varela, J. Interferon regulatory factors: beyond the antiviral response and their link to the development of autoimmune pathology. Autoimmun. Rev. 11 , 98–103 (2011). 21872684 10.1016/j.autrev.2011.08.006

3. Lohoff M Mak TW Roles of interferon-regulatory factors in T-helper-cell differentiation Nat. Rev. Immunol. 2005 5 125 135 10.1038/nri1552 15688040 Lohoff, M. & Mak, T. W. Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat. Rev. Immunol. 5 , 125–135 (2005). 15688040 10.1038/nri1552

4. Stoy N Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19 Front. Immunol. 2021 12 638446 10.3389/fimmu.2021.638446 33936053 PMC8085890 Stoy, N. Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19. Front. Immunol. 12 , 638446 (2021). 33936053 10.3389/fimmu.2021.638446 PMC8085890

5. Jensen MA Niewold TB Interferon regulatory factors: Critical mediators of human lupus Transl. Res. 2015 165 283 295 10.1016/j.trsl.2014.10.002 25445206 PMC4306637 Jensen, M. A. & Niewold, T. B. Interferon regulatory factors: Critical mediators of human lupus. Transl. Res. 165 , 283–295 (2015). 25445206 10.1016/j.trsl.2014.10.002 PMC4306637

6. Salem S Salem D Gros P Role of IRF8 in immune cells functions, protection against infections, and susceptibility to inflammatory diseases Hum. Genet. 2020 139 707 721 10.1007/s00439-020-02154-2 32232558 Salem, S., Salem, D. & Gros, P. Role of IRF8 in immune cells functions, protection against infections, and susceptibility to inflammatory diseases. Hum. Genet. 139 , 707–721 (2020). 32232558 10.1007/s00439-020-02154-2

7. Zhang Y Li H Reprogramming interferon regulatory factor signaling in cardiometabolic diseases Physiol. (Bethesda) 2017 32 210 223 10.1152/physiol.00038.2016 28404737 Zhang, Y. & Li, H. Reprogramming interferon regulatory factor signaling in cardiometabolic diseases. Physiol. (Bethesda) 32 , 210–223 (2017). 10.1152/physiol.00038.2016 28404737

8. Lukhele S The transcription factor IRF2 drives interferon-mediated CD8(+) T cell exhaustion to restrict anti-tumor immunity Immunity 2022 55 2369 2385.e2310 10.1016/j.immuni.2022.10.020 36370712 PMC9809269 Lukhele, S. et al. The transcription factor IRF2 drives interferon-mediated CD8(+) T cell exhaustion to restrict anti-tumor immunity. Immunity 55 , 2369–2385.e2310 (2022). 36370712 10.1016/j.immuni.2022.10.020 PMC9809269

9. Alfarano G Audano M Di Chiaro P Interferon regulatory factor 1 (IRF1) controls the metabolic programmes of low-grade pancreatic cancer cells Gut 2023 72 109 128 10.1136/gutjnl-2021-325811 35568393 Alfarano, G., Audano, M. & Di Chiaro, P. Interferon regulatory factor 1 (IRF1) controls the metabolic programmes of low-grade pancreatic cancer cells. Gut 72 , 109–128 (2023). 35568393 10.1136/gutjnl-2021-325811

10. Nguyen H Hiscott J Pitha PM The growing family of interferon regulatory factors Cytokine Growth Factor. Rev. 1997 8 293 312 10.1016/S1359-6101(97)00019-1 9620643 Nguyen, H., Hiscott, J. & Pitha, P. M. The growing family of interferon regulatory factors. Cytokine Growth Factor. Rev. 8 , 293–312 (1997). 9620643 10.1016/s1359-6101(97)00019-1

11. Nehyba J Hrdlicková R Burnside J Bose HR Jr A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein Mol. Cell. Biol. 2002 22 3942 3957 10.1128/MCB.22.11.3942-3957.2002 11997525 PMC133824 Nehyba, J., Hrdlicková, R., Burnside, J. & Bose, H. R. Jr A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein. Mol. Cell. Biol. 22 , 3942–3957 (2002). 11997525 10.1128/MCB.22.11.3942-3957.2002 PMC133824

12. Zhao X Characterization of DNA binding and nuclear retention identifies zebrafish IRF11 as a positive regulator of IFN antiviral response J. Immunol. 2020 205 237 250 10.4049/jimmunol.2000245 32471880 Zhao, X. et al. Characterization of DNA binding and nuclear retention identifies zebrafish IRF11 as a positive regulator of IFN antiviral response. J. Immunol. 205 , 237–250 (2020). 32471880 10.4049/jimmunol.2000245

13. Fujita T Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN-beta gene regulatory elements EMBO. J. 1988 7 3397 3405 10.1002/j.1460-2075.1988.tb03213.x 2850164 PMC454838 Fujita, T. et al. Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN-beta gene regulatory elements. EMBO. J. 7 , 3397–3405 (1988). 2850164 10.1002/j.1460-2075.1988.tb03213.x PMC454838

14. Miyamoto M Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements Cell 1988 54 903 913 10.1016/S0092-8674(88)91307-4 3409321 Miyamoto, M. et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 54 , 903–913 (1988). 3409321 10.1016/s0092-8674(88)91307-4

15. Harada H Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes Cell 1989 58 729 739 10.1016/0092-8674(89)90107-4 2475256 Harada, H. et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58 , 729–739 (1989). 2475256 10.1016/0092-8674(89)90107-4

16. Driggers PH An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes Proc. Natl. Acad. Sci. USA 1990 87 3743 3747 10.1073/pnas.87.10.3743 2111015 PMC53979 Driggers, P. H. et al. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc. Natl. Acad. Sci. USA 87 , 3743–3747 (1990). 2111015 10.1073/pnas.87.10.3743 PMC53979

17. Nelson N Marks MS Driggers PH Ozato K Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription Mol. Cell. Biol. 1993 13 588 599 7678054 10.1128/mcb.13.1.588 PMC358938 Nelson, N., Marks, M. S., Driggers, P. H. & Ozato, K. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol. Cell. Biol. 13 , 588–599 (1993). 7678054 10.1128/mcb.13.1.588 PMC358938

18. Fu XY ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains Proc. Natl. Acad. Sci. USA 1990 87 8555 8559 10.1073/pnas.87.21.8555 2236065 PMC54995 Fu, X. Y. et al. ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc. Natl. Acad. Sci. USA 87 , 8555–8559 (1990). 2236065 10.1073/pnas.87.21.8555 PMC54995

19. Kessler DS Veals SA Fu XY Levy DE Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator Genes. Dev. 1990 4 1753 1765 10.1101/gad.4.10.1753 2249773 Kessler, D. S., Veals, S. A., Fu, X. Y. & Levy, D. E. Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes. Dev. 4 , 1753–1765 (1990). 2249773 10.1101/gad.4.10.1753

20. Fu XY The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction Proc. Natl. Acad. Sci. USA 1992 89 7840 7843 10.1073/pnas.89.16.7840 1502204 PMC49807 Fu, X. Y. et al. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc. Natl. Acad. Sci. USA 89 , 7840–7843 (1992). 1502204 10.1073/pnas.89.16.7840 PMC49807

21. Au WC Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes Proc. Natl Acad. Sci. USA 1995 92 11657 11661 10.1073/pnas.92.25.11657 8524823 PMC40461 Au, W. C. et al. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc. Natl Acad. Sci. USA 92 , 11657–11661 (1995). 8524823 10.1073/pnas.92.25.11657 PMC40461

22. Matsuyama T Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE) Nucleic Acids Res. 1995 23 2127 2136 10.1093/nar/23.12.2127 7541907 PMC306999 Matsuyama, T. et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res. 23 , 2127–2136 (1995). 7541907 10.1093/nar/23.12.2127 PMC306999

23. Mittrücker HW Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function Science 1997 275 540 543 10.1126/science.275.5299.540 29158347 Mittrücker, H. W. et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275 , 540–543 (1997). 29158347

24. Eisenbeis CF Singh H Storb U Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator Genes. Dev. 1995 9 1377 1387 10.1101/gad.9.11.1377 7797077 Eisenbeis, C. F., Singh, H. & Storb, U. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes. Dev. 9 , 1377–1387 (1995). 7797077 10.1101/gad.9.11.1377

25. Yamagata T A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes Mol. Cell. Biol. 1996 16 1283 1294 10.1128/MCB.16.4.1283 8657101 PMC231112 Yamagata, T. et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol. Cell. Biol. 16 , 1283–1294 (1996). 8657101 10.1128/MCB.16.4.1283 PMC231112

26. Marecki S Fenton MJ The role of IRF-4 in transcriptional regulation J. Interferon Cytokine Res. 2002 22 121 133 10.1089/107999002753452737 11846983 Marecki, S. & Fenton, M. J. The role of IRF-4 in transcriptional regulation. J. Interferon Cytokine Res. 22 , 121–133 (2002). 11846983 10.1089/107999002753452737

27. Taniguchi T Ogasawara K Takaoka A Tanaka N IRF family of transcription factors as regulators of host defense Annu. Rev. Immunol. 2001 19 623 655 10.1146/annurev.immunol.19.1.623 11244049 Taniguchi, T., Ogasawara, K., Takaoka, A. & Tanaka, N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19 , 623–655 (2001). 11244049 10.1146/annurev.immunol.19.1.623

28. Barnes BJ Moore PA Pitha PM Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes J. Biol. Chem. 2001 276 23382 23390 10.1074/jbc.M101216200 11303025 Barnes, B. J., Moore, P. A. & Pitha, P. M. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J. Biol. Chem. 276 , 23382–23390 (2001). 11303025 10.1074/jbc.M101216200

29. Schutte BC Microdeletions at chromosome bands 1q32-q41 as a cause of Van der Woude syndrome Am. J. Med. Genet. 1999 84 145 150 10.1002/(SICI)1096-8628(19990521)84:2<145::AID-AJMG11>3.0.CO;2-L 10323740 Schutte, B. C. et al. Microdeletions at chromosome bands 1q32-q41 as a cause of Van der Woude syndrome. Am. J. Med. Genet. 84 , 145–150 (1999). 10323740 10.1002/(sici)1096-8628(19990521)84:2<145::aid-ajmg11>3.0.co;2-l

30. Kumaran S Dogra S Kanwar AJ Van der Woude syndrome Clin. Exp. Dermatol. 2004 29 434 10.1111/j.1365-2230.2004.01556.x 15245554 Kumaran, S., Dogra, S. & Kanwar, A. J. Van der Woude syndrome. Clin. Exp. Dermatol. 29 , 434 (2004). 15245554 10.1111/j.1365-2230.2004.01556.x

31. Zhang L Pagano JS IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency Mol. Cell. Biol. 1997 17 5748 5757 10.1128/MCB.17.10.5748 9315633 PMC232423 Zhang, L. & Pagano, J. S. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol. Cell. Biol. 17 , 5748–5757 (1997). 9315633 10.1128/mcb.17.10.5748 PMC232423

32. Zhou H Tang YD Zheng C Revisiting IRF1-mediated antiviral innate immunity Cytokine Growth Factor. Rev. 2022 64 1 6 10.1016/j.cytogfr.2022.01.004 35090813 Zhou, H., Tang, Y. D. & Zheng, C. Revisiting IRF1-mediated antiviral innate immunity. Cytokine Growth Factor. Rev. 64 , 1–6 (2022). 35090813 10.1016/j.cytogfr.2022.01.004

33. Trujillo-Ochoa JL Kazemian M Afzali B The role of transcription factors in shaping regulatory T cell identity Nat. Rev. Immunol. 2023 23 842 856 10.1038/s41577-023-00893-7 37336954 PMC10893967 Trujillo-Ochoa, J. L., Kazemian, M. & Afzali, B. The role of transcription factors in shaping regulatory T cell identity. Nat. Rev. Immunol. 23 , 842–856 (2023). 37336954 10.1038/s41577-023-00893-7 PMC10893967

34. Roberts BK Collado G Barnes BJ Role of interferon regulatory factor 5 (IRF5) in tumor progression: Prognostic and therapeutic potential Biochim. Biophys. Acta Rev. Cancer 2024 1879 189061 10.1016/j.bbcan.2023.189061 38141865 PMC11977173 Roberts, B. K., Collado, G. & Barnes, B. J. Role of interferon regulatory factor 5 (IRF5) in tumor progression: Prognostic and therapeutic potential. Biochim. Biophys. Acta Rev. Cancer 1879 , 189061 (2024). 38141865 10.1016/j.bbcan.2023.189061 PMC11977173

35. Fujita T Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways Proc. Natl Acad. Sci. Usa. 1989 86 9936 9940 10.1073/pnas.86.24.9936 2557635 PMC298617 Fujita, T. et al. Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways. Proc. Natl Acad. Sci. Usa. 86 , 9936–9940 (1989). 2557635 10.1073/pnas.86.24.9936 PMC298617

36. Au WC Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes J. Biol. Chem. 1998 273 29210 29217 10.1074/jbc.273.44.29210 9786932 Au, W. C. et al. Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J. Biol. Chem. 273 , 29210–29217 (1998). 9786932 10.1074/jbc.273.44.29210

37. Hiscott J Triggering the innate antiviral response through IRF-3 activation J. Biol. Chem. 2007 282 15325 15329 10.1074/jbc.R700002200 17395583 Hiscott, J. Triggering the innate antiviral response through IRF-3 activation. J. Biol. Chem. 282 , 15325–15329 (2007). 17395583 10.1074/jbc.R700002200

38. Lin R Mamane Y Hiscott J Multiple regulatory domains control IRF-7 activity in response to virus infection J. Biol. Chem. 2000 275 34320 34327 10.1074/jbc.M002814200 10893229 Lin, R., Mamane, Y. & Hiscott, J. Multiple regulatory domains control IRF-7 activity in response to virus infection. J. Biol. Chem. 275 , 34320–34327 (2000). 10893229 10.1074/jbc.M002814200

39. Zhang L Wu L Hong K Pagano JS Intracellular signaling molecules activated by Epstein-Barr virus for induction of interferon regulatory factor 7 J. Virol. 2001 75 12393 12401 10.1128/JVI.75.24.12393-12401.2001 11711629 PMC116135 Zhang, L., Wu, L., Hong, K. & Pagano, J. S. Intracellular signaling molecules activated by Epstein-Barr virus for induction of interferon regulatory factor 7. J. Virol. 75 , 12393–12401 (2001). 11711629 10.1128/JVI.75.24.12393-12401.2001 PMC116135

40. Zhang L Pagano JS Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1 J. Virol. 2000 74 1061 1068 10.1128/JVI.74.3.1061-1068.2000 10627515 PMC111439 Zhang, L. & Pagano, J. S. Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1. J. Virol. 74 , 1061–1068 (2000). 10627515 10.1128/jvi.74.3.1061-1068.2000 PMC111439

41. Kim TK Chemotherapeutic DNA-damaging drugs activate interferon regulatory factor-7 by the mitogen-activated protein kinase kinase-4-cJun NH2-terminal kinase pathway Cancer Res. 2000 60 1153 1156 10728664 Kim, T. K. et al. Chemotherapeutic DNA-damaging drugs activate interferon regulatory factor-7 by the mitogen-activated protein kinase kinase-4-cJun NH2-terminal kinase pathway. Cancer Res. 60 , 1153–1156 (2000). 10728664

42. Zhang L Pagano JS Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1 J. Virol. 2001 75 341 350 10.1128/JVI.75.1.341-350.2001 11119603 PMC113927 Zhang, L. & Pagano, J. S. Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1. J. Virol. 75 , 341–350 (2001). 11119603 10.1128/JVI.75.1.341-350.2001 PMC113927

43. Shindo H Interferon regulatory factor-4 activates IL-2 and IL-4 promoters in cooperation with c-Rel Cytokine 2011 56 564 572 10.1016/j.cyto.2011.08.014 21890374 Shindo, H. et al. Interferon regulatory factor-4 activates IL-2 and IL-4 promoters in cooperation with c-Rel. Cytokine 56 , 564–572 (2011). 21890374 10.1016/j.cyto.2011.08.014

44. De Silva NS Simonetti G Heise N Klein U The diverse roles of IRF4 in late germinal center B-cell differentiation Immunol. Rev. 2012 247 73 92 10.1111/j.1600-065X.2012.01113.x 22500833 De Silva, N. S., Simonetti, G., Heise, N. & Klein, U. The diverse roles of IRF4 in late germinal center B-cell differentiation. Immunol. Rev. 247 , 73–92 (2012). 22500833 10.1111/j.1600-065X.2012.01113.x

45. Xu WD Pan HF Ye DQ Xu Y Targeting IRF4 in autoimmune diseases Autoimmun. Rev. 2012 11 918 924 10.1016/j.autrev.2012.08.011 23010632 Xu, W. D., Pan, H. F., Ye, D. Q. & Xu, Y. Targeting IRF4 in autoimmune diseases. Autoimmun. Rev. 11 , 918–924 (2012). 23010632 10.1016/j.autrev.2012.08.011

46. Kesper C Impact of the transcription factor IRF8 on limbal epithelial progenitor cells in a mouse model Exp. Eye. Res. 2022 218 108985 10.1016/j.exer.2022.108985 35227665 Kesper, C. et al. Impact of the transcription factor IRF8 on limbal epithelial progenitor cells in a mouse model. Exp. Eye. Res. 218 , 108985 (2022). 35227665 10.1016/j.exer.2022.108985

47. Li W Interferon consensus sequence-binding protein is constitutively expressed and differentially regulated in the ocular lens J. Biol. Chem. 1999 274 9686 9691 10.1074/jbc.274.14.9686 10092656 Li, W. et al. Interferon consensus sequence-binding protein is constitutively expressed and differentially regulated in the ocular lens. J. Biol. Chem. 274 , 9686–9691 (1999). 10092656 10.1074/jbc.274.14.9686

48. Jiang DS IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling Nat. Commun. 2014 5 3303 10.1038/ncomms4303 24526256 PMC3929801 Jiang, D. S. et al. IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling. Nat. Commun. 5 , 3303 (2014). 24526256 10.1038/ncomms4303 PMC3929801

49. Mancl ME Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function J. Biol. Chem. 2005 280 21078 21090 10.1074/jbc.M500543200 15805103 Mancl, M. E. et al. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J. Biol. Chem. 280 , 21078–21090 (2005). 15805103 10.1074/jbc.M500543200

50. Gothe F Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency J. Allergy Clin. Immunol. 2022 150 955 964.e916 10.1016/j.jaci.2022.01.026 35182547 Gothe, F. et al. Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency. J. Allergy Clin. Immunol. 150 , 955–964.e916 (2022). 35182547 10.1016/j.jaci.2022.01.026

51. Deribe YL Pawson T Dikic I Post-translational modifications in signal integration Nat. Struct. Mol. Biol. 2010 17 666 672 10.1038/nsmb.1842 20495563 Deribe, Y. L., Pawson, T. & Dikic, I. Post-translational modifications in signal integration. Nat. Struct. Mol. Biol. 17 , 666–672 (2010). 20495563 10.1038/nsmb.1842

52. Garvin AJ GSK3β-SCFFBXW7α mediated phosphorylation and ubiquitination of IRF1 are required for its transcription-dependent turnover Nucleic Acids Res 2019 47 4476 4494 10.1093/nar/gkz163 30854564 PMC6511875 Garvin, A. J. et al. GSK3β-SCFFBXW7α mediated phosphorylation and ubiquitination of IRF1 are required for its transcription-dependent turnover. Nucleic Acids Res 47 , 4476–4494 (2019). 30854564 10.1093/nar/gkz163 PMC6511875

53. Remoli AL IκB kinase-ε-mediated phosphorylation triggers IRF-1 degradation in breast cancer cells Neoplasia 2020 22 459 469 10.1016/j.neo.2020.07.004 32784074 PMC7419274 Remoli, A. L. et al. IκB kinase-ε-mediated phosphorylation triggers IRF-1 degradation in breast cancer cells. Neoplasia 22 , 459–469 (2020). 32784074 10.1016/j.neo.2020.07.004 PMC7419274

54. Kautz B Kakar R David E Eklund EA SHP1 protein-tyrosine phosphatase inhibits gp91PHOX and p67PHOX expression by inhibiting interaction of PU.1, IRF1, interferon consensus sequence-binding protein, and CREB-binding protein with homologous Cis elements in the CYBB and NCF2 genes J. Biol. Chem. 2001 276 37868 37878 10.1074/jbc.M103381200 11483597 Kautz, B., Kakar, R., David, E. & Eklund, E. A. SHP1 protein-tyrosine phosphatase inhibits gp91PHOX and p67PHOX expression by inhibiting interaction of PU.1, IRF1, interferon consensus sequence-binding protein, and CREB-binding protein with homologous Cis elements in the CYBB and NCF2 genes. J. Biol. Chem. 276 , 37868–37878 (2001). 11483597 10.1074/jbc.M103381200

55. Lin R Hiscott J A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity Mol. Cell. Biochem. 1999 191 169 180 10.1023/A:1006850009017 10094406 Lin, R. & Hiscott, J. A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity. Mol. Cell. Biochem. 191 , 169–180 (1999). 10094406

56. Lin R Heylbroeck C Pitha PM Hiscott J Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation Mol. Cell. Biol. 1998 18 2986 2996 10.1128/MCB.18.5.2986 9566918 PMC110678 Lin, R., Heylbroeck, C., Pitha, P. M. & Hiscott, J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18 , 2986–2996 (1998). 9566918 10.1128/mcb.18.5.2986 PMC110678

57. Sharma S Triggering the interferon antiviral response through an IKK-related pathway Science 2003 300 1148 1151 10.1126/science.1081315 12702806 Sharma, S. et al. Triggering the interferon antiviral response through an IKK-related pathway. Science 300 , 1148–1151 (2003). 12702806 10.1126/science.1081315

58. Hemmi H The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection J. Exp. Med. 2004 199 1641 1650 10.1084/jem.20040520 15210742 PMC2212809 Hemmi, H. et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J. Exp. Med. 199 , 1641–1650 (2004). 15210742 10.1084/jem.20040520 PMC2212809

59. Fitzgerald KA IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway Nat. Immunol. 2003 4 491 496 10.1038/ni921 12692549 Fitzgerald, K. A. et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4 , 491–496 (2003). 12692549 10.1038/ni921

60. Lin R Mamane Y Hiscott J Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains Mol. Cell. Biol. 1999 19 2465 2474 10.1128/MCB.19.4.2465 10082512 PMC84039 Lin, R., Mamane, Y. & Hiscott, J. Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains. Mol. Cell. Biol. 19 , 2465–2474 (1999). 10082512 10.1128/mcb.19.4.2465 PMC84039

61. Xiao J Targeting 7-dehydrocholesterol reductase integrates cholesterol metabolism and IRF3 activation to eliminate infection Immunity 2020 52 109 122.e106 10.1016/j.immuni.2019.11.015 31882361 Xiao, J. et al. Targeting 7-dehydrocholesterol reductase integrates cholesterol metabolism and IRF3 activation to eliminate infection. Immunity 52 , 109–122.e106 (2020). 31882361 10.1016/j.immuni.2019.11.015

62. Zhang B The TAK1-JNK cascade is required for IRF3 function in the innate immune response Cell. Res. 2009 19 412 428 10.1038/cr.2009.8 19153595 Zhang, B. et al. The TAK1-JNK cascade is required for IRF3 function in the innate immune response. Cell. Res. 19 , 412–428 (2009). 19153595 10.1038/cr.2009.8

63. Xu J IRF3-binding lncRNA-ISIR strengthens interferon production in viral infection and autoinflammation Cell. Rep. 2021 37 109926 10.1016/j.celrep.2021.109926 34731629 Xu, J. et al. IRF3-binding lncRNA-ISIR strengthens interferon production in viral infection and autoinflammation. Cell. Rep. 37 , 109926 (2021). 34731629 10.1016/j.celrep.2021.109926

64. Wang S LPA maintains innate antiviral immunity in a pro-active state via STK38L-mediated IRF3 Ser303 phosphorylation Cell. Rep. 2022 41 111661 10.1016/j.celrep.2022.111661 36417850 Wang, S. et al. LPA maintains innate antiviral immunity in a pro-active state via STK38L-mediated IRF3 Ser303 phosphorylation. Cell. Rep. 41 , 111661 (2022). 36417850 10.1016/j.celrep.2022.111661

65. Meng F Mst1 shuts off cytosolic antiviral defense through IRF3 phosphorylation Genes. Dev. 2016 30 1086 1100 10.1101/gad.277533.116 27125670 PMC4863739 Meng, F. et al. Mst1 shuts off cytosolic antiviral defense through IRF3 phosphorylation. Genes. Dev. 30 , 1086–1100 (2016). 27125670 10.1101/gad.277533.116 PMC4863739

66. Wang L LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required Oncogene 2017 36 2265 2274 10.1038/onc.2016.380 27819673 PMC5685659 Wang, L. et al. LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required. Oncogene 36 , 2265–2274 (2017). 27819673 10.1038/onc.2016.380 PMC5685659

67. Biswas PS Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice J. Clin. Invest. 2010 120 3280 3295 10.1172/JCI42856 20697158 PMC2929726 Biswas, P. S. et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J. Clin. Invest. 120 , 3280–3295 (2010). 20697158 10.1172/JCI42856 PMC2929726

68. Ngwa, C. et al. Phosphorylation of microglial IRF5 and IRF4 by IRAK4 regulates inflammatory responses to ischemia. Cells 10 , 276 (2021). 10.3390/cells10020276 PMC7912637 33573200

69. Ren J Chen X Chen ZJ IKKβ is an IRF5 kinase that instigates inflammation Proc. Natl. Acad. Sci. USA 2014 111 17438 17443 10.1073/pnas.1418516111 25326420 PMC4267374 Ren, J., Chen, X. & Chen, Z. J. IKKβ is an IRF5 kinase that instigates inflammation. Proc. Natl. Acad. Sci. USA 111 , 17438–17443 (2014). 25326420 10.1073/pnas.1418516111 PMC4267374

70. Chang Foreman HC Van Scoy S Cheng TF Reich NC Activation of interferon regulatory factor 5 by site specific phosphorylation PLoS. One 2012 7 e33098 10.1371/journal.pone.0033098 22412986 PMC3297630 Chang Foreman, H. C., Van Scoy, S., Cheng, T. F. & Reich, N. C. Activation of interferon regulatory factor 5 by site specific phosphorylation. PLoS. One 7 , e33098 (2012). 22412986 10.1371/journal.pone.0033098 PMC3297630

71. Lopez-Pelaez M Protein kinase IKKβ-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells Proc. Natl Acad. Sci. Usa. 2014 111 17432 17437 10.1073/pnas.1418399111 25326418 PMC4267347 Lopez-Pelaez, M. et al. Protein kinase IKKβ-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells. Proc. Natl Acad. Sci. Usa. 111 , 17432–17437 (2014). 25326418 10.1073/pnas.1418399111 PMC4267347

72. Balkhi MY Fitzgerald KA Pitha PM IKKalpha negatively regulates IRF-5 function in a MyD88-TRAF6 pathway Cell. Signal. 2010 22 117 127 10.1016/j.cellsig.2009.09.021 19786094 Balkhi, M. Y., Fitzgerald, K. A. & Pitha, P. M. IKKalpha negatively regulates IRF-5 function in a MyD88-TRAF6 pathway. Cell. Signal. 22 , 117–127 (2010). 19786094 10.1016/j.cellsig.2009.09.021

73. Oberbeck N The RIPK4-IRF6 signalling axis safeguards epidermal differentiation and barrier function Nature 2019 574 249 253 10.1038/s41586-019-1615-3 31578523 Oberbeck, N. et al. The RIPK4-IRF6 signalling axis safeguards epidermal differentiation and barrier function. Nature 574 , 249–253 (2019). 31578523 10.1038/s41586-019-1615-3

74. Kwa MQ Receptor-interacting protein kinase 4 and interferon regulatory factor 6 function as a signaling axis to regulate keratinocyte differentiation J. Biol. Chem. 2014 289 31077 31087 10.1074/jbc.M114.589382 25246526 PMC4223312 Kwa, M. Q. et al. Receptor-interacting protein kinase 4 and interferon regulatory factor 6 function as a signaling axis to regulate keratinocyte differentiation. J. Biol. Chem. 289 , 31077–31087 (2014). 25246526 10.1074/jbc.M114.589382 PMC4223312

75. Uematsu S Interleukin-1 receptor-associated kinase-1 plays an essential role for toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction J. Exp. Med. 2005 201 915 923 10.1084/jem.20042372 15767370 PMC2213113 Uematsu, S. et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J. Exp. Med. 201 , 915–923 (2005). 15767370 10.1084/jem.20042372 PMC2213113

76. Hoshino K IkappaB kinase-alpha is critical for interferon-alpha production induced by toll-like receptors 7 and 9 Nature 2006 440 949 953 10.1038/nature04641 16612387 Hoshino, K. et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by toll-like receptors 7 and 9. Nature 440 , 949–953 (2006). 16612387 10.1038/nature04641

77. Pfaller CK Conzelmann KK Measles virus V protein is a decoy substrate for IkappaB kinase alpha and prevents Toll-like receptor 7/9-mediated interferon induction J. Virol. 2008 82 12365 12373 10.1128/JVI.01321-08 18922877 PMC2593327 Pfaller, C. K. & Conzelmann, K. K. Measles virus V protein is a decoy substrate for IkappaB kinase alpha and prevents Toll-like receptor 7/9-mediated interferon induction. J. Virol. 82 , 12365–12373 (2008). 18922877 10.1128/JVI.01321-08 PMC2593327

78. Wang L Protein phosphatase 1 abrogates IRF7-mediated type I IFN response in antiviral immunity Eur. J. Immunol. 2016 46 2409 2419 10.1002/eji.201646491 27469204 PMC5175453 Wang, L. et al. Protein phosphatase 1 abrogates IRF7-mediated type I IFN response in antiviral immunity. Eur. J. Immunol. 46 , 2409–2419 (2016). 27469204 10.1002/eji.201646491 PMC5175453

79. Smith EJ IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or Ikappa B kinase but is blocked by Vaccinia virus E3L protein J. Biol. Chem. 2001 276 8951 8957 10.1074/jbc.M008717200 11124948 Smith, E. J. et al. IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or Ikappa B kinase but is blocked by Vaccinia virus E3L protein. J. Biol. Chem. 276 , 8951–8957 (2001). 11124948 10.1074/jbc.M008717200

80. Lee KJ Lee H Joo CH Negative Regulation of IKKε-Mediated IRF7 Phosphorylation by HSP70 J. Immunol. 2020 204 2562 2574 10.4049/jimmunol.1900297 32169844 Lee, K. J., Lee, H. & Joo, C. H. Negative Regulation of IKKε-Mediated IRF7 Phosphorylation by HSP70. J. Immunol. 204 , 2562–2574 (2020). 32169844 10.4049/jimmunol.1900297

81. Liang Q ORF45 of Kaposi’s sarcoma-associated herpesvirus inhibits phosphorylation of interferon regulatory factor 7 by IKKε and TBK1 as an alternative substrate J. Virol. 2012 86 10162 10172 10.1128/JVI.05224-11 22787218 PMC3446610 Liang, Q. et al. ORF45 of Kaposi’s sarcoma-associated herpesvirus inhibits phosphorylation of interferon regulatory factor 7 by IKKε and TBK1 as an alternative substrate. J. Virol. 86 , 10162–10172 (2012). 22787218 10.1128/JVI.05224-11 PMC3446610

82. Liu BQ Jin J Li YY Ubiquitination modification: critical regulation of IRF family stability and activity Sci. China Life. Sci. 2021 64 957 965 10.1007/s11427-020-1796-0 33141302 PMC7607542 Liu, B. Q., Jin, J. & Li, Y. Y. Ubiquitination modification: critical regulation of IRF family stability and activity. Sci. China Life. Sci. 64 , 957–965 (2021). 33141302 10.1007/s11427-020-1796-0 PMC7607542

83. Popovic D Vucic D Dikic I Ubiquitination in disease pathogenesis and treatment Nat. Med. 2014 20 1242 1253 10.1038/nm.3739 25375928 Popovic, D., Vucic, D. & Dikic, I. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 20 , 1242–1253 (2014). 25375928 10.1038/nm.3739

84. Pion E Narayan V Eckert M Ball KL Role of the IRF-1 enhancer domain in signalling polyubiquitination and degradation Cell. Signal. 2009 21 1479 1487 10.1016/j.cellsig.2009.05.004 19450680 Pion, E., Narayan, V., Eckert, M. & Ball, K. L. Role of the IRF-1 enhancer domain in signalling polyubiquitination and degradation. Cell. Signal. 21 , 1479–1487 (2009). 19450680 10.1016/j.cellsig.2009.05.004

85. Nakagawa K Yokosawa H Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability Eur. J. Biochem. 2000 267 1680 1686 10.1046/j.1432-1327.2000.01163.x 10712599 Nakagawa, K. & Yokosawa, H. Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability. Eur. J. Biochem. 267 , 1680–1686 (2000). 10712599 10.1046/j.1432-1327.2000.01163.x

86. Remoli, A. L. et al. HIV-1 tat recruits HDM2 E3 ligase to target IRF-1 for ubiquitination and proteasomal degradation. mBio 7 , e01528-16 (2016). 10.1128/mBio.01528-16 PMC5082900 27795392

87. Tulli L Src family kinases regulate interferon regulatory factor 1 K63 ubiquitination following activation by TLR7/8 vaccine adjuvant in human monocytes and B cells Front. Immunol. 2018 9 330 10.3389/fimmu.2018.00330 29545793 PMC5837968 Tulli, L. et al. Src family kinases regulate interferon regulatory factor 1 K63 ubiquitination following activation by TLR7/8 vaccine adjuvant in human monocytes and B cells. Front. Immunol. 9 , 330 (2018). 29545793 10.3389/fimmu.2018.00330 PMC5837968

88. Harikumar KB K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5 Nat. Immunol. 2014 15 231 238 10.1038/ni.2810 24464131 PMC3976678 Harikumar, K. B. et al. K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5. Nat. Immunol. 15 , 231–238 (2014). 24464131 10.1038/ni.2810 PMC3976678

89. Wang Y African swine fever virus MGF360-14L negatively regulates type I interferon signaling by targeting IRF3 Front. Cell. Infect. Microbiol. 2021 11 818969 10.3389/fcimb.2021.818969 35096660 PMC8790226 Wang, Y. et al. African swine fever virus MGF360-14L negatively regulates type I interferon signaling by targeting IRF3. Front. Cell. Infect. Microbiol. 11 , 818969 (2021). 35096660 10.3389/fcimb.2021.818969 PMC8790226

90. Zhang M Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3 Cell. Res. 2008 18 1096 1104 10.1038/cr.2008.277 18711448 Zhang, M. et al. Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3. Cell. Res. 18 , 1096–1104 (2008). 18711448 10.1038/cr.2008.277

91. Chen X Ubiquitin E3 ligase MID1 inhibits the innate immune response by ubiquitinating IRF3 Immunology 2021 163 278 292 10.1111/imm.13315 33513265 PMC8207362 Chen, X. et al. Ubiquitin E3 ligase MID1 inhibits the innate immune response by ubiquitinating IRF3. Immunology 163 , 278–292 (2021). 33513265 10.1111/imm.13315 PMC8207362

92. Zhang W JMJD6 negatively regulates cytosolic RNA induced antiviral signaling by recruiting RNF5 to promote activated IRF3 K48 ubiquitination PLoS. Pathog. 2021 17 e1009366 10.1371/journal.ppat.1009366 33684176 PMC7971890 Zhang, W. et al. JMJD6 negatively regulates cytosolic RNA induced antiviral signaling by recruiting RNF5 to promote activated IRF3 K48 ubiquitination. PLoS. Pathog. 17 , e1009366 (2021). 33684176 10.1371/journal.ppat.1009366 PMC7971890

93. Ran Y SENP2 negatively regulates cellular antiviral response by deSUMOylating IRF3 and conditioning it for ubiquitination and degradation J. Mol. Cell. Biol. 2011 3 283 292 10.1093/jmcb/mjr020 22028379 Ran, Y. et al. SENP2 negatively regulates cellular antiviral response by deSUMOylating IRF3 and conditioning it for ubiquitination and degradation. J. Mol. Cell. Biol. 3 , 283–292 (2011). 22028379 10.1093/jmcb/mjr020

94. Chattopadhyay S Ubiquitination of the transcription factor IRF-3 activates RIPA, the apoptotic pathway that protects mice from viral pathogenesis Immunity 2016 44 1151 1161 10.1016/j.immuni.2016.04.009 27178468 PMC4991351 Chattopadhyay, S. et al. Ubiquitination of the transcription factor IRF-3 activates RIPA, the apoptotic pathway that protects mice from viral pathogenesis. Immunity 44 , 1151–1161 (2016). 27178468 10.1016/j.immuni.2016.04.009 PMC4991351

95. Raja R Sen GC The antiviral action of the RIG-I induced pathway of apoptosis (RIPA) is enhanced by its ability to degrade Otulin, which deubiquitinates IRF3 Cell. Death. Differ. 2022 29 504 513 10.1038/s41418-021-00870-4 34545182 PMC8901756 Raja, R. & Sen, G. C. The antiviral action of the RIG-I induced pathway of apoptosis (RIPA) is enhanced by its ability to degrade Otulin, which deubiquitinates IRF3. Cell. Death. Differ. 29 , 504–513 (2022). 34545182 10.1038/s41418-021-00870-4 PMC8901756

96. Wang J RNF2 promotes the progression of colon cancer by regulating ubiquitination and degradation of IRF4 Biochim. Biophys. Acta Mol. Cell. Res. 2022 1869 119162 10.1016/j.bbamcr.2021.119162 34670117 Wang, J. et al. RNF2 promotes the progression of colon cancer by regulating ubiquitination and degradation of IRF4. Biochim. Biophys. Acta Mol. Cell. Res. 1869 , 119162 (2022). 34670117 10.1016/j.bbamcr.2021.119162

97. Sun X microRNA-155-5p initiates childhood acute lymphoblastic leukemia by regulating the IRF4/CDK6/CBL axis Lab. Invest. 2022 102 411 421 10.1038/s41374-021-00638-x 34775495 Sun, X. et al. microRNA-155-5p initiates childhood acute lymphoblastic leukemia by regulating the IRF4/CDK6/CBL axis. Lab. Invest. 102 , 411–421 (2022). 34775495 10.1038/s41374-021-00638-x

98. Li X Cbl ubiquitin ligases control B cell exit from the germinal-center reaction Immunity 2018 48 530 541.e536 10.1016/j.immuni.2018.03.006 29562201 Li, X. et al. Cbl ubiquitin ligases control B cell exit from the germinal-center reaction. Immunity 48 , 530–541.e536 (2018). 29562201 10.1016/j.immuni.2018.03.006

99. Guo Z Ubiquitin specific peptidase 4 stabilizes interferon regulatory factor protein and promotes its function to facilitate interleukin-4 expression in T helper type 2 cells Int. J. Mol. Med. 2017 40 979 986 10.3892/ijmm.2017.3087 28791349 PMC5593473 Guo, Z. et al. Ubiquitin specific peptidase 4 stabilizes interferon regulatory factor protein and promotes its function to facilitate interleukin-4 expression in T helper type 2 cells. Int. J. Mol. Med. 40 , 979–986 (2017). 28791349 10.3892/ijmm.2017.3087 PMC5593473

100. Balkhi MY Fitzgerald KA Pitha PM Functional regulation of MyD88-activated interferon regulatory factor 5 by K63-linked polyubiquitination Mol. Cell. Biol. 2008 28 7296 7308 10.1128/MCB.00662-08 18824541 PMC2593423 Balkhi, M. Y., Fitzgerald, K. A. & Pitha, P. M. Functional regulation of MyD88-activated interferon regulatory factor 5 by K63-linked polyubiquitination. Mol. Cell. Biol. 28 , 7296–7308 (2008). 18824541 10.1128/MCB.00662-08 PMC2593423

101. Kim D Cytosolic pellino-1-mediated K63-linked ubiquitination of IRF5 in M1 macrophages regulates glucose intolerance in obesity Cell. Rep. 2017 20 832 845 10.1016/j.celrep.2017.06.088 28746869 Kim, D. et al. Cytosolic pellino-1-mediated K63-linked ubiquitination of IRF5 in M1 macrophages regulates glucose intolerance in obesity. Cell. Rep. 20 , 832–845 (2017). 28746869 10.1016/j.celrep.2017.06.088

102. Chen H Peli1 deletion in macrophages attenuates myocardial ischemia/reperfusion injury by suppressing M1 polarization J. Leukoc. Biol. 2023 113 95 108 10.1093/jleuko/qiac012 36822176 Chen, H. et al. Peli1 deletion in macrophages attenuates myocardial ischemia/reperfusion injury by suppressing M1 polarization. J. Leukoc. Biol. 113 , 95–108 (2023). 36822176 10.1093/jleuko/qiac012

103. Yu Y Wang SE Hayward GS The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation Immunity 2005 22 59 70 10.1016/j.immuni.2004.11.011 15664159 Yu, Y., Wang, S. E. & Hayward, G. S. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 22 , 59–70 (2005). 15664159 10.1016/j.immuni.2004.11.011

104. Yu Y Hayward GS The ubiquitin E3 ligase RAUL negatively regulates type i interferon through ubiquitination of the transcription factors IRF7 and IRF3 Immunity 2010 33 863 877 10.1016/j.immuni.2010.11.027 21167755 PMC3012379 Yu, Y. & Hayward, G. S. The ubiquitin E3 ligase RAUL negatively regulates type i interferon through ubiquitination of the transcription factors IRF7 and IRF3. Immunity 33 , 863–877 (2010). 21167755 10.1016/j.immuni.2010.11.027 PMC3012379

105. Ning S Pagano JS The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7 J. Virol. 2010 84 6130 6138 10.1128/JVI.00364-10 20392859 PMC2876664 Ning, S. & Pagano, J. S. The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7. J. Virol. 84 , 6130–6138 (2010). 20392859 10.1128/JVI.00364-10 PMC2876664

106. Wang J Negative regulation of Nmi on virus-triggered type I IFN production by targeting IRF7 J. Immunol. 2013 191 3393 3399 10.4049/jimmunol.1300740 23956435 Wang, J. et al. Negative regulation of Nmi on virus-triggered type I IFN production by targeting IRF7. J. Immunol. 191 , 3393–3399 (2013). 23956435 10.4049/jimmunol.1300740

107. Young JA Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production J. Biol. Chem. 2011 286 6521 6531 10.1074/jbc.M110.172288 21183682 PMC3057824 Young, J. A. et al. Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production. J. Biol. Chem. 286 , 6521–6531 (2011). 21183682 10.1074/jbc.M110.172288 PMC3057824

108. Huye LE Ning S Kelliher M Pagano JS Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination Mol. Cell. Biol. 2007 27 2910 2918 10.1128/MCB.02256-06 17296724 PMC1899925 Huye, L. E., Ning, S., Kelliher, M. & Pagano, J. S. Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Mol. Cell. Biol. 27 , 2910–2918 (2007). 17296724 10.1128/MCB.02256-06 PMC1899925

109. Ning S TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1 Mol. Cell. Biol. 2008 28 6536 6546 10.1128/MCB.00785-08 18710948 PMC2577435 Ning, S. et al. TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. Mol. Cell. Biol. 28 , 6536–6546 (2008). 18710948 10.1128/MCB.00785-08 PMC2577435

110. Ling T TARBP2 inhibits IRF7 activation by suppressing TRAF6-mediated K63-linked ubiquitination of IRF7 Mol. Immunol. 2019 109 116 125 10.1016/j.molimm.2019.02.019 30927622 Ling, T. et al. TARBP2 inhibits IRF7 activation by suppressing TRAF6-mediated K63-linked ubiquitination of IRF7. Mol. Immunol. 109 , 116–125 (2019). 30927622 10.1016/j.molimm.2019.02.019

111. Xiong H Ubiquitin-dependent degradation of interferon regulatory factor-8 mediated by Cbl down-regulates interleukin-12 expression J. Biol. Chem. 2005 280 23531 23539 10.1074/jbc.M414296200 15837792 Xiong, H. et al. Ubiquitin-dependent degradation of interferon regulatory factor-8 mediated by Cbl down-regulates interleukin-12 expression. J. Biol. Chem. 280 , 23531–23539 (2005). 15837792 10.1074/jbc.M414296200

112. Kong HJ Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages J. Immunol. 2007 179 26 30 10.4049/jimmunol.179.1.26 17579016 Kong, H. J. et al. Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J. Immunol. 179 , 26–30 (2007). 17579016 10.4049/jimmunol.179.1.26

113. Lin R USP4 interacts and positively regulates IRF8 function via K48-linked deubiquitination in regulatory T cells FEBS Lett. 2017 591 1677 1686 10.1002/1873-3468.12668 28477415 Lin, R. et al. USP4 interacts and positively regulates IRF8 function via K48-linked deubiquitination in regulatory T cells. FEBS Lett. 591 , 1677–1686 (2017). 28477415 10.1002/1873-3468.12668

114. Zhang M Herpes simplex virus type 2 inhibits type I IFN signaling mediated by the novel E3 ubiquitin protein ligase activity of viral protein ICP22 J. Immunol. 2020 205 1281 1292 10.4049/jimmunol.2000418 32699158 Zhang, M. et al. Herpes simplex virus type 2 inhibits type I IFN signaling mediated by the novel E3 ubiquitin protein ligase activity of viral protein ICP22. J. Immunol. 205 , 1281–1292 (2020). 32699158 10.4049/jimmunol.2000418

115. Vertegaal ACO Signalling mechanisms and cellular functions of SUMO Nat. Rev. Mol. Cell. Biol. 2022 23 715 731 10.1038/s41580-022-00500-y 35750927 Vertegaal, A. C. O. Signalling mechanisms and cellular functions of SUMO. Nat. Rev. Mol. Cell. Biol. 23 , 715–731 (2022). 35750927 10.1038/s41580-022-00500-y

116. Liang YC SUMO5, a novel poly-SUMO isoform, regulates PML nuclear bodies Sci. Rep. 2016 6 26509 10.1038/srep26509 27211601 PMC4876461 Liang, Y. C. et al. SUMO5, a novel poly-SUMO isoform, regulates PML nuclear bodies. Sci. Rep. 6 , 26509 (2016). 27211601 10.1038/srep26509 PMC4876461

117. Bergink S Jentsch S Principles of ubiquitin and SUMO modifications in DNA repair Nature 2009 458 461 467 10.1038/nature07963 19325626 Bergink, S. & Jentsch, S. Principles of ubiquitin and SUMO modifications in DNA repair. Nature 458 , 461–467 (2009). 19325626 10.1038/nature07963

118. Meulmeester E Melchior F Cell biology: SUMO Nature 2008 452 709 711 10.1038/452709a 18401402 Meulmeester, E. & Melchior, F. Cell biology: SUMO. Nature 452 , 709–711 (2008). 18401402 10.1038/452709a

119. Kunz, K., Piller, T. & Müller, S. SUMO-specific proteases and isopeptidases of the SENP family at a glance. J. Cell. Sci . 131 , jcs211904 (2018). 10.1242/jcs.211904 29559551

120. Nakagawa K Yokosawa H PIAS3 induces SUMO-1 modification and transcriptional repression of IRF-1 FEBS Lett. 2002 530 204 208 10.1016/S0014-5793(02)03486-5 12387893 Nakagawa, K. & Yokosawa, H. PIAS3 induces SUMO-1 modification and transcriptional repression of IRF-1. FEBS Lett. 530 , 204–208 (2002). 12387893 10.1016/s0014-5793(02)03486-5

121. Kim EJ Park JS Um SJ Ubc9-mediated sumoylation leads to transcriptional repression of IRF-1 Biochem. Biophys. Res. Commun. 2008 377 952 956 10.1016/j.bbrc.2008.10.092 18955028 Kim, E. J., Park, J. S. & Um, S. J. Ubc9-mediated sumoylation leads to transcriptional repression of IRF-1. Biochem. Biophys. Res. Commun. 377 , 952–956 (2008). 18955028 10.1016/j.bbrc.2008.10.092

122. Park SM SUMOylated IRF-1 shows oncogenic potential by mimicking IRF-2 Biochem. Biophys. Res. Commun. 2010 391 926 930 10.1016/j.bbrc.2009.11.166 19962964 Park, S. M. et al. SUMOylated IRF-1 shows oncogenic potential by mimicking IRF-2. Biochem. Biophys. Res. Commun. 391 , 926–930 (2010). 19962964 10.1016/j.bbrc.2009.11.166

123. Park J Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis Proc. Natl. Acad. Sci. USA 2007 104 17028 17033 10.1073/pnas.0609852104 17942705 PMC2040422 Park, J. et al. Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis. Proc. Natl. Acad. Sci. USA 104 , 17028–17033 (2007). 17942705 10.1073/pnas.0609852104 PMC2040422

124. Sun T α-Lipoic acid (α-LA) inhibits the transcriptional activity of interferon regulatory factor 1 (IRF-1) via SUMOylation Toxicol. Vitr. 2014 28 1242 1248 10.1016/j.tiv.2014.06.003 24975507 Sun, T. et al. α-Lipoic acid (α-LA) inhibits the transcriptional activity of interferon regulatory factor 1 (IRF-1) via SUMOylation. Toxicol. Vitr. 28 , 1242–1248 (2014). 10.1016/j.tiv.2014.06.003 24975507

125. Jeong HY 5-Azacytidine modulates interferon regulatory factor 1 in macrophages to exert a cardioprotective effect Sci. Rep. 2015 5 15768 10.1038/srep15768 26510961 PMC4625165 Jeong, H. Y. et al. 5-Azacytidine modulates interferon regulatory factor 1 in macrophages to exert a cardioprotective effect. Sci. Rep. 5 , 15768 (2015). 26510961 10.1038/srep15768 PMC4625165

126. Han KJ Jiang L Shu HB Regulation of IRF2 transcriptional activity by its sumoylation Biochem. Biophys. Res. Commun. 2008 372 772 778 10.1016/j.bbrc.2008.05.103 18514056 Han, K. J., Jiang, L. & Shu, H. B. Regulation of IRF2 transcriptional activity by its sumoylation. Biochem. Biophys. Res. Commun. 372 , 772–778 (2008). 18514056 10.1016/j.bbrc.2008.05.103

127. Kubota T Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression J. Biol. Chem. 2008 283 25660 25670 10.1074/jbc.M804479200 18635538 PMC2533075 Kubota, T. et al. Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J. Biol. Chem. 283 , 25660–25670 (2008). 18635538 10.1074/jbc.M804479200 PMC2533075

128. Maarifi G MxA mediates SUMO-induced resistance to vesicular stomatitis virus J. Virol. 2016 90 6598 6610 10.1128/JVI.00722-16 27170750 PMC4936121 Maarifi, G. et al. MxA mediates SUMO-induced resistance to vesicular stomatitis virus. J. Virol. 90 , 6598–6610 (2016). 27170750 10.1128/JVI.00722-16 PMC4936121

129. Chang TH Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery PLoS. Pathog. 2009 5 e1000493 10.1371/journal.ppat.1000493 19557165 PMC2696038 Chang, T. H. et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS. Pathog. 5 , e1000493 (2009). 19557165 10.1371/journal.ppat.1000493 PMC2696038

130. Bentz GL Shackelford J Pagano JS Epstein-Barr virus latent membrane protein 1 regulates the function of interferon regulatory factor 7 by inducing its sumoylation J. Virol. 2012 86 12251 12261 10.1128/JVI.01407-12 22951831 PMC3486478 Bentz, G. L., Shackelford, J. & Pagano, J. S. Epstein-Barr virus latent membrane protein 1 regulates the function of interferon regulatory factor 7 by inducing its sumoylation. J. Virol. 86 , 12251–12261 (2012). 22951831 10.1128/JVI.01407-12 PMC3486478

131. Liang Q Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7 J. Immunol. 2011 187 4754 4763 10.4049/jimmunol.1101704 21940674 PMC3197880 Liang, Q. et al. Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7. J. Immunol. 187 , 4754–4763 (2011). 21940674 10.4049/jimmunol.1101704 PMC3197880

132. Wang F Loss of ubiquitin-conjugating enzyme E2 (Ubc9) in macrophages exacerbates multiple low-dose streptozotocin-induced diabetes by attenuating M2 macrophage polarization Cell. Death. Dis. 2019 10 892 10.1038/s41419-019-2130-z 31767832 PMC6877645 Wang, F. et al. Loss of ubiquitin-conjugating enzyme E2 (Ubc9) in macrophages exacerbates multiple low-dose streptozotocin-induced diabetes by attenuating M2 macrophage polarization. Cell. Death. Dis. 10 , 892 (2019). 31767832 10.1038/s41419-019-2130-z PMC6877645

133. Liu J TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma Aging (Albany NY) 2020 12 20308 20331 10.18632/aging.103804 33091876 PMC7655206 Liu, J. et al. TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma. Aging (Albany NY) 12 , 20308–20331 (2020). 33091876 10.18632/aging.103804 PMC7655206

134. Zhang Y SENP3 suppresses osteoclastogenesis by de-conjugating SUMO2/3 from IRF8 in bone marrow-derived monocytes Cell. Rep. 2020 30 1951 1963.e1954 10.1016/j.celrep.2020.01.036 32049023 Zhang, Y. et al. SENP3 suppresses osteoclastogenesis by de-conjugating SUMO2/3 from IRF8 in bone marrow-derived monocytes. Cell. Rep. 30 , 1951–1963.e1954 (2020). 32049023 10.1016/j.celrep.2020.01.036

135. Chang TH The small ubiquitin-like modifier-deconjugating enzyme sentrin-specific peptidase 1 switches IFN regulatory factor 8 from a repressor to an activator during macrophage activation J. Immunol. 2012 189 3548 3556 10.4049/jimmunol.1201104 22942423 PMC4158928 Chang, T. H. et al. The small ubiquitin-like modifier-deconjugating enzyme sentrin-specific peptidase 1 switches IFN regulatory factor 8 from a repressor to an activator during macrophage activation. J. Immunol. 189 , 3548–3556 (2012). 22942423 10.4049/jimmunol.1201104 PMC4158928

136. Masumi A Ozato K Coactivator p300 acetylates the interferon regulatory factor-2 in U937 cells following phorbol ester treatment J. Biol. Chem. 2001 276 20973 20980 10.1074/jbc.M101707200 11304541 Masumi, A. & Ozato, K. Coactivator p300 acetylates the interferon regulatory factor-2 in U937 cells following phorbol ester treatment. J. Biol. Chem. 276 , 20973–20980 (2001). 11304541 10.1074/jbc.M101707200

137. Qiu W Sublytic C5b-9 triggers glomerular mesangial cell apoptosis via XAF1 gene activation mediated by p300-dependent IRF-1 acetylation Cell. Death. Dis. 2014 5 e1176 10.1038/cddis.2014.153 24743731 PMC4001307 Qiu, W. et al. Sublytic C5b-9 triggers glomerular mesangial cell apoptosis via XAF1 gene activation mediated by p300-dependent IRF-1 acetylation. Cell. Death. Dis. 5 , e1176 (2014). 24743731 10.1038/cddis.2014.153 PMC4001307

138. Wu Y Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity Nat. Cancer 2023 4 382 400 10.1038/s43018-023-00522-1 36894639 PMC10042735 Wu, Y. et al. Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity. Nat. Cancer 4 , 382–400 (2023). 36894639 10.1038/s43018-023-00522-1 PMC10042735

139. Masumi A Interferon regulatory factor-2 regulates cell growth through its acetylation J. Biol. Chem. 2003 278 25401 25407 10.1074/jbc.M213037200 12738767 Masumi, A. et al. Interferon regulatory factor-2 regulates cell growth through its acetylation. J. Biol. Chem. 278 , 25401–25407 (2003). 12738767 10.1074/jbc.M213037200

140. Masumi A Nucleolin is involved in interferon regulatory factor-2-dependent transcriptional activation Oncogene 2006 25 5113 5124 10.1038/sj.onc.1209522 16582966 Masumi, A. et al. Nucleolin is involved in interferon regulatory factor-2-dependent transcriptional activation. Oncogene 25 , 5113–5124 (2006). 16582966 10.1038/sj.onc.1209522

141. Wang C The methyltransferase NSD3 promotes antiviral innate immunity via direct lysine methylation of IRF3 J. Exp. Med. 2017 214 3597 3610 10.1084/jem.20170856 29101251 PMC5716042 Wang, C. et al. The methyltransferase NSD3 promotes antiviral innate immunity via direct lysine methylation of IRF3. J. Exp. Med. 214 , 3597–3610 (2017). 29101251 10.1084/jem.20170856 PMC5716042

142. Mino T Takeuchi O NSD3 keeps IRF3 active J. Exp. Med. 2017 214 3475 3476 10.1084/jem.20171980 29158375 PMC5716047 Mino, T. & Takeuchi, O. NSD3 keeps IRF3 active. J. Exp. Med. 214 , 3475–3476 (2017). 29158375 10.1084/jem.20171980 PMC5716047

143. Wang J Arginine methylation by PRMT2 promotes IFN-β production through TLR4/IRF3 signaling pathway Mol. Immunol. 2021 139 202 210 10.1016/j.molimm.2021.08.014 34583098 Wang, J. et al. Arginine methylation by PRMT2 promotes IFN-β production through TLR4/IRF3 signaling pathway. Mol. Immunol. 139 , 202–210 (2021). 34583098 10.1016/j.molimm.2021.08.014

144. Huai W KAT8 selectively inhibits antiviral immunity by acetylating IRF3 J. Exp. Med. 2019 216 772 785 10.1084/jem.20181773 30842237 PMC6446880 Huai, W. et al. KAT8 selectively inhibits antiviral immunity by acetylating IRF3. J. Exp. Med. 216 , 772–785 (2019). 30842237 10.1084/jem.20181773 PMC6446880

145. Caillaud A Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding J. Biol. Chem. 2002 277 49417 49421 10.1074/jbc.M207484200 12374802 Caillaud, A. et al. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J. Biol. Chem. 277 , 49417–49421 (2002). 12374802 10.1074/jbc.M207484200

146. Qin Z Deactylation by SIRT1 enables liquid-liquid phase separation of IRF3/IRF7 in innate antiviral immunity Nat. Immunol. 2022 23 1193 1207 10.1038/s41590-022-01269-0 35879450 Qin, Z. et al. Deactylation by SIRT1 enables liquid-liquid phase separation of IRF3/IRF7 in innate antiviral immunity. Nat. Immunol. 23 , 1193–1207 (2022). 35879450 10.1038/s41590-022-01269-0

147. Acidereli H Turut FA Cevik O Acetylation of interferon regulatory factor-5 suppresses androgen receptor and downregulates expression of Sox2 Cell. Biochem. Funct. 2021 39 667 678 10.1002/cbf.3633 33780016 Acidereli, H., Turut, F. A. & Cevik, O. Acetylation of interferon regulatory factor-5 suppresses androgen receptor and downregulates expression of Sox2. Cell. Biochem. Funct. 39 , 667–678 (2021). 33780016 10.1002/cbf.3633

148. Tang X Acetylation-dependent signal transduction for type I interferon receptor Cell 2007 131 93 105 10.1016/j.cell.2007.07.034 17923090 Tang, X. et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 131 , 93–105 (2007). 17923090 10.1016/j.cell.2007.07.034

149. Worbs T Hammerschmidt SI Förster R Dendritic cell migration in health and disease Nat. Rev. Immunol. 2017 17 30 48 10.1038/nri.2016.116 27890914 Worbs, T., Hammerschmidt, S. I. & Förster, R. Dendritic cell migration in health and disease. Nat. Rev. Immunol. 17 , 30–48 (2017). 27890914 10.1038/nri.2016.116

150. Collin M Bigley V Human dendritic cell subsets: an update Immunology 2018 154 3 20 10.1111/imm.12888 29313948 PMC5904714 Collin, M. & Bigley, V. Human dendritic cell subsets: an update. Immunology 154 , 3–20 (2018). 29313948 10.1111/imm.12888 PMC5904714

151. Tailor P Tamura T Ozato K IRF family proteins and type I interferon induction in dendritic cells Cell. Res. 2006 16 134 140 10.1038/sj.cr.7310018 16474425 Tailor, P., Tamura, T. & Ozato, K. IRF family proteins and type I interferon induction in dendritic cells. Cell. Res. 16 , 134–140 (2006). 16474425 10.1038/sj.cr.7310018

152. Suzuki S Critical roles of interferon regulatory factor 4 in CD11bhighCD8alpha- dendritic cell development Proc. Natl Acad. Sci. USA 2004 101 8981 8986 10.1073/pnas.0402139101 15184678 PMC428458 Suzuki, S. et al. Critical roles of interferon regulatory factor 4 in CD11bhighCD8alpha- dendritic cell development. Proc. Natl Acad. Sci. USA 101 , 8981–8986 (2004). 15184678 10.1073/pnas.0402139101 PMC428458

153. Tsujimura H Tamura T Ozato K Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells J. Immunol. 2003 170 1131 1135 10.4049/jimmunol.170.3.1131 12538667 Tsujimura, H., Tamura, T. & Ozato, K. Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells. J. Immunol. 170 , 1131–1135 (2003). 12538667 10.4049/jimmunol.170.3.1131

154. Tamura T IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity J. Immunol. 2005 174 2573 2581 10.4049/jimmunol.174.5.2573 15728463 Tamura, T. et al. IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J. Immunol. 174 , 2573–2581 (2005). 15728463 10.4049/jimmunol.174.5.2573

155. Schiavoni G ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells J. Exp. Med. 2002 196 1415 1425 10.1084/jem.20021263 12461077 PMC2194263 Schiavoni, G. et al. ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. J. Exp. Med. 196 , 1415–1425 (2002). 12461077 10.1084/jem.20021263 PMC2194263

156. Aliberti J Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells Blood 2003 101 305 310 10.1182/blood-2002-04-1088 12393690 Aliberti, J. et al. Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells. Blood 101 , 305–310 (2003). 12393690 10.1182/blood-2002-04-1088

157. Lança T IRF8 deficiency induces the transcriptional, functional, and epigenetic reprogramming of cDC1 into the cDC2 lineage Immunity 2022 55 1431 1447.e1411 10.1016/j.immuni.2022.06.006 35830859 Lança, T. et al. IRF8 deficiency induces the transcriptional, functional, and epigenetic reprogramming of cDC1 into the cDC2 lineage. Immunity 55 , 1431–1447.e1411 (2022). 35830859 10.1016/j.immuni.2022.06.006

158. Gabriele L IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features J. Leukoc. Biol. 2006 80 1500 1511 10.1189/jlb.0406246 16966383 Gabriele, L. et al. IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. J. Leukoc. Biol. 80 , 1500–1511 (2006). 16966383 10.1189/jlb.0406246

159. Ichikawa E Defective development of splenic and epidermal CD4+ dendritic cells in mice deficient for IFN regulatory factor-2 Proc. Natl Acad. Sci. USA 2004 101 3909 3914 10.1073/pnas.0400610101 15004277 PMC374343 Ichikawa, E. et al. Defective development of splenic and epidermal CD4+ dendritic cells in mice deficient for IFN regulatory factor-2. Proc. Natl Acad. Sci. USA 101 , 3909–3914 (2004). 15004277 10.1073/pnas.0400610101 PMC374343

160. Negishi, H., Taniguchi, T. & Yanai, H. The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family. Cold. Spring. Harb. Perspect. Biol . 10 , a028423 (2018). 10.1101/cshperspect.a028423 PMC6211389 28963109

161. Petro TM IFN regulatory factor 3 in health and disease J. Immunol. 2020 205 1981 1989 10.4049/jimmunol.2000462 33020188 Petro, T. M. IFN regulatory factor 3 in health and disease. J. Immunol. 205 , 1981–1989 (2020). 33020188 10.4049/jimmunol.2000462

162. Negishi H Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses Nat. Immunol. 2012 13 659 666 10.1038/ni.2307 22610141 Negishi, H. et al. Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat. Immunol. 13 , 659–666 (2012). 22610141 10.1038/ni.2307

163. Matta B Song S Li D Barnes BJ Interferon regulatory factor signaling in autoimmune disease Cytokine 2017 98 15 26 10.1016/j.cyto.2017.02.006 28283223 PMC8033540 Matta, B., Song, S., Li, D. & Barnes, B. J. Interferon regulatory factor signaling in autoimmune disease. Cytokine 98 , 15–26 (2017). 28283223 10.1016/j.cyto.2017.02.006 PMC8033540

164. Qing F Liu Z Interferon regulatory factor 7 in inflammation, cancer and infection Front. Immunol. 2023 14 1190841 10.3389/fimmu.2023.1190841 37251373 PMC10213216 Qing, F. & Liu, Z. Interferon regulatory factor 7 in inflammation, cancer and infection. Front. Immunol. 14 , 1190841 (2023). 37251373 10.3389/fimmu.2023.1190841 PMC10213216

165. Al Hamrashdi M Brady G Regulation of IRF3 activation in human antiviral signaling pathways Biochem. Pharmacol. 2022 200 115026 10.1016/j.bcp.2022.115026 35367198 Al Hamrashdi, M. & Brady, G. Regulation of IRF3 activation in human antiviral signaling pathways. Biochem. Pharmacol. 200 , 115026 (2022). 35367198 10.1016/j.bcp.2022.115026

166. Almuttaqi H Udalova IA Advances and challenges in targeting IRF5, a key regulator of inflammation FEBS J. 2019 286 1624 1637 10.1111/febs.14654 30199605 PMC6563445 Almuttaqi, H. & Udalova, I. A. Advances and challenges in targeting IRF5, a key regulator of inflammation. FEBS J. 286 , 1624–1637 (2019). 30199605 10.1111/febs.14654 PMC6563445

167. Lazear HM IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling PLoS. Pathog. 2013 9 e1003118 10.1371/journal.ppat.1003118 23300459 PMC3536698 Lazear, H. M. et al. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS. Pathog. 9 , e1003118 (2013). 23300459 10.1371/journal.ppat.1003118 PMC3536698

168. Panda D IRF1 maintains optimal constitutive expression of antiviral genes and regulates the early antiviral response Front. Immunol. 2019 10 1019 10.3389/fimmu.2019.01019 31156620 PMC6529937 Panda, D. et al. IRF1 maintains optimal constitutive expression of antiviral genes and regulates the early antiviral response. Front. Immunol. 10 , 1019 (2019). 31156620 10.3389/fimmu.2019.01019 PMC6529937

169. Xia X Wang W Yin K Wang S Interferon regulatory factor 8 governs myeloid cell development Cytokine Growth Factor. Rev. 2020 55 48 57 10.1016/j.cytogfr.2020.03.003 32327344 Xia, X., Wang, W., Yin, K. & Wang, S. Interferon regulatory factor 8 governs myeloid cell development. Cytokine Growth Factor. Rev. 55 , 48–57 (2020). 32327344 10.1016/j.cytogfr.2020.03.003

170. Tait Wojno ED Hunter CA Stumhofer JS The Immunobiology of the Interleukin-12 Family: Room for Discovery Immunity 2019 50 851 870 10.1016/j.immuni.2019.03.011 30995503 PMC6472917 Tait Wojno, E. D., Hunter, C. A. & Stumhofer, J. S. The Immunobiology of the Interleukin-12 Family: Room for Discovery. Immunity 50 , 851–870 (2019). 30995503 10.1016/j.immuni.2019.03.011 PMC6472917

171. Verstockt B IL-12 and IL-23 pathway inhibition in inflammatory bowel disease Nat. Rev. Gastroenterol. Hepatol. 2023 20 433 446 10.1038/s41575-023-00768-1 37069321 PMC10958371 Verstockt, B. et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 20 , 433–446 (2023). 37069321 10.1038/s41575-023-00768-1 PMC10958371

172. Kröger A Activities of IRF-1 J. Interferon Cytokine Res. 2002 22 5 14 10.1089/107999002753452610 11846971 Kröger, A. et al. Activities of IRF-1. J. Interferon Cytokine Res. 22 , 5–14 (2002). 11846971 10.1089/107999002753452610

173. Ng LG Liu Z Kwok I Ginhoux F Origin and heterogeneity of tissue myeloid cells: A focus on GMP-derived monocytes and neutrophils Annu. Rev. Immunol. 2023 41 375 404 10.1146/annurev-immunol-081022-113627 37126421 Ng, L. G., Liu, Z., Kwok, I. & Ginhoux, F. Origin and heterogeneity of tissue myeloid cells: A focus on GMP-derived monocytes and neutrophils. Annu. Rev. Immunol. 41 , 375–404 (2023). 37126421 10.1146/annurev-immunol-081022-113627

174. Holtschke T Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene Cell 1996 87 307 317 10.1016/S0092-8674(00)81348-3 8861914 Holtschke, T. et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87 , 307–317 (1996). 8861914 10.1016/s0092-8674(00)81348-3

175. Scheller M Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein Blood 1999 94 3764 3771 10.1182/blood.V94.11.3764 10572090 Scheller, M. et al. Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein. Blood 94 , 3764–3771 (1999). 10572090

176. Schmidt M The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells Blood 2004 103 4142 4149 10.1182/blood-2003-01-0285 14976051 Schmidt, M. et al. The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells. Blood 103 , 4142–4149 (2004). 14976051 10.1182/blood-2003-01-0285

177. Diaz-Blanco E Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase Leukemia 2007 21 494 504 10.1038/sj.leu.2404549 17252012 Diaz-Blanco, E. et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 21 , 494–504 (2007). 17252012 10.1038/sj.leu.2404549

178. Zhao Y mTOR masters monocyte development in bone marrow by decreasing the inhibition of STAT5 on IRF8 Blood 2018 131 1587 1599 10.1182/blood-2017-04-777128 29463562 Zhao, Y. et al. mTOR masters monocyte development in bone marrow by decreasing the inhibition of STAT5 on IRF8. Blood 131 , 1587–1599 (2018). 29463562 10.1182/blood-2017-04-777128

179. Li P IRF8 and IRF3 cooperatively regulate rapid interferon-β induction in human blood monocytes Blood 2011 117 2847 2854 10.1182/blood-2010-07-294272 21228327 Li, P. et al. IRF8 and IRF3 cooperatively regulate rapid interferon-β induction in human blood monocytes. Blood 117 , 2847–2854 (2011). 21228327 10.1182/blood-2010-07-294272

180. Rosenbauer F Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion EMBO J. 2002 21 211 220 10.1093/emboj/21.3.211 11823414 PMC125345 Rosenbauer, F. et al. Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion. EMBO J. 21 , 211–220 (2002). 11823414 10.1093/emboj/21.3.211 PMC125345

181. Tamura T Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages Blood 2005 106 1938 1947 10.1182/blood-2005-01-0080 15947094 PMC1895144 Tamura, T. et al. Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages. Blood 106 , 1938–1947 (2005). 15947094 10.1182/blood-2005-01-0080 PMC1895144

182. Dror N Identification of IRF-8 and IRF-1 target genes in activated macrophages Mol. Immunol. 2007 44 338 346 10.1016/j.molimm.2006.02.026 16597464 Dror, N. et al. Identification of IRF-8 and IRF-1 target genes in activated macrophages. Mol. Immunol. 44 , 338–346 (2007). 16597464 10.1016/j.molimm.2006.02.026

183. Tamura T ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages Immunity 2000 13 155 165 10.1016/S1074-7613(00)00016-9 10981959 Tamura, T. et al. ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. Immunity 13 , 155–165 (2000). 10981959 10.1016/s1074-7613(00)00016-9

184. Karki R IRF8 regulates transcription of naips for NLRC4 inflammasome activation Cell 2018 173 920 933.e913 10.1016/j.cell.2018.02.055 29576451 PMC5935577 Karki, R. et al. IRF8 regulates transcription of naips for NLRC4 inflammasome activation. Cell 173 , 920–933.e913 (2018). 29576451 10.1016/j.cell.2018.02.055 PMC5935577

185. Gupta M IRF8 directs stress-induced autophagy in macrophages and promotes clearance of Listeria monocytogenes Nat. Commun. 2015 6 6379 10.1038/ncomms7379 25775030 PMC4363081 Gupta, M. et al. IRF8 directs stress-induced autophagy in macrophages and promotes clearance of Listeria monocytogenes. Nat. Commun. 6 , 6379 (2015). 25775030 10.1038/ncomms7379 PMC4363081

186. Sjöstrand M Expression of the immune regulator tripartite-motif 21 is controlled by IFN regulatory factors J. Immunol. 2013 191 3753 3763 10.4049/jimmunol.1202341 23975864 Sjöstrand, M. et al. Expression of the immune regulator tripartite-motif 21 is controlled by IFN regulatory factors. J. Immunol. 191 , 3753–3763 (2013). 23975864 10.4049/jimmunol.1202341

187. Blanco JC Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression J. Exp. Med. 2000 191 2131 2144 10.1084/jem.191.12.2131 10859338 PMC2193204 Blanco, J. C. et al. Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J. Exp. Med. 191 , 2131–2144 (2000). 10859338 10.1084/jem.191.12.2131 PMC2193204

188. Hobart M IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo J. Immunol. 1997 158 4260 4269 10.4049/jimmunol.158.9.4260 9126988 Hobart, M. et al. IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo. J. Immunol. 158 , 4260–4269 (1997). 9126988

189. Kimura T Involvement of the IRF-1 transcription factor in antiviral responses to interferons Science 1994 264 1921 1924 10.1126/science.8009222 8009222 Kimura, T. et al. Involvement of the IRF-1 transcription factor in antiviral responses to interferons. Science 264 , 1921–1924 (1994). 8009222 10.1126/science.8009222

190. Blériot C Chakarov S Ginhoux F Determinants of resident tissue macrophage identity and function Immunity 2020 52 957 970 10.1016/j.immuni.2020.05.014 32553181 Blériot, C., Chakarov, S. & Ginhoux, F. Determinants of resident tissue macrophage identity and function. Immunity 52 , 957–970 (2020). 32553181 10.1016/j.immuni.2020.05.014

191. Park MD Silvin A Ginhoux F Merad M Macrophages in health and disease Cell 2022 185 4259 4279 10.1016/j.cell.2022.10.007 36368305 PMC9908006 Park, M. D., Silvin, A., Ginhoux, F. & Merad, M. Macrophages in health and disease. Cell 185 , 4259–4279 (2022). 36368305 10.1016/j.cell.2022.10.007 PMC9908006

192. Colonna M Butovsky O Microglia function in the central nervous system during health and neurodegeneration Annu. Rev. Immunol. 2017 35 441 468 10.1146/annurev-immunol-051116-052358 28226226 PMC8167938 Colonna, M. & Butovsky, O. Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Immunol. 35 , 441–468 (2017). 28226226 10.1146/annurev-immunol-051116-052358 PMC8167938

193. Borst K Dumas AA Prinz M Microglia: Immune and non-immune functions Immunity 2021 54 2194 2208 10.1016/j.immuni.2021.09.014 34644556 Borst, K., Dumas, A. A. & Prinz, M. Microglia: Immune and non-immune functions. Immunity 54 , 2194–2208 (2021). 34644556 10.1016/j.immuni.2021.09.014

194. Zhou N Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition Protein Cell. 2019 10 87 103 10.1007/s13238-018-0599-3 30484118 PMC6340890 Zhou, N. et al. Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition. Protein Cell. 10 , 87–103 (2019). 30484118 10.1007/s13238-018-0599-3 PMC6340890

195. Masuda T IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype Cell. Rep. 2012 1 334 340 10.1016/j.celrep.2012.02.014 22832225 PMC4158926 Masuda, T. et al. IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype. Cell. Rep. 1 , 334–340 (2012). 22832225 10.1016/j.celrep.2012.02.014 PMC4158926

196. Zhou Y Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease Nat. Med. 2020 26 131 142 10.1038/s41591-019-0695-9 31932797 PMC6980793 Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26 , 131–142 (2020). 31932797 10.1038/s41591-019-0695-9 PMC6980793

197. Masuda T Transcription factor IRF1 is responsible for IRF8-mediated IL-1β expression in reactive microglia J. Pharmacol. Sci. 2015 128 216 220 10.1016/j.jphs.2015.08.002 26318672 Masuda, T. et al. Transcription factor IRF1 is responsible for IRF8-mediated IL-1β expression in reactive microglia. J. Pharmacol. Sci. 128 , 216–220 (2015). 26318672 10.1016/j.jphs.2015.08.002

198. Feinberg PA Elevated TNF-α leads to neural circuit instability in the absence of interferon regulatory factor 8 J. Neurosci. 2022 42 6171 6185 10.1523/JNEUROSCI.0601-22.2022 35790400 PMC9374154 Feinberg, P. A. et al. Elevated TNF-α leads to neural circuit instability in the absence of interferon regulatory factor 8. J. Neurosci. 42 , 6171–6185 (2022). 35790400 10.1523/JNEUROSCI.0601-22.2022 PMC9374154

199. Ivashkiv LB Metabolic-epigenetic coupling in osteoclast differentiation Nat. Med. 2015 21 212 213 10.1038/nm.3815 25742453 PMC4795459 Ivashkiv, L. B. Metabolic-epigenetic coupling in osteoclast differentiation. Nat. Med. 21 , 212–213 (2015). 25742453 10.1038/nm.3815 PMC4795459

200. Zhao B Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis Nat. Med. 2009 15 1066 1071 10.1038/nm.2007 19718038 PMC2755267 Zhao, B. et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med. 15 , 1066–1071 (2009). 19718038 10.1038/nm.2007 PMC2755267

201. Izawa N Cooperation of PU.1 with IRF8 and NFATc1 defines chromatin landscapes during RANKL-induced osteoclastogenesis J. Bone Miner. Res. 2019 34 1143 1154 10.1002/jbmr.3689 30721543 Izawa, N. et al. Cooperation of PU.1 with IRF8 and NFATc1 defines chromatin landscapes during RANKL-induced osteoclastogenesis. J. Bone Miner. Res. 34 , 1143–1154 (2019). 30721543 10.1002/jbmr.3689

202. Saito E Down-regulation of Irf8 by Lyz2-cre/loxP accelerates osteoclast differentiation in vitro Cytotechnology 2017 69 443 450 10.1007/s10616-016-0013-z 27502007 PMC5461233 Saito, E. et al. Down-regulation of Irf8 by Lyz2-cre/loxP accelerates osteoclast differentiation in vitro. Cytotechnology 69 , 443–450 (2017). 27502007 10.1007/s10616-016-0013-z PMC5461233

203. Thumbigere-Math V Inactivating mutation in IRF8 promotes osteoclast transcriptional programs and increases susceptibility to tooth root resorption J. Bone Miner. Res. 2019 34 1155 1168 10.1002/jbmr.3690 30840779 PMC6663587 Thumbigere-Math, V. et al. Inactivating mutation in IRF8 promotes osteoclast transcriptional programs and increases susceptibility to tooth root resorption. J. Bone Miner. Res. 34 , 1155–1168 (2019). 30840779 10.1002/jbmr.3690 PMC6663587

204. Xia Y TGFβ reprograms TNF stimulation of macrophages towards a non-canonical pathway driving inflammatory osteoclastogenesis Nat. Commun. 2022 13 3920 10.1038/s41467-022-31475-1 35798734 PMC9263175 Xia, Y. et al. TGFβ reprograms TNF stimulation of macrophages towards a non-canonical pathway driving inflammatory osteoclastogenesis. Nat. Commun. 13 , 3920 (2022). 35798734 10.1038/s41467-022-31475-1 PMC9263175

205. Gabrilovich DI Myeloid-derived suppressor cells Cancer Immunol. Res. 2017 5 3 8 10.1158/2326-6066.CIR-16-0297 28052991 PMC5426480 Gabrilovich, D. I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5 , 3–8 (2017). 28052991 10.1158/2326-6066.CIR-16-0297 PMC5426480

206. Li K Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer Signal. Transduct. Target. Ther. 2021 6 362 10.1038/s41392-021-00670-9 34620838 PMC8497485 Li, K. et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal. Transduct. Target. Ther. 6 , 362 (2021). 34620838 10.1038/s41392-021-00670-9 PMC8497485

207. Wu Y Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy Mol. Cancer 2022 21 184 10.1186/s12943-022-01657-y 36163047 PMC9513992 Wu, Y. et al. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol. Cancer 21 , 184 (2022). 36163047 10.1186/s12943-022-01657-y PMC9513992

208. Waight JD Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis J. Clin. Invest. 2013 123 4464 4478 10.1172/JCI68189 24091328 PMC3784535 Waight, J. D. et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J. Clin. Invest. 123 , 4464–4478 (2013). 24091328 10.1172/JCI68189 PMC3784535

209. Paschall AV IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation J. Immunol. 2015 194 2369 2379 10.4049/jimmunol.1402412 25646302 PMC4340766 Paschall, A. V. et al. IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation. J. Immunol. 194 , 2369–2379 (2015). 25646302 10.4049/jimmunol.1402412 PMC4340766

210. Yang J Cutting edge: IRF8 regulates Bax transcription in vivo in primary myeloid cells J. Immunol. 2011 187 4426 4430 10.4049/jimmunol.1101034 21949018 PMC3197864 Yang, J. et al. Cutting edge: IRF8 regulates Bax transcription in vivo in primary myeloid cells. J. Immunol. 187 , 4426–4430 (2011). 21949018 10.4049/jimmunol.1101034 PMC3197864

211. Cumbo C IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis Exp. Hematol. Oncol. 2021 10 58 10.1186/s40164-021-00253-y 34952638 PMC8705160 Cumbo, C. et al. IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis. Exp. Hematol. Oncol. 10 , 58 (2021). 34952638 10.1186/s40164-021-00253-y PMC8705160

212. Lu J Liang T Li P Yin Q Regulatory effects of IRF4 on immune cells in the tumor microenvironment Front. Immunol. 2023 14 1086803 10.3389/fimmu.2023.1086803 36814912 PMC9939821 Lu, J., Liang, T., Li, P. & Yin, Q. Regulatory effects of IRF4 on immune cells in the tumor microenvironment. Front. Immunol. 14 , 1086803 (2023). 36814912 10.3389/fimmu.2023.1086803 PMC9939821

213. Nam S Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function J. Leukoc. Biol. 2016 100 1273 1284 10.1189/jlb.1A0215-068RR 27601624 Nam, S. et al. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function. J. Leukoc. Biol. 100 , 1273–1284 (2016). 27601624 10.1189/jlb.1A0215-068RR

214. Yang Q IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer Oncogene 2017 36 2969 2980 10.1038/onc.2016.448 28092673 Yang, Q. et al. IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer. Oncogene 36 , 2969–2980 (2017). 28092673 10.1038/onc.2016.448

215. Lian RH Kumar V Murine natural killer cell progenitors and their requirements for development Semin. Immunol. 2002 14 453 460 10.1016/S1044532302000805 12457618 Lian, R. H. & Kumar, V. Murine natural killer cell progenitors and their requirements for development. Semin. Immunol. 14 , 453–460 (2002). 12457618 10.1016/s1044532302000805

216. Taki S IFN regulatory factor-2 deficiency revealed a novel checkpoint critical for the generation of peripheral NK cells J. Immunol. 2005 174 6005 6012 10.4049/jimmunol.174.10.6005 15879093 Taki, S. et al. IFN regulatory factor-2 deficiency revealed a novel checkpoint critical for the generation of peripheral NK cells. J. Immunol. 174 , 6005–6012 (2005). 15879093 10.4049/jimmunol.174.10.6005

217. Maffei R The dynamic functions of IRF4 in B cell malignancies Clin. Exp. Med. 2023 23 1171 1180 10.1007/s10238-022-00968-0 36495369 PMC10390622 Maffei, R. et al. The dynamic functions of IRF4 in B cell malignancies. Clin. Exp. Med. 23 , 1171–1180 (2023). 36495369 10.1007/s10238-022-00968-0 PMC10390622

218. Cook SL Franke MC Sievert EP Sciammas R A Synchronous IRF4-Dependent Gene Regulatory Network in B and Helper T Cells Orchestrating the Antibody Response Trends Immunol. 2020 41 614 628 10.1016/j.it.2020.05.001 32467029 PMC8722497 Cook, S. L., Franke, M. C., Sievert, E. P. & Sciammas, R. A Synchronous IRF4-Dependent Gene Regulatory Network in B and Helper T Cells Orchestrating the Antibody Response. Trends Immunol. 41 , 614–628 (2020). 32467029 10.1016/j.it.2020.05.001 PMC8722497

219. Lu R Medina KL Lancki DW Singh H IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development Genes. Dev. 2003 17 1703 1708 10.1101/gad.1104803 12832394 PMC196178 Lu, R., Medina, K. L., Lancki, D. W. & Singh, H. IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes. Dev. 17 , 1703–1708 (2003). 12832394 10.1101/gad.1104803 PMC196178

220. Cattoretti G Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance J. Immunol. 2006 177 6930 6939 10.4049/jimmunol.177.10.6930 17082608 Cattoretti, G. et al. Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J. Immunol. 177 , 6930–6939 (2006). 17082608 10.4049/jimmunol.177.10.6930

221. Falini B A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells Blood 2000 95 2084 2092 10.1182/blood.V95.6.2084 10706878 Falini, B. et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95 , 2084–2092 (2000). 10706878

222. Sciammas R Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation Immunity 2006 25 225 236 10.1016/j.immuni.2006.07.009 16919487 Sciammas, R. et al. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 25 , 225–236 (2006). 16919487 10.1016/j.immuni.2006.07.009

223. Zhan F Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development Blood 2003 101 1128 1140 10.1182/blood-2002-06-1737 12393520 Zhan, F. et al. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101 , 1128–1140 (2003). 12393520 10.1182/blood-2002-06-1737

224. Lee CH Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein J. Exp. Med. 2006 203 63 72 10.1084/jem.20051450 16380510 PMC2118063 Lee, C. H. et al. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J. Exp. Med. 203 , 63–72 (2006). 16380510 10.1084/jem.20051450 PMC2118063

225. Ashby KM Hogquist KA A guide to thymic selection of T cells Nat. Rev. Immunol. 2024 24 103 117 10.1038/s41577-023-00911-8 37464188 Ashby, K. M. & Hogquist, K. A. A guide to thymic selection of T cells. Nat. Rev. Immunol. 24 , 103–117 (2024). 37464188 10.1038/s41577-023-00911-8

226. Shrikant PA Regulating functional cell fates in CD8 T cells Immunol. Res. 2010 46 12 22 10.1007/s12026-009-8130-9 19859830 PMC5049497 Shrikant, P. A. et al. Regulating functional cell fates in CD8 T cells. Immunol. Res. 46 , 12–22 (2010). 19859830 10.1007/s12026-009-8130-9 PMC5049497

227. Visekruna A Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation Eur. J. Immunol. 2013 43 606 618 10.1002/eji.201242825 23254356 Visekruna, A. et al. Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation. Eur. J. Immunol. 43 , 606–618 (2013). 23254356 10.1002/eji.201242825

228. Yen HR Tc17 CD8 T cells: functional plasticity and subset diversity J. Immunol. 2009 183 7161 7168 10.4049/jimmunol.0900368 19917680 PMC3082359 Yen, H. R. et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J. Immunol. 183 , 7161–7168 (2009). 19917680 10.4049/jimmunol.0900368 PMC3082359

229. Huber M IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis J. Clin. Invest. 2013 123 247 260 10.1172/JCI63681 23221338 PMC3533283 Huber, M. et al. IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis. J. Clin. Invest. 123 , 247–260 (2013). 23221338 10.1172/JCI63681 PMC3533283

230. Matsuyama T Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development Cell 1993 75 83 97 10.1016/S0092-8674(05)80086-8 8402903 Matsuyama, T. et al. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75 , 83–97 (1993). 8402903

231. Hida S CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling Immunity 2000 13 643 655 10.1016/S1074-7613(00)00064-9 11114377 Hida, S. et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 13 , 643–655 (2000). 11114377 10.1016/s1074-7613(00)00064-9

232. Taki S Multistage regulation of Th1-type immune responses by the transcription factor IRF-1 Immunity 1997 6 673 679 10.1016/S1074-7613(00)80443-4 9208840 Taki, S. et al. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 6 , 673–679 (1997). 9208840 10.1016/s1074-7613(00)80443-4

233. Hida S Tadachi M Saito T Taki S Negative control of basophil expansion by IRF-2 critical for the regulation of Th1/Th2 balance Blood 2005 106 2011 2017 10.1182/blood-2005-04-1344 15914553 Hida, S., Tadachi, M., Saito, T. & Taki, S. Negative control of basophil expansion by IRF-2 critical for the regulation of Th1/Th2 balance. Blood 106 , 2011–2017 (2005). 15914553 10.1182/blood-2005-04-1344

234. Theofilopoulos AN Koundouris S Kono DH Lawson BR The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity Arthritis Res. 2001 3 136 141 10.1186/ar290 11299053 PMC128889 Theofilopoulos, A. N., Koundouris, S., Kono, D. H. & Lawson, B. R. The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 3 , 136–141 (2001). 11299053 10.1186/ar290 PMC128889

235. Feng D Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching Eur. J. Immunol. 2012 42 1477 1487 10.1002/eji.201141642 22678902 PMC3684952 Feng, D. et al. Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching. Eur. J. Immunol. 42 , 1477–1487 (2012). 22678902 10.1002/eji.201141642 PMC3684952

236. Brune Z Rice MR Barnes BJ Potential T cell-intrinsic regulatory roles for IRF5 via cytokine modulation in T helper subset differentiation and function Front. Immunol. 2020 11 1143 10.3389/fimmu.2020.01143 32582209 PMC7283537 Brune, Z., Rice, M. R. & Barnes, B. J. Potential T cell-intrinsic regulatory roles for IRF5 via cytokine modulation in T helper subset differentiation and function. Front. Immunol. 11 , 1143 (2020). 32582209 10.3389/fimmu.2020.01143 PMC7283537

237. Walker JA McKenzie ANJ T(H)2 cell development and function Nat. Rev. Immunol. 2018 18 121 133 10.1038/nri.2017.118 29082915 Walker, J. A. & McKenzie, A. N. J. T(H)2 cell development and function. Nat. Rev. Immunol. 18 , 121–133 (2018). 29082915 10.1038/nri.2017.118

238. Biswas PS Bhagat G Pernis AB IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis? Immunol. Rev. 2010 233 79 96 10.1111/j.0105-2896.2009.00864.x 20192994 PMC2920730 Biswas, P. S., Bhagat, G. & Pernis, A. B. IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis? Immunol. Rev. 233 , 79–96 (2010). 20192994 10.1111/j.0105-2896.2009.00864.x PMC2920730

239. Honma K Interferon regulatory factor 4 differentially regulates the production of Th2 cytokines in naive vs. effector/memory CD4+ T cells Proc. Natl Acad. Sci. USA 2008 105 15890 15895 10.1073/pnas.0803171105 18836070 PMC2572975 Honma, K. et al. Interferon regulatory factor 4 differentially regulates the production of Th2 cytokines in naive vs. effector/memory CD4+ T cells. Proc. Natl Acad. Sci. USA 105 , 15890–15895 (2008). 18836070 10.1073/pnas.0803171105 PMC2572975

240. Jefferies CA Regulating IRFs in IFN driven disease Front. Immunol. 2019 10 325 10.3389/fimmu.2019.00325 30984161 PMC6449421 Jefferies, C. A. Regulating IRFs in IFN driven disease. Front. Immunol. 10 , 325 (2019). 30984161 10.3389/fimmu.2019.00325 PMC6449421

241. Yagi R Zhu J Paul WE An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation Int. Immunol. 2011 23 415 420 10.1093/intimm/dxr029 21632975 PMC3123974 Yagi, R., Zhu, J. & Paul, W. E. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. Int. Immunol. 23 , 415–420 (2011). 21632975 10.1093/intimm/dxr029 PMC3123974

242. Zhu J Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses Nat. Immunol. 2004 5 1157 1165 10.1038/ni1128 15475959 Zhu, J. et al. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat. Immunol. 5 , 1157–1165 (2004). 15475959 10.1038/ni1128

243. Fang CM Unique contribution of IRF-5-Ikaros axis to the B-cell IgG2a response Genes. Immun. 2012 13 421 430 10.1038/gene.2012.10 22535200 PMC3628768 Fang, C. M. et al. Unique contribution of IRF-5-Ikaros axis to the B-cell IgG2a response. Genes. Immun. 13 , 421–430 (2012). 22535200 10.1038/gene.2012.10 PMC3628768

244. Huber M Lohoff M IRF4 at the crossroads of effector T-cell fate decision Eur. J. Immunol. 2014 44 1886 1895 10.1002/eji.201344279 24782159 Huber, M. & Lohoff, M. IRF4 at the crossroads of effector T-cell fate decision. Eur. J. Immunol. 44 , 1886–1895 (2014). 24782159 10.1002/eji.201344279

245. Jabeen R Th9 cell development requires a BATF-regulated transcriptional network J. Clin. Invest. 2013 123 4641 4653 10.1172/JCI69489 24216482 PMC3809790 Jabeen, R. et al. Th9 cell development requires a BATF-regulated transcriptional network. J. Clin. Invest. 123 , 4641–4653 (2013). 24216482 10.1172/JCI69489 PMC3809790

246. Chang HC The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation Nat. Immunol. 2010 11 527 534 10.1038/ni.1867 20431622 PMC3136246 Chang, H. C. et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat. Immunol. 11 , 527–534 (2010). 20431622 10.1038/ni.1867 PMC3136246

247. Brüstle A The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4 Nat. Immunol. 2007 8 958 966 10.1038/ni1500 17676043 Brüstle, A. et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat. Immunol. 8 , 958–966 (2007). 17676043 10.1038/ni1500

248. Wang J Zhao X Wan YY Intricacies of TGF-β signaling in Treg and Th17 cell biology Cell. Mol. Immunol. 2023 20 1002 1022 10.1038/s41423-023-01036-7 37217798 PMC10468540 Wang, J., Zhao, X. & Wan, Y. Y. Intricacies of TGF-β signaling in Treg and Th17 cell biology. Cell. Mol. Immunol. 20 , 1002–1022 (2023). 37217798 10.1038/s41423-023-01036-7 PMC10468540

249. Mudter J The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6 J. Clin. Invest. 2008 118 2415 2426 18535667 10.1172/JCI33227 PMC2413182 Mudter, J. et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J. Clin. Invest. 118 , 2415–2426 (2008). 18535667 10.1172/JCI33227 PMC2413182

250. Mudter J IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo Inflamm. Bowel. Dis. 2011 17 1343 1358 10.1002/ibd.21476 21305677 Mudter, J. et al. IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo. Inflamm. Bowel. Dis. 17 , 1343–1358 (2011). 21305677 10.1002/ibd.21476

251. Huber M IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype Proc. Natl. Acad. Sci. USA 2008 105 20846 20851 10.1073/pnas.0809077106 19088203 PMC2634912 Huber, M. et al. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc. Natl. Acad. Sci. USA 105 , 20846–20851 (2008). 19088203 10.1073/pnas.0809077106 PMC2634912

252. Gutiérrez-Melo N Baumjohann D T follicular helper cells in cancer Trends Cancer 2023 9 309 325 10.1016/j.trecan.2022.12.007 36642575 Gutiérrez-Melo, N. & Baumjohann, D. T follicular helper cells in cancer. Trends Cancer 9 , 309–325 (2023). 36642575 10.1016/j.trecan.2022.12.007

253. Liu X Nurieva RI Dong C Transcriptional regulation of follicular T-helper (Tfh) cells Immunol. Rev. 2013 252 139 145 10.1111/imr.12040 23405901 PMC3579502 Liu, X., Nurieva, R. I. & Dong, C. Transcriptional regulation of follicular T-helper (Tfh) cells. Immunol. Rev. 252 , 139–145 (2013). 23405901 10.1111/imr.12040 PMC3579502

254. Kwon H Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors Immunity 2009 31 941 952 10.1016/j.immuni.2009.10.008 20064451 PMC3272079 Kwon, H. et al. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 31 , 941–952 (2009). 20064451 10.1016/j.immuni.2009.10.008 PMC3272079

255. Ise W The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells Nat. Immunol. 2011 12 536 543 10.1038/ni.2037 21572431 PMC3117275 Ise, W. et al. The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat. Immunol. 12 , 536–543 (2011). 21572431 10.1038/ni.2037 PMC3117275

256. Betz BC Batf coordinates multiple aspects of B and T cell function required for normal antibody responses J. Exp. Med. 2010 207 933 942 10.1084/jem.20091548 20421391 PMC2867277 Betz, B. C. et al. Batf coordinates multiple aspects of B and T cell function required for normal antibody responses. J. Exp. Med. 207 , 933–942 (2010). 20421391 10.1084/jem.20091548 PMC2867277

257. Ponnusamy K The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma Haematologica 2022 107 721 732 10.3324/haematol.2020.274480 33596642 PMC8883568 Ponnusamy, K. et al. The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma. Haematologica 107 , 721–732 (2022). 33596642 10.3324/haematol.2020.274480 PMC8883568

258. Hu G Barnes BJ IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway J. Biol. Chem. 2009 284 2767 2777 10.1074/jbc.M804744200 19028697 Hu, G. & Barnes, B. J. IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway. J. Biol. Chem. 284 , 2767–2777 (2009). 19028697 10.1074/jbc.M804744200

259. Massimino M IRF5 promotes the proliferation of human thyroid cancer cells Mol. Cancer 2012 11 21 10.1186/1476-4598-11-21 22507190 PMC3444366 Massimino, M. et al. IRF5 promotes the proliferation of human thyroid cancer cells. Mol. Cancer 11 , 21 (2012). 22507190 10.1186/1476-4598-11-21 PMC3444366

260. Botti E Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas Proc. Natl Acad. Sci. USA 2011 108 13710 13715 10.1073/pnas.1110931108 21807998 PMC3158164 Botti, E. et al. Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. Proc. Natl Acad. Sci. USA 108 , 13710–13715 (2011). 21807998 10.1073/pnas.1110931108 PMC3158164

261. Xu L The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma Cancer Lett. 2018 431 230 243 10.1016/j.canlet.2017.10.016 29111349 Xu, L. et al. The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma. Cancer Lett. 431 , 230–243 (2018). 29111349 10.1016/j.canlet.2017.10.016

262. Ma X Inhibition of KIF20A by transcription factor IRF6 affects the progression of renal clear cell carcinoma Cancer Cell. Int. 2021 21 246 10.1186/s12935-021-01879-y 33941190 PMC8091794 Ma, X. et al. Inhibition of KIF20A by transcription factor IRF6 affects the progression of renal clear cell carcinoma. Cancer Cell. Int. 21 , 246 (2021). 33941190 10.1186/s12935-021-01879-y PMC8091794

263. Lu J Lin28A promotes IRF6-regulated aerobic glycolysis in glioma cells by stabilizing SNHG14 Cell. Death. Dis. 2020 11 447 10.1038/s41419-020-2650-6 32527996 PMC7289837 Lu, J. et al. Lin28A promotes IRF6-regulated aerobic glycolysis in glioma cells by stabilizing SNHG14. Cell. Death. Dis. 11 , 447 (2020). 32527996 10.1038/s41419-020-2650-6 PMC7289837

264. Chattopadhyay S Sen GC RIG-I-like receptor-induced IRF3 mediated pathway of apoptosis (RIPA): a new antiviral pathway Protein Cell. 2017 8 165 168 10.1007/s13238-016-0334-x 27815826 PMC5326620 Chattopadhyay, S. & Sen, G. C. RIG-I-like receptor-induced IRF3 mediated pathway of apoptosis (RIPA): a new antiviral pathway. Protein Cell. 8 , 165–168 (2017). 27815826 10.1007/s13238-016-0334-x PMC5326620

265. Chattopadhyay S Yamashita M Zhang Y Sen GC The IRF-3/Bax-mediated apoptotic pathway, activated by viral cytoplasmic RNA and DNA, inhibits virus replication J. Virol. 2011 85 3708 3716 10.1128/JVI.02133-10 21307205 PMC3126131 Chattopadhyay, S., Yamashita, M., Zhang, Y. & Sen, G. C. The IRF-3/Bax-mediated apoptotic pathway, activated by viral cytoplasmic RNA and DNA, inhibits virus replication. J. Virol. 85 , 3708–3716 (2011). 21307205 10.1128/JVI.02133-10 PMC3126131

266. White CL Chattopadhyay S Sen GC Phosphatidylinositol 3-kinase signaling delays sendai virus-induced apoptosis by preventing XIAP degradation J. Virol. 2011 85 5224 5227 10.1128/JVI.00053-11 21367892 PMC3126159 White, C. L., Chattopadhyay, S. & Sen, G. C. Phosphatidylinositol 3-kinase signaling delays sendai virus-induced apoptosis by preventing XIAP degradation. J. Virol. 85 , 5224–5227 (2011). 21367892 10.1128/JVI.00053-11 PMC3126159

267. Sanz-Garcia C The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute-on-chronic ethanol administration in mice J. Hepatol. 2019 70 974 984 10.1016/j.jhep.2019.01.021 30710579 PMC6462245 Sanz-Garcia, C. et al. The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute-on-chronic ethanol administration in mice. J. Hepatol. 70 , 974–984 (2019). 30710579 10.1016/j.jhep.2019.01.021 PMC6462245

268. Wang L Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases Cell. Death. Dis. 2023 14 851 10.1038/s41419-023-06370-2 38129399 PMC10739961 Wang, L. et al. Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases. Cell. Death. Dis. 14 , 851 (2023). 38129399 10.1038/s41419-023-06370-2 PMC10739961

269. Malireddi RKS Kesavardhana S Kanneganti TD ZBP1 and TAK1: Master Regulators of NLRP3 Inflammasome/Pyroptosis, Apoptosis, and Necroptosis (PAN-optosis) Front. Cell. Infect. Microbiol. 2019 9 406 10.3389/fcimb.2019.00406 31850239 PMC6902032 Malireddi, R. K. S., Kesavardhana, S. & Kanneganti, T. D. ZBP1 and TAK1: Master Regulators of NLRP3 Inflammasome/Pyroptosis, Apoptosis, and Necroptosis (PAN-optosis). Front. Cell. Infect. Microbiol. 9 , 406 (2019). 31850239 10.3389/fcimb.2019.00406 PMC6902032

270. Sharma BR Karki R Rajesh Y Kanneganti TD Immune regulator IRF1 contributes to ZBP1-, AIM2-, RIPK1-, and NLRP12-PANoptosome activation and inflammatory cell death (PANoptosis) J. Biol. Chem. 2023 299 105141 10.1016/j.jbc.2023.105141 37557956 PMC10494469 Sharma, B. R., Karki, R., Rajesh, Y. & Kanneganti, T. D. Immune regulator IRF1 contributes to ZBP1-, AIM2-, RIPK1-, and NLRP12-PANoptosome activation and inflammatory cell death (PANoptosis). J. Biol. Chem. 299 , 105141 (2023). 37557956 10.1016/j.jbc.2023.105141 PMC10494469

271. Kuriakose T Zheng M Neale G Kanneganti TD IRF1 Is a Transcriptional Regulator of ZBP1 Promoting NLRP3 Inflammasome Activation and Cell Death during Influenza Virus Infection J. Immunol. 2018 200 1489 1495 10.4049/jimmunol.1701538 29321274 PMC6483084 Kuriakose, T., Zheng, M., Neale, G. & Kanneganti, T. D. IRF1 Is a Transcriptional Regulator of ZBP1 Promoting NLRP3 Inflammasome Activation and Cell Death during Influenza Virus Infection. J. Immunol. 200 , 1489–1495 (2018). 29321274 10.4049/jimmunol.1701538 PMC6483084

272. Man SM The transcription factor IRF1 and guanylate-binding proteins target activation of the AIM2 inflammasome by Francisella infection Nat. Immunol. 2015 16 467 475 10.1038/ni.3118 25774715 PMC4406811 Man, S. M. et al. The transcription factor IRF1 and guanylate-binding proteins target activation of the AIM2 inflammasome by Francisella infection. Nat. Immunol. 16 , 467–475 (2015). 25774715 10.1038/ni.3118 PMC4406811

273. Karki R Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes Cell 2021 184 149 168.e117 10.1016/j.cell.2020.11.025 33278357 PMC7674074 Karki, R. et al. Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell 184 , 149–168.e117 (2021). 33278357 10.1016/j.cell.2020.11.025 PMC7674074

274. Sundaram B NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs Cell 2023 186 2783 2801.e2720 10.1016/j.cell.2023.05.005 37267949 PMC10330523 Sundaram, B. et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. Cell 186 , 2783–2801.e2720 (2023). 37267949 10.1016/j.cell.2023.05.005 PMC10330523

275. Karki, R. et al. Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer. JCI. Insight . 5 , e136720 (2020). 10.1172/jci.insight.136720 PMC7406299 32554929

276. Zhuang Y Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1 Hepatology 2024 79 752 767 37725754 10.1097/HEP.0000000000000611 PMC10948324 Zhuang, Y. et al. Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1. Hepatology 79 , 752–767 (2024). 37725754 10.1097/HEP.0000000000000611 PMC10948324

277. Kondo S Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes Nat. Genet. 2002 32 285 289 10.1038/ng985 12219090 PMC3169431 Kondo, S. et al. Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. Nat. Genet. 32 , 285–289 (2002). 12219090 10.1038/ng985 PMC3169431

278. Ingraham CR Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6) Nat. Genet. 2006 38 1335 1340 10.1038/ng1903 17041601 PMC2082114 Ingraham, C. R. et al. Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). Nat. Genet. 38 , 1335–1340 (2006). 17041601 10.1083/ng1903 PMC2082114

279. Richardson RJ Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch Nat. Genet. 2006 38 1329 1334 10.1038/ng1894 17041603 Richardson, R. J. et al. Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch. Nat. Genet. 38 , 1329–1334 (2006). 17041603 10.1038/ng1894

280. Restivo G IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes EMBO J. 2011 30 4571 4585 10.1038/emboj.2011.325 21909072 PMC3243593 Restivo, G. et al. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. EMBO J. 30 , 4571–4585 (2011). 21909072 10.1038/emboj.2011.325 PMC3243593

281. Fitzgerald KA Kagan JC Toll-like receptors and the control of immunity Cell 2020 180 1044 1066 10.1016/j.cell.2020.02.041 32164908 PMC9358771 Fitzgerald, K. A. & Kagan, J. C. Toll-like receptors and the control of immunity. Cell 180 , 1044–1066 (2020). 32164908 10.1016/j.cell.2020.02.041 PMC9358771

282. Kawai T Akira S The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors Nat. Immunol. 2010 11 373 384 10.1038/ni.1863 20404851 Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11 , 373–384 (2010). 20404851 10.1038/ni.1863

283. Li D Wu M Pattern recognition receptors in health and diseases Signal. Transduct. Target. Ther. 2021 6 291 10.1038/s41392-021-00687-0 34344870 PMC8333067 Li, D. & Wu, M. Pattern recognition receptors in health and diseases. Signal. Transduct. Target. Ther. 6 , 291 (2021). 34344870 10.1038/s41392-021-00687-0 PMC8333067

284. Honda K Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling Proc. Natl Acad. Sci. Usa. 2004 101 15416 15421 10.1073/pnas.0406933101 15492225 PMC523464 Honda, K. et al. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc. Natl Acad. Sci. Usa. 101 , 15416–15421 (2004). 15492225 10.1073/pnas.0406933101 PMC523464

285. Kawai T Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6 Nat. Immunol. 2004 5 1061 1068 10.1038/ni1118 15361868 Kawai, T. et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5 , 1061–1068 (2004). 15361868 10.1038/ni1118

286. del Fresno C Interferon-β production via Dectin-1-Syk-IRF5 signaling in dendritic cells is crucial for immunity to C. albicans Immunity 2013 38 1176 1186 10.1016/j.immuni.2013.05.010 23770228 del Fresno, C. et al. Interferon-β production via Dectin-1-Syk-IRF5 signaling in dendritic cells is crucial for immunity to C. albicans. Immunity 38 , 1176–1186 (2013). 23770228 10.1016/j.immuni.2013.05.010

287. Takaoka A Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors Nature 2005 434 243 249 10.1038/nature03308 15665823 Takaoka, A. et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434 , 243–249 (2005). 15665823 10.1038/nature03308

288. Barnes BJ Kellum MJ Field AE Pitha PM Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes Mol. Cell. Biol. 2002 22 5721 5740 10.1128/MCB.22.16.5721-5740.2002 12138184 PMC133975 Barnes, B. J., Kellum, M. J., Field, A. E. & Pitha, P. M. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol. Cell. Biol. 22 , 5721–5740 (2002). 12138184 10.1128/MCB.22.16.5721-5740.2002 PMC133975

289. Feng D Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression J. Immunol. 2010 185 6003 6012 10.4049/jimmunol.1000482 20935208 PMC3233222 Feng, D. et al. Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. J. Immunol. 185 , 6003–6012 (2010). 20935208 10.4049/jimmunol.1000482 PMC3233222

290. Yang C CXCL4 synergizes with TLR8 for TBK1-IRF5 activation, epigenomic remodeling and inflammatory response in human monocytes Nat. Commun. 2022 13 3426 10.1038/s41467-022-31132-7 35701499 PMC9195402 Yang, C. et al. CXCL4 synergizes with TLR8 for TBK1-IRF5 activation, epigenomic remodeling and inflammatory response in human monocytes. Nat. Commun. 13 , 3426 (2022). 35701499 10.1038/s41467-022-31132-7 PMC9195402

291. Pradhan, P. et al. TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation. Sci. Adv . 7 , eabd4235 (2021). 10.1126/sciadv.abd4235 PMC7806213 33523878

292. Heinz LX TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9 Nature 2020 581 316 322 10.1038/s41586-020-2282-0 32433612 PMC7610944 Heinz, L. X. et al. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Nature 581 , 316–322 (2020). 32433612 10.1038/s41586-020-2282-0 PMC7610944

293. Zhang H SLC15A4 controls endolysosomal TLR7-9 responses by recruiting the innate immune adaptor TASL Cell. Rep. 2023 42 112916 10.1016/j.celrep.2023.112916 37527038 Zhang, H. et al. SLC15A4 controls endolysosomal TLR7-9 responses by recruiting the innate immune adaptor TASL. Cell. Rep. 42 , 112916 (2023). 37527038 10.1016/j.celrep.2023.112916

294. Briard B Fungal ligands released by innate immune effectors promote inflammasome activation during Aspergillus fumigatus infection Nat. Microbiol. 2019 4 316 327 10.1038/s41564-018-0298-0 30510167 PMC6619501 Briard, B. et al. Fungal ligands released by innate immune effectors promote inflammasome activation during Aspergillus fumigatus infection. Nat. Microbiol. 4 , 316–327 (2019). 30510167 10.1038/s41564-018-0298-0 PMC6619501

295. Tailor P The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8 Immunity 2007 27 228 239 10.1016/j.immuni.2007.06.009 17702615 PMC2768351 Tailor, P. et al. The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity 27 , 228–239 (2007). 17702615 10.1016/j.immuni.2007.06.009 PMC2768351

296. Zhao J IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways J. Biol. Chem. 2006 281 10073 10080 10.1074/jbc.M507788200 16484229 Zhao, J. et al. IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. J. Biol. Chem. 281 , 10073–10080 (2006). 16484229 10.1074/jbc.M507788200

297. Shi G IRF-8/miR-451a regulates M-MDSC differentiation via the AMPK/mTOR signal pathway during lupus development Cell. Death. Discov. 2021 7 179 10.1038/s41420-021-00568-z 34282122 PMC8289825 Shi, G. et al. IRF-8/miR-451a regulates M-MDSC differentiation via the AMPK/mTOR signal pathway during lupus development. Cell. Death. Discov. 7 , 179 (2021). 34282122 10.1038/s41420-021-00568-z PMC8289825

298. Li D IRF8 Impacts Self-Renewal of Hematopoietic Stem Cells by Regulating TLR9 Signaling Pathway of Innate Immune Cells Adv. Sci. (Weinh.). 2021 8 e2101031 34365741 10.1002/advs.202101031 PMC8498865 Li, D. et al. IRF8 Impacts Self-Renewal of Hematopoietic Stem Cells by Regulating TLR9 Signaling Pathway of Innate Immune Cells. Adv. Sci. (Weinh.). 8 , e2101031 (2021). 34365741 10.1002/advs.202101031 PMC8498865

299. Goubau D Deddouche S Reis e Sousa C Cytosolic sensing of viruses Immunity 2013 38 855 869 10.1016/j.immuni.2013.05.007 23706667 PMC7111113 Goubau, D., Deddouche, S. & Reis e Sousa, C. Cytosolic sensing of viruses. Immunity 38 , 855–869 (2013). 23706667 10.1016/j.immuni.2013.05.007 PMC7111113

300. Rehwinkel J Gack MU RIG-I-like receptors: Their regulation and roles in RNA sensing Nat. Rev. Immunol. 2020 20 537 551 10.1038/s41577-020-0288-3 32203325 PMC7094958 Rehwinkel, J. & Gack, M. U. RIG-I-like receptors: Their regulation and roles in RNA sensing. Nat. Rev. Immunol. 20 , 537–551 (2020). 32203325 10.1038/s41577-020-0288-3 PMC7094958

301. Yoneyama M Viral RNA detection by RIG-I-like receptors Curr. Opin. Immunol. 2015 32 48 53 10.1016/j.coi.2014.12.012 25594890 Yoneyama, M. et al. Viral RNA detection by RIG-I-like receptors. Curr. Opin. Immunol. 32 , 48–53 (2015). 25594890 10.1016/j.coi.2014.12.012

302. Sakaguchi S Essential role of IRF-3 in lipopolysaccharide-induced interferon-beta gene expression and endotoxin shock Biochem. Biophys. Res. Commun. 2003 306 860 866 10.1016/S0006-291X(03)01049-0 12821121 Sakaguchi, S. et al. Essential role of IRF-3 in lipopolysaccharide-induced interferon-beta gene expression and endotoxin shock. Biochem. Biophys. Res. Commun. 306 , 860–866 (2003). 12821121 10.1016/s0006-291x(03)01049-0

303. Panne D McWhirter SM Maniatis T Harrison SC Interferon regulatory factor 3 is regulated by a dual phosphorylation-dependent switch J. Biol. Chem. 2007 282 22816 22822 10.1074/jbc.M703019200 17526488 Panne, D., McWhirter, S. M., Maniatis, T. & Harrison, S. C. Interferon regulatory factor 3 is regulated by a dual phosphorylation-dependent switch. J. Biol. Chem. 282 , 22816–22822 (2007). 17526488 10.1074/jbc.M703019200

304. Liu S Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation Science 2015 347 aaa2630 10.1126/science.aaa2630 25636800 Liu, S. et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 347 , aaa2630 (2015). 25636800 10.1126/science.aaa2630

305. Yin X MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells Cell. Rep. 2021 34 108628 10.1016/j.celrep.2020.108628 33440148 PMC7832566 Yin, X. et al. MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. Cell. Rep. 34 , 108628 (2021). 33440148 10.1016/j.celrep.2020.108628 PMC7832566

306. Ruffner H Reis LF Näf D Weissmann C Induction of type I interferon genes and interferon-inducible genes in embryonal stem cells devoid of interferon regulatory factor 1 Proc. Natl Acad. Sci. Usa. 1993 90 11503 11507 10.1073/pnas.90.24.11503 8265581 PMC48012 Ruffner, H., Reis, L. F., Näf, D. & Weissmann, C. Induction of type I interferon genes and interferon-inducible genes in embryonal stem cells devoid of interferon regulatory factor 1. Proc. Natl Acad. Sci. Usa. 90 , 11503–11507 (1993). 8265581 10.1073/pnas.90.24.11503 PMC48012

307. Rosain J Human IRF1 governs macrophagic IFN-γ immunity to mycobacteria Cell 2023 186 621 645.e633 10.1016/j.cell.2022.12.038 36736301 PMC9907019 Rosain, J. et al. Human IRF1 governs macrophagic IFN-γ immunity to mycobacteria. Cell 186 , 621–645.e633 (2023). 36736301 10.1016/j.cell.2022.12.038 PMC9907019

308. Ishii KJ A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA Nat. Immunol. 2006 7 40 48 10.1038/ni1282 16286919 Ishii, K. J. et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol. 7 , 40–48 (2006). 16286919 10.1038/ni1282

309. Takaoka A DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response Nature 2007 448 501 505 10.1038/nature06013 17618271 Takaoka, A. et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448 , 501–505 (2007). 17618271 10.1038/nature06013

310. Lei Y Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity Cell 2023 186 3013 3032.e3022 10.1016/j.cell.2023.05.039 37352855 PMC10330843 Lei, Y. et al. Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity. Cell 186 , 3013–3032.e3022 (2023). 37352855 10.1016/j.cell.2023.05.039 PMC10330843

311. Di Paolo NC The transcription factor IRF3 triggers “defensive suicide” necrosis in response to viral and bacterial pathogens Cell. Rep. 2013 3 1840 1846 10.1016/j.celrep.2013.05.025 23770239 PMC3718285 Di Paolo, N. C. et al. The transcription factor IRF3 triggers “defensive suicide” necrosis in response to viral and bacterial pathogens. Cell. Rep. 3 , 1840–1846 (2013). 23770239 10.1016/j.celrep.2013.05.025 PMC3718285

312. Cevik O Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma J. Biol. Chem. 2017 292 21676 21689 10.1074/jbc.M117.792721 29079574 PMC5766933 Cevik, O. et al. Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma. J. Biol. Chem. 292 , 21676–21689 (2017). 29079574 10.1074/jbc.M117.792721 PMC5766933

313. Nie S The protective effect of interfering TLR9-IRF5 signaling pathway on the development of CVB3-induced myocarditis Clin. Immunol. 2019 207 24 35 10.1016/j.clim.2019.07.002 31279856 Nie, S. et al. The protective effect of interfering TLR9-IRF5 signaling pathway on the development of CVB3-induced myocarditis. Clin. Immunol. 207 , 24–35 (2019). 31279856 10.1016/j.clim.2019.07.002

314. Carmona-Pérez, L. et al. The TLR7/IRF-5 axis sensitizes memory CD4+ T cells to Fas-mediated apoptosis during HIV-1 infection. JCI. Insight . 8 , e167329 (2023). 10.1172/jci.insight.167329 PMC10371351 37227774

315. Liu Y Airway acidification impaired host defense against Pseudomonas aeruginosa infection by promoting type 1 interferon β response Emerg. Microbes Infect. 2022 11 2132 2146 10.1080/22221751.2022.2110524 35930458 PMC9487950 Liu, Y. et al. Airway acidification impaired host defense against Pseudomonas aeruginosa infection by promoting type 1 interferon β response. Emerg. Microbes Infect. 11 , 2132–2146 (2022). 35930458 10.1080/22221751.2022.2110524 PMC9487950

316. Puthia M IRF7 inhibition prevents destructive innate immunity-A target for nonantibiotic therapy of bacterial infections Sci. Transl. Med. 2016 8 336ra359 10.1126/scitranslmed.aaf1156 27122612 Puthia, M. et al. IRF7 inhibition prevents destructive innate immunity-A target for nonantibiotic therapy of bacterial infections. Sci. Transl. Med. 8 , 336ra359 (2016). 10.1126/scitranslmed.aaf1156 27122612

317. Schoggins JW Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity Nature 2014 505 691 695 10.1038/nature12862 24284630 PMC4077721 Schoggins, J. W. et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505 , 691–695 (2014). 24284630 10.1038/nature12862 PMC4077721

318. Mboko, W. P. et al . Interferon Regulatory Factor 1 and Type I Interferon Cooperate To Control Acute Gammaherpesvirus Infection. J. Virol . 91 , e01444-16 (2017). 10.1128/JVI.01444-16 PMC5165188 27795415

319. Feng H Zhang YB Gui JF Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses PLoS. Pathog. 2021 17 e1009220 10.1371/journal.ppat.1009220 33476326 PMC7819612 Feng, H., Zhang, Y. B. & Gui, J. F. Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses. PLoS. Pathog. 17 , e1009220 (2021). 33476326 10.1371/journal.ppat.1009220 PMC7819612

320. Loevenich S Human Metapneumovirus Induces IRF1 via TANK-Binding Kinase 1 and Type I IFN Front. Immunol. 2021 12 563336 10.3389/fimmu.2021.563336 34248923 PMC8264192 Loevenich, S. et al. Human Metapneumovirus Induces IRF1 via TANK-Binding Kinase 1 and Type I IFN. Front. Immunol. 12 , 563336 (2021). 34248923 10.3389/fimmu.2021.563336 PMC8264192

321. Yamane D Basal expression of interferon regulatory factor 1 drives intrinsic hepatocyte resistance to multiple RNA viruses Nat. Microbiol. 2019 4 1096 1104 10.1038/s41564-019-0425-6 30988429 PMC6588457 Yamane, D. et al. Basal expression of interferon regulatory factor 1 drives intrinsic hepatocyte resistance to multiple RNA viruses. Nat. Microbiol. 4 , 1096–1104 (2019). 30988429 10.1038/s41564-019-0425-6 PMC6588457

322. Wang, J. et al. IRF1 Promotes the Innate Immune Response to Viral Infection by Enhancing the Activation of IRF3. J. Virol . 94 , e01231-20 (2020). 10.1128/JVI.01231-20 PMC7592201 32878885

323. Ren K IRF2 inhibits ZIKV replication by promoting FAM111A expression to enhance the host restriction effect of RFC3 Virol. J. 2021 18 256 10.1186/s12985-021-01724-8 34930359 PMC8691090 Ren, K. et al. IRF2 inhibits ZIKV replication by promoting FAM111A expression to enhance the host restriction effect of RFC3. Virol. J. 18 , 256 (2021). 34930359 10.1186/s12985-021-01724-8 PMC8691090

324. Panda D Triad of human cellular proteins, IRF2, FAM111A, and RFC3, restrict replication of orthopoxvirus SPI-1 host-range mutants Proc. Natl Acad. Sci. USA 2017 114 3720 3725 10.1073/pnas.1700678114 28320935 PMC5389286 Panda, D. et al. Triad of human cellular proteins, IRF2, FAM111A, and RFC3, restrict replication of orthopoxvirus SPI-1 host-range mutants. Proc. Natl Acad. Sci. USA 114 , 3720–3725 (2017). 28320935 10.1073/pnas.1700678114 PMC5389286

325. Persyn E IRF2 is required for development and functional maturation of human NK cells Front. Immunol. 2022 13 1038821 10.3389/fimmu.2022.1038821 36544762 PMC9762550 Persyn, E. et al. IRF2 is required for development and functional maturation of human NK cells. Front. Immunol. 13 , 1038821 (2022). 36544762 10.3389/fimmu.2022.1038821 PMC9762550

326. Glanz A Transcriptional and Non-Transcriptional Activation, Posttranslational Modifications, and Antiviral Functions of Interferon Regulatory Factor 3 and Viral Antagonism by the SARS-Coronavirus Viruses 2021 13 575 10.3390/v13040575 33805458 PMC8066409 Glanz, A. et al. Transcriptional and Non-Transcriptional Activation, Posttranslational Modifications, and Antiviral Functions of Interferon Regulatory Factor 3 and Viral Antagonism by the SARS-Coronavirus. Viruses 13 , 575 (2021). 33805458 10.3390/v13040575 PMC8066409

327. Popli S Chakravarty S Fan S Glanz A IRF3 inhibits nuclear translocation of NF-κB to prevent viral inflammation Proc. Natl Acad. Sci. Usa. 2022 119 e2121385119 10.1073/pnas.2121385119 36067309 PMC9478676 Popli, S., Chakravarty, S., Fan, S. & Glanz, A. IRF3 inhibits nuclear translocation of NF-κB to prevent viral inflammation. Proc. Natl Acad. Sci. Usa. 119 , e2121385119 (2022). 36067309 10.1073/pnas.2121385119 PMC9478676

328. Canivet C Both IRF3 and especially IRF7 play a key role to orchestrate an effective cerebral inflammatory response in a mouse model of herpes simplex virus encephalitis J. Neurovirol. 2018 24 761 768 10.1007/s13365-018-0666-9 30094631 Canivet, C. et al. Both IRF3 and especially IRF7 play a key role to orchestrate an effective cerebral inflammatory response in a mouse model of herpes simplex virus encephalitis. J. Neurovirol. 24 , 761–768 (2018). 30094631 10.1007/s13365-018-0666-9

329. Andersen LL Functional IRF3 deficiency in a patient with herpes simplex encephalitis J. Exp. Med. 2015 212 1371 1379 10.1084/jem.20142274 26216125 PMC4548062 Andersen, L. L. et al. Functional IRF3 deficiency in a patient with herpes simplex encephalitis. J. Exp. Med. 212 , 1371–1379 (2015). 26216125 10.1084/jem.20142274 PMC4548062

330. Campbell, T. M. & Liu, Z. Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency. J. Exp. Med . 219 , e20220202 (2022). 10.1084/jem.20220202 PMC9178406 35670811

331. Tucker, M. H. et al. IRF7 and UNC93B1 variants in an infant with recurrent herpes simplex virus infection. J. Clin. Invest . 133 , e154016 (2023). 10.1172/JCI154016 PMC10231989 37097753

332. Clohisey S Baillie JK Host susceptibility to severe influenza A virus infection Crit. Care. 2019 23 303 10.1186/s13054-019-2566-7 31488196 PMC6729070 Clohisey, S. & Baillie, J. K. Host susceptibility to severe influenza A virus infection. Crit. Care. 23 , 303 (2019). 31488196 10.1186/s13054-019-2566-7 PMC6729070

333. Hernandez N Melki I Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency J. Exp. Med. 2018 215 2567 2585 10.1084/jem.20180628 30143481 PMC6170168 Hernandez, N. & Melki, I. Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency. J. Exp. Med. 215 , 2567–2585 (2018). 30143481 10.1084/jem.20180628 PMC6170168

334. Ji W TBK1 and IRF3 are potential therapeutic targets in Enterovirus A71-associated diseases PLoS. Negl. Trop. Dis. 2023 17 e0011001 10.1371/journal.pntd.0011001 36626364 PMC9831319 Ji, W. et al. TBK1 and IRF3 are potential therapeutic targets in Enterovirus A71-associated diseases. PLoS. Negl. Trop. Dis. 17 , e0011001 (2023). 36626364 10.1371/journal.pntd.0011001 PMC9831319

335. Man K Transcription Factor IRF4 Promotes CD8(+) T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection Immunity 2017 47 1129 1141.e1125 10.1016/j.immuni.2017.11.021 29246443 Man, K. et al. Transcription Factor IRF4 Promotes CD8(+) T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection. Immunity 47 , 1129–1141.e1125 (2017). 29246443 10.1016/j.immuni.2017.11.021

336. Grusdat M IRF4 and BATF are critical for CD8 + T-cell function following infection with LCMV Cell. Death. Differ. 2014 21 1050 1060 10.1038/cdd.2014.19 24531538 PMC4207473 Grusdat, M. et al. IRF4 and BATF are critical for CD8 + T-cell function following infection with LCMV. Cell. Death. Differ. 21 , 1050–1060 (2014). 24531538 10.1038/cdd.2014.19 PMC4207473

337. Yanai H Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression Proc. Natl Acad. Sci. USA 2007 104 3402 3407 10.1073/pnas.0611559104 17360658 PMC1805533 Yanai, H. et al. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc. Natl Acad. Sci. USA 104 , 3402–3407 (2007). 17360658 10.1073/pnas.0611559104 PMC1805533

338. Thackray LB Interferon regulatory factor 5-dependent immune responses in the draining lymph node protect against West Nile virus infection J. Virol. 2014 88 11007 11021 10.1128/JVI.01545-14 25031348 PMC4178807 Thackray, L. B. et al. Interferon regulatory factor 5-dependent immune responses in the draining lymph node protect against West Nile virus infection. J. Virol. 88 , 11007–11021 (2014). 25031348 10.1128/JVI.01545-14 PMC4178807

339. Song J Human cytomegalovirus induces and exploits Roquin to counteract the IRF1-mediated antiviral state Proc. Natl Acad. Sci. USA 2019 116 18619 18628 10.1073/pnas.1909314116 31451648 PMC6744924 Song, J. et al. Human cytomegalovirus induces and exploits Roquin to counteract the IRF1-mediated antiviral state. Proc. Natl Acad. Sci. USA 116 , 18619–18628 (2019). 31451648 10.1073/pnas.1909314116 PMC6744924

340. Ueki IF Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon λ and antiviral defense in airway epithelium J. Exp. Med. 2013 210 1929 1936 10.1084/jem.20121401 23999497 PMC3782052 Ueki, I. F. et al. Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon λ and antiviral defense in airway epithelium. J. Exp. Med. 210 , 1929–1936 (2013). 23999497 10.1084/jem.20121401 PMC3782052

341. Cheng X Ratner L HIV-2 Vpx protein interacts with interferon regulatory factor 5 (IRF5) and inhibits its function J. Biol. Chem. 2014 289 9146 9157 10.1074/jbc.M113.534321 24532789 PMC3979364 Cheng, X. & Ratner, L. HIV-2 Vpx protein interacts with interferon regulatory factor 5 (IRF5) and inhibits its function. J. Biol. Chem. 289 , 9146–9157 (2014). 24532789 10.1074/jbc.M113.534321 PMC3979364

342. Su S Modulation of innate immune response to viruses including SARS-CoV-2 by progesterone Signal. Transduct. Target. Ther. 2022 7 137 10.1038/s41392-022-00981-5 35468896 PMC9035769 Su, S. et al. Modulation of innate immune response to viruses including SARS-CoV-2 by progesterone. Signal. Transduct. Target. Ther. 7 , 137 (2022). 35468896 10.1038/s41392-022-00981-5 PMC9035769

343. Yoo JS Sasaki M SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis Nat. Commun. 2021 12 6602 10.1038/s41467-021-26910-8 34782627 PMC8594428 Yoo, J. S. & Sasaki, M. SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis. Nat. Commun. 12 , 6602 (2021). 34782627 10.1038/s41467-021-26910-8 PMC8594428

344. Hall R SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export PLoS. Pathog. 2022 18 e1010349 10.1371/journal.ppat.1010349 36007063 PMC9451085 Hall, R. et al. SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export. PLoS. Pathog. 18 , e1010349 (2022). 36007063 10.1371/journal.ppat.1010349 PMC9451085

345. Rashid F Roles and functions of SARS-CoV-2 proteins in host immune evasion Front. Immunol. 2022 13 940756 10.3389/fimmu.2022.940756 36003396 PMC9394213 Rashid, F. et al. Roles and functions of SARS-CoV-2 proteins in host immune evasion. Front. Immunol. 13 , 940756 (2022). 36003396 10.3389/fimmu.2022.940756 PMC9394213

346. Moustaqil M Ollivier E SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species Emerg. Microbes Infect. 2021 10 178 195 10.1080/22221751.2020.1870414 33372854 PMC7850364 Moustaqil, M. & Ollivier, E. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species. Emerg. Microbes Infect. 10 , 178–195 (2021). 33372854 10.1080/22221751.2020.1870414 PMC7850364

347. Shin D Mukherjee R Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity Nature 2020 587 657 662 10.1038/s41586-020-2601-5 32726803 PMC7116779 Shin, D. & Mukherjee, R. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587 , 657–662 (2020). 32726803 10.1038/s41586-020-2601-5 PMC7116779

348. Wang W SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation Cell. Mol. Immunol. 2021 18 945 953 10.1038/s41423-020-00619-y 33637958 PMC7907794 Wang, W. et al. SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Cell. Mol. Immunol. 18 , 945–953 (2021). 33637958 10.1038/s41423-020-00619-y PMC7907794

349. Zheng Y SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules Signal. Transduct. Target. Ther. 2022 7 22 10.1038/s41392-022-00878-3 35075101 PMC8785035 Zheng, Y. et al. SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules. Signal. Transduct. Target. Ther. 7 , 22 (2022). 35075101 10.1038/s41392-022-00878-3 PMC8785035

350. Feng K SARS-CoV-2 NSP13 interacts with host IRF3, blocking antiviral immune responses J. Med. Virol. 2023 95 e28881 10.1002/jmv.28881 37314155 Feng, K. et al. SARS-CoV-2 NSP13 interacts with host IRF3, blocking antiviral immune responses. J. Med. Virol. 95 , e28881 (2023). 37314155 10.1002/jmv.28881

351. Fung SY SARS-CoV-2 main protease suppresses type I interferon production by preventing nuclear translocation of phosphorylated IRF3 Int. J. Biol. Sci. 2021 17 1547 1554 10.7150/ijbs.59943 33907518 PMC8071772 Fung, S. Y. et al. SARS-CoV-2 main protease suppresses type I interferon production by preventing nuclear translocation of phosphorylated IRF3. Int. J. Biol. Sci. 17 , 1547–1554 (2021). 33907518 10.7150/ijbs.59943 PMC8071772

352. Shin J SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1 Metabolism 2022 133 155236 10.1016/j.metabol.2022.155236 35688210 PMC9173833 Shin, J. et al. SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1. Metabolism 133 , 155236 (2022). 35688210 10.1016/j.metabol.2022.155236 PMC9173833

353. Huang HC Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion J. Med. Virol. 2023 95 e28478 10.1002/jmv.28478 36609964 PMC10107526 Huang, H. C. et al. Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. J. Med. Virol. 95 , e28478 (2023). 36609964 10.1002/jmv.28478 PMC10107526

354. Zhang, Q. & Bastard, P. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370 , eabd4570 (2020). 10.1126/science.abd4570 PMC7857407 32972995

355. Lévy, R. & Zhang, P. Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child. Proc. Natl. Acad. Sci. USA . 118 , e2114390118 (2021). 10.1073/pnas.2114390118 PMC8609338 34702736

356. Mishra R Banerjea AC SARS-CoV-2 Spike Targets USP33-IRF9 Axis via Exosomal miR-148a to Activate Human Microglia Front. Immunol. 2021 12 656700 10.3389/fimmu.2021.656700 33936086 PMC8079643 Mishra, R. & Banerjea, A. C. SARS-CoV-2 Spike Targets USP33-IRF9 Axis via Exosomal miR-148a to Activate Human Microglia. Front. Immunol. 12 , 656700 (2021). 33936086 10.3389/fimmu.2021.656700 PMC8079643

357. Gidon A The Tumor Necrosis Factor Alpha and Interleukin 6 Auto-paracrine Signaling Loop Controls Mycobacterium avium Infection via Induction of IRF1/IRG1 in Human Primary Macrophages mBio 2021 12 e0212121 10.1128/mBio.02121-21 34607464 PMC8546851 Gidon, A. et al. The Tumor Necrosis Factor Alpha and Interleukin 6 Auto-paracrine Signaling Loop Controls Mycobacterium avium Infection via Induction of IRF1/IRG1 in Human Primary Macrophages. mBio 12 , e0212121 (2021). 34607464 10.1128/mBio.02121-21 PMC8546851

358. Zhou X Interferon regulatory factor 1 eliminates mycobacteria by suppressing p70 S6 kinase via mechanistic target of rapamycin signaling J. Infect. 2019 79 262 276 10.1016/j.jinf.2019.06.007 31226272 Zhou, X. et al. Interferon regulatory factor 1 eliminates mycobacteria by suppressing p70 S6 kinase via mechanistic target of rapamycin signaling. J. Infect. 79 , 262–276 (2019). 31226272 10.1016/j.jinf.2019.06.007

359. Schmalzl A Leupold T Kreiss L Interferon regulatory factor 1 (IRF-1) promotes intestinal group 3 innate lymphoid responses during Citrobacter rodentium infection Nat. Commun. 2022 13 5730 10.1038/s41467-022-33326-5 36175404 PMC9522774 Schmalzl, A., Leupold, T. & Kreiss, L. Interferon regulatory factor 1 (IRF-1) promotes intestinal group 3 innate lymphoid responses during Citrobacter rodentium infection. Nat. Commun. 13 , 5730 (2022). 36175404 10.1038/s41467-022-33326-5 PMC9522774

360. Yoon GS Interferon regulatory factor-1 in flagellin-induced reprogramming: potential protective role of CXCL10 in cornea innate defense against Pseudomonas aeruginosa infection Invest. Ophthalmol. Vis. Sci. 2013 54 7510 7521 10.1167/iovs.13-12453 24130180 PMC3832217 Yoon, G. S. et al. Interferon regulatory factor-1 in flagellin-induced reprogramming: potential protective role of CXCL10 in cornea innate defense against Pseudomonas aeruginosa infection. Invest. Ophthalmol. Vis. Sci. 54 , 7510–7521 (2013). 24130180 10.1167/iovs.13-12453 PMC3832217

361. Li, Q., Liu, C., Yue, R. & El-Ashram, S. cGAS/STING/TBK1/IRF3 Signaling Pathway Activates BMDCs Maturation Following Mycobacterium bovis Infection. Int. J. Mol. Sci . 20 , 895 (2019). 10.3390/ijms20040895 PMC6412216 30791397

362. Cui Y Mycobacterium bovis Induces Endoplasmic Reticulum Stress Mediated-Apoptosis by Activating IRF3 in a Murine Macrophage Cell Line Front. Cell. Infect. Microbiol. 2016 6 182 10.3389/fcimb.2016.00182 28018864 PMC5149527 Cui, Y. et al. Mycobacterium bovis Induces Endoplasmic Reticulum Stress Mediated-Apoptosis by Activating IRF3 in a Murine Macrophage Cell Line. Front. Cell. Infect. Microbiol. 6 , 182 (2016). 28018864 10.3389/fcimb.2016.00182 PMC5149527

363. Cheng Y Schorey JS Mycobacterium tuberculosis-induced IFN-β production requires cytosolic DNA and RNA sensing pathways J. Exp. Med. 2018 215 2919 2935 10.1084/jem.20180508 30337468 PMC6219742 Cheng, Y. & Schorey, J. S. Mycobacterium tuberculosis-induced IFN-β production requires cytosolic DNA and RNA sensing pathways. J. Exp. Med. 215 , 2919–2935 (2018). 30337468 10.1084/jem.20180508 PMC6219742

364. Pandey AK NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis PLoS. Pathog. 2009 5 e1000500 10.1371/journal.ppat.1000500 19578435 PMC2698121 Pandey, A. K. et al. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS. Pathog. 5 , e1000500 (2009). 19578435 10.1371/journal.ppat.1000500 PMC2698121

365. Zhang Z MicroRNA-31 mediated by interferon regulatory factor 7 signaling facilitates control of Mycobacterium tuberculosis infection Int. J. Med. Microbiol. 2022 312 151569 10.1016/j.ijmm.2022.151569 36274382 Zhang, Z. et al. MicroRNA-31 mediated by interferon regulatory factor 7 signaling facilitates control of Mycobacterium tuberculosis infection. Int. J. Med. Microbiol. 312 , 151569 (2022). 36274382 10.1016/j.ijmm.2022.151569

366. Skjesol A Yurchenko M The TLR4 adaptor TRAM controls the phagocytosis of Gram-negative bacteria by interacting with the Rab11-family interacting protein 2 PLoS. Pathog. 2019 15 e1007684 10.1371/journal.ppat.1007684 30883606 PMC6438586 Skjesol, A. & Yurchenko, M. The TLR4 adaptor TRAM controls the phagocytosis of Gram-negative bacteria by interacting with the Rab11-family interacting protein 2. PLoS. Pathog. 15 , e1007684 (2019). 30883606 10.1371/journal.ppat.1007684 PMC6438586

367. Dooyema SDR Helicobacter pylori actively suppresses innate immune nucleic acid receptors Gut. Microbes 2022 14 2105102 10.1080/19490976.2022.2105102 35905376 PMC9341374 Dooyema, S. D. R. et al. Helicobacter pylori actively suppresses innate immune nucleic acid receptors. Gut. Microbes 14 , 2105102 (2022). 35905376 10.1080/19490976.2022.2105102 PMC9341374

368. Yu X Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality Immunity 2016 45 1093 1107 10.1016/j.immuni.2016.10.001 27793594 PMC7128466 Yu, X. et al. Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality. Immunity 45 , 1093–1107 (2016). 27793594 10.1016/j.immuni.2016.10.001 PMC7128466

369. Yu X Inflammasome activation negatively regulates MyD88-IRF7 type I IFN signaling and anti-malaria immunity Nat. Commun. 2018 9 4964 10.1038/s41467-018-07384-7 30470758 PMC6251914 Yu, X. et al. Inflammasome activation negatively regulates MyD88-IRF7 type I IFN signaling and anti-malaria immunity. Nat. Commun. 9 , 4964 (2018). 30470758 10.1038/s41467-018-07384-7 PMC6251914

370. Swanson RV Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate Mycobacterium tuberculosis control Nat. Immunol. 2023 24 855 868 10.1038/s41590-023-01476-3 37012543 PMC11133959 Swanson, R. V. et al. Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate Mycobacterium tuberculosis control. Nat. Immunol. 24 , 855–868 (2023). 37012543 10.1038/s41590-023-01476-3 PMC11133959

371. Harberts, A. & Schmidt, C. Interferon regulatory factor 4 controls effector functions of CD8(+) memory T cells. Proc. Natl. Acad. Sci. USA 118 , e2014553118 (2021). 10.1073/pnas.2014553118 PMC8072204 33859042

372. Pandey SP Yan J Turner JR Abraham C Reducing IRF5 expression attenuates colitis in mice, but impairs the clearance of intestinal pathogens Mucosal. Immunol. 2019 12 874 887 10.1038/s41385-019-0165-1 31053739 PMC6688861 Pandey, S. P., Yan, J., Turner, J. R. & Abraham, C. Reducing IRF5 expression attenuates colitis in mice, but impairs the clearance of intestinal pathogens. Mucosal. Immunol. 12 , 874–887 (2019). 31053739 10.1038/s41385-019-0165-1 PMC6688861

373. Hedl M Yan J Witt H IRF5 Is Required for Bacterial Clearance in Human M1-Polarized Macrophages, and IRF5 Immune-Mediated Disease Risk Variants Modulate This Outcome J. Immunol. 2019 202 920 930 10.4049/jimmunol.1800226 30593537 PMC6585431 Hedl, M., Yan, J. & Witt, H. IRF5 Is Required for Bacterial Clearance in Human M1-Polarized Macrophages, and IRF5 Immune-Mediated Disease Risk Variants Modulate This Outcome. J. Immunol. 202 , 920–930 (2019). 30593537 10.4049/jimmunol.1800226 PMC6585431

374. Corbin, A. L., Gomez-Vazquez, M. & Berthold, D. L. IRF5 guides monocytes toward an inflammatory CD11c(+) macrophage phenotype and promotes intestinal inflammation. Sci. Immunol . 5 , eaax6085 (2020). 10.1126/sciimmunol.aax6085 PMC7611075 32444476

375. Mathy NW The Long Non-Coding RNA Nostrill Regulates Transcription of Irf7 Through Interaction With NF-κB p65 to Enhance Intestinal Epithelial Defense Against Cryptosporidium parvum Front. Immunol. 2022 13 863957 10.3389/fimmu.2022.863957 35464447 PMC9021721 Mathy, N. W. et al. The Long Non-Coding RNA Nostrill Regulates Transcription of Irf7 Through Interaction With NF-κB p65 to Enhance Intestinal Epithelial Defense Against Cryptosporidium parvum. Front. Immunol. 13 , 863957 (2022). 35464447 10.3389/fimmu.2022.863957 PMC9021721

376. Karki R Lee E Sharma BR IRF8 Regulates Gram-Negative Bacteria-Mediated NLRP3 Inflammasome Activation and Cell Death J. Immunol. 2020 204 2514 2522 10.4049/jimmunol.1901508 32205422 PMC7291389 Karki, R., Lee, E. & Sharma, B. R. IRF8 Regulates Gram-Negative Bacteria-Mediated NLRP3 Inflammasome Activation and Cell Death. J. Immunol. 204 , 2514–2522 (2020). 32205422 10.4049/jimmunol.1901508 PMC7291389

377. Biondo C Recognition of fungal RNA by TLR7 has a nonredundant role in host defense against experimental candidiasis Eur. J. Immunol. 2012 42 2632 2643 10.1002/eji.201242532 22777843 Biondo, C. et al. Recognition of fungal RNA by TLR7 has a nonredundant role in host defense against experimental candidiasis. Eur. J. Immunol. 42 , 2632–2643 (2012). 22777843 10.1002/eji.201242532

378. Yang L InsP(3)R-SEC5 interaction on phagosomes modulates innate immunity to Candida albicans by promoting cytosolic Ca(2+) elevation and TBK1 activity Bmc. Biol. 2018 16 46 10.1186/s12915-018-0507-6 29703257 PMC5921305 Yang, L. et al. InsP(3)R-SEC5 interaction on phagosomes modulates innate immunity to Candida albicans by promoting cytosolic Ca(2+) elevation and TBK1 activity. Bmc. Biol. 16 , 46 (2018). 29703257 10.1186/s12915-018-0507-6 PMC5921305

379. Brown Harding H Candida albicans extracellular vesicles trigger type I IFN signalling via cGAS and STING Nat. Microbiol. 2024 9 95 107 10.1038/s41564-023-01546-0 38168615 PMC10959075 Brown Harding, H. et al. Candida albicans extracellular vesicles trigger type I IFN signalling via cGAS and STING. Nat. Microbiol. 9 , 95–107 (2024). 38168615 10.1038/s41564-023-01546-0 PMC10959075

380. Li F C-type lectin receptor 2d forms homodimers and heterodimers with TLR2 to negatively regulate IRF5-mediated antifungal immunity Nat. Commun. 2023 14 6718 10.1038/s41467-023-42216-3 37872182 PMC10593818 Li, F. et al. C-type lectin receptor 2d forms homodimers and heterodimers with TLR2 to negatively regulate IRF5-mediated antifungal immunity. Nat. Commun. 14 , 6718 (2023). 37872182 10.1038/s41467-023-42216-3 PMC10593818

381. Qing F IRF7 Exacerbates Candida albicans Infection by Compromising CD209-Mediated Phagocytosis and Autophagy-Mediated Killing in Macrophages J. Immunol. 2024 212 1932 1944 10.4049/jimmunol.2300826 38709167 Qing, F. et al. IRF7 Exacerbates Candida albicans Infection by Compromising CD209-Mediated Phagocytosis and Autophagy-Mediated Killing in Macrophages. J. Immunol. 212 , 1932–1944 (2024). 38709167 10.4049/jimmunol.2300826

382. Wevers BA Fungal engagement of the C-type lectin mincle suppresses dectin-1-induced antifungal immunity Cell. Host. Microbe 2014 15 494 505 10.1016/j.chom.2014.03.008 24721577 Wevers, B. A. et al. Fungal engagement of the C-type lectin mincle suppresses dectin-1-induced antifungal immunity. Cell. Host. Microbe 15 , 494–505 (2014). 24721577 10.1016/j.chom.2014.03.008

383. Wiesner DL Regulatory T Cell Induction and Retention in the Lungs Drives Suppression of Detrimental Type 2 Th Cells During Pulmonary Cryptococcal Infection J. Immunol. 2016 196 365 374 10.4049/jimmunol.1501871 26590316 PMC4685009 Wiesner, D. L. et al. Regulatory T Cell Induction and Retention in the Lungs Drives Suppression of Detrimental Type 2 Th Cells During Pulmonary Cryptococcal Infection. J. Immunol. 196 , 365–374 (2016). 26590316 10.4049/jimmunol.1501871 PMC4685009

384. Valdez PA Prostaglandin E2 suppresses antifungal immunity by inhibiting interferon regulatory factor 4 function and interleukin-17 expression in T cells Immunity 2012 36 668 679 10.1016/j.immuni.2012.02.013 22464170 PMC3334441 Valdez, P. A. et al. Prostaglandin E2 suppresses antifungal immunity by inhibiting interferon regulatory factor 4 function and interleukin-17 expression in T cells. Immunity 36 , 668–679 (2012). 22464170 10.1016/j.immuni.2012.02.013 PMC3334441

385. Harada H Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2 Science 1993 259 971 974 10.1126/science.8438157 8438157 Harada, H. et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 259 , 971–974 (1993). 8438157 10.1126/science.8438157

386. van der Weyden L Genome-wide in vivo screen identifies novel host regulators of metastatic colonization Nature 2017 541 233 236 10.1038/nature20792 28052056 PMC5603286 van der Weyden, L. et al. Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. Nature 541 , 233–236 (2017). 28052056 10.1038/nature20792 PMC5603286

387. Jeong SI XAF1 forms a positive feedback loop with IRF-1 to drive apoptotic stress response and suppress tumorigenesis Cell. Death. Dis. 2018 9 806 10.1038/s41419-018-0867-4 30042418 PMC6057933 Jeong, S. I. et al. XAF1 forms a positive feedback loop with IRF-1 to drive apoptotic stress response and suppress tumorigenesis. Cell. Death. Dis. 9 , 806 (2018). 30042418 10.1038/s41419-018-0867-4 PMC6057933

388. Yanai H Negishi H Taniguchi T The IRF family of transcription factors: Inception, impact and implications in oncogenesis Oncoimmunology 2012 1 1376 1386 10.4161/onci.22475 23243601 PMC3518510 Yanai, H., Negishi, H. & Taniguchi, T. The IRF family of transcription factors: Inception, impact and implications in oncogenesis. Oncoimmunology 1 , 1376–1386 (2012). 23243601 10.4161/onci.22475 PMC3518510

389. Shao L Hou W Scharping NE IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell Cancer Immunol. Res. 2019 7 1258 1266 10.1158/2326-6066.CIR-18-0711 31239318 PMC6677597 Shao, L., Hou, W. & Scharping, N. E. IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell. Cancer Immunol. Res. 7 , 1258–1266 (2019). 31239318 10.1158/2326-6066.CIR-18-0711 PMC6677597

390. Kriegsman BA Vangala P Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression J. Immunol. 2019 203 1999 2010 10.4049/jimmunol.1900475 31471524 PMC6761035 Kriegsman, B. A. & Vangala, P. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression. J. Immunol. 203 , 1999–2010 (2019). 31471524 10.4049/jimmunol.1900475 PMC6761035

391. Arnold M Global Burden of 5 Major Types of Gastrointestinal Cancer Gastroenterology 2020 159 335 349.e315 10.1053/j.gastro.2020.02.068 32247694 PMC8630546 Arnold, M. et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology 159 , 335–349.e315 (2020). 32247694 10.1053/j.gastro.2020.02.068 PMC8630546

392. Wang Y Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers Cancer Res. 2007 67 2535 2543 10.1158/0008-5472.CAN-06-3530 17363571 Wang, Y. et al. Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res. 67 , 2535–2543 (2007). 17363571 10.1158/0008-5472.CAN-06-3530

393. Wang Y Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers Cancer Res. 2008 68 1136 1143 10.1158/0008-5472.CAN-07-5021 18281489 Wang, Y. et al. Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res. 68 , 1136–1143 (2008). 18281489 10.1158/0008-5472.CAN-07-5021

394. Huang J Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response Cancer Lett. 2019 459 86 99 10.1016/j.canlet.2019.05.038 31173852 Huang, J. et al. Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response. Cancer Lett. 459 , 86–99 (2019). 31173852 10.1016/j.canlet.2019.05.038

395. Watson GA Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma Neoplasia 2006 8 31 37 10.1593/neo.05559 16533423 PMC1584287 Watson, G. A. et al. Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma. Neoplasia 8 , 31–37 (2006). 16533423 10.1593/neo.05559 PMC1584287

396. Zhou Y FOXM1c promotes oesophageal cancer metastasis by transcriptionally regulating IRF1 expression Cell. Prolif. 2019 52 e12553 10.1111/cpr.12553 30485581 PMC6496730 Zhou, Y. et al. FOXM1c promotes oesophageal cancer metastasis by transcriptionally regulating IRF1 expression. Cell. Prolif. 52 , e12553 (2019). 30485581 10.1111/cpr.12553 PMC6496730

397. Wierstra I FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy Adv. Cancer Res. 2013 119 191 419 10.1016/B978-0-12-407190-2.00016-2 23870513 Wierstra, I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv. Cancer Res. 119 , 191–419 (2013). 23870513 10.1016/B978-0-12-407190-2.00016-2

398. Zhang CF Relationship between polymorphism of IRF-3 gene codon 427 and esophageal cancer in Anyang population of China Beijing. Da. Xue. Xue. Bao. Yi. Xue. Ban. 2004 36 345 347 15303122 Zhang, C. F. et al. Relationship between polymorphism of IRF-3 gene codon 427 and esophageal cancer in Anyang population of China. Beijing. Da. Xue. Xue. Bao. Yi. Xue. Ban. 36 , 345–347 (2004). 15303122

399. Dai W Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma J. Pathol. 2017 242 500 510 10.1002/path.4925 28608921 Dai, W. et al. Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma. J. Pathol. 242 , 500–510 (2017). 28608921 10.1002/path.4925

400. Chen J Genomic profiling of 766 cancer-related genes in archived esophageal normal and carcinoma tissues Int. J. Cancer 2008 122 2249 2254 10.1002/ijc.23397 18241037 Chen, J. et al. Genomic profiling of 766 cancer-related genes in archived esophageal normal and carcinoma tissues. Int. J. Cancer 122 , 2249–2254 (2008). 18241037 10.1002/ijc.23397

401. Sun R Prognostic significance of interferon regulating factor 4 in esophageal squamous cell carcinoma Biochem. Biophys. Res. Commun. 2018 506 685 691 10.1016/j.bbrc.2018.10.142 30376993 Sun, R. et al. Prognostic significance of interferon regulating factor 4 in esophageal squamous cell carcinoma. Biochem. Biophys. Res. Commun. 506 , 685–691 (2018). 30376993 10.1016/j.bbrc.2018.10.142

402. Nozawa H Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer Int. J. Cancer 1998 77 522 527 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W 9679752 Nozawa, H. et al. Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. Int. J. Cancer 77 , 522–527 (1998). 9679752 10.1002/(sici)1097-0215(19980812)77:4<522::aid-ijc8>3.0.co;2-w

403. Gao J IRF-1 transcriptionally upregulates PUMA, which mediates the mitochondrial apoptotic pathway in IRF-1-induced apoptosis in cancer cells Cell. Death. Differ. 2010 17 699 709 10.1038/cdd.2009.156 19851330 PMC2838929 Gao, J. et al. IRF-1 transcriptionally upregulates PUMA, which mediates the mitochondrial apoptotic pathway in IRF-1-induced apoptosis in cancer cells. Cell. Death. Differ. 17 , 699–709 (2010). 19851330 10.1038/cdd.2009.156 PMC2838929

404. Gao J Tian Y Zhang J Overexpression of interferon regulatory factor 1 enhances chemosensitivity to 5-fluorouracil in gastric cancer cells J. Cancer Res. Ther. 2012 8 57 61 10.4103/0973-1482.95175 22531515 Gao, J., Tian, Y. & Zhang, J. Overexpression of interferon regulatory factor 1 enhances chemosensitivity to 5-fluorouracil in gastric cancer cells. J. Cancer Res. Ther. 8 , 57–61 (2012). 22531515 10.4103/0973-1482.95175

405. Yuan J Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer Cancer Lett. 2019 457 28 39 10.1016/j.canlet.2019.05.006 31078735 Yuan, J. et al. Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer. Cancer Lett. 457 , 28–39 (2019). 31078735 10.1016/j.canlet.2019.05.006

406. Tan L Interferon regulatory factor-1 suppresses DNA damage response and reverses chemotherapy resistance by downregulating the expression of RAD51 in gastric cancer Am. J. Cancer Res. 2020 10 1255 1270 32368400 PMC7191096 Tan, L. et al. Interferon regulatory factor-1 suppresses DNA damage response and reverses chemotherapy resistance by downregulating the expression of RAD51 in gastric cancer. Am. J. Cancer Res. 10 , 1255–1270 (2020). 32368400 PMC7191096

407. Yuan J MIR17HG-miR-18a/19a axis, regulated by interferon regulatory factor-1, promotes gastric cancer metastasis via Wnt/β-catenin signalling Cell. Death. Dis. 2019 10 454 10.1038/s41419-019-1685-z 31186404 PMC6560107 Yuan, J. et al. MIR17HG-miR-18a/19a axis, regulated by interferon regulatory factor-1, promotes gastric cancer metastasis via Wnt/β-catenin signalling. Cell. Death. Dis. 10 , 454 (2019). 31186404 10.1038/s41419-019-1685-z PMC6560107

408. Chen YJ MicroRNA-18a modulates P53 expression by targeting IRF2 in gastric cancer patients J. Gastroenterol. Hepatol. 2016 31 155 163 10.1111/jgh.13041 26173586 Chen, Y. J. et al. MicroRNA-18a modulates P53 expression by targeting IRF2 in gastric cancer patients. J. Gastroenterol. Hepatol. 31 , 155–163 (2016). 26173586 10.1111/jgh.13041

409. Chen YJ IRF-2 Inhibits Gastric Cancer Invasion and Migration by Down-Regulating MMP-1 Dig. Dis. Sci. 2020 65 168 177 10.1007/s10620-019-05739-8 31350707 Chen, Y. J. et al. IRF-2 Inhibits Gastric Cancer Invasion and Migration by Down-Regulating MMP-1. Dig. Dis. Sci. 65 , 168–177 (2020). 31350707 10.1007/s10620-019-05739-8

410. Chen YJ IRF-2 inhibits cancer proliferation by promoting AMER-1 transcription in human gastric cancer J. Transl. Med. 2022 20 68 10.1186/s12967-022-03275-0 35115027 PMC8812234 Chen, Y. J. et al. IRF-2 inhibits cancer proliferation by promoting AMER-1 transcription in human gastric cancer. J. Transl. Med. 20 , 68 (2022). 35115027 10.1186/s12967-022-03275-0 PMC8812234

411. Jiao S Targeting IRF3 as a YAP agonist therapy against gastric cancer J. Exp. Med. 2018 215 699 718 10.1084/jem.20171116 29339449 PMC5789414 Jiao, S. et al. Targeting IRF3 as a YAP agonist therapy against gastric cancer. J. Exp. Med. 215 , 699–718 (2018). 29339449 10.1084/jem.20171116 PMC5789414

412. Qiao Y Li T Zheng S Wang H The Hippo pathway as a drug target in gastric cancer Cancer Lett. 2018 420 14 25 10.1016/j.canlet.2018.01.062 29408652 Qiao, Y., Li, T., Zheng, S. & Wang, H. The Hippo pathway as a drug target in gastric cancer. Cancer Lett. 420 , 14–25 (2018). 29408652 10.1016/j.canlet.2018.01.062

413. Zhang T microRNA-365 inhibits YAP through TLR4-mediated IRF3 phosphorylation and thereby alleviates gastric precancerous lesions Cancer Cell. Int. 2020 20 549 10.1186/s12935-020-01578-0 33292210 PMC7664090 Zhang, T. et al. microRNA-365 inhibits YAP through TLR4-mediated IRF3 phosphorylation and thereby alleviates gastric precancerous lesions. Cancer Cell. Int. 20 , 549 (2020). 33292210 10.1186/s12935-020-01578-0 PMC7664090

414. Yamashita M DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae Cancer Sci. 2010 101 1708 1716 10.1111/j.1349-7006.2010.01581.x 20507321 PMC11158968 Yamashita, M. et al. DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae. Cancer Sci. 101 , 1708–1716 (2010). 20507321 10.1111/j.1349-7006.2010.01581.x PMC11158968

415. Jee CD Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma Eur. J. Cancer 2009 45 1282 1293 10.1016/j.ejca.2008.12.027 19195878 Jee, C. D. et al. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur. J. Cancer 45 , 1282–1293 (2009). 19195878 10.1016/j.ejca.2008.12.027

416. Li D IRF6 Is Directly Regulated by ZEB1 and ELF3, and Predicts a Favorable Prognosis in Gastric Cancer Front. Oncol. 2019 9 220 10.3389/fonc.2019.00220 31019894 PMC6458252 Li, D. et al. IRF6 Is Directly Regulated by ZEB1 and ELF3, and Predicts a Favorable Prognosis in Gastric Cancer. Front. Oncol. 9 , 220 (2019). 31019894 10.3389/fonc.2019.00220 PMC6458252

417. Du J Cytoplasmic localization of IRF5 induces Wnt5a/E-cadherin degradation and promotes gastric cancer cells metastasis Cancer Gene. Ther. 2023 30 866 877 10.1038/s41417-023-00596-0 36782048 Du, J. et al. Cytoplasmic localization of IRF5 induces Wnt5a/E-cadherin degradation and promotes gastric cancer cells metastasis. Cancer Gene. Ther. 30 , 866–877 (2023). 36782048 10.1038/s41417-023-00596-0

418. Xing Y Chen H Guo Z Zhou X Circular RNA circ0007360 Attenuates Gastric Cancer Progression by Altering the miR-762/IRF7 Axis Front. Cell. Dev. Biol. 2022 10 789073 10.3389/fcell.2022.789073 35252169 PMC8891931 Xing, Y., Chen, H., Guo, Z. & Zhou, X. Circular RNA circ0007360 Attenuates Gastric Cancer Progression by Altering the miR-762/IRF7 Axis. Front. Cell. Dev. Biol. 10 , 789073 (2022). 35252169 10.3389/fcell.2022.789073 PMC8891931

419. Fu K Single-cell RNA sequencing of immune cells in gastric cancer patients Aging (Albany NY) 2020 12 2747 2763 10.18632/aging.102774 32039830 PMC7041746 Fu, K. et al. Single-cell RNA sequencing of immune cells in gastric cancer patients. Aging (Albany NY) 12 , 2747–2763 (2020). 32039830 10.18632/aging.102774 PMC7041746

420. Yan Y Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells Cancer Immunol. Immunother. 2020 69 1891 1903 10.1007/s00262-020-02586-9 32377817 PMC10112362 Yan, Y. et al. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol. Immunother. 69 , 1891–1903 (2020). 32377817 10.1007/s00262-020-02586-9 PMC10112362

421. Lin YH Repression of microRNA-130b by thyroid hormone enhances cell motility J. Hepatol. 2015 62 1328 1340 10.1016/j.jhep.2014.12.035 25617495 Lin, Y. H. et al. Repression of microRNA-130b by thyroid hormone enhances cell motility. J. Hepatol. 62 , 1328–1340 (2015). 25617495 10.1016/j.jhep.2014.12.035

422. Wang R Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells Inflammation 2022 45 308 330 10.1007/s10753-021-01547-3 34536158 Wang, R. et al. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells. Inflammation 45 , 308–330 (2022). 34536158 10.1007/s10753-021-01547-3

423. Wang Z Pan B SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape Sci. Signal. 2023 16 eabq3362 10.1126/scisignal.abq3362 36917642 Wang, Z. & Pan, B. SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape. Sci. Signal. 16 , eabq3362 (2023). 36917642 10.1126/scisignal.abq3362

424. Yu M miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma Int. J. Oncol. 2017 50 975 983 10.3892/ijo.2017.3852 28098858 Yu, M. et al. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma. Int. J. Oncol. 50 , 975–983 (2017). 28098858 10.3892/ijo.2017.3852

425. Li P Interferon-γ induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1) Cancer Lett. 2012 314 213 222 10.1016/j.canlet.2011.09.031 22056812 PMC3487386 Li, P. et al. Interferon-γ induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1). Cancer Lett. 314 , 213–222 (2012). 22056812 10.1016/j.canlet.2011.09.031 PMC3487386

426. Kröger A Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in mice Cancer Res. 2001 61 2609 2617 11289138 Kröger, A. et al. Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in mice. Cancer Res. 61 , 2609–2617 (2001). 11289138

427. Zekri AR Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1 Eur. J. Gastroenterol. Hepatol. 2010 22 450 456 10.1097/MEG.0b013e3283329d00 19858727 Zekri, A. R. et al. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1. Eur. J. Gastroenterol. Hepatol. 22 , 450–456 (2010). 19858727 10.1097/MEG.0b013e3283329d00

428. Yi Y Interferon regulatory factor (IRF)-1 and IRF-2 are associated with prognosis and tumor invasion in HCC Ann. Surg. Oncol. 2013 20 267 276 10.1245/s10434-012-2487-z 22805863 Yi, Y. et al. Interferon regulatory factor (IRF)-1 and IRF-2 are associated with prognosis and tumor invasion in HCC. Ann. Surg. Oncol. 20 , 267–276 (2013). 22805863 10.1245/s10434-012-2487-z

429. Moriyama Y Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma Clin. Cancer Res. 2001 7 1293 1298 11350897 Moriyama, Y. et al. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma. Clin. Cancer Res. 7 , 1293–1298 (2001). 11350897

430. Yan Y Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells Br. J. Cancer 2021 125 101 111 10.1038/s41416-021-01337-6 33772151 PMC8257880 Yan, Y. et al. Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells. Br. J. Cancer 125 , 101–111 (2021). 33772151 10.1038/s41416-021-01337-6 PMC8257880

431. Yan Y Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC) Cancer Lett. 2021 506 95 106 10.1016/j.canlet.2021.03.002 33689775 PMC8009854 Yan, Y. et al. Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett. 506 , 95–106 (2021). 33689775 10.1016/j.canlet.2021.03.002 PMC8009854

432. Wan PQ Analysis of the relationship between microRNA-31 and interferon regulatory factor-1 in hepatocellular carcinoma cells Eur. Rev. Med. Pharmacol. Sci. 2020 24 647 654 32016965 10.26355/eurrev_202001_20041 Wan, P. Q. et al. Analysis of the relationship between microRNA-31 and interferon regulatory factor-1 in hepatocellular carcinoma cells. Eur. Rev. Med. Pharmacol. Sci. 24 , 647–654 (2020). 32016965 10.26355/eurrev_202001_20041

433. Yan Y MicroRNA-23a downregulates the expression of interferon regulatory factor-1 in hepatocellular carcinoma cells Oncol. Rep. 2016 36 633 640 10.3892/or.2016.4864 27279136 PMC4933546 Yan, Y. et al. MicroRNA-23a downregulates the expression of interferon regulatory factor-1 in hepatocellular carcinoma cells. Oncol. Rep. 36 , 633–640 (2016). 27279136 10.3892/or.2016.4864 PMC4933546

434. Dong K MicroRNA-301a (miR-301a) is induced in hepatocellular carcinoma (HCC) and down- regulates the expression of interferon regulatory factor-1 Biochem. Biophys. Res. Commun. 2020 524 273 279 10.1016/j.bbrc.2020.01.034 31987500 PMC7857543 Dong, K. et al. MicroRNA-301a (miR-301a) is induced in hepatocellular carcinoma (HCC) and down- regulates the expression of interferon regulatory factor-1. Biochem. Biophys. Res. Commun. 524 , 273–279 (2020). 31987500 10.1016/j.bbrc.2020.01.034 PMC7857543

435. Yu W NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-γ/p-STAT1/IRF1 pathway Immunology 2023 169 69 82 10.1111/imm.13611 36420610 Yu, W. et al. NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-γ/p-STAT1/IRF1 pathway. Immunology 169 , 69–82 (2023). 36420610 10.1111/imm.13611

436. Guichard C Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma Nat. Genet. 2012 44 694 698 10.1038/ng.2256 22561517 PMC3819251 Guichard, C. et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44 , 694–698 (2012). 22561517 10.1038/ng.2256 PMC3819251

437. Guo Y IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin Transl. Oncol. 2021 14 101059 10.1016/j.tranon.2021.101059 33735820 PMC7988337 Guo, Y. et al. IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin. Transl. Oncol. 14 , 101059 (2021). 33735820 10.1016/j.tranon.2021.101059 PMC7988337

438. Yu H Major Vault Protein Promotes Hepatocellular Carcinoma Through Targeting Interferon Regulatory Factor 2 and Decreasing p53 Activity Hepatology 2020 72 518 534 10.1002/hep.31045 31758709 Yu, H. et al. Major Vault Protein Promotes Hepatocellular Carcinoma Through Targeting Interferon Regulatory Factor 2 and Decreasing p53 Activity. Hepatology 72 , 518–534 (2020). 31758709 10.1002/hep.31045

439. Yuan MM TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis Bmc. Cancer 2015 15 245 10.1186/s12885-015-1262-5 25884709 PMC4435918 Yuan, M. M. et al. TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis. Bmc. Cancer 15 , 245 (2015). 25884709 10.1186/s12885-015-1262-5 PMC4435918

440. Qi, Z. et al. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma. Biosci. Rep . 40 , BSR20202603 (2020). 10.1042/BSR20202603 PMC7569205 33006365

441. Kim GW Imam H HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC Hepatology 2021 73 533 547 10.1002/hep.31313 32394474 PMC7655655 Kim, G. W. & Imam, H. HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC. Hepatology 73 , 533–547 (2021). 32394474 10.1002/hep.31313 PMC7655655

442. Du SS Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation Int. J. Radiat. Oncol. Biol. Phys. 2022 112 1243 1255 10.1016/j.ijrobp.2021.12.162 34986380 Du, S. S. et al. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. Int. J. Radiat. Oncol. Biol. Phys. 112 , 1243–1255 (2022). 34986380 10.1016/j.ijrobp.2021.12.162

443. Ma H Kang Z Foo TK Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway Hepatology 2023 77 33 47 35006619 10.1002/hep.32335 PMC9271123 Ma, H., Kang, Z. & Foo, T. K. Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway. Hepatology 77 , 33–47 (2023). 35006619 10.1002/hep.32335 PMC9271123

444. Yuan J Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma Int. Immunopharmacol. 2022 113 109411 10.1016/j.intimp.2022.109411 36461603 Yuan, J. et al. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma. Int. Immunopharmacol. 113 , 109411 (2022). 36461603 10.1016/j.intimp.2022.109411

445. Shin SH Identification of novel methylation markers in hepatocellular carcinoma using a methylation array J. Korean Med. Sci. 2010 25 1152 1159 10.3346/jkms.2010.25.8.1152 20676325 PMC2908783 Shin, S. H. et al. Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. J. Korean Med. Sci. 25 , 1152–1159 (2010). 20676325 10.3346/jkms.2010.25.8.1152 PMC2908783

446. Yu J Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis Cell. Res. 2003 13 319 333 10.1038/sj.cr.7290177 14672555 Yu, J. et al. Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell. Res. 13 , 319–333 (2003). 14672555 10.1038/sj.cr.7290177

447. Wu H Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy Hepatology 2022 76 1602 1616 10.1002/hep.32316 34989013 PMC9256853 Wu, H. et al. Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy. Hepatology 76 , 1602–1616 (2022). 34989013 10.1002/hep.32316 PMC9256853

448. Tamada Y p48 Overexpression enhances interferon-mediated expression and activity of double-stranded RNA-dependent protein kinase in human hepatoma cells J. Hepatol. 2002 37 493 499 10.1016/S0168-8278(02)00232-5 12217603 Tamada, Y. et al. p48 Overexpression enhances interferon-mediated expression and activity of double-stranded RNA-dependent protein kinase in human hepatoma cells. J. Hepatol. 37 , 493–499 (2002). 12217603 10.1016/s0168-8278(02)00232-5

449. Wu WZ Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells Oncology 2004 67 428 440 10.1159/000082928 15714000 Wu, W. Z. et al. Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells. Oncology 67 , 428–440 (2004). 15714000 10.1159/000082928

450. Qian YB P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma Cancer 2006 107 1562 1569 10.1002/cncr.22206 16948122 Qian, Y. B. et al. P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer 107 , 1562–1569 (2006). 16948122 10.1002/cncr.22206

451. Huang X Zhang G Liang T Subtyping for pancreatic cancer precision therapy Trends Pharmacol. Sci. 2022 43 482 494 10.1016/j.tips.2022.03.005 35400559 Huang, X., Zhang, G. & Liang, T. Subtyping for pancreatic cancer precision therapy. Trends Pharmacol. Sci. 43 , 482–494 (2022). 35400559 10.1016/j.tips.2022.03.005

452. Sakai T The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer Pancreas 2014 43 909 916 10.1097/MPA.0000000000000116 24632547 Sakai, T. et al. The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer. Pancreas 43 , 909–916 (2014). 24632547 10.1097/MPA.0000000000000116

453. Hannes S Karlowitz R van Wijk SJL The Smac mimetic BV6 cooperates with STING to induce necroptosis in apoptosis-resistant pancreatic carcinoma cells Cell. Death. Dis. 2021 12 816 10.1038/s41419-021-04014-x 34462421 PMC8405653 Hannes, S., Karlowitz, R. & van Wijk, S. J. L. The Smac mimetic BV6 cooperates with STING to induce necroptosis in apoptosis-resistant pancreatic carcinoma cells. Cell. Death. Dis. 12 , 816 (2021). 34462421 10.1038/s41419-021-04014-x PMC8405653

454. Somerville TDD Xu Y Wu XS Maia-Silva D ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer Proc. Natl Acad. Sci. Usa. 2020 117 11471 11482 10.1073/pnas.1921484117 32385160 PMC7261015 Somerville, T. D. D., Xu, Y., Wu, X. S. & Maia-Silva, D. ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer. Proc. Natl Acad. Sci. Usa. 117 , 11471–11482 (2020). 32385160 10.1073/pnas.1921484117 PMC7261015

455. Cui L IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells Tumour Biol. 2012 33 247 255 10.1007/s13277-011-0273-3 22119988 Cui, L. et al. IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 33 , 247–255 (2012). 22119988 10.1007/s13277-011-0273-3

456. Zhang K Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer Bmc. Genom. Data. 2022 23 5 10.1186/s12863-021-01019-5 35012444 PMC8751298 Zhang, K. et al. Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer. Bmc. Genom. Data. 23 , 5 (2022). 35012444 10.1186/s12863-021-01019-5 PMC8751298

457. Kou YQ Prognostic-Related Biomarkers in Pancreatic Ductal Adenocarcinoma Correlating with Immune Infiltrates Based on Proteomics Med. Sci. Monit. 2023 29 e938785 10.12659/MSM.938785 36905103 PMC10015732 Kou, Y. Q. et al. Prognostic-Related Biomarkers in Pancreatic Ductal Adenocarcinoma Correlating with Immune Infiltrates Based on Proteomics. Med. Sci. Monit. 29 , e938785 (2023). 36905103 10.12659/MSM.938785 PMC10015732

458. Liu W Identifying a novel IRF3/circUHRF1/miR-1306-5p/ARL4C axis in pancreatic ductal adenocarcinoma progression Cell. Cycle 2022 21 392 405 10.1080/15384101.2021.2020450 34983293 PMC8855851 Liu, W. et al. Identifying a novel IRF3/circUHRF1/miR-1306-5p/ARL4C axis in pancreatic ductal adenocarcinoma progression. Cell. Cycle 21 , 392–405 (2022). 34983293 10.1080/15384101.2021.2020450 PMC8855851

459. Xie, W. & Li, X. The Pyroptosis-Related Gene Prognostic Index Associated with Tumor Immune Infiltration for Pancreatic Cancer. Int. J. Mol. Sci . 23 , 6178 (2022). 10.3390/ijms23116178 PMC9180955 35682857

460. Metzger P Kirchleitner SV Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model Cancer Immunol. Immunother. 2020 69 2101 2112 10.1007/s00262-020-02605-9 32448983 PMC7511276 Metzger, P. & Kirchleitner, S. V. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model. Cancer Immunol. Immunother. 69 , 2101–2112 (2020). 32448983 10.1007/s00262-020-02605-9 PMC7511276

461. Muthalagu N Monteverde T Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma Cancer Discov. 2020 10 872 887 10.1158/2159-8290.CD-19-0620 32200350 PMC7611248 Muthalagu, N. & Monteverde, T. Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma. Cancer Discov. 10 , 872–887 (2020). 32200350 10.1158/2159-8290.CD-19-0620 PMC7611248

462. Meyer MA Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance Nat. Commun. 2018 9 1250 10.1038/s41467-018-03600-6 29593283 PMC5871846 Meyer, M. A. et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat. Commun. 9 , 1250 (2018). 29593283 10.1038/s41467-018-03600-6 PMC5871846

463. Hong M IRF1 inhibits the proliferation and metastasis of colorectal cancer by suppressing the RAS-RAC1 pathway Cancer Manag. Res. 2019 11 369 378 10.2147/CMAR.S186236 30643462 PMC6317468 Hong, M. et al. IRF1 inhibits the proliferation and metastasis of colorectal cancer by suppressing the RAS-RAC1 pathway. Cancer Manag. Res. 11 , 369–378 (2019). 30643462 10.2147/CMAR.S186236 PMC6317468

464. Wu Y Zhang S Yan J IRF1 association with tumor immune microenvironment and use as a diagnostic biomarker for colorectal cancer recurrence Oncol. Lett. 2020 19 1759 1770 32194669 10.3892/ol.2020.11289 PMC7039159 Wu, Y., Zhang, S. & Yan, J. IRF1 association with tumor immune microenvironment and use as a diagnostic biomarker for colorectal cancer recurrence. Oncol. Lett. 19 , 1759–1770 (2020). 32194669 10.3892/ol.2020.11289 PMC7039159

465. Yuan L IRF1 Inhibits Autophagy-Mediated Proliferation of Colorectal Cancer via Targeting ATG13 Cancer Invest. 2022 40 35 45 10.1080/07357907.2021.1961265 34313498 Yuan, L. et al. IRF1 Inhibits Autophagy-Mediated Proliferation of Colorectal Cancer via Targeting ATG13. Cancer Invest. 40 , 35–45 (2022). 34313498 10.1080/07357907.2021.1961265

466. Sun B Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes Int. J. Cancer 2019 145 1648 1659 10.1002/ijc.32196 30734278 Sun, B. et al. Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes. Int. J. Cancer 145 , 1648–1659 (2019). 30734278 10.1002/ijc.32196

467. Liao W KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer Cancer Cell. 2019 35 559 572.e557 10.1016/j.ccell.2019.02.008 30905761 PMC6467776 Liao, W. et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 35 , 559–572.e557 (2019). 30905761 10.1016/j.ccell.2019.02.008 PMC6467776

468. Chen YJ Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer J. Transl. Med. 2021 19 379 10.1186/s12967-021-03054-3 34488791 PMC8422700 Chen, Y. J. et al. Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer. J. Transl. Med. 19 , 379 (2021). 34488791 10.1186/s12967-021-03054-3 PMC8422700

469. You W Di A Zhang L Zhao G Effects of wogonin on the growth and metastasis of colon cancer through the Hippo signaling pathway Bioengineered 2022 13 2586 2597 10.1080/21655979.2021.2019173 35037825 PMC8973922 You, W., Di, A., Zhang, L. & Zhao, G. Effects of wogonin on the growth and metastasis of colon cancer through the Hippo signaling pathway. Bioengineered 13 , 2586–2597 (2022). 35037825 10.1080/21655979.2021.2019173 PMC8973922

470. Tian M IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of β-catenin Nat. Commun. 2020 11 5762 10.1038/s41467-020-19627-7 33188184 PMC7666182 Tian, M. et al. IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of β-catenin. Nat. Commun. 11 , 5762 (2020). 33188184 10.1038/s41467-020-19627-7 PMC7666182

471. Ding C β-catenin regulates IRF3-mediated innate immune signalling in colorectal cancer Cell. Prolif. 2018 51 e12464 10.1111/cpr.12464 30004146 PMC6528881 Ding, C. et al. β-catenin regulates IRF3-mediated innate immune signalling in colorectal cancer. Cell. Prolif. 51 , e12464 (2018). 30004146 10.1111/cpr.12464 PMC6528881

472. Corrigendum. Cell Prolif 54 , e12655, (2021). 10.1111/cpr.12655 PMC7941234 33687128

473. Kießler, M. et al. Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer. J. Immunother. Cancer . 9 , e001813 (2021). 10.1136/jitc-2020-001813 PMC7993360 33762320

474. Roulois D DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts Cell 2015 162 961 973 10.1016/j.cell.2015.07.056 26317465 PMC4843502 Roulois, D. et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell 162 , 961–973 (2015). 26317465 10.1016/j.cell.2015.07.056 PMC4843502

475. Udden SMN NOD2 Suppresses Colorectal Tumorigenesis via Downregulation of the TLR Pathways Cell. Rep. 2017 19 2756 2770 10.1016/j.celrep.2017.05.084 28658623 PMC6032983 Udden, S. M. N. et al. NOD2 Suppresses Colorectal Tumorigenesis via Downregulation of the TLR Pathways. Cell. Rep. 19 , 2756–2770 (2017). 28658623 10.1016/j.celrep.2017.05.084 PMC6032983

476. Zhou Y Integrated multi-omics data analyses for exploring the co-occurring and mutually exclusive gene alteration events in colorectal cancer Hum. Mutat. 2020 41 1588 1599 10.1002/humu.24059 32485022 Zhou, Y. et al. Integrated multi-omics data analyses for exploring the co-occurring and mutually exclusive gene alteration events in colorectal cancer. Hum. Mutat. 41 , 1588–1599 (2020). 32485022 10.1002/humu.24059

477. Hu G Barnes BJ Interferon regulatory factor-5-regulated pathways as a target for colorectal cancer therapeutics Expert. Rev. Anticancer. Ther. 2006 6 775 784 10.1586/14737140.6.5.775 16759167 Hu, G. & Barnes, B. J. Interferon regulatory factor-5-regulated pathways as a target for colorectal cancer therapeutics. Expert. Rev. Anticancer. Ther. 6 , 775–784 (2006). 16759167 10.1586/14737140.6.5.775

478. Arnold, I. C. et al. The GM-CSF-IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses. J. Exp. Med . 217 , e20190706 (2020). 10.1084/jem.20190706 PMC7953737 32970801

479. Tan L The interferon regulatory factor 6 promotes cisplatin sensitivity in colorectal cancer Bioengineered 2022 13 10504 10517 10.1080/21655979.2022.2062103 35443865 PMC9161955 Tan, L. et al. The interferon regulatory factor 6 promotes cisplatin sensitivity in colorectal cancer. Bioengineered 13 , 10504–10517 (2022). 35443865 10.1080/21655979.2022.2062103 PMC9161955

480. Ibrahim ML Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis Cell. Rep. 2018 25 3036 3046.e3036 10.1016/j.celrep.2018.11.050 30540937 PMC6319669 Ibrahim, M. L. et al. Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis. Cell. Rep. 25 , 3036–3046.e3036 (2018). 30540937 10.1016/j.celrep.2018.11.050 PMC6319669

481. Klement JD An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion J. Clin. Invest. 2018 128 5549 5560 10.1172/JCI123360 30395540 PMC6264631 Klement, J. D. et al. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J. Clin. Invest. 128 , 5549–5560 (2018). 30395540 10.1172/JCI123360 PMC6264631

482. Sharma, B. R. et al. The Transcription Factor IRF9 Promotes Colorectal Cancer via Modulating the IL-6/STAT3 Signaling Axis. Cancers (Basel) 14 , 919 (2022). 10.3390/cancers14040919 PMC8869918 35205671

483. Thai AA Lung cancer Lancet 2021 398 535 554 10.1016/S0140-6736(21)00312-3 34273294 Thai, A. A. et al. Lung cancer. Lancet 398 , 535–554 (2021). 34273294 10.1016/S0140-6736(21)00312-3

484. Lahiri A Lung cancer immunotherapy: progress, pitfalls, and promises Mol. Cancer 2023 22 40 10.1186/s12943-023-01740-y 36810079 PMC9942077 Lahiri, A. et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol. Cancer 22 , 40 (2023). 36810079 10.1186/s12943-023-01740-y PMC9942077

485. Huang JX IRF1 Negatively Regulates Oncogenic KPNA2 Expression Under Growth Stimulation and Hypoxia in Lung Cancer Cells Onco. Targets Ther. 2019 12 11475 11486 10.2147/OTT.S221832 31920336 PMC6939401 Huang, J. X. et al. IRF1 Negatively Regulates Oncogenic KPNA2 Expression Under Growth Stimulation and Hypoxia in Lung Cancer Cells. Onco. Targets Ther. 12 , 11475–11486 (2019). 31920336 10.2147/OTT.S221832 PMC6939401

486. Zhang L Interferon regulatory factor-1 regulates cisplatin-induced apoptosis and autophagy in A549 lung cancer cells Med. Oncol. 2022 39 38 10.1007/s12032-021-01638-z 35092496 PMC8800914 Zhang, L. et al. Interferon regulatory factor-1 regulates cisplatin-induced apoptosis and autophagy in A549 lung cancer cells. Med. Oncol. 39 , 38 (2022). 35092496 10.1007/s12032-021-01638-z PMC8800914

487. Chan YC Chang YC Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFNγ axis Oncogene 2020 39 2509 2522 10.1038/s41388-020-1160-4 31988456 Chan, Y. C. & Chang, Y. C. Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFNγ axis. Oncogene 39 , 2509–2522 (2020). 31988456 10.1038/s41388-020-1160-4

488. Qi L An individualized gene expression signature for prediction of lung adenocarcinoma metastases Mol. Oncol. 2017 11 1630 1645 10.1002/1878-0261.12137 28922552 PMC5663997 Qi, L. et al. An individualized gene expression signature for prediction of lung adenocarcinoma metastases. Mol. Oncol. 11 , 1630–1645 (2017). 28922552 10.1002/1878-0261.12137 PMC5663997

489. Liang C MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer Cell. Death. Dis. 2017 8 e2764 10.1038/cddis.2017.145 28471447 PMC5520692 Liang, C. et al. MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer. Cell. Death. Dis. 8 , e2764 (2017). 28471447 10.1038/cddis.2017.145 PMC5520692

490. Jin JJ Overexpression of miR-1290 contributes to cell proliferation and invasion of non small cell lung cancer by targeting interferon regulatory factor 2 Int. J. Biochem. Cell. Biol. 2018 95 113 120 10.1016/j.biocel.2017.12.017 29275213 Jin, J. J. et al. Overexpression of miR-1290 contributes to cell proliferation and invasion of non small cell lung cancer by targeting interferon regulatory factor 2. Int. J. Biochem. Cell. Biol. 95 , 113–120 (2018). 29275213 10.1016/j.biocel.2017.12.017

491. Ma J LncRNA GAS5 modulates the progression of non-small cell lung cancer through repressing miR-221-3p and up-regulating IRF2 Diagn. Pathol. 2021 16 46 10.1186/s13000-021-01108-0 34022918 PMC8140465 Ma, J. et al. LncRNA GAS5 modulates the progression of non-small cell lung cancer through repressing miR-221-3p and up-regulating IRF2. Diagn. Pathol. 16 , 46 (2021). 34022918 10.1186/s13000-021-01108-0 PMC8140465

492. Xiao XH He SY ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway Eur. Rev. Med. Pharmacol. Sci. 2020 24 3130 3142 32271431 10.26355/eurrev_202003_20680 Xiao, X. H. & He, S. Y. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 24 , 3130–3142 (2020). 32271431 10.26355/eurrev_202003_20680

493. Liu F Upregulation of microRNA-450 inhibits the progression of lung cancer in vitro and in vivo by targeting interferon regulatory factor 2 Int. J. Mol. Med. 2016 38 283 290 10.3892/ijmm.2016.2612 27246609 Liu, F. et al. Upregulation of microRNA-450 inhibits the progression of lung cancer in vitro and in vivo by targeting interferon regulatory factor 2. Int. J. Mol. Med. 38 , 283–290 (2016). 27246609 10.3892/ijmm.2016.2612

494. Yi L Interferon regulatory factor 3 mediates Poly(I:C)-induced innate immune response and apoptosis in non‑small cell lung cancer Int. J. Oncol. 2018 52 1623 1632 29512705 10.3892/ijo.2018.4300 Yi, L. et al. Interferon regulatory factor 3 mediates Poly(I:C)-induced innate immune response and apoptosis in non‑small cell lung cancer. Int. J. Oncol. 52 , 1623–1632 (2018). 29512705 10.3892/ijo.2018.4300

495. Gong K EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer Nat. Cancer 2020 1 394 409 10.1038/s43018-020-0048-0 33269343 PMC7706867 Gong, K. et al. EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nat. Cancer 1 , 394–409 (2020). 33269343 10.1038/s43018-020-0048-0 PMC7706867

496. Zhang N PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer Clin. Transl. Oncol. 2021 23 1827 1837 10.1007/s12094-021-02591-z 33774805 Zhang, N. et al. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer. Clin. Transl. Oncol. 23 , 1827–1837 (2021). 33774805 10.1007/s12094-021-02591-z

497. Taniguchi H WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC Cell. Rep. 2022 39 110814 10.1016/j.celrep.2022.110814 35584676 PMC9449677 Taniguchi, H. et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell. Rep. 39 , 110814 (2022). 35584676 10.1016/j.celrep.2022.110814 PMC9449677

498. Zhou L Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer Cancer Lett. 2021 500 163 171 10.1016/j.canlet.2020.11.049 33278498 Zhou, L. et al. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. Cancer Lett. 500 , 163–171 (2021). 33278498 10.1016/j.canlet.2020.11.049

499. Sen T Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer Cancer Discov. 2019 9 646 661 10.1158/2159-8290.CD-18-1020 30777870 PMC6563834 Sen, T. et al. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov. 9 , 646–661 (2019). 30777870 10.1158/2159-8290.CD-18-1020 PMC6563834

500. Long Y GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer Signal. Transduct. Target. Ther. 2023 8 48 10.1038/s41392-022-01224-3 36725837 PMC9892510 Long, Y. et al. GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer. Signal. Transduct. Target. Ther. 8 , 48 (2023). 36725837 10.1038/s41392-022-01224-3 PMC9892510

501. Wu YY CPEB4 and IRF4 expression in peripheral mononuclear cells are potential prognostic factors for advanced lung cancer J. Formos. Med. Assoc. 2017 116 114 122 10.1016/j.jfma.2016.01.009 27113098 Wu, Y. Y. et al. CPEB4 and IRF4 expression in peripheral mononuclear cells are potential prognostic factors for advanced lung cancer. J. Formos. Med. Assoc. 116 , 114–122 (2017). 27113098 10.1016/j.jfma.2016.01.009

502. Li X Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma Front. Oncol. 2021 11 698465 10.3389/fonc.2021.698465 34195096 PMC8236722 Li, X. et al. Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma. Front. Oncol. 11 , 698465 (2021). 34195096 10.3389/fonc.2021.698465 PMC8236722

503. Chen HY A five-gene signature and clinical outcome in non-small-cell lung cancer N. Engl. J. Med. 2007 356 11 20 10.1056/NEJMoa060096 17202451 Chen, H. Y. et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356 , 11–20 (2007). 17202451 10.1056/NEJMoa060096

504. Gao J Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1 J. Exp. Clin. Cancer Res. 2022 41 295 10.1186/s13046-022-02505-z 36209117 PMC9547453 Gao, J. et al. Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1. J. Exp. Clin. Cancer Res. 41 , 295 (2022). 36209117 10.1186/s13046-022-02505-z PMC9547453

505. Carbó JM León TE Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment Cancer Res. 2021 81 968 985 10.1158/0008-5472.CAN-19-3360 33361391 Carbó, J. M. & León, T. E. Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment. Cancer Res. 81 , 968–985 (2021). 33361391 10.1158/0008-5472.CAN-19-3360

506. Alvisi G IRF4 instructs effector Treg differentiation and immune suppression in human cancer J. Clin. Invest. 2020 130 3137 3150 10.1172/JCI130426 32125291 PMC7260038 Alvisi, G. et al. IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J. Clin. Invest. 130 , 3137–3150 (2020). 32125291 10.1172/JCI130426 PMC7260038

507. Feng DD Transcription factor E2F1 positively regulates interferon regulatory factor 5 expression in non-small cell lung cancer Onco. Targets Ther. 2019 12 6907 6915 10.2147/OTT.S215701 31692554 PMC6711570 Feng, D. D. et al. Transcription factor E2F1 positively regulates interferon regulatory factor 5 expression in non-small cell lung cancer. Onco. Targets Ther. 12 , 6907–6915 (2019). 31692554 10.2147/OTT.S215701 PMC6711570

508. Guo J A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer Lung. Cancer 2019 135 47 55 10.1016/j.lungcan.2019.07.008 31447002 Guo, J. et al. A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer. Lung. Cancer 135 , 47–55 (2019). 31447002 10.1016/j.lungcan.2019.07.008

509. Yamashina T Cancer stem-like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells Cancer Res. 2014 74 2698 2709 10.1158/0008-5472.CAN-13-2169 24638980 Yamashina, T. et al. Cancer stem-like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells. Cancer Res. 74 , 2698–2709 (2014). 24638980 10.1158/0008-5472.CAN-13-2169

510. Liu Y Interferon regulatory factor 6 correlates with the progression of non-small cell lung cancer and can be regulated by miR-320 J. Pharm. Pharmacol. 2021 73 682 691 10.1093/jpp/rgab009 33772297 Liu, Y. et al. Interferon regulatory factor 6 correlates with the progression of non-small cell lung cancer and can be regulated by miR-320. J. Pharm. Pharmacol. 73 , 682–691 (2021). 33772297 10.1093/jpp/rgab009

511. Huang L IRF7 and IFIT2 in mediating different hemorrhage outcomes for non-small cell lung cancer after bevacizumab treatment J. Thorac. Dis. 2023 15 2022 2036 10.21037/jtd-23-389 37197507 PMC10183489 Huang, L. et al. IRF7 and IFIT2 in mediating different hemorrhage outcomes for non-small cell lung cancer after bevacizumab treatment. J. Thorac. Dis. 15 , 2022–2036 (2023). 37197507 10.21037/jtd-23-389 PMC10183489

512. Lai Q Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells Oncogene 2018 37 2302 2312 10.1038/s41388-018-0125-3 29422611 Lai, Q. et al. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells. Oncogene 37 , 2302–2312 (2018). 29422611 10.1038/s41388-018-0125-3

513. Suzuki M Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer Oncol. Lett. 2014 8 1025 1030 10.3892/ol.2014.2234 25120651 PMC4114630 Suzuki, M. et al. Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer. Oncol. Lett. 8 , 1025–1030 (2014). 25120651 10.3892/ol.2014.2234 PMC4114630

514. Liang J IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function Cell. Cycle 2019 18 3300 3312 10.1080/15384101.2019.1674053 31594449 PMC6927690 Liang, J. et al. IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function. Cell. Cycle 18 , 3300–3312 (2019). 31594449 10.1080/15384101.2019.1674053 PMC6927690

515. Li L Integrated analysis of dysregulated long non-coding RNAs/microRNAs/mRNAs in metastasis of lung adenocarcinoma J. Transl. Med. 2018 16 372 10.1186/s12967-018-1732-z 30587197 PMC6307237 Li, L. et al. Integrated analysis of dysregulated long non-coding RNAs/microRNAs/mRNAs in metastasis of lung adenocarcinoma. J. Transl. Med. 16 , 372 (2018). 30587197 10.1186/s12967-018-1732-z PMC6307237

516. Brunn, D. & Turkowski, K. Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. Cancers (Basel) 13 , 208 (2021). 10.3390/cancers13020208 PMC7827113 33430083

517. Cohen S Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma Gynecol. Oncol. 2014 134 591 598 10.1016/j.ygyno.2014.06.025 24995581 Cohen, S. et al. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. Gynecol. Oncol. 134 , 591–598 (2014). 24995581 10.1016/j.ygyno.2014.06.025

518. Padmanabhan S IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling Cell. Signal. 2022 97 110400 10.1016/j.cellsig.2022.110400 35820543 PMC9357219 Padmanabhan, S. et al. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling. Cell. Signal. 97 , 110400 (2022). 35820543 10.1016/j.cellsig.2022.110400 PMC9357219

519. Huang SL Chang TC Chao CCK Sun NK TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer Biochem. Pharmacol. 2021 186 114456 10.1016/j.bcp.2021.114456 33556340 Huang, S. L., Chang, T. C., Chao, C. C. K. & Sun, N. K. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer. Biochem. Pharmacol. 186 , 114456 (2021). 33556340 10.1016/j.bcp.2021.114456

520. Pavan S Olivero M Corà D Di Renzo MF IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness Eur. J. Cancer 2013 49 964 973 10.1016/j.ejca.2012.09.024 23079474 Pavan, S., Olivero, M., Corà, D. & Di Renzo, M. F. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness. Eur. J. Cancer 49 , 964–973 (2013). 23079474 10.1016/j.ejca.2012.09.024

521. Zhang J Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer Cell. Death. Differ. 2021 28 139 155 10.1038/s41418-020-0588-y 32678307 PMC7853139 Zhang, J. et al. Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer. Cell. Death. Differ. 28 , 139–155 (2021). 32678307 10.1038/s41418-020-0588-y PMC7853139

522. Cornelison, R. et al. CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer. Cancers (Basel) 13 , 5056 (2021). 10.3390/cancers13205056 PMC8533980 34680204

523. Heimes AS A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients Arch. Gynecol. Obstet. 2019 299 239 246 10.1007/s00404-018-4941-z 30357498 Heimes, A. S. et al. A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients. Arch. Gynecol. Obstet. 299 , 239–246 (2019). 30357498 10.1007/s00404-018-4941-z

524. Zhang F Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers Nat. Commun. 2019 10 3974 10.1038/s41467-019-11911-5 31481662 PMC6722139 Zhang, F. et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat. Commun. 10 , 3974 (2019). 31481662 10.1038/s41467-019-11911-5 PMC6722139

525. Hoffmann M Rak A Ptak A Bisphenol A and its derivatives decrease expression of chemerin, which reverses its stimulatory action in ovarian cancer cells Toxicol. Lett. 2018 291 61 69 10.1016/j.toxlet.2018.04.004 29653259 Hoffmann, M., Rak, A. & Ptak, A. Bisphenol A and its derivatives decrease expression of chemerin, which reverses its stimulatory action in ovarian cancer cells. Toxicol. Lett. 291 , 61–69 (2018). 29653259 10.1016/j.toxlet.2018.04.004

526. Schmitt, M. et al. Anti-Tumoral Effect of Chemerin on Ovarian Cancer Cell Lines Mediated by Activation of Interferon Alpha Response. Cancers (Basel) 14 , 4108 (2022). 10.3390/cancers14174108 PMC9454566 36077645

527. Tang DG Understanding and targeting prostate cancer cell heterogeneity and plasticity Semin. Cancer Biol. 2022 82 68 93 10.1016/j.semcancer.2021.11.001 34844845 PMC9106849 Tang, D. G. Understanding and targeting prostate cancer cell heterogeneity and plasticity. Semin. Cancer Biol. 82 , 68–93 (2022). 34844845 10.1016/j.semcancer.2021.11.001 PMC9106849

528. Cheng Y Wang D Jiang J Huang W Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression Prostate 2020 80 640 652 10.1002/pros.23976 32282098 Cheng, Y., Wang, D., Jiang, J. & Huang, W. Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression. Prostate 80 , 640–652 (2020). 32282098 10.1002/pros.23976

529. Sonkusre P Cameotra SS Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation J. Nanobiotechnology. 2017 15 43 10.1186/s12951-017-0276-3 28592284 PMC5463494 Sonkusre, P. & Cameotra, S. S. Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation. J. Nanobiotechnology. 15 , 43 (2017). 28592284 10.1186/s12951-017-0276-3 PMC5463494

530. Bachmann SB DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells Mol. Cancer 2014 13 125 10.1186/1476-4598-13-125 24886089 PMC4070648 Bachmann, S. B. et al. DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. Mol. Cancer 13 , 125 (2014). 24886089 10.1186/1476-4598-13-125 PMC4070648

531. Wu H Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance Cancer Res. 2020 80 2927 2939 10.1158/0008-5472.CAN-19-2549 32341037 PMC9601976 Wu, H. et al. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. Cancer Res. 80 , 2927–2939 (2020). 32341037 10.1158/0008-5472.CAN-19-2549 PMC9601976

532. Kneitz B Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3 Cancer Res. 2014 74 2591 2603 10.1158/0008-5472.CAN-13-1606 24607843 Kneitz, B. et al. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res. 74 , 2591–2603 (2014). 24607843 10.1158/0008-5472.CAN-13-1606

533. Deveci Ozkan A Kaleli S Anti-inflammatory effects of nobiletin on TLR4/TRIF/IRF3 and TLR9/IRF7 signaling pathways in prostate cancer cells Immunopharmacol. Immunotoxicol. 2020 42 93 100 10.1080/08923973.2020.1725040 32048561 Deveci Ozkan, A. & Kaleli, S. Anti-inflammatory effects of nobiletin on TLR4/TRIF/IRF3 and TLR9/IRF7 signaling pathways in prostate cancer cells. Immunopharmacol. Immunotoxicol. 42 , 93–100 (2020). 32048561 10.1080/08923973.2020.1725040

534. Zhao Y Overexpression of Interferon Regulatory Factor 7 (IRF7) Reduces Bone Metastasis of Prostate Cancer Cells in Mice Oncol. Res. 2017 25 511 522 10.3727/096504016X14756226781802 27733217 PMC7841009 Zhao, Y. et al. Overexpression of Interferon Regulatory Factor 7 (IRF7) Reduces Bone Metastasis of Prostate Cancer Cells in Mice. Oncol. Res. 25 , 511–522 (2017). 27733217 10.3727/096504016X14756226781802 PMC7841009

535. Yu SJ Kim HS Cho SW Sohn J IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1 Exp. Mol. Med. 2004 36 372 379 10.1038/emm.2004.49 15365257 Yu, S. J., Kim, H. S., Cho, S. W. & Sohn, J. IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1. Exp. Mol. Med. 36 , 372–379 (2004). 15365257 10.1038/emm.2004.49

536. Tomita Y Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells Int. J. Cancer 2003 104 400 408 10.1002/ijc.10956 12584735 Tomita, Y. et al. Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int. J. Cancer 104 , 400–408 (2003). 12584735 10.1002/ijc.10956

537. Kong SK Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma Lab. Invest. 2022 102 352 362 10.1038/s41374-021-00703-5 34789838 Kong, S. K. et al. Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma. Lab. Invest. 102 , 352–362 (2022). 34789838 10.1038/s41374-021-00703-5

538. Wu J Overexpression of IRF3 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma Int. J. Gen. Med. 2021 14 5675 5692 10.2147/IJGM.S328225 34557022 PMC8454526 Wu, J. et al. Overexpression of IRF3 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma. Int. J. Gen. Med. 14 , 5675–5692 (2021). 34557022 10.2147/IJGM.S328225 PMC8454526

539. Zeng X Li L Hu Z Peng D Integrated Multi-Omics Analysis Identified PTPRG and CHL1 as Key Regulators of Immunophenotypes in Clear Cell Renal Cell Carcinoma(ccRCC) Front. Oncol. 2022 12 832027 10.3389/fonc.2022.832027 35433461 PMC9005830 Zeng, X., Li, L., Hu, Z. & Peng, D. Integrated Multi-Omics Analysis Identified PTPRG and CHL1 as Key Regulators of Immunophenotypes in Clear Cell Renal Cell Carcinoma(ccRCC). Front. Oncol. 12 , 832027 (2022). 35433461 10.3389/fonc.2022.832027 PMC9005830

540. Wang H ZNF692 promote proliferation through transcriptional repression of essential genes in clear cell renal carcinoma Biochem. Biophys. Res. Commun. 2023 671 255 262 10.1016/j.bbrc.2023.06.014 37307709 Wang, H. et al. ZNF692 promote proliferation through transcriptional repression of essential genes in clear cell renal carcinoma. Biochem. Biophys. Res. Commun. 671 , 255–262 (2023). 37307709 10.1016/j.bbrc.2023.06.014

541. Li Z Decreased interferon regulatory factor 6 expression due to DNA hypermethylation predicts an unfavorable prognosis in clear cell renal cell carcinoma J. Cancer 2021 12 6640 6655 10.7150/jca.62394 34659554 PMC8518015 Li, Z. et al. Decreased interferon regulatory factor 6 expression due to DNA hypermethylation predicts an unfavorable prognosis in clear cell renal cell carcinoma. J. Cancer 12 , 6640–6655 (2021). 34659554 10.7150/jca.62394 PMC8518015

542. Wang Y Gene Expression Microarray Data Meta-Analysis Identifies Candidate Genes and Molecular Mechanism Associated with Clear Cell Renal Cell Carcinoma Cell. J. 2020 22 386 393 31863665 10.22074/cellj.2020.6561 PMC6947001 Wang, Y. et al. Gene Expression Microarray Data Meta-Analysis Identifies Candidate Genes and Molecular Mechanism Associated with Clear Cell Renal Cell Carcinoma. Cell. J. 22 , 386–393 (2020). 31863665 10.22074/cellj.2020.6561 PMC6947001

543. Lin L Cai J Circular RNA circ-EGLN3 promotes renal cell carcinoma proliferation and aggressiveness via miR-1299-mediated IRF7 activation J. Cell. Biochem. 2020 121 4377 4385 10.1002/jcb.29620 31904147 Lin, L. & Cai, J. Circular RNA circ-EGLN3 promotes renal cell carcinoma proliferation and aggressiveness via miR-1299-mediated IRF7 activation. J. Cell. Biochem. 121 , 4377–4385 (2020). 31904147 10.1002/jcb.29620

544. Muhitch JB Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma J. Immunother. Cancer 2019 7 155 10.1186/s40425-019-0630-0 31221219 PMC6585080 Muhitch, J. B. et al. Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma. J. Immunother. Cancer 7 , 155 (2019). 31221219 10.1186/s40425-019-0630-0 PMC6585080

545. Zhang Q Interferon regulatory factor 8 functions as a tumor suppressor in renal cell carcinoma and its promoter methylation is associated with patient poor prognosis Cancer Lett. 2014 354 227 234 10.1016/j.canlet.2014.07.040 25109451 Zhang, Q. et al. Interferon regulatory factor 8 functions as a tumor suppressor in renal cell carcinoma and its promoter methylation is associated with patient poor prognosis. Cancer Lett. 354 , 227–234 (2014). 25109451 10.1016/j.canlet.2014.07.040

546. Nixon BG Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer Immunity 2022 55 2044 2058.e2045 10.1016/j.immuni.2022.10.002 36288724 PMC9649891 Nixon, B. G. et al. Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. Immunity 55 , 2044–2058.e2045 (2022). 36288724 10.1016/j.immuni.2022.10.002 PMC9649891

547. Kamaraj B Al-Subaie AM Ahmad F Surapaneni KM Effect of novel leukemia mutations (K75E & E222K) on interferon regulatory factor 1 and its interaction with DNA: insights from molecular dynamics simulations and docking studies J. Biomol. Struct. Dyn. 2021 39 5235 5247 10.1080/07391102.2020.1784790 32619131 Kamaraj, B., Al-Subaie, A. M., Ahmad, F. & Surapaneni, K. M. Effect of novel leukemia mutations (K75E & E222K) on interferon regulatory factor 1 and its interaction with DNA: insights from molecular dynamics simulations and docking studies. J. Biomol. Struct. Dyn. 39 , 5235–5247 (2021). 32619131 10.1080/07391102.2020.1784790

548. Semmes EC Vijayakrishnan J Leveraging Genome and Phenome-Wide Association Studies to Investigate Genetic Risk of Acute Lymphoblastic Leukemia Cancer Epidemiol. Biomark. Prev. 2020 29 1606 1614 10.1158/1055-9965.EPI-20-0113 PMC7415687 32467347 Semmes, E. C. & Vijayakrishnan, J. Leveraging Genome and Phenome-Wide Association Studies to Investigate Genetic Risk of Acute Lymphoblastic Leukemia. Cancer Epidemiol. Biomark. Prev. 29 , 1606–1614 (2020). 10.1158/1055-9965.EPI-20-0113 PMC7415687 32467347

549. Manzella L Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia Curr. Cancer Drug. Targets 2016 16 594 605 10.2174/1568009616666160105105857 26728039 Manzella, L. et al. Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia. Curr. Cancer Drug. Targets 16 , 594–605 (2016). 26728039 10.2174/1568009616666160105105857

550. Mathew NR Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells Nat. Med. 2018 24 282 291 10.1038/nm.4484 29431743 PMC6029618 Mathew, N. R. et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat. Med. 24 , 282–291 (2018). 29431743 10.1038/nm.4484 PMC6029618

551. Wang H Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion Oncogene 2022 41 2303 2314 10.1038/s41388-022-02233-w 35256780 PMC9010288 Wang, H. et al. Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion. Oncogene 41 , 2303–2314 (2022). 35256780 10.1038/s41388-022-02233-w PMC9010288

552. Yang X Repolarizing heterogeneous leukemia-associated macrophages with more M1 characteristics eliminates their pro-leukemic effects Oncoimmunology 2018 7 e1412910 10.1080/2162402X.2017.1412910 29632729 PMC5889280 Yang, X. et al. Repolarizing heterogeneous leukemia-associated macrophages with more M1 characteristics eliminates their pro-leukemic effects. Oncoimmunology 7 , e1412910 (2018). 29632729 10.1080/2162402X.2017.1412910 PMC5889280

553. Tian WL The IRF9-SIRT1-P53 axis is involved in the growth of human acute myeloid leukemia Exp. Cell. Res. 2018 365 185 193 10.1016/j.yexcr.2018.02.036 29501566 Tian, W. L. et al. The IRF9-SIRT1-P53 axis is involved in the growth of human acute myeloid leukemia. Exp. Cell. Res. 365 , 185–193 (2018). 29501566 10.1016/j.yexcr.2018.02.036

554. Zhang F IRF2-INPP4B axis participates in the development of acute myeloid leukemia by regulating cell growth and survival Gene 2017 627 9 14 10.1016/j.gene.2017.06.001 28579269 Zhang, F. et al. IRF2-INPP4B axis participates in the development of acute myeloid leukemia by regulating cell growth and survival. Gene 627 , 9–14 (2017). 28579269 10.1016/j.gene.2017.06.001

555. Zhang F IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells Biol. Res. 2019 52 11 10.1186/s40659-019-0218-7 30876449 PMC6419480 Zhang, F. et al. IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells. Biol. Res. 52 , 11 (2019). 30876449 10.1186/s40659-019-0218-7 PMC6419480

556. Zhang F IRF2-INPP4B axis inhibits apoptosis of acute myeloid leukaemia cells via regulating T helper 1/2 cell differentiation Cell. Biochem. Funct. 2020 38 582 590 10.1002/cbf.3511 32115737 Zhang, F. et al. IRF2-INPP4B axis inhibits apoptosis of acute myeloid leukaemia cells via regulating T helper 1/2 cell differentiation. Cell. Biochem. Funct. 38 , 582–590 (2020). 32115737 10.1002/cbf.3511

557. Zhang F Exosomes derived from human bone marrow mesenchymal stem cells transfer miR-222-3p to suppress acute myeloid leukemia cell proliferation by targeting IRF2/INPP4B Mol. Cell. Probes. 2020 51 101513 10.1016/j.mcp.2020.101513 31968218 Zhang, F. et al. Exosomes derived from human bone marrow mesenchymal stem cells transfer miR-222-3p to suppress acute myeloid leukemia cell proliferation by targeting IRF2/INPP4B. Mol. Cell. Probes. 51 , 101513 (2020). 31968218 10.1016/j.mcp.2020.101513

558. Tian WL IRF3 is involved in human acute myeloid leukemia through regulating the expression of miR-155 Biochem. Biophys. Res. Commun. 2016 478 1130 1135 10.1016/j.bbrc.2016.08.080 27530922 Tian, W. L. et al. IRF3 is involved in human acute myeloid leukemia through regulating the expression of miR-155. Biochem. Biophys. Res. Commun. 478 , 1130–1135 (2016). 27530922 10.1016/j.bbrc.2016.08.080

559. Di Bernardo MC A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia Nat. Genet. 2008 40 1204 1210 10.1038/ng.219 18758461 Di Bernardo, M. C. et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40 , 1204–1210 (2008). 18758461 10.1038/ng.219

560. Wang J Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility Front. Genet. 2021 12 554948 10.3389/fgene.2021.554948 34220922 PMC8248805 Wang, J. et al. Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility. Front. Genet. 12 , 554948 (2021). 34220922 10.3389/fgene.2021.554948 PMC8248805

561. Maffei, R., Fiorcari, S., Benatti, S. & Atene, C. G. IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. 35 , 1330-1343, (2021). 10.1038/s41375-021-01178-5 33623139

562. Asslaber D B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion Blood 2019 134 1717 1729 10.1182/blood.2019000973 31537531 PMC6895374 Asslaber, D. et al. B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion. Blood 134 , 1717–1729 (2019). 31537531 10.1182/blood.2019000973 PMC6895374

563. Zhang Y Zeng X Correlation of the transcription factors IRF4 and BACH2 with the abnormal NFATC1 expression in T cells from chronic myeloid leukemia patients Hematology 2022 27 523 529 10.1080/16078454.2022.2066245 35544467 Zhang, Y. & Zeng, X. Correlation of the transcription factors IRF4 and BACH2 with the abnormal NFATC1 expression in T cells from chronic myeloid leukemia patients. Hematology 27 , 523–529 (2022). 35544467 10.1080/16078454.2022.2066245

564. Tarantini F IRF4 Gene Expression on the Trail of Molecular Response: Looking at Chronic Myeloid Leukemia from Another Perspective Acta Haematol. 2023 146 37 43 10.1159/000527173 36195064 Tarantini, F. et al. IRF4 Gene Expression on the Trail of Molecular Response: Looking at Chronic Myeloid Leukemia from Another Perspective. Acta Haematol. 146 , 37–43 (2023). 36195064 10.1159/000527173

565. Pang SH PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia Leukemia 2016 30 1375 1387 10.1038/leu.2016.27 26932576 PMC5179358 Pang, S. H. et al. PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia. Leukemia 30 , 1375–1387 (2016). 26932576 10.1038/leu.2016.27 PMC5179358

566. So AY Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias Blood 2014 124 1502 1512 10.1182/blood-2014-02-553842 25006123 PMC4148772 So, A. Y. et al. Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias. Blood 124 , 1502–1512 (2014). 25006123 10.1182/blood-2014-02-553842 PMC4148772

567. Wong RWJ Feed-forward regulatory loop driven by IRF4 and NF-κB in adult T-cell leukemia/lymphoma Blood 2020 135 934 947 10.1182/blood.2019002639 31972002 Wong, R. W. J. et al. Feed-forward regulatory loop driven by IRF4 and NF-κB in adult T-cell leukemia/lymphoma. Blood 135 , 934–947 (2020). 31972002 10.1182/blood.2019002639

568. Sakamoto H Ando K Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth Cancer Sci. 2022 113 4092 4103 10.1111/cas.15550 36047964 PMC9746047 Sakamoto, H. & Ando, K. Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth. Cancer Sci. 113 , 4092–4103 (2022). 36047964 10.1111/cas.15550 PMC9746047

569. Watanabe T The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia Cancer Res. 2013 73 6642 6653 10.1158/0008-5472.CAN-13-0802 24242069 Watanabe, T. et al. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia. Cancer Res. 73 , 6642–6653 (2013). 24242069 10.1158/0008-5472.CAN-13-0802

570. Hu X IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia Cancer Res. 2011 71 2882 2891 10.1158/0008-5472.CAN-10-2493 21487040 PMC3078194 Hu, X. et al. IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res. 71 , 2882–2891 (2011). 21487040 10.1158/0008-5472.CAN-10-2493 PMC3078194

571. Scheller M Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance J. Exp. Med. 2013 210 2239 2256 10.1084/jem.20130706 24101380 PMC3804946 Scheller, M. et al. Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance. J. Exp. Med. 210 , 2239–2256 (2013). 24101380 10.1084/jem.20130706 PMC3804946

572. Gaillard C Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia Blood. Adv. 2018 2 2462 2466 10.1182/bloodadvances.2018018929 30266821 PMC6177650 Gaillard, C. et al. Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia. Blood. Adv. 2 , 2462–2466 (2018). 30266821 10.1182/bloodadvances.2018018929 PMC6177650

573. Zhou Y Silencing of IRF8 Mediated by m6A Modification Promotes the Progression of T-Cell Acute Lymphoblastic Leukemia Adv. Sci. (Weinh.). 2023 10 e2201724 36478193 10.1002/advs.202201724 PMC9839875 Zhou, Y. et al. Silencing of IRF8 Mediated by m6A Modification Promotes the Progression of T-Cell Acute Lymphoblastic Leukemia. Adv. Sci. (Weinh.). 10 , e2201724 (2023). 36478193 10.1002/advs.202201724 PMC9839875

574. Liss, F. et al. IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells. Cancers (Basel) 13 , 764 (2021). 10.3390/cancers13040764 PMC7917770 33673123

575. Zhuang H Loss of IRF8 inhibits the growth of acute myeloid leukemia cells Ann. Hematol. 2023 102 1063 1072 10.1007/s00277-023-05156-y 36959484 Zhuang, H. et al. Loss of IRF8 inhibits the growth of acute myeloid leukemia cells. Ann. Hematol. 102 , 1063–1072 (2023). 36959484 10.1007/s00277-023-05156-y

576. Cao Z ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency Mol. Cell. 2021 81 3604 3622.e3610 10.1016/j.molcel.2021.07.018 34358447 PMC8932643 Cao, Z. et al. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. Mol. Cell. 81 , 3604–3622.e3610 (2021). 34358447 10.1016/j.molcel.2021.07.018 PMC8932643

577. Pingul BY Dissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia iScience 2022 25 105139 10.1016/j.isci.2022.105139 36193052 PMC9526175 Pingul, B. Y. et al. Dissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia. iScience 25 , 105139 (2022). 36193052 10.1016/j.isci.2022.105139 PMC9526175

578. Wiseman DH Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome EBioMedicine 2020 58 102904 10.1016/j.ebiom.2020.102904 32763828 PMC7403890 Wiseman, D. H. et al. Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome. EBioMedicine 58 , 102904 (2020). 32763828 10.1016/j.ebiom.2020.102904 PMC7403890

579. Wang Q Lin Z RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway Blood 2022 139 59 72 10.1182/blood.2020009856 34411225 Wang, Q. & Lin, Z. RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood 139 , 59–72 (2022). 34411225 10.1182/blood.2020009856

580. Xing L Wang S Liu J BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression Clin. Cancer Res. 2021 27 5376 5388 10.1158/1078-0432.CCR-21-1621 34301753 PMC8783926 Xing, L., Wang, S. & Liu, J. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clin. Cancer Res. 27 , 5376–5388 (2021). 34301753 10.1158/1078-0432.CCR-21-1621 PMC8783926

581. Tsubaki M Macrophage inflammatory protein-1α induces osteoclast formation by activation of the MEK/ERK/c-Fos pathway and inhibition of the p38MAPK/IRF-3/IFN-β pathway J. Cell. Biochem. 2010 111 1661 1672 10.1002/jcb.22907 21053363 Tsubaki, M. et al. Macrophage inflammatory protein-1α induces osteoclast formation by activation of the MEK/ERK/c-Fos pathway and inhibition of the p38MAPK/IRF-3/IFN-β pathway. J. Cell. Biochem. 111 , 1661–1672 (2010). 21053363 10.1002/jcb.22907

582. Liu H He J Bagheri-Yarmand R Osteocyte CIITA aggravates osteolytic bone lesions in myeloma Nat. Commun. 2022 13 3684 10.1038/s41467-022-31356-7 35760800 PMC9237076 Liu, H., He, J. & Bagheri-Yarmand, R. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nat. Commun. 13 , 3684 (2022). 35760800 10.1038/s41467-022-31356-7 PMC9237076

583. Fedele PL Liao Y Gong JN Yao Y The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival Leukemia 2021 35 2114 2118 10.1038/s41375-020-01078-0 33149265 Fedele, P. L., Liao, Y., Gong, J. N. & Yao, Y. The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. Leukemia 35 , 2114–2118 (2021). 33149265 10.1038/s41375-020-01078-0

584. Katsarou A Trasanidis N Ponnusamy K Kostopoulos IV MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis Blood. Adv. 2023 7 6395 6410 10.1182/bloodadvances.2023009772 37224458 PMC10598502 Katsarou, A., Trasanidis, N., Ponnusamy, K. & Kostopoulos, I. V. MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis. Blood. Adv. 7 , 6395–6410 (2023). 37224458 10.1182/bloodadvances.2023009772 PMC10598502

585. Du L Liu W Pichiorri F Rosen ST SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide Cancer Gene. Ther. 2023 30 567 574 10.1038/s41417-022-00450-9 35338347 PMC10104776 Du, L., Liu, W., Pichiorri, F. & Rosen, S. T. SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide. Cancer Gene. Ther. 30 , 567–574 (2023). 35338347 10.1038/s41417-022-00450-9 PMC10104776

586. Mougiakakos D Bach C Böttcher M The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages Cancer Immunol. Res. 2021 9 265 278 10.1158/2326-6066.CIR-20-0555 33563611 Mougiakakos, D., Bach, C. & Böttcher, M. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages. Cancer Immunol. Res. 9 , 265–278 (2021). 33563611 10.1158/2326-6066.CIR-20-0555

587. Mondala PK Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption Cell. Stem. Cell. 2021 28 623 636.e629 10.1016/j.stem.2020.12.017 33476575 PMC8026723 Mondala, P. K. et al. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell. Stem. Cell. 28 , 623–636.e629 (2021). 33476575 10.1016/j.stem.2020.12.017 PMC8026723

588. Morelli E Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo Leukemia 2015 29 2173 2183 10.1038/leu.2015.124 25987254 PMC4635336 Morelli, E. et al. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia 29 , 2173–2183 (2015). 25987254 10.1038/leu.2015.124 PMC4635336

589. Wang QS Identification of Immune-Related Genes for Risk Stratification in Multiple Myeloma Based on Whole Bone Marrow Gene Expression Profiling Front. Genet. 2022 13 897886 10.3389/fgene.2022.897886 35692836 PMC9178200 Wang, Q. S. et al. Identification of Immune-Related Genes for Risk Stratification in Multiple Myeloma Based on Whole Bone Marrow Gene Expression Profiling. Front. Genet. 13 , 897886 (2022). 35692836 10.3389/fgene.2022.897886 PMC9178200

590. Waller RG Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes Hum. Mol. Genet. 2021 30 1142 1153 10.1093/hmg/ddab066 33751038 PMC8188404 Waller, R. G. et al. Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Hum. Mol. Genet. 30 , 1142–1153 (2021). 33751038 10.1093/hmg/ddab066 PMC8188404

591. Liu R m(6)A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease Theranostics 2022 12 7760 7774 10.7150/thno.76852 36451863 PMC9706590 Liu, R. et al. m(6)A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease. Theranostics 12 , 7760–7774 (2022). 36451863 10.7150/thno.76852 PMC9706590

592. Giannouli S Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression Ann. Rheum. Dis. 2004 63 578 582 10.1136/ard.2003.012948 15082491 PMC1754981 Giannouli, S. et al. Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. Ann. Rheum. Dis. 63 , 578–582 (2004). 15082491 10.1136/ard.2003.012948 PMC1754981

593. Pinheiro RF Metze K Silva MR Chauffaille Mde L The ambiguous role of interferon regulatory factor-1 (IRF-1) immunoexpression in myelodysplastic syndrome Leuk. Res. 2009 33 1308 1312 10.1016/j.leukres.2009.03.008 19345417 Pinheiro, R. F., Metze, K., Silva, M. R. & Chauffaille Mde, L. The ambiguous role of interferon regulatory factor-1 (IRF-1) immunoexpression in myelodysplastic syndrome. Leuk. Res. 33 , 1308–1312 (2009). 19345417 10.1016/j.leukres.2009.03.008

594. de Sousa JC Dysregulation of interferon regulatory genes reinforces the concept of chronic immune response in myelodysplastic syndrome pathogenesis Hematol. Oncol. 2019 37 523 526 10.1002/hon.2608 30920666 de Sousa, J. C. et al. Dysregulation of interferon regulatory genes reinforces the concept of chronic immune response in myelodysplastic syndrome pathogenesis. Hematol. Oncol. 37 , 523–526 (2019). 30920666 10.1002/hon.2608

595. de Oliveira RTG ERVs-TLR3-IRF axis is linked to myelodysplastic syndrome pathogenesis Med. Oncol. 2021 38 27 10.1007/s12032-021-01466-1 33594613 de Oliveira, R. T. G. et al. ERVs-TLR3-IRF axis is linked to myelodysplastic syndrome pathogenesis. Med. Oncol. 38 , 27 (2021). 33594613 10.1007/s12032-021-01466-1

596. Le Y Screening and identification of key candidate genes and pathways in myelodysplastic syndrome by bioinformatic analysis PeerJ 2019 7 e8162 10.7717/peerj.8162 31803541 PMC6886488 Le, Y. Screening and identification of key candidate genes and pathways in myelodysplastic syndrome by bioinformatic analysis. PeerJ 7 , e8162 (2019). 31803541 10.7717/peerj.8162 PMC6886488

597. Wang S CTLA-4 blockade induces tumor pyroptosis via CD8(+) T cells in head and neck squamous cell carcinoma Mol. Ther. 2023 31 2154 2168 10.1016/j.ymthe.2023.02.023 36869589 PMC10362385 Wang, S. et al. CTLA-4 blockade induces tumor pyroptosis via CD8(+) T cells in head and neck squamous cell carcinoma. Mol. Ther. 31 , 2154–2168 (2023). 36869589 10.1016/j.ymthe.2023.02.023 PMC10362385

598. Li X Yang W IRF2-induced Claudin-7 suppresses cell proliferation, invasion and migration of oral squamous cell carcinoma Exp. Ther. Med. 2022 23 7 10.3892/etm.2021.10929 34815759 PMC8593875 Li, X. & Yang, W. IRF2-induced Claudin-7 suppresses cell proliferation, invasion and migration of oral squamous cell carcinoma. Exp. Ther. Med. 23 , 7 (2022). 34815759 10.3892/etm.2021.10929 PMC8593875

599. Jin S The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma Mol. Cancer 2022 21 97 10.1186/s12943-022-01572-2 35395767 PMC8994291 Jin, S. et al. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma. Mol. Cancer 21 , 97 (2022). 35395767 10.1186/s12943-022-01572-2 PMC8994291

600. Yan, Y., Gauthier, M. A. & Malik, A. The NOTCH-RIPK4-IRF6-ELOVL4 Axis Suppresses Squamous Cell Carcinoma. Cancers (Basel) 15 , 737 (2023). 10.3390/cancers15030737 PMC9913669 36765696

601. Ke L Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis Proc. Natl Acad. Sci. Usa. 2017 114 9683 9688 10.1073/pnas.1705236114 28831010 PMC5594663 Ke, L. et al. Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis. Proc. Natl Acad. Sci. Usa. 114 , 9683–9688 (2017). 28831010 10.1073/pnas.1705236114 PMC5594663

602. Qi CL The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis J. Exp. Clin. Cancer Res. 2021 40 390 10.1186/s13046-021-02191-3 34893086 PMC8662847 Qi, C. L. et al. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis. J. Exp. Clin. Cancer Res. 40 , 390 (2021). 34893086 10.1186/s13046-021-02191-3 PMC8662847

603. Ge J Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1 Cancer Res. 2021 81 5074 5088 10.1158/0008-5472.CAN-20-4321 34321242 PMC8974435 Ge, J. et al. Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1. Cancer Res. 81 , 5074–5088 (2021). 34321242 10.1158/0008-5472.CAN-20-4321 PMC8974435

604. Wan P Zhang J Du Q Geller DA The clinical significance and biological function of interferon regulatory factor 1 in cholangiocarcinoma Biomed. Pharmacother. 2018 97 771 777 10.1016/j.biopha.2017.10.096 29107934 Wan, P., Zhang, J., Du, Q. & Geller, D. A. The clinical significance and biological function of interferon regulatory factor 1 in cholangiocarcinoma. Biomed. Pharmacother. 97 , 771–777 (2018). 29107934 10.1016/j.biopha.2017.10.096

605. Wan P miR-383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1 J. Cell. Biochem. 2018 119 9720 9729 10.1002/jcb.27286 30145803 Wan, P. et al. miR-383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1. J. Cell. Biochem. 119 , 9720–9729 (2018). 30145803 10.1002/jcb.27286

606. Wei CX IRF4-induced upregulation of lncRNA SOX2-OT promotes cell proliferation and metastasis in cholangiocarcinoma by regulating SOX2 and PI3K/AKT signaling Eur. Rev. Med. Pharmacol. Sci. 2018 22 8169 8178 30556855 10.26355/eurrev_201812_16509 Wei, C. X. et al. IRF4-induced upregulation of lncRNA SOX2-OT promotes cell proliferation and metastasis in cholangiocarcinoma by regulating SOX2 and PI3K/AKT signaling. Eur. Rev. Med. Pharmacol. Sci. 22 , 8169–8178 (2018). 30556855 10.26355/eurrev_201812_16509

607. Meyer-Schaller N A dual role of Irf1 in maintaining epithelial identity but also enabling EMT and metastasis formation of breast cancer cells Oncogene 2020 39 4728 4740 10.1038/s41388-020-1326-0 32404986 Meyer-Schaller, N. et al. A dual role of Irf1 in maintaining epithelial identity but also enabling EMT and metastasis formation of breast cancer cells. Oncogene 39 , 4728–4740 (2020). 32404986 10.1038/s41388-020-1326-0

608. Wu B UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer Theranostics 2022 12 5086 5102 10.7150/thno.74989 35836797 PMC9274738 Wu, B. et al. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer. Theranostics 12 , 5086–5102 (2022). 35836797 10.7150/thno.74989 PMC9274738

609. Schwartz-Roberts JL Interferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fate Cancer Res. 2015 75 1046 1055 10.1158/0008-5472.CAN-14-1851 25576084 PMC4359953 Schwartz-Roberts, J. L. et al. Interferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fate. Cancer Res. 75 , 1046–1055 (2015). 25576084 10.1158/0008-5472.CAN-14-1851 PMC4359953

610. Armstrong MJ IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition Cancer Biol. Ther. 2015 16 1029 1041 10.1080/15384047.2015.1046646 26011589 PMC4622679 Armstrong, M. J. et al. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition. Cancer Biol. Ther. 16 , 1029–1041 (2015). 26011589 10.1080/15384047.2015.1046646 PMC4622679

611. Luker KE Pica CM Schreiber RD Piwnica-Worms D Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells Cancer Res. 2001 61 6540 6547 11522652 Luker, K. E., Pica, C. M., Schreiber, R. D. & Piwnica-Worms, D. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res. 61 , 6540–6547 (2001). 11522652

612. Brockwell NK Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC Npj. Precis. Oncol. 2019 3 21 10.1038/s41698-019-0093-2 31482136 PMC6715634 Brockwell, N. K. et al. Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. Npj. Precis. Oncol. 3 , 21 (2019). 31482136 10.1038/s41698-019-0093-2 PMC6715634

613. Bernardo AR Cosgaya JM Aranda A Jiménez-Lara AM Pro-apoptotic signaling induced by Retinoic acid and dsRNA is under the control of Interferon Regulatory Factor-3 in breast cancer cells Apoptosis 2017 22 920 932 10.1007/s10495-017-1377-z 28409399 Bernardo, A. R., Cosgaya, J. M., Aranda, A. & Jiménez-Lara, A. M. Pro-apoptotic signaling induced by Retinoic acid and dsRNA is under the control of Interferon Regulatory Factor-3 in breast cancer cells. Apoptosis 22 , 920–932 (2017). 28409399 10.1007/s10495-017-1377-z

614. Lu X Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway Ann. Med. 2023 55 2210845 10.1080/07853890.2023.2210845 37162544 PMC10173802 Lu, X. et al. Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway. Ann. Med. 55 , 2210845 (2023). 37162544 10.1080/07853890.2023.2210845 PMC10173802

615. Pantelidou C Sonzogni O PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer Cancer Discov. 2019 9 722 737 10.1158/2159-8290.CD-18-1218 31015319 PMC6548644 Pantelidou, C. & Sonzogni, O. PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov. 9 , 722–737 (2019). 31015319 10.1158/2159-8290.CD-18-1218 PMC6548644

616. Vernier M Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4 Oncogene 2020 39 6406 6420 10.1038/s41388-020-01438-1 32855526 PMC7544553 Vernier, M. et al. Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4. Oncogene 39 , 6406–6420 (2020). 32855526 10.1038/s41388-020-01438-1 PMC7544553

617. Heimes AS Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer J. Cancer Res. Clin. Oncol. 2017 143 1123 1131 10.1007/s00432-017-2377-7 28251349 PMC11819188 Heimes, A. S. et al. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer. J. Cancer Res. Clin. Oncol. 143 , 1123–1131 (2017). 28251349 10.1007/s00432-017-2377-7 PMC11819188

618. Pimenta EM Barnes BJ A conserved region within interferon regulatory factor 5 controls breast cancer cell migration through a cytoplasmic and transcription-independent mechanism Mol. Cancer 2015 14 32 10.1186/s12943-015-0305-5 25649192 PMC4326371 Pimenta, E. M. & Barnes, B. J. A conserved region within interferon regulatory factor 5 controls breast cancer cell migration through a cytoplasmic and transcription-independent mechanism. Mol. Cancer 14 , 32 (2015). 25649192 10.1186/s12943-015-0305-5 PMC4326371

619. Bi X Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis Breast Cancer Res. 2011 13 R111 10.1186/bcr3053 22053985 PMC3326553 Bi, X. et al. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res. 13 , R111 (2011). 22053985 10.1186/bcr3053 PMC3326553

620. Xu HF Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression Cancer Manag. Res. 2019 11 5557 5572 10.2147/CMAR.S203060 31417306 PMC6594015 Xu, H. F. et al. Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression. Cancer Manag. Res. 11 , 5557–5572 (2019). 31417306 10.2147/CMAR.S203060 PMC6594015

621. Liu X Chipurupalli S ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth Cell. Death. Dis. 2022 13 687 10.1038/s41419-022-05117-9 35933456 PMC9357009 Liu, X. & Chipurupalli, S. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth. Cell. Death. Dis. 13 , 687 (2022). 35933456 10.1038/s41419-022-05117-9 PMC9357009

622. Khan IA ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth Breast Cancer Res. 2018 20 151 10.1186/s13058-018-1080-1 30545388 PMC6293553 Khan, I. A. et al. ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth. Breast Cancer Res. 20 , 151 (2018). 30545388 10.1186/s13058-018-1080-1 PMC6293553

623. de Mingo Pulido Á TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer Cancer Cell. 2018 33 60 74.e66 10.1016/j.ccell.2017.11.019 29316433 PMC5764109 de Mingo Pulido, Á. et al. TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell. 33 , 60–74.e66 (2018). 29316433 10.1016/j.ccell.2017.11.019 PMC5764109

624. Cohen PA Jhingran A Oaknin A Denny L Cervical cancer Lancet 2019 393 169 182 10.1016/S0140-6736(18)32470-X 30638582 Cohen, P. A., Jhingran, A., Oaknin, A. & Denny, L. Cervical cancer. Lancet 393 , 169–182 (2019). 30638582 10.1016/S0140-6736(18)32470-X

625. Rho, S. B., Lee, S. H., Byun, H. J. & Kim, B. R. IRF-1 Inhibits Angiogenic Activity of HPV16 E6 Oncoprotein in Cervical Cancer. Int. J. Mol. Sci . 21 , 7622 (2020). 10.3390/ijms21207622 PMC7589982 33076322

626. Walch-Rückheim B STAT3/IRF1 Pathway Activation Sensitizes Cervical Cancer Cells to Chemotherapeutic Drugs Cancer Res. 2016 76 3872 3883 10.1158/0008-5472.CAN-14-1306 27216197 Walch-Rückheim, B. et al. STAT3/IRF1 Pathway Activation Sensitizes Cervical Cancer Cells to Chemotherapeutic Drugs. Cancer Res. 76 , 3872–3883 (2016). 27216197 10.1158/0008-5472.CAN-14-1306

627. Lee SH IFN-gamma/IRF-1-induced p27kip1 down-regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer Febs. Lett. 2005 579 1027 1033 10.1016/j.febslet.2005.01.005 15710386 Lee, S. H. et al. IFN-gamma/IRF-1-induced p27kip1 down-regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer. Febs. Lett. 579 , 1027–1033 (2005). 15710386 10.1016/j.febslet.2005.01.005

628. Deng ZM Dai FF Zhou Q Cheng YX Hsa_circ_0000301 facilitates the progression of cervical cancer by targeting miR-1228-3p/IRF4 Axis Bmc. Cancer 2021 21 583 10.1186/s12885-021-08331-4 34020619 PMC8140416 Deng, Z. M., Dai, F. F., Zhou, Q. & Cheng, Y. X. Hsa_circ_0000301 facilitates the progression of cervical cancer by targeting miR-1228-3p/IRF4 Axis. Bmc. Cancer 21 , 583 (2021). 34020619 10.1186/s12885-021-08331-4 PMC8140416

629. Ren Y Dong J He P miR-587 promotes cervical cancer by repressing interferon regulatory factor 6 J. Gene. Med. 2020 22 e3257 10.1002/jgm.3257 32749750 Ren, Y., Dong, J. & He, P. miR-587 promotes cervical cancer by repressing interferon regulatory factor 6. J. Gene. Med. 22 , e3257 (2020). 32749750 10.1002/jgm.3257

630. Kuroboshi H Interferon regulatory factor-1 expression in human uterine endometrial carcinoma Gynecol. Oncol. 2003 91 354 358 10.1016/S0090-8258(03)00515-8 14599866 Kuroboshi, H. et al. Interferon regulatory factor-1 expression in human uterine endometrial carcinoma. Gynecol. Oncol. 91 , 354–358 (2003). 14599866 10.1016/s0090-8258(03)00515-8

631. Gao K SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis Cell. Death. Differ. 2023 30 475 487 10.1038/s41418-022-01097-7 36481790 PMC9950446 Gao, K. et al. SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis. Cell. Death. Differ. 30 , 475–487 (2023). 36481790 10.1038/s41418-022-01097-7 PMC9950446

632. Zeng X IL6 Induces mtDNA Leakage to Affect the Immune Escape of Endometrial Carcinoma via cGAS-STING J. Immunol. Res. 2022 2022 3815853 10.1155/2022/3815853 35692503 PMC9184159 Zeng, X. et al. IL6 Induces mtDNA Leakage to Affect the Immune Escape of Endometrial Carcinoma via cGAS-STING. J. Immunol. Res. 2022 , 3815853 (2022). 35692503 10.1155/2022/3815853 PMC9184159

633. Nakamura K ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer Gynecol. Oncol. 2022 166 326 333 10.1016/j.ygyno.2022.05.026 35697535 Nakamura, K. et al. ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer. Gynecol. Oncol. 166 , 326–333 (2022). 35697535 10.1016/j.ygyno.2022.05.026

634. Ghislat, G. et al. NF-κB-dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity. Sci. Immunol . 6 , eabg3570 (2021). 10.1126/sciimmunol.abg3570 34244313

635. Zhou S IRF1 expression might be a biomarker of CD8+ T cell infiltration in cutaneous melanoma Expert. Rev. Clin. Immunol. 2022 18 1319 1327 10.1080/1744666X.2022.2141228 36300336 Zhou, S. et al. IRF1 expression might be a biomarker of CD8+ T cell infiltration in cutaneous melanoma. Expert. Rev. Clin. Immunol. 18 , 1319–1327 (2022). 36300336 10.1080/1744666X.2022.2141228

636. Mirjačić Martinović K Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma J. Clin. Pathol. 2016 69 300 306 10.1136/jclinpath-2015-203107 26442832 Mirjačić Martinović, K. et al. Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma. J. Clin. Pathol. 69 , 300–306 (2016). 26442832 10.1136/jclinpath-2015-203107

637. Yokoyama S SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis Cancer Res. 2021 81 6131 6141 10.1158/0008-5472.CAN-21-2078 34728538 PMC8678351 Yokoyama, S. et al. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis. Cancer Res. 81 , 6131–6141 (2021). 34728538 10.1158/0008-5472.CAN-21-2078 PMC8678351

638. Wang W Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-κB Contributes to UV Radiation-Induced Immune Suppression Cancer Res. 2019 79 2909 2922 10.1158/0008-5472.CAN-18-3134 30737234 PMC6548650 Wang, W. et al. Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-κB Contributes to UV Radiation-Induced Immune Suppression. Cancer Res. 79 , 2909–2922 (2019). 30737234 10.1158/0008-5472.CAN-18-3134 PMC6548650

639. Occhigrossi L D’Eletto M Transglutaminase type 2-dependent crosslinking of IRF3 in dying melanoma cells Cell. Death. Discov. 2022 8 498 10.1038/s41420-022-01278-w 36572679 PMC9792452 Occhigrossi, L. & D’Eletto, M. Transglutaminase type 2-dependent crosslinking of IRF3 in dying melanoma cells. Cell. Death. Discov. 8 , 498 (2022). 36572679 10.1038/s41420-022-01278-w PMC9792452

640. Musick M Yu X Immunotherapeutic effects of intratumorally injected Zymosan-Adenovirus conjugates encoding constant active IRF3 in a melanoma mouse model Immunol. Res. 2023 71 197 212 10.1007/s12026-022-09336-2 36418765 Musick, M. & Yu, X. Immunotherapeutic effects of intratumorally injected Zymosan-Adenovirus conjugates encoding constant active IRF3 in a melanoma mouse model. Immunol. Res. 71 , 197–212 (2023). 36418765 10.1007/s12026-022-09336-2

641. Humblin E IRF8-dependent molecular complexes control the Th9 transcriptional program Nat. Commun. 2017 8 2085 10.1038/s41467-017-01070-w 29233972 PMC5727025 Humblin, E. et al. IRF8-dependent molecular complexes control the Th9 transcriptional program. Nat. Commun. 8 , 2085 (2017). 29233972 10.1038/s41467-017-01070-w PMC5727025

642. Wang D Increased IRF9-STAT2 Signaling Leads to Adaptive Resistance toward Targeted Therapy in Melanoma by Restraining GSDME-Dependent Pyroptosis J. Invest. Dermatol. 2022 142 2476 2487.e2479 10.1016/j.jid.2022.01.024 35148998 Wang, D. et al. Increased IRF9-STAT2 Signaling Leads to Adaptive Resistance toward Targeted Therapy in Melanoma by Restraining GSDME-Dependent Pyroptosis. J. Invest. Dermatol. 142 , 2476–2487.e2479 (2022). 35148998 10.1016/j.jid.2022.01.024

643. Chu Z Gu L Hu Y Zhang X STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming Nat. Commun. 2022 13 1859 10.1038/s41467-022-29541-9 35388001 PMC8986786 Chu, Z., Gu, L., Hu, Y. & Zhang, X. STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. Nat. Commun. 13 , 1859 (2022). 35388001 10.1038/s41467-022-29541-9 PMC8986786

644. Sancéau J Hiscott J Delattre O Wietzerbin J IFN-beta induces serine phosphorylation of Stat-1 in Ewing’s sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7 Oncogene 2000 19 3372 3383 10.1038/sj.onc.1203670 10918594 Sancéau, J., Hiscott, J., Delattre, O. & Wietzerbin, J. IFN-beta induces serine phosphorylation of Stat-1 in Ewing’s sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 19 , 3372–3383 (2000). 10918594 10.1038/sj.onc.1203670

645. Ma Z MiR-134, Mediated by IRF1, Suppresses Tumorigenesis and Progression by Targeting VEGFA and MYCN in Osteosarcoma Anticancer. Agents Med. Chem. 2020 20 1197 1208 10.2174/1871520620666200402074752 32238141 Ma, Z. et al. MiR-134, Mediated by IRF1, Suppresses Tumorigenesis and Progression by Targeting VEGFA and MYCN in Osteosarcoma. Anticancer. Agents Med. Chem. 20 , 1197–1208 (2020). 32238141 10.2174/1871520620666200402074752

646. Zhang X The CtBP1-HDAC1/2-IRF1 transcriptional complex represses the expression of the long noncoding RNA GAS5 in human osteosarcoma cells Int. J. Biol. Sci. 2019 15 1460 1471 10.7150/ijbs.33529 31337976 PMC6643137 Zhang, X. et al. The CtBP1-HDAC1/2-IRF1 transcriptional complex represses the expression of the long noncoding RNA GAS5 in human osteosarcoma cells. Int. J. Biol. Sci. 15 , 1460–1471 (2019). 31337976 10.7150/ijbs.33529 PMC6643137

647. Cheng JP miR-4295 promotes cell proliferation, migration and invasion of osteosarcoma through targeting interferon regulatory factor 1 Oncol. Lett. 2020 20 260 10.3892/ol.2020.12123 32989394 PMC7517570 Cheng, J. P. et al. miR-4295 promotes cell proliferation, migration and invasion of osteosarcoma through targeting interferon regulatory factor 1. Oncol. Lett. 20 , 260 (2020). 32989394 10.3892/ol.2020.12123 PMC7517570

648. Lu C miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2 Oncol. Lett. 2018 16 3150 3156 30127908 10.3892/ol.2018.9032 PMC6096157 Lu, C. et al. miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2. Oncol. Lett. 16 , 3150–3156 (2018). 30127908 10.3892/ol.2018.9032 PMC6096157

649. Wu W SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma Cell. Death. Dis. 2022 13 523 10.1038/s41419-022-04980-w 35662245 PMC9166744 Wu, W. et al. SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma. Cell. Death. Dis. 13 , 523 (2022). 35662245 10.1038/s41419-022-04980-w PMC9166744

650. Li Z IRF7 inhibits the Warburg effect via transcriptional suppression of PKM2 in osteosarcoma Int. J. Biol. Sci. 2022 18 30 42 10.7150/ijbs.65255 34975316 PMC8692136 Li, Z. et al. IRF7 inhibits the Warburg effect via transcriptional suppression of PKM2 in osteosarcoma. Int. J. Biol. Sci. 18 , 30–42 (2022). 34975316 10.7150/ijbs.65255 PMC8692136

651. Li Z Erratum: IRF7 inhibits the Warburg effect via transcriptional suppression of PKM2 in osteosarcoma: Erratum Int. J. Biol. Sci. 2022 18 6229 6230 10.7150/ijbs.79598 36439882 PMC9682534 Li, Z. et al. Erratum: IRF7 inhibits the Warburg effect via transcriptional suppression of PKM2 in osteosarcoma: Erratum. Int. J. Biol. Sci. 18 , 6229–6230 (2022). 36439882 10.7150/ijbs.79598 PMC9682534

652. Ni X Wu W Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against PTEN-null glioblastoma Sci. Adv. 2022 8 eabl5165 10.1126/sciadv.abl5165 35857445 PMC9269888 Ni, X. & Wu, W. Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against PTEN-null glioblastoma. Sci. Adv. 8 , eabl5165 (2022). 35857445 10.1126/sciadv.abl5165 PMC9269888

653. Tong S IRF2-ferroptosis related gene is associated with prognosis and EMT in gliomas Transl. Oncol. 2022 26 101544 10.1016/j.tranon.2022.101544 36156371 PMC9508157 Tong, S. et al. IRF2-ferroptosis related gene is associated with prognosis and EMT in gliomas. Transl. Oncol. 26 , 101544 (2022). 36156371 10.1016/j.tranon.2022.101544 PMC9508157

654. Tarassishin L Lee SC Interferon regulatory factor 3 alters glioma inflammatory and invasive properties J. Neurooncol. 2013 113 185 194 10.1007/s11060-013-1109-3 23512614 Tarassishin, L. & Lee, S. C. Interferon regulatory factor 3 alters glioma inflammatory and invasive properties. J. Neurooncol. 113 , 185–194 (2013). 23512614 10.1007/s11060-013-1109-3

655. Pattwell SS Holland EC Putting Glioblastoma in Its Place: IRF3 Inhibits Invasion Trends Mol. Med. 2017 23 773 776 10.1016/j.molmed.2017.07.008 28774478 PMC5843370 Pattwell, S. S. & Holland, E. C. Putting Glioblastoma in Its Place: IRF3 Inhibits Invasion. Trends Mol. Med. 23 , 773–776 (2017). 28774478 10.1016/j.molmed.2017.07.008 PMC5843370

656. Pencheva N Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness Cell. Rep. 2017 20 48 60 10.1016/j.celrep.2017.06.036 28683323 Pencheva, N. et al. Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness. Cell. Rep. 20 , 48–60 (2017). 28683323 10.1016/j.celrep.2017.06.036

657. Yang T A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization Acta Pharm. Sin. B. 2022 12 2658 2671 10.1016/j.apsb.2022.02.009 35755286 PMC9214068 Yang, T. et al. A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization. Acta Pharm. Sin. B. 12 , 2658–2671 (2022). 35755286 10.1016/j.apsb.2022.02.009 PMC9214068

658. Li C Guan N Liu F T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma J. Neurooncol. 2023 162 93 108 10.1007/s11060-023-04257-y 36854924 Li, C., Guan, N. & Liu, F. T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma. J. Neurooncol. 162 , 93–108 (2023). 36854924 10.1007/s11060-023-04257-y

659. Shah D Comba A A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1 Oncoimmunology 2021 10 1939601 10.1080/2162402X.2021.1939601 34249474 PMC8244780 Shah, D. & Comba, A. A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1. Oncoimmunology 10 , 1939601 (2021). 34249474 10.1080/2162402X.2021.1939601 PMC8244780

660. Tang R Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease Inflamm. Bowel. Dis. 2014 20 1950 1961 10.1097/MIB.0000000000000192 25208103 Tang, R. et al. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease. Inflamm. Bowel. Dis. 20 , 1950–1961 (2014). 25208103 10.1097/MIB.0000000000000192

661. Tan G An IRF1-dependent Pathway of TNFα-induced Shedding in Intestinal Epithelial Cells J. Crohns. Colitis 2022 16 133 142 10.1093/ecco-jcc/jjab134 34309645 Tan, G. et al. An IRF1-dependent Pathway of TNFα-induced Shedding in Intestinal Epithelial Cells. J. Crohns. Colitis 16 , 133–142 (2022). 34309645 10.1093/ecco-jcc/jjab134

662. Xu H Fu J TNF-α Enhances the Therapeutic Effects of MenSC-Derived Small Extracellular Vesicles on Inflammatory Bowel Disease through Macrophage Polarization by miR-24-3p Stem. Cells Int. 2023 2023 2988907 10.1155/2023/2988907 36895784 PMC9991477 Xu, H. & Fu, J. TNF-α Enhances the Therapeutic Effects of MenSC-Derived Small Extracellular Vesicles on Inflammatory Bowel Disease through Macrophage Polarization by miR-24-3p. Stem. Cells Int. 2023 , 2988907 (2023). 36895784 10.1155/2023/2988907 PMC9991477

663. Wang KW Enhanced susceptibility to chemically induced colitis caused by excessive endosomal TLR signaling in LRBA-deficient mice Proc. Natl Acad. Sci. USA 2019 116 11380 11389 10.1073/pnas.1901407116 31097594 PMC6561264 Wang, K. W. et al. Enhanced susceptibility to chemically induced colitis caused by excessive endosomal TLR signaling in LRBA-deficient mice. Proc. Natl Acad. Sci. USA 116 , 11380–11389 (2019). 31097594 10.1073/pnas.1901407116 PMC6561264

664. Chiriac MT Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is Increased in Mucosa of Patients With Inflammatory Bowel Disease Gastroenterology 2017 153 123 138.e128 10.1053/j.gastro.2017.03.015 28342759 Chiriac, M. T. et al. Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is Increased in Mucosa of Patients With Inflammatory Bowel Disease. Gastroenterology 153 , 123–138.e128 (2017). 28342759 10.1053/j.gastro.2017.03.015

665. Buchele V Th17 Cell-Mediated Colitis Is Positively Regulated by Interferon Regulatory Factor 4 in a T Cell-Extrinsic Manner Front. Immunol. 2020 11 590893 10.3389/fimmu.2020.590893 33584655 PMC7879684 Buchele, V. et al. Th17 Cell-Mediated Colitis Is Positively Regulated by Interferon Regulatory Factor 4 in a T Cell-Extrinsic Manner. Front. Immunol. 11 , 590893 (2020). 33584655 10.3389/fimmu.2020.590893 PMC7879684

666. Zhu X 1,25‑Dihydroxyvitamin D regulates macrophage polarization and ameliorates experimental inflammatory bowel disease by suppressing miR-125b Int. Immunopharmacol. 2019 67 106 118 10.1016/j.intimp.2018.12.015 30540970 Zhu, X. et al. 1,25‑Dihydroxyvitamin D regulates macrophage polarization and ameliorates experimental inflammatory bowel disease by suppressing miR-125b. Int. Immunopharmacol. 67 , 106–118 (2019). 30540970 10.1016/j.intimp.2018.12.015

667. Zhu W Baicalin ameliorates experimental inflammatory bowel disease through polarization of macrophages to an M2 phenotype Int. Immunopharmacol. 2016 35 119 126 10.1016/j.intimp.2016.03.030 27039210 Zhu, W. et al. Baicalin ameliorates experimental inflammatory bowel disease through polarization of macrophages to an M2 phenotype. Int. Immunopharmacol. 35 , 119–126 (2016). 27039210 10.1016/j.intimp.2016.03.030

668. Yan J T Cell-Intrinsic IRF5 Regulates T Cell Signaling, Migration, and Differentiation and Promotes Intestinal Inflammation Cell. Rep. 2020 31 107820 10.1016/j.celrep.2020.107820 32610123 PMC7409536 Yan, J. et al. T Cell-Intrinsic IRF5 Regulates T Cell Signaling, Migration, and Differentiation and Promotes Intestinal Inflammation. Cell. Rep. 31 , 107820 (2020). 32610123 10.1016/j.celrep.2020.107820 PMC7409536

669. Kayama H Heme ameliorates dextran sodium sulfate-induced colitis through providing intestinal macrophages with noninflammatory profiles Proc. Natl Acad. Sci. USA 2018 115 8418 8423 10.1073/pnas.1808426115 30061415 PMC6099887 Kayama, H. et al. Heme ameliorates dextran sodium sulfate-induced colitis through providing intestinal macrophages with noninflammatory profiles. Proc. Natl Acad. Sci. USA 115 , 8418–8423 (2018). 30061415 10.1073/pnas.1808426115 PMC6099887

670. Ryzhakov G Almuttaqi H Corbin AL Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation Nat. Commun. 2021 12 6702 10.1038/s41467-021-27038-5 34795257 PMC8602323 Ryzhakov, G., Almuttaqi, H. & Corbin, A. L. Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation. Nat. Commun. 12 , 6702 (2021). 34795257 10.1038/s41467-021-27038-5 PMC8602323

671. Lu J Thalidomide Attenuates Colitis and Is Associated with the Suppression of M1 Macrophage Polarization by Targeting the Transcription Factor IRF5 Dig. Dis. Sci. 2021 66 3803 3812 10.1007/s10620-021-07067-2 34085173 Lu, J. et al. Thalidomide Attenuates Colitis and Is Associated with the Suppression of M1 Macrophage Polarization by Targeting the Transcription Factor IRF5. Dig. Dis. Sci. 66 , 3803–3812 (2021). 34085173 10.1007/s10620-021-07067-2

672. Lin Z microRNA-144/451 decreases dendritic cell bioactivity via targeting interferon-regulatory factor 5 to limit DSS-induced colitis Front. Immunol. 2022 13 928593 10.3389/fimmu.2022.928593 35967345 PMC9372465 Lin, Z. et al. microRNA-144/451 decreases dendritic cell bioactivity via targeting interferon-regulatory factor 5 to limit DSS-induced colitis. Front. Immunol. 13 , 928593 (2022). 35967345 10.3389/fimmu.2022.928593 PMC9372465

673. Zhang R T follicular helper cells restricted by IRF8 contribute to T cell-mediated inflammation J. Autoimmun. 2019 96 113 122 10.1016/j.jaut.2018.09.001 30241692 PMC6310655 Zhang, R. et al. T follicular helper cells restricted by IRF8 contribute to T cell-mediated inflammation. J. Autoimmun. 96 , 113–122 (2019). 30241692 10.1016/j.jaut.2018.09.001 PMC6310655

674. Veiga N Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target J. Control. Release 2019 313 33 41 10.1016/j.jconrel.2019.10.001 31634546 Veiga, N. et al. Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target. J. Control. Release 313 , 33–41 (2019). 31634546 10.1016/j.jconrel.2019.10.001

675. Landgraf-Rauf K IRF-1 SNPs influence the risk for childhood allergic asthma: A critical role for pro-inflammatory immune regulation Pediatr. Allergy Immunol. 2018 29 34 41 10.1111/pai.12821 29047170 Landgraf-Rauf, K. et al. IRF-1 SNPs influence the risk for childhood allergic asthma: A critical role for pro-inflammatory immune regulation. Pediatr. Allergy Immunol. 29 , 34–41 (2018). 29047170 10.1111/pai.12821

676. Kumar A Genetic association of key Th1/Th2 pathway candidate genes, IRF2, IL6, IFNGR2, STAT4 and IL4RA, with atopic asthma in the Indian population J. Hum. Genet. 2015 60 443 448 10.1038/jhg.2015.45 25994869 Kumar, A. et al. Genetic association of key Th1/Th2 pathway candidate genes, IRF2, IL6, IFNGR2, STAT4 and IL4RA, with atopic asthma in the Indian population. J. Hum. Genet. 60 , 443–448 (2015). 25994869 10.1038/jhg.2015.45

677. Ozasa K Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor Front. Immunol. 2019 10 2212 10.3389/fimmu.2019.02212 31616416 PMC6775192 Ozasa, K. et al. Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor. Front. Immunol. 10 , 2212 (2019). 31616416 10.3389/fimmu.2019.02212 PMC6775192

678. Marichal T Interferon response factor 3 is essential for house dust mite-induced airway allergy J. Allergy Clin. Immunol. 2010 126 836 844.e813 10.1016/j.jaci.2010.06.009 20673978 Marichal, T. et al. Interferon response factor 3 is essential for house dust mite-induced airway allergy. J. Allergy Clin. Immunol. 126 , 836–844.e813 (2010). 20673978 10.1016/j.jaci.2010.06.009

679. He J IRF-7 Is a Critical Regulator of Type 2 Innate Lymphoid Cells in Allergic Airway Inflammation Cell. Rep. 2019 29 2718 2730.e2716 10.1016/j.celrep.2019.10.077 31775040 He, J. et al. IRF-7 Is a Critical Regulator of Type 2 Innate Lymphoid Cells in Allergic Airway Inflammation. Cell. Rep. 29 , 2718–2730.e2716 (2019). 31775040 10.1016/j.celrep.2019.10.077

680. Park SJ Tilianin attenuates HDM-induced allergic asthma by suppressing Th2-immune responses via downregulation of IRF4 in dendritic cells Phytomedicine 2021 80 153392 10.1016/j.phymed.2020.153392 33113503 Park, S. J. et al. Tilianin attenuates HDM-induced allergic asthma by suppressing Th2-immune responses via downregulation of IRF4 in dendritic cells. Phytomedicine 80 , 153392 (2021). 33113503 10.1016/j.phymed.2020.153392

681. Xia L lnc-BAZ2B promotes M2 macrophage activation and inflammation in children with asthma through stabilizing BAZ2B pre-mRNA J. Allergy Clin. Immunol. 2021 147 921 932.e929 10.1016/j.jaci.2020.06.034 32712329 Xia, L. et al. lnc-BAZ2B promotes M2 macrophage activation and inflammation in children with asthma through stabilizing BAZ2B pre-mRNA. J. Allergy Clin. Immunol. 147 , 921–932.e929 (2021). 32712329 10.1016/j.jaci.2020.06.034

682. Corrigendum. J. Allergy. Clin. Immunol . 149 , 1134-1135, (2022). 10.1016/j.jaci.2021.12.757 35249638

683. Hwang SS RHS6 coordinately regulates the Th2 cytokine genes by recruiting GATA3, SATB1, and IRF4 Allergy 2017 72 772 782 10.1111/all.13078 27878828 Hwang, S. S. et al. RHS6 coordinately regulates the Th2 cytokine genes by recruiting GATA3, SATB1, and IRF4. Allergy 72 , 772–782 (2017). 27878828 10.1111/all.13078

684. Kim SB Anthriscus sylvestris root extract reduces allergic lung inflammation by regulating interferon regulatory factor 4-mediated Th2 cell activation J. Ethnopharmacol. 2019 232 165 175 10.1016/j.jep.2018.12.016 30552991 Kim, S. B. et al. Anthriscus sylvestris root extract reduces allergic lung inflammation by regulating interferon regulatory factor 4-mediated Th2 cell activation. J. Ethnopharmacol. 232 , 165–175 (2019). 30552991 10.1016/j.jep.2018.12.016

685. Staudt V Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells Immunity 2010 33 192 202 10.1016/j.immuni.2010.07.014 20674401 Staudt, V. et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 33 , 192–202 (2010). 20674401 10.1016/j.immuni.2010.07.014

686. Oriss, T. B. et al. IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice. JCI. Insight . 2 , e91019 (2017). 10.1172/jci.insight.91019 PMC5436536 28515358

687. Swindell WR Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites Clin. Transl. Med. 2015 4 13 10.1186/s40169-015-0054-5 25883770 PMC4392043 Swindell, W. R. et al. Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites. Clin. Transl. Med. 4 , 13 (2015). 25883770 10.1186/s40169-015-0054-5 PMC4392043

688. Kuai L Celastrol Attenuates Psoriasiform Inflammation by Targeting the IRF1/GSTM3 Axis J. Invest. Dermatol. 2022 142 2281 2285.e2211 10.1016/j.jid.2022.01.018 35134440 Kuai, L. et al. Celastrol Attenuates Psoriasiform Inflammation by Targeting the IRF1/GSTM3 Axis. J. Invest. Dermatol. 142 , 2281–2285.e2211 (2022). 35134440 10.1016/j.jid.2022.01.018

689. Lin SH Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation J. Dermatol. Sci. 2018 91 276 284 10.1016/j.jdermsci.2018.05.009 29914850 Lin, S. H. et al. Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation. J. Dermatol. Sci. 91 , 276–284 (2018). 29914850 10.1016/j.jdermsci.2018.05.009

690. Parkinson J Variation at the IRF2 gene and susceptibility to psoriasis in chromosome 4q-linked families J. Invest. Dermatol. 2004 122 640 643 10.1046/j.0022-202X.2004.22135.x 15086546 Parkinson, J. et al. Variation at the IRF2 gene and susceptibility to psoriasis in chromosome 4q-linked families. J. Invest. Dermatol. 122 , 640–643 (2004). 15086546 10.1046/j.0022-202X.2004.22135.x

691. Foerster J Evaluation of the IRF-2 gene as a candidate for PSORS3 J. Invest. Dermatol. 2004 122 61 64 10.1046/j.0022-202X.2003.22104.x 14962090 Foerster, J. et al. Evaluation of the IRF-2 gene as a candidate for PSORS3. J. Invest. Dermatol. 122 , 61–64 (2004). 14962090 10.1046/j.0022-202X.2003.22104.x

692. van der Fits L In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered J. Invest. Dermatol. 2004 122 51 60 10.1046/j.0022-202X.2003.22113.x 14962089 van der Fits, L. et al. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J. Invest. Dermatol. 122 , 51–60 (2004). 14962089 10.1046/j.0022-202X.2003.22113.x

693. Kawaguchi M IRF-2 haploinsufficiency causes enhanced imiquimod-induced psoriasis-like skin inflammation J. Dermatol. Sci. 2018 90 35 45 10.1016/j.jdermsci.2017.12.014 29305258 Kawaguchi, M. et al. IRF-2 haploinsufficiency causes enhanced imiquimod-induced psoriasis-like skin inflammation. J. Dermatol. Sci. 90 , 35–45 (2018). 29305258 10.1016/j.jdermsci.2017.12.014

694. Xiaohong L Activation of the STING-IRF3 pathway involved in psoriasis with diabetes mellitus J. Cell. Mol. Med. 2022 26 2139 2151 10.1111/jcmm.17236 35174638 PMC8995451 Xiaohong, L. et al. Activation of the STING-IRF3 pathway involved in psoriasis with diabetes mellitus. J. Cell. Mol. Med. 26 , 2139–2151 (2022). 35174638 10.1111/jcmm.17236 PMC8995451

695. Ni A Expression of IRF-4 and IBP in skin lesions of patients with psoriasis vulgaris J. Huazhong. Univ. Sci. Technol. Med. Sci. 2012 32 287 290 10.1007/s11596-012-0050-6 22528235 Ni, A. et al. Expression of IRF-4 and IBP in skin lesions of patients with psoriasis vulgaris. J. Huazhong. Univ. Sci. Technol. Med. Sci. 32 , 287–290 (2012). 10.1007/s11596-012-0050-6 22528235

696. Cai Y Differential Roles of the mTOR-STAT3 Signaling in Dermal γδ T Cell Effector Function in Skin Inflammation Cell. Rep. 2019 27 3034 3048.e3035 10.1016/j.celrep.2019.05.019 31167146 PMC6617524 Cai, Y. et al. Differential Roles of the mTOR-STAT3 Signaling in Dermal γδ T Cell Effector Function in Skin Inflammation. Cell. Rep. 27 , 3034–3048.e3035 (2019). 31167146 10.1016/j.celrep.2019.05.019 PMC6617524

697. Nakao, M. & Miyagaki, T. Exacerbated Imiquimod-Induced Psoriasis-Like Skin Inflammation in IRF5-Deficient Mice. Int. J. Mol. Sci . 21 , 3681 (2020). 10.3390/ijms21103681 PMC7279463 32456211

698. Raposo RA Antiviral gene expression in psoriasis J. Eur. Acad. Dermatol. Venereol. 2015 29 1951 1957 10.1111/jdv.13091 25809693 PMC4580491 Raposo, R. A. et al. Antiviral gene expression in psoriasis. J. Eur. Acad. Dermatol. Venereol. 29 , 1951–1957 (2015). 25809693 10.1111/jdv.13091 PMC4580491

699. Jin L A BET inhibitor, NHWD-870, can downregulate dendritic cells maturation via the IRF7-mediated signaling pathway to ameliorate imiquimod-induced psoriasis-like murine skin inflammation Eur. J. Pharmacol. 2024 968 176382 10.1016/j.ejphar.2024.176382 38311277 Jin, L. et al. A BET inhibitor, NHWD-870, can downregulate dendritic cells maturation via the IRF7-mediated signaling pathway to ameliorate imiquimod-induced psoriasis-like murine skin inflammation. Eur. J. Pharmacol. 968 , 176382 (2024). 38311277 10.1016/j.ejphar.2024.176382

700. Zhou B Zdhhc2 Is Essential for Plasmacytoid Dendritic Cells Mediated Inflammatory Response in Psoriasis Front. Immunol. 2020 11 607442 10.3389/fimmu.2020.607442 33488612 PMC7819861 Zhou, B. et al. Zdhhc2 Is Essential for Plasmacytoid Dendritic Cells Mediated Inflammatory Response in Psoriasis. Front. Immunol. 11 , 607442 (2020). 33488612 10.3389/fimmu.2020.607442 PMC7819861

701. Morell M SIDT1 plays a key role in type I IFN responses to nucleic acids in plasmacytoid dendritic cells and mediates the pathogenesis of an imiquimod-induced psoriasis model EBioMedicine 2022 76 103808 10.1016/j.ebiom.2021.103808 35065421 PMC8784643 Morell, M. et al. SIDT1 plays a key role in type I IFN responses to nucleic acids in plasmacytoid dendritic cells and mediates the pathogenesis of an imiquimod-induced psoriasis model. EBioMedicine 76 , 103808 (2022). 35065421 10.1016/j.ebiom.2021.103808 PMC8784643

702. Su W Exploring the Pathogenesis of Psoriasis Complicated With Atherosclerosis via Microarray Data Analysis Front. Immunol. 2021 12 667690 10.3389/fimmu.2021.667690 34122426 PMC8190392 Su, W. et al. Exploring the Pathogenesis of Psoriasis Complicated With Atherosclerosis via Microarray Data Analysis. Front. Immunol. 12 , 667690 (2021). 34122426 10.3389/fimmu.2021.667690 PMC8190392

703. Zolotarenko A Integrated computational approach to the analysis of RNA-seq data reveals new transcriptional regulators of psoriasis Exp. Mol. Med. 2016 48 e268 10.1038/emm.2016.97 27811935 PMC5133374 Zolotarenko, A. et al. Integrated computational approach to the analysis of RNA-seq data reveals new transcriptional regulators of psoriasis. Exp. Mol. Med. 48 , e268 (2016). 27811935 10.1038/emm.2016.97 PMC5133374

704. Gao PS Genetic variants in interferon regulatory factor 2 (IRF2) are associated with atopic dermatitis and eczema herpeticum J. Invest. Dermatol. 2012 132 650 657 10.1038/jid.2011.374 22113474 PMC3278591 Gao, P. S. et al. Genetic variants in interferon regulatory factor 2 (IRF2) are associated with atopic dermatitis and eczema herpeticum. J. Invest. Dermatol. 132 , 650–657 (2012). 22113474 10.1038/jid.2011.374 PMC3278591

705. Li C Lu Y Han X Identification of Effective Diagnostic Biomarkers and Immune Cell Infiltration in Atopic Dermatitis by Comprehensive Bioinformatics Analysis Front. Mol. Biosci. 2022 9 917077 10.3389/fmolb.2022.917077 35911963 PMC9330059 Li, C., Lu, Y. & Han, X. Identification of Effective Diagnostic Biomarkers and Immune Cell Infiltration in Atopic Dermatitis by Comprehensive Bioinformatics Analysis. Front. Mol. Biosci. 9 , 917077 (2022). 35911963 10.3389/fmolb.2022.917077 PMC9330059

706. Leung YT Interferon regulatory factor 1 and histone H4 acetylation in systemic lupus erythematosus Epigenetics 2015 10 191 199 10.1080/15592294.2015.1009764 25611806 PMC4622916 Leung, Y. T. et al. Interferon regulatory factor 1 and histone H4 acetylation in systemic lupus erythematosus. Epigenetics 10 , 191–199 (2015). 25611806 10.1080/15592294.2015.1009764 PMC4622916

707. Corrigendum. Epigenetics 10 , 891, (2015).

708. Zhang Z Interferon regulatory factor 1 marks activated genes and can induce target gene expression in systemic lupus erythematosus Arthritis Rheumatol. 2015 67 785 796 10.1002/art.38964 25418955 PMC4342285 Zhang, Z. et al. Interferon regulatory factor 1 marks activated genes and can induce target gene expression in systemic lupus erythematosus. Arthritis Rheumatol. 67 , 785–796 (2015). 25418955 10.1002/art.38964 PMC4342285

709. Misidentified Band in Figure in the Article by Zhang et al (Arthritis Rheumatol, March 2015). Arthritis. Rheumatol . 67 , 2481, (2015). 10.1002/art.39308 26309053

710. Liu J Berthier CC Kahlenberg JM Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1 Arthritis Rheumatol. 2017 69 1840 1849 10.1002/art.40166 28564495 PMC5575977 Liu, J., Berthier, C. C. & Kahlenberg, J. M. Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1. Arthritis Rheumatol. 69 , 1840–1849 (2017). 28564495 10.1002/art.40166 PMC5575977

711. Chen J HDAC1 potentiates CD4 + T cell activation by inhibiting miR-124 and promoting IRF1 in systemic lupus erythematosus Cell. Immunol. 2021 362 104284 10.1016/j.cellimm.2021.104284 33550188 Chen, J. et al. HDAC1 potentiates CD4 + T cell activation by inhibiting miR-124 and promoting IRF1 in systemic lupus erythematosus. Cell. Immunol. 362 , 104284 (2021). 33550188 10.1016/j.cellimm.2021.104284

712. Han X MicroRNA-130b Ameliorates Murine Lupus Nephritis Through Targeting the Type I Interferon Pathway on Renal Mesangial Cells Arthritis Rheumatol. 2016 68 2232 2243 10.1002/art.39725 27111096 Han, X. et al. MicroRNA-130b Ameliorates Murine Lupus Nephritis Through Targeting the Type I Interferon Pathway on Renal Mesangial Cells. Arthritis Rheumatol. 68 , 2232–2243 (2016). 27111096 10.1002/art.39725

713. Zhang F Independent Replication on Genome-Wide Association Study Signals Identifies IRF3 as a Novel Locus for Systemic Lupus Erythematosus Front. Genet. 2020 11 600 10.3389/fgene.2020.00600 32719713 PMC7348047 Zhang, F. et al. Independent Replication on Genome-Wide Association Study Signals Identifies IRF3 as a Novel Locus for Systemic Lupus Erythematosus. Front. Genet. 11 , 600 (2020). 32719713 10.3389/fgene.2020.00600 PMC7348047

714. Xu, Z. Q. et al. CircELK4 Contributes to Lupus Nephritis by Acting as a miR-27b-3p Sponge to Regulate STING/IRF3/IFN-I Signaling. 44 , 2106-2119, (2021). 10.1007/s10753-021-01487-y 34091806

715. Yoo EJ Macrophage transcription factor TonEBP promotes systemic lupus erythematosus and kidney injury via damage-induced signaling pathways Kidney Int. 2023 104 163 180 10.1016/j.kint.2023.03.030 37088425 Yoo, E. J. et al. Macrophage transcription factor TonEBP promotes systemic lupus erythematosus and kidney injury via damage-induced signaling pathways. Kidney Int. 104 , 163–180 (2023). 37088425 10.1016/j.kint.2023.03.030

716. Zheng X AKT2 reduces IFNβ1 production to modulate antiviral responses and systemic lupus erythematosus Embo. J. 2022 41 e108016 10.15252/embj.2021108016 35191555 PMC8922272 Zheng, X. et al. AKT2 reduces IFNβ1 production to modulate antiviral responses and systemic lupus erythematosus. Embo. J. 41 , e108016 (2022). 35191555 10.15252/embj.2021108016 PMC8922272

717. Faridi MH CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus J. Clin. Invest. 2017 127 1271 1283 10.1172/JCI88442 28263189 PMC5373862 Faridi, M. H. et al. CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. J. Clin. Invest. 127 , 1271–1283 (2017). 28263189 10.1172/JCI88442 PMC5373862

718. Yao M Identification of Molecular Markers Associated With the Pathophysiology and Treatment of Lupus Nephritis Based on Integrated Transcriptome Analysis Front. Genet. 2020 11 583629 10.3389/fgene.2020.583629 33384713 PMC7770169 Yao, M. et al. Identification of Molecular Markers Associated With the Pathophysiology and Treatment of Lupus Nephritis Based on Integrated Transcriptome Analysis. Front. Genet. 11 , 583629 (2020). 33384713 10.3389/fgene.2020.583629 PMC7770169

719. Luque A Noncanonical immunomodulatory activity of complement regulator C4BP(β-) limits the development of lupus nephritis Kidney Int. 2020 97 551 566 10.1016/j.kint.2019.10.016 31982108 Luque, A. et al. Noncanonical immunomodulatory activity of complement regulator C4BP(β-) limits the development of lupus nephritis. Kidney Int. 97 , 551–566 (2020). 31982108 10.1016/j.kint.2019.10.016

720. Coit P Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role for genetic factors in the lupus-associated DNA methylation signature Ann. Rheum. Dis. 2022 81 1428 1437 10.1136/annrheumdis-2022-222656 35710306 PMC10259175 Coit, P. et al. Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role for genetic factors in the lupus-associated DNA methylation signature. Ann. Rheum. Dis. 81 , 1428–1437 (2022). 35710306 10.1136/annrheumdis-2022-222656 PMC10259175

721. Miyagawa F Tagaya Y Essential Requirement for IFN Regulatory Factor 7 in Autoantibody Production but Not Development of Nephritis in Murine Lupus J. Immunol. 2016 197 2167 2176 10.4049/jimmunol.1502445 27527596 Miyagawa, F. & Tagaya, Y. Essential Requirement for IFN Regulatory Factor 7 in Autoantibody Production but Not Development of Nephritis in Murine Lupus. J. Immunol. 197 , 2167–2176 (2016). 27527596 10.4049/jimmunol.1502445

722. Chandrasekaran U Regulation of Effector Treg Cells in Murine Lupus Arthritis Rheumatol. 2016 68 1454 1466 10.1002/art.39599 26816213 PMC5825185 Chandrasekaran, U. et al. Regulation of Effector Treg Cells in Murine Lupus. Arthritis Rheumatol. 68 , 1454–1466 (2016). 26816213 10.1002/art.39599 PMC5825185

723. Lech M IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production J. Am. Soc. Nephrol. 2011 22 1443 1452 10.1681/ASN.2010121260 21742731 PMC3148699 Lech, M. et al. IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production. J. Am. Soc. Nephrol. 22 , 1443–1452 (2011). 21742731 10.1681/ASN.2010121260 PMC3148699

724. Graham RR A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus Nat. Genet. 2006 38 550 555 10.1038/ng1782 16642019 Graham, R. R. et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 38 , 550–555 (2006). 16642019 10.1038/ng1782

725. Graham RR Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus Proc. Natl Acad. Sci. Usa. 2007 104 6758 6763 10.1073/pnas.0701266104 17412832 PMC1847749 Graham, R. R. et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl Acad. Sci. Usa. 104 , 6758–6763 (2007). 17412832 10.1073/pnas.0701266104 PMC1847749

726. Barnes BJ Genetic Versus Non-genetic Drivers of SLE: Implications of IRF5 Dysregulation in Both Roads Leading to SLE Curr. Rheumatol. Rep. 2019 21 2 10.1007/s11926-019-0803-3 30645688 PMC11977172 Barnes, B. J. Genetic Versus Non-genetic Drivers of SLE: Implications of IRF5 Dysregulation in Both Roads Leading to SLE. Curr. Rheumatol. Rep. 21 , 2 (2019). 30645688 10.1007/s11926-019-0803-3 PMC11977172

727. Hou G Integrative Functional Genomics Identifies Systemic Lupus Erythematosus Causal Genetic Variant in the IRF5 Risk Locus Arthritis Rheumatol. 2023 75 574 585 10.1002/art.42390 36245280 Hou, G. et al. Integrative Functional Genomics Identifies Systemic Lupus Erythematosus Causal Genetic Variant in the IRF5 Risk Locus. Arthritis Rheumatol. 75 , 574–585 (2023). 36245280 10.1002/art.42390

728. Li, D. et al. IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE. JCI. Insight . 5 , e124020 (2020). 10.1172/jci.insight.124020 PMC7098722 31877114

729. De S B Cell-Intrinsic Role for IRF5 in TLR9/BCR-Induced Human B Cell Activation, Proliferation, and Plasmablast Differentiation Front. Immunol. 2017 8 1938 10.3389/fimmu.2017.01938 29367853 PMC5768180 De, S. et al. B Cell-Intrinsic Role for IRF5 in TLR9/BCR-Induced Human B Cell Activation, Proliferation, and Plasmablast Differentiation. Front. Immunol. 8 , 1938 (2017). 29367853 10.3389/fimmu.2017.01938 PMC5768180

730. Pellerin, A. et al. Monoallelic IRF5 deficiency in B cells prevents murine lupus. JCI. Insight . 6 , (2021). 10.1172/jci.insight.141395 PMC8410043 34197340

731. Ban T Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease Nat. Commun. 2021 12 4379 10.1038/s41467-021-24609-4 34282144 PMC8290003 Ban, T. et al. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease. Nat. Commun. 12 , 4379 (2021). 34282144 10.1038/s41467-021-24609-4 PMC8290003

732. Song S Inhibition of IRF5 hyperactivation protects from lupus onset and severity J. Clin. Invest. 2020 130 6700 6717 10.1172/JCI120288 32897883 PMC7685739 Song, S. et al. Inhibition of IRF5 hyperactivation protects from lupus onset and severity. J. Clin. Invest. 130 , 6700–6717 (2020). 32897883 10.1172/JCI120288 PMC7685739

733. Zhou T Zhu X Ye Z Wang YF Lupus enhancer risk variant causes dysregulation of IRF8 through cooperative lncRNA and DNA methylation machinery Nat. Commun. 2022 13 1855 10.1038/s41467-022-29514-y 35388006 PMC8987079 Zhou, T., Zhu, X., Ye, Z. & Wang, Y. F. Lupus enhancer risk variant causes dysregulation of IRF8 through cooperative lncRNA and DNA methylation machinery. Nat. Commun. 13 , 1855 (2022). 35388006 10.1038/s41467-022-29514-y PMC8987079

734. Ji J Myeloid-derived suppressor cells contribute to systemic lupus erythaematosus by regulating differentiation of Th17 cells and Tregs Clin. Sci. (Lond.). 2016 130 1453 1467 10.1042/CS20160311 27231253 Ji, J. et al. Myeloid-derived suppressor cells contribute to systemic lupus erythaematosus by regulating differentiation of Th17 cells and Tregs. Clin. Sci. (Lond.). 130 , 1453–1467 (2016). 27231253 10.1042/CS20160311

735. Smith S MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE J. Autoimmun. 2017 79 105 111 10.1016/j.jaut.2017.03.003 28318807 Smith, S. et al. MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. J. Autoimmun. 79 , 105–111 (2017). 28318807 10.1016/j.jaut.2017.03.003

736. Deng Y Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses EBioMedicine 2021 70 103477 10.1016/j.ebiom.2021.103477 34284174 PMC8318865 Deng, Y. et al. Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses. EBioMedicine 70 , 103477 (2021). 34284174 10.1016/j.ebiom.2021.103477 PMC8318865

737. Annibali V Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients J. Neuroimmunol. 2018 324 165 171 10.1016/j.jneuroim.2018.09.005 30270021 Annibali, V. et al. Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. J. Neuroimmunol. 324 , 165–171 (2018). 30270021 10.1016/j.jneuroim.2018.09.005

738. Kortam MA MAGI2-AS3 and miR-374b-5p as Putative Regulators of Multiple Sclerosis via Modulating the PTEN/AKT/IRF-3/IFN-β Axis: New Clinical Insights Acs. Chem. Neurosci. 2023 14 1107 1118 10.1021/acschemneuro.2c00653 36878000 Kortam, M. A. et al. MAGI2-AS3 and miR-374b-5p as Putative Regulators of Multiple Sclerosis via Modulating the PTEN/AKT/IRF-3/IFN-β Axis: New Clinical Insights. Acs. Chem. Neurosci. 14 , 1107–1118 (2023). 36878000 10.1021/acschemneuro.2c00653

739. Khaw YM Anwar S Estrogen receptor alpha signaling in dendritic cells modulates autoimmune disease phenotype in mice Embo. Rep. 2023 24 e54228 10.15252/embr.202154228 36633157 PMC9986829 Khaw, Y. M. & Anwar, S. Estrogen receptor alpha signaling in dendritic cells modulates autoimmune disease phenotype in mice. Embo. Rep. 24 , e54228 (2023). 36633157 10.15252/embr.202154228 PMC9986829

740. Sha Y Markovic-Plese S Activated IL-1RI Signaling Pathway Induces Th17 Cell Differentiation via Interferon Regulatory Factor 4 Signaling in Patients with Relapsing-Remitting Multiple Sclerosis Front. Immunol. 2016 7 543 10.3389/fimmu.2016.00543 27965670 PMC5126112 Sha, Y. & Markovic-Plese, S. Activated IL-1RI Signaling Pathway Induces Th17 Cell Differentiation via Interferon Regulatory Factor 4 Signaling in Patients with Relapsing-Remitting Multiple Sclerosis. Front. Immunol. 7 , 543 (2016). 27965670 10.3389/fimmu.2016.00543 PMC5126112

741. Zhao M Sun D Guan Y Wang Z Disulfiram and Diphenhydramine Hydrochloride Upregulate miR-30a to Suppress IL-17-Associated Autoimmune Inflammation J. Neurosci. 2016 36 9253 9266 10.1523/JNEUROSCI.4587-15.2016 27581464 PMC6601909 Zhao, M., Sun, D., Guan, Y. & Wang, Z. Disulfiram and Diphenhydramine Hydrochloride Upregulate miR-30a to Suppress IL-17-Associated Autoimmune Inflammation. J. Neurosci. 36 , 9253–9266 (2016). 27581464 10.1523/JNEUROSCI.4587-15.2016 PMC6601909

742. Kiselev I Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability Mult. Scler. Relat. Disord. 2019 29 130 136 10.1016/j.msard.2019.01.033 30711878 Kiselev, I. et al. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability. Mult. Scler. Relat. Disord. 29 , 130–136 (2019). 30711878 10.1016/j.msard.2019.01.033

743. Kowalec K Wright GEB Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis Nat. Genet. 2018 50 1081 1085 10.1038/s41588-018-0168-y 30013178 PMC6513312 Kowalec, K. & Wright, G. E. B. Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis. Nat. Genet. 50 , 1081–1085 (2018). 30013178 10.1038/s41588-018-0168-y PMC6513312

744. Hoppmann N New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis Brain 2015 138 902 917 10.1093/brain/awu408 25665584 Hoppmann, N. et al. New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis. Brain 138 , 902–917 (2015). 25665584 10.1093/brain/awu408

745. Kotelnikova E MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis Proc. Natl Acad. Sci. USA 2019 116 9671 9676 10.1073/pnas.1818347116 31004050 PMC6510997 Kotelnikova, E. et al. MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis. Proc. Natl Acad. Sci. USA 116 , 9671–9676 (2019). 31004050 10.1073/pnas.1818347116 PMC6510997

746. Sellebjerg F Prediction of response to interferon therapy in multiple sclerosis Acta Neurol. Scand. 2014 130 268 275 10.1111/ane.12269 24943672 Sellebjerg, F. et al. Prediction of response to interferon therapy in multiple sclerosis. Acta Neurol. Scand. 130 , 268–275 (2014). 24943672 10.1111/ane.12269

747. Yoshida Y The transcription factor IRF8 activates integrin-mediated TGF-β signaling and promotes neuroinflammation Immunity 2014 40 187 198 10.1016/j.immuni.2013.11.022 24485804 PMC4105266 Yoshida, Y. et al. The transcription factor IRF8 activates integrin-mediated TGF-β signaling and promotes neuroinflammation. Immunity 40 , 187–198 (2014). 24485804 10.1016/j.immuni.2013.11.022 PMC4105266

748. Wei Y Aryl hydrocarbon receptor activation drives polymorphonuclear myeloid-derived suppressor cell response and efficiently attenuates experimental Sjögren’s syndrome Cell. Mol. Immunol. 2022 19 1361 1372 10.1038/s41423-022-00943-5 36369368 PMC9709038 Wei, Y. et al. Aryl hydrocarbon receptor activation drives polymorphonuclear myeloid-derived suppressor cell response and efficiently attenuates experimental Sjögren’s syndrome. Cell. Mol. Immunol. 19 , 1361–1372 (2022). 36369368 10.1038/s41423-022-00943-5 PMC9709038

749. Xiao F Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjögren’s syndrome Signal. Transduct. Target Ther. 2022 7 274 10.1038/s41392-022-01103-x 36031634 PMC9420730 Xiao, F. et al. Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjögren’s syndrome. Signal. Transduct. Target Ther. 7 , 274 (2022). 36031634 10.1038/s41392-022-01103-x PMC9420730

750. Nordmark G Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren’s syndrome Genes. Immun. 2009 10 68 76 10.1038/gene.2008.94 19092842 Nordmark, G. et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren’s syndrome. Genes. Immun. 10 , 68–76 (2009). 19092842 10.1038/gene.2008.94

751. Ortíz-Fernández L Martín J Alarcón-Riquelme ME A Summary on the Genetics of Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, and Sjögren’s Syndrome Clin. Rev. Allergy Immunol. 2023 64 392 411 10.1007/s12016-022-08951-z 35749015 Ortíz-Fernández, L., Martín, J. & Alarcón-Riquelme, M. E. A Summary on the Genetics of Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, and Sjögren’s Syndrome. Clin. Rev. Allergy Immunol. 64 , 392–411 (2023). 35749015 10.1007/s12016-022-08951-z

752. Bonelli M IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes: JAKinibs suppress the interferon response in RA-FLSs Exp. Mol. Med. 2019 51 1 11 10.1038/s12276-019-0267-6 31285419 PMC6802656 Bonelli, M. et al. IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes: JAKinibs suppress the interferon response in RA-FLSs. Exp. Mol. Med. 51 , 1–11 (2019). 31285419 10.1038/s12276-019-0267-6 PMC6802656

753. Du Y Regulation of type I interferon signature by VGLL3 in the fibroblast-like synoviocytes of rheumatoid arthritis patients via targeting the Hippo pathway Arthritis Res. Ther. 2022 24 188 10.1186/s13075-022-02880-0 35941675 PMC9358906 Du, Y. et al. Regulation of type I interferon signature by VGLL3 in the fibroblast-like synoviocytes of rheumatoid arthritis patients via targeting the Hippo pathway. Arthritis Res. Ther. 24 , 188 (2022). 35941675 10.1186/s13075-022-02880-0 PMC9358906

754. van Hamburg JP Tas SW Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis J. Autoimmun. 2018 87 69 81 10.1016/j.jaut.2017.12.006 29254845 van Hamburg, J. P. & Tas, S. W. Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis. J. Autoimmun. 87 , 69–81 (2018). 29254845 10.1016/j.jaut.2017.12.006

755. López-Isac E Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies Arthritis Rheumatol. 2016 68 2338 2344 10.1002/art.39730 27111665 PMC5530728 López-Isac, E. et al. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. Arthritis Rheumatol. 68 , 2338–2344 (2016). 27111665 10.1002/art.39730 PMC5530728

756. Nakajima S Synovial Tissue Heterogeneity in Japanese Patients with Rheumatoid Arthritis Elucidated Using a Cell-Type Deconvolution Approach Arthritis Rheumatol. 2023 75 2130 2136 10.1002/art.42642 37390361 Nakajima, S. et al. Synovial Tissue Heterogeneity in Japanese Patients with Rheumatoid Arthritis Elucidated Using a Cell-Type Deconvolution Approach. Arthritis Rheumatol. 75 , 2130–2136 (2023). 37390361 10.1002/art.42642

757. Karami J Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review Gene 2019 702 8 16 10.1016/j.gene.2019.03.033 30904715 Karami, J. et al. Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review. Gene 702 , 8–16 (2019). 30904715 10.1016/j.gene.2019.03.033

758. Dawidowicz K The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotype Ann. Rheum. Dis. 2011 70 117 121 10.1136/ard.2010.129171 20980283 Dawidowicz, K. et al. The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotype. Ann. Rheum. Dis. 70 , 117–121 (2011). 20980283 10.1136/ard.2010.129171

759. Duffau P Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model Arthritis Rheumatol. 2015 67 3146 3157 10.1002/art.39321 26315890 PMC4661118 Duffau, P. et al. Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. Arthritis Rheumatol. 67 , 3146–3157 (2015). 26315890 10.1002/art.39321 PMC4661118

760. Cotter TG Rinella M Nonalcoholic Fatty Liver Disease 2020: The State of the Disease Gastroenterology 2020 158 1851 1864 10.1053/j.gastro.2020.01.052 32061595 Cotter, T. G. & Rinella, M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 158 , 1851–1864 (2020). 32061595 10.1053/j.gastro.2020.01.052

761. Patel SJ Liu N Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b Sci. Transl. Med. 2022 14 eabh3831 10.1126/scitranslmed.abh3831 35320000 PMC9162056 Patel, S. J. & Liu, N. Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b. Sci. Transl. Med. 14 , eabh3831 (2022). 35320000 10.1126/scitranslmed.abh3831 PMC9162056

762. Qiao JT Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease Metabolism 2018 81 13 24 10.1016/j.metabol.2017.09.010 29106945 Qiao, J. T. et al. Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease. Metabolism 81 , 13–24 (2018). 29106945 10.1016/j.metabol.2017.09.010

763. Iracheta-Vellve A Endoplasmic Reticulum Stress-induced Hepatocellular Death Pathways Mediate Liver Injury and Fibrosis via Stimulator of Interferon Genes J. Biol. Chem. 2016 291 26794 26805 10.1074/jbc.M116.736991 27810900 PMC5207187 Iracheta-Vellve, A. et al. Endoplasmic Reticulum Stress-induced Hepatocellular Death Pathways Mediate Liver Injury and Fibrosis via Stimulator of Interferon Genes. J. Biol. Chem. 291 , 26794–26805 (2016). 27810900 10.1074/jbc.M116.736991 PMC5207187

764. He J Hepatocyte nuclear factor 1A suppresses innate immune response by inducing degradation of TBK1 to inhibit steatohepatitis Genes. Dis. 2023 10 1596 1612 10.1016/j.gendis.2022.05.029 37397525 PMC10311033 He, J. et al. Hepatocyte nuclear factor 1A suppresses innate immune response by inducing degradation of TBK1 to inhibit steatohepatitis. Genes. Dis. 10 , 1596–1612 (2023). 37397525 10.1016/j.gendis.2022.05.029 PMC10311033

765. Tong J Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor γ in Mice Hepatology 2019 69 2471 2488 10.1002/hep.30559 30748020 Tong, J. et al. Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor γ in Mice. Hepatology 69 , 2471–2488 (2019). 30748020 10.1002/hep.30559

766. Li H GRP/GRPR enhances alcohol-associated liver injury via the IRF1-mediated Caspase-1 inflammasome and NOX2-dependent ROS pathway Hepatology 2023 79 392 408 37409771 10.1097/HEP.0000000000000531 Li, H. et al. GRP/GRPR enhances alcohol-associated liver injury via the IRF1-mediated Caspase-1 inflammasome and NOX2-dependent ROS pathway. Hepatology 79 , 392–408 (2023). 37409771 10.1097/HEP.0000000000000531

767. Liang S Murine macrophage autophagy protects against alcohol-induced liver injury by degrading interferon regulatory factor 1 (IRF1) and removing damaged mitochondria J. Biol. Chem. 2019 294 12359 12369 10.1074/jbc.RA119.007409 31235522 PMC6699832 Liang, S. et al. Murine macrophage autophagy protects against alcohol-induced liver injury by degrading interferon regulatory factor 1 (IRF1) and removing damaged mitochondria. J. Biol. Chem. 294 , 12359–12369 (2019). 31235522 10.1074/jbc.RA119.007409 PMC6699832

768. Petrasek J STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease Proc. Natl Acad. Sci. USA 2013 110 16544 16549 10.1073/pnas.1308331110 24052526 PMC3799324 Petrasek, J. et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc. Natl Acad. Sci. USA 110 , 16544–16549 (2013). 24052526 10.1073/pnas.1308331110 PMC3799324

769. Luther J Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation Proc. Natl Acad. Sci. USA 2020 117 11667 11673 10.1073/pnas.1911870117 32393626 PMC7261084 Luther, J. et al. Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation. Proc. Natl Acad. Sci. USA 117 , 11667–11673 (2020). 32393626 10.1073/pnas.1911870117 PMC7261084

770. Correction for Luther et al., Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation. Proc. Natl. Acad. Sci. USA . 117 , 16704, (2020). 10.1073/pnas.2010186117 PMC7368292 32631979

771. Du M Absence of Interferon Regulatory Factor 1 Protects Against Atherosclerosis in Apolipoprotein E-Deficient Mice Theranostics 2019 9 4688 4703 10.7150/thno.36862 31367250 PMC6643443 Du, M. et al. Absence of Interferon Regulatory Factor 1 Protects Against Atherosclerosis in Apolipoprotein E-Deficient Mice. Theranostics 9 , 4688–4703 (2019). 31367250 10.7150/thno.36862 PMC6643443

772. Shen Y IRF-1 contributes to the pathological phenotype of VSMCs during atherogenesis by increasing CCL19 transcription Aging (Albany NY) 2020 13 933 943 10.18632/aging.202204 33424012 PMC7835033 Shen, Y. et al. IRF-1 contributes to the pathological phenotype of VSMCs during atherogenesis by increasing CCL19 transcription. Aging (Albany NY) 13 , 933–943 (2020). 33424012 10.18632/aging.202204 PMC7835033

773. Fan X Non-canonical NF-κB contributes to endothelial pyroptosis and atherogenesis dependent on IRF-1 Transl. Res. 2023 255 1 13 10.1016/j.trsl.2022.11.001 36384204 Fan, X. et al. Non-canonical NF-κB contributes to endothelial pyroptosis and atherogenesis dependent on IRF-1. Transl. Res. 255 , 1–13 (2023). 36384204 10.1016/j.trsl.2022.11.001

774. Liu H Ablation of Interferon Regulatory Factor 3 Protects Against Atherosclerosis in Apolipoprotein E-Deficient Mice Hypertension 2017 69 510 520 10.1161/HYPERTENSIONAHA.116.08395 28115514 Liu, H. et al. Ablation of Interferon Regulatory Factor 3 Protects Against Atherosclerosis in Apolipoprotein E-Deficient Mice. Hypertension 69 , 510–520 (2017). 28115514 10.1161/HYPERTENSIONAHA.116.08395

775. Seneviratne AN Interferon Regulatory Factor 5 Controls Necrotic Core Formation in Atherosclerotic Lesions by Impairing Efferocytosis Circulation 2017 136 1140 1154 10.1161/CIRCULATIONAHA.117.027844 28698173 PMC5598917 Seneviratne, A. N. et al. Interferon Regulatory Factor 5 Controls Necrotic Core Formation in Atherosclerotic Lesions by Impairing Efferocytosis. Circulation 136 , 1140–1154 (2017). 28698173 10.1161/CIRCULATIONAHA.117.027844 PMC5598917

776. Edsfeldt A Swart M Singh P Dib L Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of rupture-prone atherosclerotic plaques Eur. Heart J. 2022 43 1864 1877 10.1093/eurheartj/ehab920 35567557 PMC9113304 Edsfeldt, A., Swart, M., Singh, P. & Dib, L. Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of rupture-prone atherosclerotic plaques. Eur. Heart J. 43 , 1864–1877 (2022). 35567557 10.1093/eurheartj/ehab920 PMC9113304

777. Leipner J Myeloid cell-specific Irf5 deficiency stabilizes atherosclerotic plaques in Apoe(-/-) mice Mol. Metab. 2021 53 101250 10.1016/j.molmet.2021.101250 33991749 PMC8178123 Leipner, J. et al. Myeloid cell-specific Irf5 deficiency stabilizes atherosclerotic plaques in Apoe(-/-) mice. Mol. Metab. 53 , 101250 (2021). 33991749 10.1016/j.molmet.2021.101250 PMC8178123

778. Tsiantoulas D B Cell-Activating Factor Neutralization Aggravates Atherosclerosis Circulation 2018 138 2263 2273 10.1161/CIRCULATIONAHA.117.032790 29858401 PMC6181204 Tsiantoulas, D. et al. B Cell-Activating Factor Neutralization Aggravates Atherosclerosis. Circulation 138 , 2263–2273 (2018). 29858401 10.1161/CIRCULATIONAHA.117.032790 PMC6181204

779. Senatus L RAGE impairs murine diabetic atherosclerosis regression and implicates IRF7 in macrophage inflammation and cholesterol metabolism Jci. Insight 2020 5 e137289 10.1172/jci.insight.137289 32641587 PMC7406264 Senatus, L. et al. RAGE impairs murine diabetic atherosclerosis regression and implicates IRF7 in macrophage inflammation and cholesterol metabolism. Jci. Insight 5 , e137289 (2020). 32641587 10.1172/jci.insight.137289 PMC7406264

780. Döring Y Hematopoietic interferon regulatory factor 8-deficiency accelerates atherosclerosis in mice Arterioscler. Thromb. Vasc. Biol. 2012 32 1613 1623 10.1161/ATVBAHA.111.236539 22556330 Döring, Y. et al. Hematopoietic interferon regulatory factor 8-deficiency accelerates atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 32 , 1613–1623 (2012). 22556330 10.1161/ATVBAHA.111.236539

781. Clément M Deletion of IRF8 (Interferon Regulatory Factor 8)-Dependent Dendritic Cells Abrogates Proatherogenic Adaptive Immunity Circ. Res. 2018 122 813 820 10.1161/CIRCRESAHA.118.312713 29436389 Clément, M. et al. Deletion of IRF8 (Interferon Regulatory Factor 8)-Dependent Dendritic Cells Abrogates Proatherogenic Adaptive Immunity. Circ. Res. 122 , 813–820 (2018). 29436389 10.1161/CIRCRESAHA.118.312713

782. Guo M Inhibition of IFN regulatory factor-1 down-regulate Th1 cell function in patients with acute coronary syndrome J. Clin. Immunol. 2010 30 241 252 10.1007/s10875-010-9367-8 20177960 Guo, M. et al. Inhibition of IFN regulatory factor-1 down-regulate Th1 cell function in patients with acute coronary syndrome. J. Clin. Immunol. 30 , 241–252 (2010). 20177960 10.1007/s10875-010-9367-8

783. Guo M IFN Regulatory Factor 1 Mediates Macrophage Pyroptosis Induced by Oxidized Low-Density Lipoprotein in Patients with Acute Coronary Syndrome Mediators. Inflamm. 2019 2019 2917128 10.1155/2019/2917128 31871426 PMC6913184 Guo, M. et al. IFN Regulatory Factor 1 Mediates Macrophage Pyroptosis Induced by Oxidized Low-Density Lipoprotein in Patients with Acute Coronary Syndrome. Mediators. Inflamm. 2019 , 2917128 (2019). 31871426 10.1155/2019/2917128 PMC6913184

784. Guo M IFN regulatory Factor-1 induced macrophage pyroptosis by modulating m6A modification of circ_0029589 in patients with acute coronary syndrome Int. Immunopharmacol. 2020 86 106800 10.1016/j.intimp.2020.106800 32674051 Guo, M. et al. IFN regulatory Factor-1 induced macrophage pyroptosis by modulating m6A modification of circ_0029589 in patients with acute coronary syndrome. Int. Immunopharmacol. 86 , 106800 (2020). 32674051 10.1016/j.intimp.2020.106800

785. Jiang W Chen G Pu J The transcription factor interferon regulatory factor-1 is an endogenous mediator of myocardial ischemia reperfusion injury Cell. Biol. Int. 2022 46 63 72 10.1002/cbin.11713 34658101 Jiang, W., Chen, G. & Pu, J. The transcription factor interferon regulatory factor-1 is an endogenous mediator of myocardial ischemia reperfusion injury. Cell. Biol. Int. 46 , 63–72 (2022). 34658101 10.1002/cbin.11713

786. Li, Y. et al . IRF2 contributes to myocardial infarction via regulation of GSDMD induced pyroptosis. Mol. Med. Rep . 25 , 40 (2022). 10.3892/mmr.2021.12556 PMC8674697 34878155

787. King KR IRF3 and type I interferons fuel a fatal response to myocardial infarction Nat. Med. 2017 23 1481 1487 10.1038/nm.4428 29106401 PMC6477926 King, K. R. et al. IRF3 and type I interferons fuel a fatal response to myocardial infarction. Nat. Med. 23 , 1481–1487 (2017). 29106401 10.1038/nm.4428 PMC6477926

788. Hu S The selective STING inhibitor H-151 preserves myocardial function and ameliorates cardiac fibrosis in murine myocardial infarction Int. Immunopharmacol. 2022 107 108658 10.1016/j.intimp.2022.108658 35278833 Hu, S. et al. The selective STING inhibitor H-151 preserves myocardial function and ameliorates cardiac fibrosis in murine myocardial infarction. Int. Immunopharmacol. 107 , 108658 (2022). 35278833 10.1016/j.intimp.2022.108658

789. Liu Z Increased sympathetic outflow induced by emotional stress aggravates myocardial ischemia-reperfusion injury via activation of TLR7/MyD88/IRF5 signaling pathway Inflamm. Res. 2023 72 901 913 10.1007/s00011-023-01708-0 36933018 Liu, Z. et al. Increased sympathetic outflow induced by emotional stress aggravates myocardial ischemia-reperfusion injury via activation of TLR7/MyD88/IRF5 signaling pathway. Inflamm. Res. 72 , 901–913 (2023). 36933018 10.1007/s00011-023-01708-0

790. Cui L Shexiang Tongxin Dropping Pill alleviates M1 macrophage polarization-induced inflammation and endothelial dysfunction to reduce coronary microvascular dysfunction via the Dectin-1/Syk/IRF5 pathway J. Ethnopharmacol. 2023 316 116742 10.1016/j.jep.2023.116742 37290736 Cui, L. et al. Shexiang Tongxin Dropping Pill alleviates M1 macrophage polarization-induced inflammation and endothelial dysfunction to reduce coronary microvascular dysfunction via the Dectin-1/Syk/IRF5 pathway. J. Ethnopharmacol. 316 , 116742 (2023). 37290736 10.1016/j.jep.2023.116742

791. Courties G In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing J. Am. Coll. Cardiol. 2014 63 1556 1566 10.1016/j.jacc.2013.11.023 24361318 PMC3992176 Courties, G. et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J. Am. Coll. Cardiol. 63 , 1556–1566 (2014). 24361318 10.1016/j.jacc.2013.11.023 PMC3992176

792. Fan JH Association between IRF-5 polymorphisms and risk of acute coronary syndrome Dna. Cell. Biol. 2010 29 19 23 10.1089/dna.2009.0929 19778284 Fan, J. H. et al. Association between IRF-5 polymorphisms and risk of acute coronary syndrome. Dna. Cell. Biol. 29 , 19–23 (2010). 19778284 10.1089/dna.2009.0929

793. Zhang Y Interferon regulatory factor 9 is an essential mediator of heart dysfunction and cell death following myocardial ischemia/reperfusion injury Basic. Res. Cardiol. 2014 109 434 10.1007/s00395-014-0434-9 25150882 Zhang, Y. et al. Interferon regulatory factor 9 is an essential mediator of heart dysfunction and cell death following myocardial ischemia/reperfusion injury. Basic. Res. Cardiol. 109 , 434 (2014). 25150882 10.1007/s00395-014-0434-9

794. Friesen M Activation of IRF1 in Human Adipocytes Leads to Phenotypes Associated with Metabolic Disease Stem. Cell. Rep. 2017 8 1164 1173 10.1016/j.stemcr.2017.03.014 PMC5425619 28416283 Friesen, M. et al. Activation of IRF1 in Human Adipocytes Leads to Phenotypes Associated with Metabolic Disease. Stem. Cell. Rep. 8 , 1164–1173 (2017). 10.1016/j.stemcr.2017.03.014 PMC5425619 28416283

795. Kumari M IRF3 promotes adipose inflammation and insulin resistance and represses browning J. Clin. Invest. 2016 126 2839 2854 10.1172/JCI86080 27400129 PMC4966307 Kumari, M. et al. IRF3 promotes adipose inflammation and insulin resistance and represses browning. J. Clin. Invest. 126 , 2839–2854 (2016). 27400129 10.1172/JCI86080 PMC4966307

796. Yan S IRF3 reduces adipose thermogenesis via ISG15-mediated reprogramming of glycolysis J. Clin. Invest. 2021 131 e144888 10.1172/JCI144888 33571167 PMC8011904 Yan, S. et al. IRF3 reduces adipose thermogenesis via ISG15-mediated reprogramming of glycolysis. J. Clin. Invest. 131 , e144888 (2021). 33571167 10.1172/JCI144888 PMC8011904

797. Mao Y STING-IRF3 Triggers Endothelial Inflammation in Response to Free Fatty Acid-Induced Mitochondrial Damage in Diet-Induced Obesity Arterioscler. Thromb. Vasc. Biol. 2017 37 920 929 10.1161/ATVBAHA.117.309017 28302626 PMC5408305 Mao, Y. et al. STING-IRF3 Triggers Endothelial Inflammation in Response to Free Fatty Acid-Induced Mitochondrial Damage in Diet-Induced Obesity. Arterioscler. Thromb. Vasc. Biol. 37 , 920–929 (2017). 28302626 10.1161/ATVBAHA.117.309017 PMC5408305

798. Correction to: STING-IRF3 Triggers Endothelial Inflammation in Response to Free Fatty Acid-Induced Mitochondrial Damage in Diet-Induced Obesity. Arterioscler. Thromb. Vasc. Biol . 38 , e60 (2018). 10.1161/ATV.0000000000000069 29563119

799. Hu HQ The STING-IRF3 pathway is involved in lipotoxic injury of pancreatic β cells in type 2 diabetes Mol. Cell. Endocrinol. 2020 518 110890 10.1016/j.mce.2020.110890 32781250 Hu, H. Q. et al. The STING-IRF3 pathway is involved in lipotoxic injury of pancreatic β cells in type 2 diabetes. Mol. Cell. Endocrinol. 518 , 110890 (2020). 32781250 10.1016/j.mce.2020.110890

800. Eguchi J Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization Diabetes 2013 62 3394 3403 10.2337/db12-1327 23835343 PMC3781469 Eguchi, J. et al. Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization. Diabetes 62 , 3394–3403 (2013). 23835343 10.2337/db12-1327 PMC3781469

801. Cavallari JF Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4 Cell. Metab. 2017 25 1063 1074.e1063 10.1016/j.cmet.2017.03.021 28434881 Cavallari, J. F. et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell. Metab. 25 , 1063–1074.e1063 (2017). 28434881 10.1016/j.cmet.2017.03.021

802. Sindhu, S. et al. Increased Adipose Tissue Expression of Interferon Regulatory Factor (IRF)-5 in Obesity: Association with Metabolic Inflammation. Cells 8 , 1418 (2019). 10.3390/cells8111418 PMC6912676 31718015

803. Sindhu, S. et al. Enhanced Adipose Expression of Interferon Regulatory Factor (IRF)-5 Associates with the Signatures of Metabolic Inflammation in Diabetic Obese Patients. Cells 9 , 730 (2020). 10.3390/cells9030730 PMC7140673 32188105

804. Orliaguet L Ejlalmanesh T Humbert A Early macrophage response to obesity encompasses Interferon Regulatory Factor 5 regulated mitochondrial architecture remodelling Nat. Commun. 2022 13 5089 10.1038/s41467-022-32813-z 36042203 PMC9427774 Orliaguet, L., Ejlalmanesh, T. & Humbert, A. Early macrophage response to obesity encompasses Interferon Regulatory Factor 5 regulated mitochondrial architecture remodelling. Nat. Commun. 13 , 5089 (2022). 36042203 10.1038/s41467-022-32813-z PMC9427774

805. Dalmas E Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity Nat. Med. 2015 21 610 618 10.1038/nm.3829 25939064 Dalmas, E. et al. Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity. Nat. Med. 21 , 610–618 (2015). 25939064 10.1038/nm.3829

806. Hoang AC Sasi-Szabó L Pál T Mitochondrial RNA stimulates beige adipocyte development in young mice Nat. Metab. 2022 4 1684 1696 10.1038/s42255-022-00683-w 36443525 PMC9771821 Hoang, A. C., Sasi-Szabó, L. & Pál, T. Mitochondrial RNA stimulates beige adipocyte development in young mice. Nat. Metab. 4 , 1684–1696 (2022). 36443525 10.1038/s42255-022-00683-w PMC9771821

807. Wang XA Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance Am. J. Physiol. Endocrinol. Metab. 2013 305 E485 E495 10.1152/ajpendo.00505.2012 23695216 Wang, X. A. et al. Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 305 , E485–E495 (2013). 23695216 10.1152/ajpendo.00505.2012

808. Liu, Z. et al. Melatonin alleviates inflammasome-induced pyroptosis through inhibiting NF-κB/GSDMD signal in mice adipose tissue. J. Pineal. Res . 63 , e12414 (2017). 10.1111/jpi.12414 28398673

809. Jiang H Interferon-α promotes MHC I antigen presentation of islet β cells through STAT1-IRF7 pathway in type 1 diabetes Immunology 2022 166 210 221 10.1111/imm.13468 35298836 Jiang, H. et al. Interferon-α promotes MHC I antigen presentation of islet β cells through STAT1-IRF7 pathway in type 1 diabetes. Immunology 166 , 210–221 (2022). 35298836 10.1111/imm.13468

810. Wang XA Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice Hepatology 2013 58 603 616 10.1002/hep.26368 23471885 PMC3736732 Wang, X. A. et al. Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice. Hepatology 58 , 603–616 (2013). 23471885 10.1002/hep.26368 PMC3736732

811. Jiang DS Interferon regulatory factor 1 is required for cardiac remodeling in response to pressure overload Hypertension 2014 64 77 86 10.1161/HYPERTENSIONAHA.114.03229 24732887 Jiang, D. S. et al. Interferon regulatory factor 1 is required for cardiac remodeling in response to pressure overload. Hypertension 64 , 77–86 (2014). 24732887 10.1161/HYPERTENSIONAHA.114.03229

812. Ma XM Lipotoxicity-induced mtDNA release promotes diabetic cardiomyopathy by activating the cGAS-STING pathway in obesity-related diabetes Cell. Biol. Toxicol. 2023 39 277 299 10.1007/s10565-021-09692-z 35235096 PMC10042943 Ma, X. M. et al. Lipotoxicity-induced mtDNA release promotes diabetic cardiomyopathy by activating the cGAS-STING pathway in obesity-related diabetes. Cell. Biol. Toxicol. 39 , 277–299 (2023). 35235096 10.1007/s10565-021-09692-z PMC10042943

813. Yan M Mitochondrial damage and activation of the cytosolic DNA sensor cGAS-STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice Cell. Death. Discov. 2022 8 258 10.1038/s41420-022-01046-w 35538059 PMC9091247 Yan, M. et al. Mitochondrial damage and activation of the cytosolic DNA sensor cGAS-STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice. Cell. Death. Discov. 8 , 258 (2022). 35538059 10.1038/s41420-022-01046-w PMC9091247

814. Xie R LncRNA ZNF593-AS alleviates diabetic cardiomyopathy via suppressing IRF3 signaling pathway Mol. Ther. Nucleic Acids 2023 32 689 703 10.1016/j.omtn.2023.04.025 37215148 PMC10199406 Xie, R. et al. LncRNA ZNF593-AS alleviates diabetic cardiomyopathy via suppressing IRF3 signaling pathway. Mol. Ther. Nucleic Acids 32 , 689–703 (2023). 37215148 10.1016/j.omtn.2023.04.025 PMC10199406

815. Li N STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3 Redox Biol. 2019 24 101215 10.1016/j.redox.2019.101215 31121492 PMC6529775 Li, N. et al. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3. Redox Biol. 24 , 101215 (2019). 31121492 10.1016/j.redox.2019.101215 PMC6529775

816. Garcia-Gonzalez C Dieterich C Maroli G ADAR1 Prevents Autoinflammatory Processes in the Heart Mediated by IRF7 Circ. Res. 2022 131 580 597 10.1161/CIRCRESAHA.122.320839 36000401 Garcia-Gonzalez, C., Dieterich, C. & Maroli, G. ADAR1 Prevents Autoinflammatory Processes in the Heart Mediated by IRF7. Circ. Res. 131 , 580–597 (2022). 36000401 10.1161/CIRCRESAHA.122.320839

817. Wu D Interferon Regulatory Factor-1 Mediates Alveolar Macrophage Pyroptosis During LPS-Induced Acute Lung Injury in Mice Shock 2016 46 329 338 10.1097/SHK.0000000000000595 26939040 PMC4978602 Wu, D. et al. Interferon Regulatory Factor-1 Mediates Alveolar Macrophage Pyroptosis During LPS-Induced Acute Lung Injury in Mice. Shock 46 , 329–338 (2016). 26939040 10.1097/SHK.0000000000000595 PMC4978602

818. Liu S IRF-1 Intervention in the Classical ROS-Dependent Release of NETs during LPS-Induced Acute Lung Injury in Mice Inflammation 2019 42 387 403 10.1007/s10753-018-0903-7 30315525 Liu, S. et al. IRF-1 Intervention in the Classical ROS-Dependent Release of NETs during LPS-Induced Acute Lung Injury in Mice. Inflammation 42 , 387–403 (2019). 30315525 10.1007/s10753-018-0903-7

819. Chen X Interferon regulatory factor 1 (IRF1) inhibits lung endothelial regeneration following inflammation-induced acute lung injury Clin. Sci. (Lond.). 2023 137 367 383 10.1042/CS20220876 36857175 PMC10011169 Chen, X. et al. Interferon regulatory factor 1 (IRF1) inhibits lung endothelial regeneration following inflammation-induced acute lung injury. Clin. Sci. (Lond.). 137 , 367–383 (2023). 36857175 10.1042/CS20220876 PMC10011169

820. Wang N The STING-IRF3 pathway contributes to paraquat-induced acute lung injury Toxicol. Mech. Methods 2022 32 145 157 10.1080/15376516.2021.1974133 34455893 Wang, N. et al. The STING-IRF3 pathway contributes to paraquat-induced acute lung injury. Toxicol. Mech. Methods 32 , 145–157 (2022). 34455893 10.1080/15376516.2021.1974133

821. Messaoud-Nacer Y STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS) Cell. Death. Dis. 2022 13 269 10.1038/s41419-022-04664-5 35338116 PMC8953969 Messaoud-Nacer, Y. et al. STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS). Cell. Death. Dis. 13 , 269 (2022). 35338116 10.1038/s41419-022-04664-5 PMC8953969

822. Zhang S IFIH1 Contributes to M1 Macrophage Polarization in ARDS Front. Immunol. 2020 11 580838 10.3389/fimmu.2020.580838 33519803 PMC7841399 Zhang, S. et al. IFIH1 Contributes to M1 Macrophage Polarization in ARDS. Front. Immunol. 11 , 580838 (2020). 33519803 10.3389/fimmu.2020.580838 PMC7841399

823. Zhang Y Anisodamine Enhances Macrophage M2 Polarization through Suppressing G9a-Mediated Interferon Regulatory Factor 4 Silencing to Alleviate Lipopolysaccharide-Induced Acute Lung Injury J. Pharmacol. Exp. Ther. 2022 381 247 256 10.1124/jpet.121.001019 35383125 Zhang, Y. et al. Anisodamine Enhances Macrophage M2 Polarization through Suppressing G9a-Mediated Interferon Regulatory Factor 4 Silencing to Alleviate Lipopolysaccharide-Induced Acute Lung Injury. J. Pharmacol. Exp. Ther. 381 , 247–256 (2022). 35383125 10.1124/jpet.121.001019

824. Xu Q Interferon Regulatory Factor 5 siRNA-Loaded Folate-Modified Cationic Liposomes for Acute Lung Injury Therapy J. Biomed. Nanotechnol. 2021 17 466 476 10.1166/jbn.2021.3046 33875081 Xu, Q. et al. Interferon Regulatory Factor 5 siRNA-Loaded Folate-Modified Cationic Liposomes for Acute Lung Injury Therapy. J. Biomed. Nanotechnol. 17 , 466–476 (2021). 33875081 10.1166/jbn.2021.3046

825. Gharib SA Computational identification of key biological modules and transcription factors in acute lung injury Am. J. Respir. Crit. Care. Med. 2006 173 653 658 10.1164/rccm.200509-1473OC 16387799 Gharib, S. A. et al. Computational identification of key biological modules and transcription factors in acute lung injury. Am. J. Respir. Crit. Care. Med. 173 , 653–658 (2006). 16387799 10.1164/rccm.200509-1473OC

826. Yang L Attenuation of interferon regulatory factor 7 activity in local infectious sites of trachea and lung for preventing the development of acute lung injury caused by influenza A virus Immunology 2019 157 37 51 10.1111/imm.13045 30667045 PMC6459777 Yang, L. et al. Attenuation of interferon regulatory factor 7 activity in local infectious sites of trachea and lung for preventing the development of acute lung injury caused by influenza A virus. Immunology 157 , 37–51 (2019). 30667045 10.1111/imm.13045 PMC6459777

827. Winterberg PD Reactive oxygen species and IRF1 stimulate IFNα production by proximal tubules during ischemic AKI Am. J. Physiol. Ren. Physiol. 2013 305 F164 F172 10.1152/ajprenal.00487.2012 PMC3725662 23657854 Winterberg, P. D. et al. Reactive oxygen species and IRF1 stimulate IFNα production by proximal tubules during ischemic AKI. Am. J. Physiol. Ren. Physiol. 305 , F164–F172 (2013). 10.1152/ajprenal.00487.2012 PMC3725662 23657854

828. Wang Y IRF-1 promotes inflammation early after ischemic acute kidney injury J. Am. Soc. Nephrol. 2009 20 1544 1555 10.1681/ASN.2008080843 19443641 PMC2709690 Wang, Y. et al. IRF-1 promotes inflammation early after ischemic acute kidney injury. J. Am. Soc. Nephrol. 20 , 1544–1555 (2009). 19443641 10.1681/ASN.2008080843 PMC2709690

829. Yan Q Hu Q Li G NEAT1 Regulates Calcium Oxalate Crystal-Induced Renal Tubular Oxidative Injury via miR-130/IRF1 Antioxid. Redox Signal. 2023 38 731 746 10.1089/ars.2022.0008 36242511 Yan, Q., Hu, Q. & Li, G. NEAT1 Regulates Calcium Oxalate Crystal-Induced Renal Tubular Oxidative Injury via miR-130/IRF1. Antioxid. Redox Signal. 38 , 731–746 (2023). 36242511 10.1089/ars.2022.0008

830. Yang X AhR activation attenuates calcium oxalate nephrocalcinosis by diminishing M1 macrophage polarization and promoting M2 macrophage polarization Theranostics 2020 10 12011 12025 10.7150/thno.51144 33204326 PMC7667681 Yang, X. et al. AhR activation attenuates calcium oxalate nephrocalcinosis by diminishing M1 macrophage polarization and promoting M2 macrophage polarization. Theranostics 10 , 12011–12025 (2020). 33204326 10.7150/thno.51144 PMC7667681

831. Liu H Erratum: Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis: Erratum Theranostics 2022 12 421 10.7150/thno.68830 34987656 PMC8690918 Liu, H. et al. Erratum: Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis: Erratum. Theranostics 12 , 421 (2022). 34987656 10.7150/thno.68830 PMC8690918

832. Liu H Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis Theranostics 2020 10 7319 7334 10.7150/thno.44054 32641994 PMC7330860 Liu, H. et al. Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis. Theranostics 10 , 7319–7334 (2020). 32641994 10.7150/thno.44054 PMC7330860

833. Li Y IRF-1 promotes renal fibrosis by downregulation of Klotho Faseb. j. 2020 34 4415 4429 10.1096/fj.201902446R 31965641 Li, Y. et al. IRF-1 promotes renal fibrosis by downregulation of Klotho. Faseb. j. 34 , 4415–4429 (2020). 31965641 10.1096/fj.201902446R

834. Wu H Lai CF Chang-Panesso M Humphreys BD Proximal Tubule Translational Profiling during Kidney Fibrosis Reveals Proinflammatory and Long Noncoding RNA Expression Patterns with Sexual Dimorphism J. Am. Soc. Nephrol. 2020 31 23 38 10.1681/ASN.2019040337 31537650 PMC6935009 Wu, H., Lai, C. F., Chang-Panesso, M. & Humphreys, B. D. Proximal Tubule Translational Profiling during Kidney Fibrosis Reveals Proinflammatory and Long Noncoding RNA Expression Patterns with Sexual Dimorphism. J. Am. Soc. Nephrol. 31 , 23–38 (2020). 31537650 10.1681/ASN.2019040337 PMC6935009

835. Zhao B A Genome-Wide Association Study to Identify Single-Nucleotide Polymorphisms for Acute Kidney Injury Am. J. Respir. Crit. Care. Med. 2017 195 482 490 10.1164/rccm.201603-0518OC 27576016 PMC5378420 Zhao, B. et al. A Genome-Wide Association Study to Identify Single-Nucleotide Polymorphisms for Acute Kidney Injury. Am. J. Respir. Crit. Care. Med. 195 , 482–490 (2017). 27576016 10.1164/rccm.201603-0518OC PMC5378420

836. Renken IJE No Association between Genetic Loci near IRF2 and TBX1 and Acute Kidney Injury in the Critically Ill Am. J. Respir. Crit. Care. Med. 2020 201 109 111 10.1164/rccm.201903-0633LE 31487200 Renken, I. J. E. et al. No Association between Genetic Loci near IRF2 and TBX1 and Acute Kidney Injury in the Critically Ill. Am. J. Respir. Crit. Care. Med. 201 , 109–111 (2020). 31487200 10.1164/rccm.201903-0633LE

837. Zhang Y Zhang Y Yang A Xia F Downregulation of IRF2 Alleviates Sepsis-Related Acute Kidney Injury in vitro and in vivo Drug. Des. Devel. Ther. 2021 15 5123 5132 10.2147/DDDT.S334518 34992348 PMC8710674 Zhang, Y., Zhang, Y., Yang, A. & Xia, F. Downregulation of IRF2 Alleviates Sepsis-Related Acute Kidney Injury in vitro and in vivo. Drug. Des. Devel. Ther. 15 , 5123–5132 (2021). 34992348 10.2147/DDDT.S334518 PMC8710674

838. He T Yang L Wu D Effect of interferon regulatory factor 2 on inflammatory response and oxidative stress in lipopolysaccharide-induced acute kidney injury Drug. Dev. Res. 2022 83 940 951 10.1002/ddr.21919 35088417 He, T., Yang, L. & Wu, D. Effect of interferon regulatory factor 2 on inflammatory response and oxidative stress in lipopolysaccharide-induced acute kidney injury. Drug. Dev. Res. 83 , 940–951 (2022). 35088417 10.1002/ddr.21919

839. Chen X Targeting the mechanism of IRF3 in sepsis-associated acute kidney injury via the Hippo pathway Int. Immunopharmacol. 2023 122 110625 10.1016/j.intimp.2023.110625 37441808 Chen, X. et al. Targeting the mechanism of IRF3 in sepsis-associated acute kidney injury via the Hippo pathway. Int. Immunopharmacol. 122 , 110625 (2023). 37441808 10.1016/j.intimp.2023.110625

840. Li W Tan Y Gao F Xiang M Overexpression of TRIM3 protects against LPS-induced acute kidney injury via repressing IRF3 pathway and NLRP3 inflammasome Int. Urol. Nephrol. 2022 54 1331 1342 10.1007/s11255-021-03017-z 34643859 Li, W., Tan, Y., Gao, F. & Xiang, M. Overexpression of TRIM3 protects against LPS-induced acute kidney injury via repressing IRF3 pathway and NLRP3 inflammasome. Int. Urol. Nephrol. 54 , 1331–1342 (2022). 34643859 10.1007/s11255-021-03017-z

841. Baatarjav C Komada T dsDNA-induced AIM2 pyroptosis halts aberrant inflammation during rhabdomyolysis-induced acute kidney injury Cell. Death. Differ. 2022 29 2487 2502 10.1038/s41418-022-01033-9 35739254 PMC9750976 Baatarjav, C. & Komada, T. dsDNA-induced AIM2 pyroptosis halts aberrant inflammation during rhabdomyolysis-induced acute kidney injury. Cell. Death. Differ. 29 , 2487–2502 (2022). 35739254 10.1038/s41418-022-01033-9 PMC9750976

842. Xie J Liu L The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis Nat. Commun. 2020 11 1600 10.1038/s41467-020-15383-w 32231244 PMC7105485 Xie, J. & Liu, L. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nat. Commun. 11 , 1600 (2020). 32231244 10.1038/s41467-020-15383-w PMC7105485

843. Li M Genome-Wide Meta-Analysis Identifies Three Novel Susceptibility Loci and Reveals Ethnic Heterogeneity of Genetic Susceptibility for IgA Nephropathy J. Am. Soc. Nephrol. 2020 31 2949 2963 10.1681/ASN.2019080799 32912934 PMC7790208 Li, M. et al. Genome-Wide Meta-Analysis Identifies Three Novel Susceptibility Loci and Reveals Ethnic Heterogeneity of Genetic Susceptibility for IgA Nephropathy. J. Am. Soc. Nephrol. 31 , 2949–2963 (2020). 32912934 10.1681/ASN.2019080799 PMC7790208

844. Deng YX Identification and validation of hub genes in drug induced acute kidney injury basing on integrated transcriptomic analysis Front. Immunol. 2023 14 1126348 10.3389/fimmu.2023.1126348 37063876 PMC10090697 Deng, Y. X. et al. Identification and validation of hub genes in drug induced acute kidney injury basing on integrated transcriptomic analysis. Front. Immunol. 14 , 1126348 (2023). 37063876 10.3389/fimmu.2023.1126348 PMC10090697

845. Sasaki K Deletion of Myeloid Interferon Regulatory Factor 4 (Irf4) in Mouse Model Protects against Kidney Fibrosis after Ischemic Injury by Decreased Macrophage Recruitment and Activation J. Am. Soc. Nephrol. 2021 32 1037 1052 10.1681/ASN.2020071010 33619052 PMC8259665 Sasaki, K. et al. Deletion of Myeloid Interferon Regulatory Factor 4 (Irf4) in Mouse Model Protects against Kidney Fibrosis after Ischemic Injury by Decreased Macrophage Recruitment and Activation. J. Am. Soc. Nephrol. 32 , 1037–1052 (2021). 33619052 10.1681/ASN.2020071010 PMC8259665

846. Chen M IRF-4 deficiency reduces inflammation and kidney fibrosis after folic acid-induced acute kidney injury Int. Immunopharmacol. 2021 100 108142 10.1016/j.intimp.2021.108142 34555644 Chen, M. et al. IRF-4 deficiency reduces inflammation and kidney fibrosis after folic acid-induced acute kidney injury. Int. Immunopharmacol. 100 , 108142 (2021). 34555644 10.1016/j.intimp.2021.108142

847. Gao Y Interferon regulatory factor 4 deletion protects against kidney inflammation and fibrosis in deoxycorticosterone acetate/salt hypertension J. Hypertens. 2023 41 794 810 36883469 10.1097/HJH.0000000000003401 Gao, Y. et al. Interferon regulatory factor 4 deletion protects against kidney inflammation and fibrosis in deoxycorticosterone acetate/salt hypertension. J. Hypertens. 41 , 794–810 (2023). 36883469 10.1097/HJH.0000000000003401

848. Lorenz G IFN Regulatory Factor 4 Controls Post-ischemic Inflammation and Prevents Chronic Kidney Disease Front. Immunol. 2019 10 2162 10.3389/fimmu.2019.02162 31632388 PMC6781770 Lorenz, G. et al. IFN Regulatory Factor 4 Controls Post-ischemic Inflammation and Prevents Chronic Kidney Disease. Front. Immunol. 10 , 2162 (2019). 31632388 10.3389/fimmu.2019.02162 PMC6781770

849. Liu J Li X Yang J Zhang D LncRNA ENSMUST_147219 mediates the progression of ischemic acute kidney injury by targeting the miR-221-5p/IRF6 axis Apoptosis 2022 27 531 544 10.1007/s10495-022-01730-3 35618996 PMC9308590 Liu, J., Li, X., Yang, J. & Zhang, D. LncRNA ENSMUST_147219 mediates the progression of ischemic acute kidney injury by targeting the miR-221-5p/IRF6 axis. Apoptosis 27 , 531–544 (2022). 35618996 10.1007/s10495-022-01730-3 PMC9308590

850. Kiryluk K Sanchez-Rodriguez E Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy Nat. Genet. 2023 55 1091 1105 10.1038/s41588-023-01422-x 37337107 PMC11824687 Kiryluk, K. & Sanchez-Rodriguez, E. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat. Genet. 55 , 1091–1105 (2023). 37337107 10.1038/s41588-023-01422-x PMC11824687

851. Guo C DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8 Kidney Int. 2017 92 1194 1205 10.1016/j.kint.2017.03.038 28709638 PMC5651199 Guo, C. et al. DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8. Kidney Int. 92 , 1194–1205 (2017). 28709638 10.1016/j.kint.2017.03.038 PMC5651199

852. Li N IRF8-Dependent Type I Conventional Dendritic Cells (cDC1s) Control Post-Ischemic Inflammation and Mildly Protect Against Post-Ischemic Acute Kidney Injury and Disease Front. Immunol. 2021 12 685559 10.3389/fimmu.2021.685559 34234783 PMC8255684 Li, N. et al. IRF8-Dependent Type I Conventional Dendritic Cells (cDC1s) Control Post-Ischemic Inflammation and Mildly Protect Against Post-Ischemic Acute Kidney Injury and Disease. Front. Immunol. 12 , 685559 (2021). 34234783 10.3389/fimmu.2021.685559 PMC8255684

853. Liu Y Negative Regulation of SIRT1 by IRF9 Involved in Hyperlipidemia Acute Pancreatitis Associated with Kidney Injury Dig. Dis. Sci. 2021 66 1063 1071 10.1007/s10620-020-06331-1 32462510 Liu, Y. et al. Negative Regulation of SIRT1 by IRF9 Involved in Hyperlipidemia Acute Pancreatitis Associated with Kidney Injury. Dig. Dis. Sci. 66 , 1063–1071 (2021). 32462510 10.1007/s10620-020-06331-1

854. Bialek K Novel association between TGFA, TGFB1, IRF1, PTGS2 and IKBKB single-nucleotide polymorphisms and occurrence, severity and treatment response of major depressive disorder PeerJ 2020 8 e8676 10.7717/peerj.8676 32140313 PMC7047865 Bialek, K. et al. Novel association between TGFA, TGFB1, IRF1, PTGS2 and IKBKB single-nucleotide polymorphisms and occurrence, severity and treatment response of major depressive disorder. PeerJ 8 , e8676 (2020). 32140313 10.7717/peerj.8676 PMC7047865

855. Li J Lack of interferon regulatory factor 3 leads to anxiety/depression-like behaviors through disrupting the balance of neuronal excitation and inhibition in mice Genes. Dis. 2023 10 1062 1074 10.1016/j.gendis.2022.05.003 37396521 PMC10308133 Li, J. et al. Lack of interferon regulatory factor 3 leads to anxiety/depression-like behaviors through disrupting the balance of neuronal excitation and inhibition in mice. Genes. Dis. 10 , 1062–1074 (2023). 37396521 10.1016/j.gendis.2022.05.003 PMC10308133

856. Li X Common variants of IRF3 conferring risk of schizophrenia J. Psychiatr. Res. 2015 64 67 73 10.1016/j.jpsychires.2015.03.008 25843157 Li, X. et al. Common variants of IRF3 conferring risk of schizophrenia. J. Psychiatr. Res. 64 , 67–73 (2015). 25843157 10.1016/j.jpsychires.2015.03.008

857. Lago SG Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia Brain. Behav. Immun. 2022 103 37 49 10.1016/j.bbi.2022.03.016 35381347 Lago, S. G. et al. Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia. Brain. Behav. Immun. 103 , 37–49 (2022). 35381347 10.1016/j.bbi.2022.03.016

858. Xu Q Efficacy and mechanism of cGAMP to suppress Alzheimer’s disease by elevating TREM2 Brain. Behav. Immun. 2019 81 495 508 10.1016/j.bbi.2019.07.004 31283973 Xu, Q. et al. Efficacy and mechanism of cGAMP to suppress Alzheimer’s disease by elevating TREM2. Brain. Behav. Immun. 81 , 495–508 (2019). 31283973 10.1016/j.bbi.2019.07.004

859. Guo H ZBP1 mediates the progression of Alzheimer’s disease via pyroptosis by regulating IRF3 Mol. Cell. Biochem 2023 478 2849 2860 10.1007/s11010-023-04702-6 36964897 Guo, H. et al. ZBP1 mediates the progression of Alzheimer’s disease via pyroptosis by regulating IRF3. Mol. Cell. Biochem 478 , 2849–2860 (2023). 36964897 10.1007/s11010-023-04702-6

860. Li R Silencing of IRF3 alleviates chronic neuropathic pain following chronic constriction injury Biomed. Pharmacother. 2017 88 403 408 10.1016/j.biopha.2017.01.085 28122305 Li, R. et al. Silencing of IRF3 alleviates chronic neuropathic pain following chronic constriction injury. Biomed. Pharmacother. 88 , 403–408 (2017). 28122305 10.1016/j.biopha.2017.01.085

861. Zhou Y Song WM Andhey PS Swain A Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease Nat. Med. 2020 26 131 142 10.1038/s41591-019-0695-9 31932797 PMC6980793 Zhou, Y., Song, W. M., Andhey, P. S. & Swain, A. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26 , 131–142 (2020). 31932797 10.1038/s41591-019-0695-9 PMC6980793

862. Zeng Q IRF-8 is Involved in Amyloid-β(1-40) (Aβ(1-40))-induced Microglial Activation: a New Implication in Alzheimer’s Disease J. Mol. Neurosci. 2017 63 159 164 10.1007/s12031-017-0966-1 28856571 Zeng, Q. et al. IRF-8 is Involved in Amyloid-β(1-40) (Aβ(1-40))-induced Microglial Activation: a New Implication in Alzheimer’s Disease. J. Mol. Neurosci. 63 , 159–164 (2017). 28856571 10.1007/s12031-017-0966-1

863. Huang Y IRF1-mediated downregulation of PGC1α contributes to cardiorenal syndrome type 4 Nat. Commun. 2020 11 4664 10.1038/s41467-020-18519-0 32938919 PMC7494935 Huang, Y. et al. IRF1-mediated downregulation of PGC1α contributes to cardiorenal syndrome type 4. Nat. Commun. 11 , 4664 (2020). 32938919 10.1038/s41467-020-18519-0 PMC7494935

864. Wang A Kang X Wang J Zhang S IFIH1/IRF1/STAT1 promotes sepsis associated inflammatory lung injury via activating macrophage M1 polarization Int. Immunopharmacol. 2023 114 109478 10.1016/j.intimp.2022.109478 36462334 PMC9709523 Wang, A., Kang, X., Wang, J. & Zhang, S. IFIH1/IRF1/STAT1 promotes sepsis associated inflammatory lung injury via activating macrophage M1 polarization. Int. Immunopharmacol. 114 , 109478 (2023). 36462334 10.1016/j.intimp.2022.109478 PMC9709523

865. Chen XY Interferon-regulatory factor-1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14-3-3γ axis Esc. Heart Fail. 2024 11 986 1000 10.1002/ehf2.14640 38234115 PMC10966242 Chen, X. Y. et al. Interferon-regulatory factor-1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14-3-3γ axis. Esc. Heart Fail. 11 , 986–1000 (2024). 38234115 10.1002/ehf2.14640 PMC10966242

866. Tanaka N Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 Cell 1994 77 829 839 10.1016/0092-8674(94)90132-5 8004672 Tanaka, N. et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77 , 829–839 (1994). 8004672 10.1016/0092-8674(94)90132-5

867. Testa U Impaired myelopoiesis in mice devoid of interferon regulatory factor 1 Leukemia 2004 18 1864 1871 10.1038/sj.leu.2403472 15385939 Testa, U. et al. Impaired myelopoiesis in mice devoid of interferon regulatory factor 1. Leukemia 18 , 1864–1871 (2004). 15385939 10.1038/sj.leu.2403472

868. Penninger JM The interferon regulatory transcription factor IRF-1 controls positive and negative selection of CD8+ thymocytes Immunity 1997 7 243 254 10.1016/S1074-7613(00)80527-0 9285409 Penninger, J. M. et al. The interferon regulatory transcription factor IRF-1 controls positive and negative selection of CD8+ thymocytes. Immunity 7 , 243–254 (1997). 9285409 10.1016/s1074-7613(00)80527-0

869. Lohoff M Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo Immunity 1997 6 681 689 10.1016/S1074-7613(00)80444-6 9208841 Lohoff, M. et al. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 6 , 681–689 (1997). 9208841 10.1016/s1074-7613(00)80444-6

870. Hayashi H Characterization of dsRNA-induced pancreatitis model reveals the regulatory role of IFN regulatory factor 2 (Irf2) in trypsinogen5 gene transcription Proc. Natl Acad. Sci. USA 2011 108 18766 18771 10.1073/pnas.1116273108 22042864 PMC3219097 Hayashi, H. et al. Characterization of dsRNA-induced pancreatitis model reveals the regulatory role of IFN regulatory factor 2 (Irf2) in trypsinogen5 gene transcription. Proc. Natl Acad. Sci. USA 108 , 18766–18771 (2011). 22042864 10.1073/pnas.1116273108 PMC3219097

871. Li MM Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion J. Exp. Med. 2016 213 2931 2947 10.1084/jem.20160303 27899441 PMC5154937 Li, M. M. et al. Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion. J. Exp. Med. 213 , 2931–2947 (2016). 27899441 10.1084/jem.20160303 PMC5154937

872. Lohoff M Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells J. Exp. Med. 2000 192 325 336 10.1084/jem.192.3.325 10934221 PMC2193225 Lohoff, M. et al. Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. J. Exp. Med. 192 , 325–336 (2000). 10934221 10.1084/jem.192.3.325 PMC2193225

873. Tang P Regulation of adipogenic differentiation and adipose tissue inflammation by interferon regulatory factor 3 Cell. Death. Differ. 2021 28 3022 3035 10.1038/s41418-021-00798-9 34091599 PMC8563729 Tang, P. et al. Regulation of adipogenic differentiation and adipose tissue inflammation by interferon regulatory factor 3. Cell. Death. Differ. 28 , 3022–3035 (2021). 34091599 10.1038/s41418-021-00798-9 PMC8563729

874. Negishi H Essential contribution of IRF3 to intestinal homeostasis and microbiota-mediated Tslp gene induction Proc. Natl Acad. Sci. USA 2012 109 21016 21021 10.1073/pnas.1219482110 23213237 PMC3529020 Negishi, H. et al. Essential contribution of IRF3 to intestinal homeostasis and microbiota-mediated Tslp gene induction. Proc. Natl Acad. Sci. USA 109 , 21016–21021 (2012). 23213237 10.1073/pnas.1219482110 PMC3529020

875. Moore TC Vogel AJ Petro TM Brown DM IRF3 deficiency impacts granzyme B expression and maintenance of memory T cell function in response to viral infection Microbes Infect. 2015 17 426 439 10.1016/j.micinf.2015.03.001 25777301 PMC4479197 Moore, T. C., Vogel, A. J., Petro, T. M. & Brown, D. M. IRF3 deficiency impacts granzyme B expression and maintenance of memory T cell function in response to viral infection. Microbes Infect. 17 , 426–439 (2015). 25777301 10.1016/j.micinf.2015.03.001 PMC4479197

876. Santosa EK Control of nutrient uptake by IRF4 orchestrates innate immune memory Nat. Immunol. 2023 24 1685 1697 10.1038/s41590-023-01620-z 37697097 PMC11098052 Santosa, E. K. et al. Control of nutrient uptake by IRF4 orchestrates innate immune memory. Nat. Immunol. 24 , 1685–1697 (2023). 37697097 10.1038/s41590-023-01620-z PMC11098052

877. Raczkowski F The transcription factor Interferon Regulatory Factor 4 is required for the generation of protective effector CD8+ T cells Proc. Natl Acad. Sci. USA 2013 110 15019 15024 10.1073/pnas.1309378110 23980171 PMC3773801 Raczkowski, F. et al. The transcription factor Interferon Regulatory Factor 4 is required for the generation of protective effector CD8+ T cells. Proc. Natl Acad. Sci. USA 110 , 15019–15024 (2013). 23980171 10.1073/pnas.1309378110 PMC3773801

878. Lien C Critical role of IRF-5 in regulation of B-cell differentiation Proc. Natl Acad. Sci. USA 2010 107 4664 4668 10.1073/pnas.0911193107 20176957 PMC2842054 Lien, C. et al. Critical role of IRF-5 in regulation of B-cell differentiation. Proc. Natl Acad. Sci. USA 107 , 4664–4668 (2010). 20176957 10.1073/pnas.0911193107 PMC2842054

879. Thomason HA Cooperation between the transcription factors p63 and IRF6 is essential to prevent cleft palate in mice J. Clin. Invest. 2010 120 1561 1569 10.1172/JCI40266 20424327 PMC2860913 Thomason, H. A. et al. Cooperation between the transcription factors p63 and IRF6 is essential to prevent cleft palate in mice. J. Clin. Invest. 120 , 1561–1569 (2010). 20424327 10.1172/JCI40266 PMC2860913

880. Wu M Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis Ann. Rheum. Dis. 2019 78 1583 1591 10.1136/annrheumdis-2019-215208 31439591 PMC7167109 Wu, M. et al. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis. Ann. Rheum. Dis. 78 , 1583–1591 (2019). 31439591 10.1136/annrheumdis-2019-215208 PMC7167109

881. Dror N Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells J. Biol. Chem. 2007 282 5633 5640 10.1074/jbc.M607825200 17189268 Dror, N. et al. Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells. J. Biol. Chem. 282 , 5633–5640 (2007). 17189268 10.1074/jbc.M607825200

882. Das A Murine IRF8 Mutation Offers New Insight into Osteoclast and Root Resorption J. Dent. Res. 2024 103 318 328 10.1177/00220345231222173 38343385 PMC10985390 Das, A. et al. Murine IRF8 Mutation Offers New Insight into Osteoclast and Root Resorption. J. Dent. Res. 103 , 318–328 (2024). 38343385 10.1177/00220345231222173 PMC10985390

883. Wang PX Interferon regulatory factor 9 is a key mediator of hepatic ischemia/reperfusion injury J. Hepatol. 2015 62 111 120 10.1016/j.jhep.2014.08.022 25152205 Wang, P. X. et al. Interferon regulatory factor 9 is a key mediator of hepatic ischemia/reperfusion injury. J. Hepatol. 62 , 111–120 (2015). 25152205 10.1016/j.jhep.2014.08.022

884. Yang K Hsp90 regulates activation of interferon regulatory factor 3 and TBK-1 stabilization in Sendai virus-infected cells Mol. Biol. Cell. 2006 17 1461 1471 10.1091/mbc.e05-09-0853 16394098 PMC1382332 Yang, K. et al. Hsp90 regulates activation of interferon regulatory factor 3 and TBK-1 stabilization in Sendai virus-infected cells. Mol. Biol. Cell. 17 , 1461–1471 (2006). 16394098 10.1091/mbc.E05-09-0853 PMC1382332

885. Probst P A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response Vaccine 2017 35 1964 1971 10.1016/j.vaccine.2017.01.053 28279563 PMC11514956 Probst, P. et al. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response. Vaccine 35 , 1964–1971 (2017). 28279563 10.1016/j.vaccine.2017.01.053 PMC11514956

886. Hemann EA A Small Molecule RIG-I Agonist Serves as an Adjuvant to Induce Broad Multifaceted Influenza Virus Vaccine Immunity J. Immunol. 2023 210 1247 1256 10.4049/jimmunol.2300026 36939421 PMC10149148 Hemann, E. A. et al. A Small Molecule RIG-I Agonist Serves as an Adjuvant to Induce Broad Multifaceted Influenza Virus Vaccine Immunity. J. Immunol. 210 , 1247–1256 (2023). 36939421 10.4049/jimmunol.2300026 PMC10149148

887. Boeszoermenyi A A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity Nat. Commun. 2023 14 6626 10.1038/s41467-023-42070-3 37863876 PMC10589233 Boeszoermenyi, A. et al. A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity. Nat. Commun. 14 , 6626 (2023). 37863876 10.1038/s41467-023-42070-3 PMC10589233

888. Ramírez-Carvajal L Expression of porcine fusion protein IRF7/3(5D) efficiently controls foot-and-mouth disease virus replication J. Virol. 2014 88 11140 11153 10.1128/JVI.00372-14 25031341 PMC4178809 Ramírez-Carvajal, L. et al. Expression of porcine fusion protein IRF7/3(5D) efficiently controls foot-and-mouth disease virus replication. J. Virol. 88 , 11140–11153 (2014). 25031341 10.1128/JVI.00372-14 PMC4178809